% Exported from Psilocybin Research Publication Tracker
% Tracker site: https://psilocybin-research.com
% Publication tracker: https://psilocybin-research.com/
\documentclass[11pt]{article}
\usepackage[T1]{fontenc}
\usepackage[utf8]{inputenc}
\usepackage{enumitem}
\usepackage[hidelinks]{hyperref}
\usepackage[margin=1in]{geometry}
\title{Psilocybin and Psilocin Research Export}
\author{Psilocybin Research Publication Tracker}
\date{2026-08-24}
\begin{document}
\maketitle
\noindent Exported from \href{https://psilocybin-research.com}{psilocybin-research.com}. Records: 1741.

\begin{enumerate}[leftmargin=*]
\item Kelly Carlton M., Fradet Mathieu, Bostian Catherine M., Donnelly Anna, Ellis Sara, Ostacher Michael, Aaronson Scott, Suppes Trisha (2026). \textit{Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression}. Journal of Affective Disorders. [published; Crossref]. \href{https://doi.org/10.1016/j.jad.2026.122063}{doi:10.1016/j.jad.2026.122063}.
\item Back AL, McGregor BA, Billingsley L, Blom D, Callan G, Myers S, Guy J, Kumar S, Layer M, Levin J, Perez J, Thompson P, Salmonson K, Whinney J, Thorn LL (2026). \textit{Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1177/28314425251404460}{doi:10.1177/28314425251404460}.
\item Ibi Daisuke, Takaba Rika, Yoshida Keisuke, Kawase Ririna, Kitagawa Hiroko, Matsushita Momoko, Ito Kana, Uno Shoya, Nishimura Fumiya, Kitagaki Shinji, Hiramatsu Masayuki (2026). \textit{Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress}. Neuropsychopharmacology Reports. [published; Crossref]. \href{https://doi.org/10.1002/npr2.70152}{doi:10.1002/npr2.70152}.
\item Cruz L, Beserra FR, Freind JMK, Rodrigues SE, Mograbi DC (2026). \textit{Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review.}. Journal of clinical psychology. [published; PubMed]. \href{https://doi.org/10.1002/jclp.70167}{doi:10.1002/jclp.70167}.
\item Belle Buzzi (2026). \textit{Exploring Psychedelics as Novel Therapeutics for Smoking Cessation: Mechanistic Insights from Animal Studies}. VCU Scholars Compass (Virginia Commonwealth University). [published; OpenAlex]. \href{https://doi.org/10.25772/0t5k-3r51}{doi:10.25772/0t5k-3r51}.
\item Centre for Addiction and Mental Health (2026). \textit{Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07211438}{source link}.
\item Bozkir, I. K.; Lashin, R.; Liu, T.; Pal, D.; Diba, K.; Kinsky, N. R. (2026). \textit{Psilocybin lengthens hippocampal sharp wave ripples}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.64898/2026.08.17.745042}{doi:10.64898/2026.08.17.745042}.
\item Clark Rachel N (2026). \textit{The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A Narrative Review}. Lynchburg Journal of Medical Science. [published; Crossref]. \href{https://doi.org/10.63932/3067-7106.1087}{doi:10.63932/3067-7106.1087}.
\item NYU Langone Health (2026). \textit{Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07607938}{source link}.
\item Korthuis P. Todd, Cook Ryan R., Gregoire Devin, Stauffer Christopher S., Luoma Jason B., Pertl Kellie, Des Jarlais Don, McCarty Dennis, Levander Ximena A., Hoffman Kim A., Wilson-Poe Adrianne R. (2026). \textit{Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services}. JAMA Network Open. [published; Crossref]. \href{https://doi.org/10.1001/jamanetworkopen.2026.30608}{doi:10.1001/jamanetworkopen.2026.30608}.
\item Gow, A.; Shih, E.; Reid, R.; Qian, J. J.; Mellor, C.; McInnes, L. A.; Carhart-Harris, R.; Davis, J. N. (2026). \textit{Prospective real-world evidence of mental health outcomes following supervised psilocybin services within Oregons state-regulated model}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.64898/2026.02.18.26346580}{doi:10.64898/2026.02.18.26346580}.
\item Christopher P. Albertyn, Ron Shore, Linda E. Carlson, Erika Dyck, David Clements (2026). \textit{Assessing Canadian Policy Readiness for Psychedelic-Assisted Therapy in Cancer Care}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.21983116}{doi:10.5281/zenodo.21983116}.
\item VA Office of Research and Development (2026). \textit{A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07226232}{source link}.
\item Meshkat S, Leung M, Meshkat S, Lin Q, Wijendran D, Reichelt AC, Zhang Y, Burback L, Winkler O, Greenshaw A, Monson CM, Vermetten E, Jetly R, Lou W, Zeifman RJ, Bhat V. (2026). \textit{Efficacy and Safety of Psychedelic Microdosing on Psychological Outcomes in Healthy Adults: A Systematic Review and Meta-analysis.}. CNS drugs. [published; Europe PMC]. \href{https://doi.org/10.1007/s40263-026-01325-5}{doi:10.1007/s40263-026-01325-5}.
\item Rachel Yehuda (2026). \textit{Processing Intergenerational Trauma With Psilocybin-Assisted Therapy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06899165}{source link}.
\item Sharmin Ghaznavi (2026). \textit{The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06247839}{source link}.
\item Anghel Teodora, Cojocaru Adriana, Hogea Lavinia, Costea Iuliana, Marinca Amalia, Dumache Raluca, Nussbaum Laura, Trăilă Iuliana-Anamaria (2026). \textit{Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)}. Journal of Clinical Medicine. [published; Crossref]. \href{https://doi.org/10.3390/jcm15166228}{doi:10.3390/jcm15166228}.
\item M.D. Anderson Cancer Center (2026). \textit{TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06200155}{source link}.
\item M.D. Anderson Cancer Center (2026). \textit{TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06801041}{source link}.
\item The University of Texas Health Science Center, Houston (2026). \textit{Acceptability \& Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06706232}{source link}.
\item Saanvi Gutta (2026). \textit{Psychedelic Therapy for Depression}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.21893916}{doi:10.5281/zenodo.21893916}.
\item Kaadt E, Søkilde RF, Garling HD, Raval NR, Lundgaard L, Just J, Knudsen GM, Elfving B. (2026). \textit{Psilocybin-associated microRNA changes in the pig brain: Establishing an nCounter pipeline for cross-species microRNA quantification.}. European journal of pharmacology. [published; Europe PMC]. \href{https://doi.org/10.1016/j.ejphar.2026.179222}{doi:10.1016/j.ejphar.2026.179222}.
\item Johns Hopkins University (2026). \textit{Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06656702}{source link}.
\item Charles Raison (2026). \textit{An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06512194}{source link}.
\item COMPASS Pathways (2026). \textit{A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05711940}{source link}.
\item James J. Peters Veterans Affairs Medical Center (2026). \textit{Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07251491}{source link}.
\item COMPASS Pathways (2026). \textit{A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05624268}{source link}.
\item University Health Network, Toronto (2026). \textit{Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06506019}{source link}.
\item National Institute on Aging (NIA) (2026). \textit{Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07721467}{source link}.
\item Joshua Woolley, MD, PhD (2026). \textit{The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06455293}{source link}.
\item Hörnqvist N. (2026). \textit{Correspondence: "Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy".}. Journal of affective disorders. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jad.2026.122315}{doi:10.1016/j.jad.2026.122315}.
\item Rucker JJ, Mantingh T, Kerr-Gaffney J, Bird C, Chu P, Modlin NL, Campbell-Coker K, Hambleton S, Seath P, Hignett R, Fennema D, Hampsey E, Tsapekos D, Thomas RJ, Cattell J, Jafari H, Day C, Borissova A, Lloyd M, Boardman-Pretty T, Seynaeve M, Askari F, Creed M, Baxter L, Rifkin-Zybutz R, Butler M, Jelen LA, Carter B, Young AH. (2026). \textit{Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.}. Nature medicine. [published; Europe PMC]. \href{https://doi.org/10.1038/s41591-026-04541-0}{doi:10.1038/s41591-026-04541-0}.
\item Trent Emerick (2026). \textit{Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07406828}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06731621}{source link}.
\item Chiu YT, Deutch AY, Wang W, Schmitz GP, Huang KL, Kocak DD, Llorach P, Bowyer KR, Liu B, Sciaky N, Hua K, Chen C, Mott SE, Niehaus J, DiBerto JF, English J, Walsh JJ, Scherrer G, Herman MA, Wu Z, Wetsel WC, Roth BL. (2026). \textit{A suite of engineered mice for interrogating psychedelic drug actions.}. Nature neuroscience. [published; Europe PMC]. \href{https://doi.org/10.1038/s41593-026-02375-0}{doi:10.1038/s41593-026-02375-0}.
\item University of New Mexico (2026). \textit{Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07745569}{source link}.
\item Kuypers KPC, Mason NL, Carlier A, Totomanova I, Haijen-Bongers ECHM. (2026). \textit{Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability.}. Molecular psychiatry. [published; Europe PMC]. \href{https://doi.org/10.1038/s41380-026-03801-2}{doi:10.1038/s41380-026-03801-2}.
\item Schaefer DA, Agrawal M, Mazzola E, Leff MK, Leeks C, Kematick BS, Beaussant Y. (2026). \textit{Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis.}. Journal of pain and symptom management. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jpainsymman.2026.07.030}{doi:10.1016/j.jpainsymman.2026.07.030}.
\item Sinclair Rachel (2026). \textit{Evaluating psilocybin for the management of depression: a literature review}. British Journal of Mental Health Nursing. [published; Crossref]. \href{https://doi.org/10.12968/bjmh.2025.0020}{doi:10.12968/bjmh.2025.0020}.
\item Martiadis V (2026). \textit{From trial to clinic: psilocybin's efficacy in routine treatment-resistant depression.}. The Lancet regional health. Europe. [published; PubMed]. \href{https://doi.org/10.1016/j.lanepe.2026.101780}{doi:10.1016/j.lanepe.2026.101780}.
\item Lu S, Zhang Z, Xue X, Jiang Y, Zhang C, Liu P, He D, Shen W, Yang S, Wang F (2026). \textit{Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus.}. Hearing research. [published; PubMed]. \href{https://doi.org/10.1016/j.heares.2026.109701}{doi:10.1016/j.heares.2026.109701}.
\item Mingardi J., Molteni R., Bifari F. (2026). \textit{Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depression}. Pharmacological Research. [published; Crossref]. \href{https://doi.org/10.1016/j.phrs.2026.108290}{doi:10.1016/j.phrs.2026.108290}.
\item Kishi Taro, Sakuma Kenji, Hatano Masakazu, Uchida Hiroyuki, Iwata Nakao (2026). \textit{Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis}. Journal of Affective Disorders. [published; Crossref]. \href{https://doi.org/10.1016/j.jad.2026.121675}{doi:10.1016/j.jad.2026.121675}.
\item Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Carhart-Harris Robin, Croal Megan, Feifel David, Hellerstein David J., Husain Muhammad I., Kelly John R., Kirlic Namik, Licht Rasmus W., Marwood Lindsey, Nowakowska Ania, Páleníček Tomáš, Repantis Dimitris, Schoevers Robert A., Simmons Hollie, Soares Jair C., Somers Metten, Tsai Joyce, Wahba Mourad, Williams Ella, Young Allan H., Young Matthew B., Zisook Sidney, Malievskaia Ekaterina (2026). \textit{The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis}. Journal of Affective Disorders. [published; Crossref]. \href{https://doi.org/10.1016/j.jad.2026.121662}{doi:10.1016/j.jad.2026.121662}.
\item University of Washington (2026). \textit{A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07336238}{source link}.
\item Sergio R Pérez Rosal, Sonya Faber, M. Myriah MacIntyre, Monnica Williams (2026). \textit{Retreat from racism: A psychedelic group experience for racial stress and trauma}. Psychedelics. [published; OpenAlex]. \href{https://doi.org/10.1016/j.psyche.2026.100031}{doi:10.1016/j.psyche.2026.100031}.
\item Joshua Rosenblat (2026). \textit{Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07737990}{source link}.
\item Tel-Aviv Sourasky Medical Center (2026). \textit{Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07737054}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06512220}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06518720}{source link}.
\item Sams Caitlyn Hanna, Davis Jasmine, Ramdas Anuradha, Delgoda Rupika, Vidot Denise, Reid Marvin, De La Haye Winston (2026). \textit{Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from Jamaica}. Frontiers in Psychiatry. [published; Crossref]. \href{https://doi.org/10.3389/fpsyt.2026.1876189}{doi:10.3389/fpsyt.2026.1876189}.
\item Jones GH, Gilbert JR, Johnston JN, Akula N, Schulmann A, Arakelian M, Peng S, Yuan P, Winful EA, Yavi M, Quintanilla B, Elkahloun A, Moaddel R, Henter ID, Greenstein D, Machado-Vieira R, Bartley CM, Kadriu B, Amit M, Rezvani K, Kvarta MD, McMahon FJ, Zarate CA (2026). \textit{Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-026-03777-z}{doi:10.1038/s41380-026-03777-z}.
\item Pontifícia Universidade Católica do Rio de Janeiro (2026). \textit{Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07732166}{source link}.
\item Wilkowska A, Nizgorska-Ohler J, Cubała WJ (2026). \textit{Candidate Biomarkers of Bipolar Disorder Progression: Implications for Ketamine and Psychedelic Interventions.}. Molecular neurobiology. [published; PubMed]. \href{https://doi.org/10.1007/s12035-026-06086-2}{doi:10.1007/s12035-026-06086-2}.
\item Danial Beniameen, Armya Beniameen (2026). \textit{A Systematic Review of EEG Predictors and Correlates of Psilocybin’s Treatment in Depression}. Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal. [published; OpenAlex]. \href{https://doi.org/10.26685/urncst.1027}{doi:10.26685/urncst.1027}.
\item O'Callaghan C, Kallianis V, Ross M (2026). \textit{Participants' Music Experiences Associated With Psychedelic-Assisted Psychotherapy for Life-Threatening Illness: Interpretivist Research.}. Journal of music therapy. [published; PubMed]. \href{https://doi.org/10.1093/jmt/thag015}{doi:10.1093/jmt/thag015}.
\item Johns Hopkins University (2026). \textit{Psilocybin and Affective Function in Chronic Lower Back Pain Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06355414}{source link}.
\item Usona Institute (2026). \textit{A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06308653}{source link}.
\item Ohio State University (2026). \textit{A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06820723}{source link}.
\item University of California, San Diego (2026). \textit{Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06814522}{source link}.
\item Yale University (2026). \textit{The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07610369}{source link}.
\item Bartosz Niciński, Magdalena Kloc, Ewa Wiench, Natasza Millan, Aleksandra Blicharz, Wojciech Kozdraś, Lidia Kozaczko, Gabriela Szewczyk, Elżbieta Bukowczan, Alicja Zając, Damian Broda, Alicja Benecka (2026). \textit{Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of Depression}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.21406174}{doi:10.5281/zenodo.21406174}.
\item Diamond Therapeutics Inc. (2026). \textit{A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of Psilocybin}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07710027}{source link}.
\item Çağrı Özkurt (2026). \textit{Publication bias in randomized trials of psilocybin for depression: a Robust Bayesian Meta-Analysis}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/6gy8v\_v1}{doi:10.31234/osf.io/6gy8v\_v1}.
\item Jakub Bajer, Aleksandra Włodarczyk, Hubert Kulawinek, Julia Obersztyn, Krzysztof Kasparek, Marta Czech, Grzegorz Kasparek, Adrianna Szczecińska, Wiktoria Glanert, Aleksandra Mliczek, Piotr Mrozek (2026). \textit{Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2026.94.73071}{doi:10.12775/jehs.2026.94.73071}.
\item Khyber Medical University Peshawar (2026). \textit{Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07703722}{source link}.
\item Hörnqvist Nils (2026). \textit{Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview}. Journal of Psychedelic Studies. [published; Crossref]. \href{https://doi.org/10.1556/2054.2026.00505}{doi:10.1556/2054.2026.00505}.
\item Brinzei OV. (2026). \textit{MDMA and Psilocybin-Assisted Therapy in Australia: Early Real-World Prescribing, Safety Monitoring and Regulatory Developments}. ScienceOpen Preprints. [preprint; Europe PMC]. \href{https://doi.org/10.14293/pr2199.004090.v1}{doi:10.14293/pr2199.004090.v1}.
\item Nele Böhm, Frank Euteneuer (2026). \textit{Psilocybin bei Depression: Systematisches Review und Meta-Analyse zur antidepressiven Wirksamkeit}. OSF. [preprint; OpenAlex]. \href{https://doi.org/10.17605/osf.io/axgjw}{doi:10.17605/osf.io/axgjw}.
\item Bruyère Health Research Institute. (2026). \textit{PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07063862}{source link}.
\item Ottawa Hospital Research Institute (2026). \textit{PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04754061}{source link}.
\item University Health Network, Toronto (2026). \textit{Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06341426}{source link}.
\item Yale University (2026). \textit{Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06624137}{source link}.
\item Paslawski Wojciech, Doyon Daniel, Ekman Carl Johan, Yngwe Hampus, Mamula Dejan, Zareba-Paslawska Justyna, Beckman Maria, Xu Zhi-Qing David, Hökfelt Tomas, Tiger Mikael, Lundberg Johan, Svenningsson Per (2026). \textit{CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder}. Neuropsychopharmacology. [published; Crossref]. \href{https://doi.org/10.1038/s41386-026-02490-3}{doi:10.1038/s41386-026-02490-3}.
\item Omar Azuara-Antonio, Erika Rubí De La Cruz-Elizaldeb, José Eduardo Carmona-Rodriguez, Lesly Idaliht Hernandez-Martinez (2026). \textit{Psilocybe Poisoning: Pathophysiology, Classification and Treatment. A Clinical Case Review}. Mexican Journal of Medical Research ICSA. [published; OpenAlex]. \href{https://doi.org/10.29057/mjmr.v14i28.16493}{doi:10.29057/mjmr.v14i28.16493}.
\item Whitfield Henry J., Schepers Jan, Mason Natasha L., Luca Maria, Kuypers Kim P. C. (2026). \textit{Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventions}. Journal of Psychedelic Studies. [published; Crossref]. \href{https://doi.org/10.1556/2054.2026.00530}{doi:10.1556/2054.2026.00530}.
\item Matthew A. Boehm, Oriana Mayorga (2026). \textit{Policy Considerations for Psychedelics in Research and Medicine - What’s Next on the Schedule?}. Journal of Science Policy \& Governance. [published; OpenAlex]. \href{https://doi.org/10.38126/jspg280103}{doi:10.38126/jspg280103}.
\item Seale M. (2026). \textit{Sexual identity as a moderator of associations between lifetime MDMA/ecstasy or psilocybin use and mental health outcomes: An exploratory analysis of a nationally representative sample using NSDUH 2015-2019}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-10208910/v1}{doi:10.21203/rs.3.rs-10208910/v1}.
\item Meyer Thomas D, Vale Lauren N, Ibrahim Maya, Olmos Carolina, Quevedo João, Soares Jair C (2026). \textit{Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study}. BMJ Open. [published; Crossref]. \href{https://doi.org/10.1136/bmjopen-2026-118471}{doi:10.1136/bmjopen-2026-118471}.
\item Hummel Haley M., Obrochta Alexia N., Kerr David C. R., Cservenka Anita (2026). \textit{Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms}. Journal of Drug Issues. [published; Crossref]. \href{https://doi.org/10.1177/00220426261466154}{doi:10.1177/00220426261466154}.
\item Smith SA, Mohammad H, Lee LHN, Dennett L, Smith S, Burback L, Winkler O, Greenshaw A, Jetly R, Kennedy SH, Bhat V, Swainson J, Vermetten E, Cao B, Li XM, Zhang Y (2026). \textit{Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-026-07110-y}{doi:10.1007/s00213-026-07110-y}.
\item Centre Hospitalier Universitaire de Nīmes (2026). \textit{Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07638553}{source link}.
\item Pasquini Lorenzo, Vohryzek Jakub, Escrichs Anira, Perl Yonatan Sanz, Ponce-Alvarez Adrian, Idesis Sebastian, Girn Manesh, Roseman Leor, Mitchell Jennifer M., Gazzaley Adam, Kringelbach Morten, Nutt David J., Lyons Taylor, Carhart-Harris Robin L., Deco Gustavo (2026). \textit{Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits}. Human Brain Mapping. [published; Crossref]. \href{https://doi.org/10.1002/hbm.70596}{doi:10.1002/hbm.70596}.
\item Sabani Astrit, Khatak Adnan (2026). \textit{Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidence}. Annals of Medicine \& Surgery. [published; Crossref]. \href{https://doi.org/10.1097/ms9.0000000000005244}{doi:10.1097/ms9.0000000000005244}.
\item Grant Jon E., Boutouis Sophia, O’Brien Margaret, Avila Laurie, Neelapu Megha, Ehsan Dustin (2026). \textit{An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder}. Clinical Neuropharmacology. [published; Crossref]. \href{https://doi.org/10.1097/wnf.0000000000000683}{doi:10.1097/wnf.0000000000000683}.
\item Junior WSC, Bezerra KS, Matias EGC, Oliveira JIN, Fulco UL (2026). \textit{MFCC-DFT mapping of ligand recognition at the 5-HT receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.}. Physical chemistry chemical physics: PCCP. [published; PubMed]. \href{https://doi.org/10.1039/d6cp00943c}{doi:10.1039/d6cp00943c}.
\item Brar PS, Price RB, Ross S, Tofighi B, Sarpal DK (2026). \textit{The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811261456191}{doi:10.1177/02698811261456191}.
\item Askey T, Lasrado R, Maiarú M, Stephens GJ (2026). \textit{Psilocybin as a novel treatment for chronic pain.}. British journal of pharmacology. [published; PubMed]. \href{https://doi.org/10.1111/bph.17420}{doi:10.1111/bph.17420}.
\item Nutt DJ, Hunt P, Schlag AK, Fitzgerald P (2026). \textit{The Australia story: Current status and future challenges for the clinical applications of psychedelics.}. British journal of pharmacology. [published; PubMed]. \href{https://doi.org/10.1111/bph.17398}{doi:10.1111/bph.17398}.
\item Sharp T, Ippolito A (2026). \textit{Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT receptor agonists.}. British journal of pharmacology. [published; PubMed]. \href{https://doi.org/10.1111/bph.70050}{doi:10.1111/bph.70050}.
\item Hoyer D (2026). \textit{Psychedelics, entactogens and psychoplastogens for depression and related disorders.}. British journal of pharmacology. [published; PubMed]. \href{https://doi.org/10.1111/bph.70088}{doi:10.1111/bph.70088}.
\item Ippolito A, Vasudevan S, Hurley S, Gilmour G, Westhorpe F, Churchill G, Sharp T (2026). \textit{Evidence that 5-HT receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.}. British journal of pharmacology. [published; PubMed]. \href{https://doi.org/10.1111/bph.70109}{doi:10.1111/bph.70109}.
\item Wittenkeller L, Gudelsky G, Winhusen TJ, Amato D (2026). \textit{Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology.}. British journal of pharmacology. [published; PubMed]. \href{https://doi.org/10.1111/bph.70181}{doi:10.1111/bph.70181}.
\item Arikci Denis, Borgulya Joran, Straumann Isabelle, Vizeli Patrick, Luethi Dino, Thomann Jan, Rudin Deborah, Vukalovic Ina, Eckert Anne, Liechti Matthias E., Holze Friederike (2026). \textit{Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants}. Neuropsychopharmacology. [published; Crossref]. \href{https://doi.org/10.1038/s41386-026-02428-9}{doi:10.1038/s41386-026-02428-9}.
\item Giri Y, Furst P, Loo CK, Clark SR, Tibrewal P (2026). \textit{Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia.}. The Australian and New Zealand journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1177/00048674261450390}{doi:10.1177/00048674261450390}.
\item Estela-Fernandez CA, Mohamed Yousif Elsheikh R, Beatrice DB, A Alhendal A, Irene Ewe C, Montesinos SY, Wensel J, Mishra AP, Yousif AA, Ali HT (2026). \textit{Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations.}. Neuropsychiatrie: Klinik, Diagnostik, Therapie und Rehabilitation: Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater. [published; PubMed]. \href{https://doi.org/10.1007/s40211-026-00584-4}{doi:10.1007/s40211-026-00584-4}.
\item Du Yingjie, Zhao Xiangting, Yao Yishan, Li Yunfeng, Wang Guyan, Zhang Liming (2026). \textit{Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex}. Journal of Psychopharmacology. [published; Crossref]. \href{https://doi.org/10.1177/02698811261453819}{doi:10.1177/02698811261453819}.
\item Dagnino PC, Acero-Pousa I, Carhart-Harris RL, Erritzoe D, Nutt DJ, Kringelbach ML, Perl YS, Deco G. (2026). \textit{Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitalopram}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.64898/2026.06.22.733731}{doi:10.64898/2026.06.22.733731}.
\item University Hospital, Basel, Switzerland (2026). \textit{Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06884514}{source link}.
\item Anthony P King (2026). \textit{A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07104916}{source link}.
\item Guidetti C, Fava M, Papakostas GI (2026). \textit{Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-026-03722-0}{doi:10.1038/s41380-026-03722-0}.
\item Łoś Aleksandra, Szkodziński Kacper, Jakubczyk Inga, Maternia Jagoda, Majowicz-Czaszyńska Karolina, Pempuś Wiktoria, Król Nikola, Tomaszek Barbara, Blok Aleksandra, Wiater Dominik, Płodzień Gabriela (2026). \textit{PSILOCYBIN IN THE TREATMENT OF DEPRESSIVE DISORDERS: CLINICAL EVIDENCE AND ITS POTENTIAL TO ADDRESS THE GLOBAL MENTAL HEALTH CRISIS - A REVIEW}. International Journal of Innovative Technologies in Social Science. [published; Crossref]. \href{https://doi.org/10.31435/ijitss.2(50).2026.5755}{doi:10.31435/ijitss.2(50).2026.5755}.
\item Mauro Pettorruso, Giacomo d’Andrea, Antonio Inserra, Clara Cavallotto, Stefano Censi, Étienne Billard, Antonio Di Stefano, Luisa De Risio, Maria Giulia Tullo, Claudio D’Addario, Giorgio Di Lorenzo, Richard G. Wise, Stefano L. Sensi, Francesca Zoratto, Giovanni Martinotti (2026). \textit{Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care}. Translational Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1038/s41398-026-04203-2}{doi:10.1038/s41398-026-04203-2}.
\item Yale University (2026). \textit{Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07449351}{source link}.
\item University Health Network, Toronto (2026). \textit{Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07048743}{source link}.
\item Seillier L, Seillier A, Zvolska MA, Šlamberová R (2026). \textit{Blocking 5-HT2B receptors abolishes psilocybin's efficacy in the rat forced swim test.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811261458349}{doi:10.1177/02698811261458349}.
\item Frick A, Blest-Hopley G, Grin M, Erritzoe D, Nutt D, Carhart-Harris R. (2026). \textit{Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9880403/v1}{doi:10.21203/rs.3.rs-9880403/v1}.
\item Berg CJ, McCready DM, LoParco CR, Schubel LC, Romm KF, Thakkar S, Williams J, Cavazos-Rehg PA, Yang YT (2026). \textit{Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2026.2685527}{doi:10.1080/02791072.2026.2685527}.
\item Bhat A, Zolali E, Sakib MA, Rahimian M, McMahon LR, German N, Obeng S (2026). \textit{Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.6c00202}{doi:10.1021/acschemneuro.6c00202}.
\item Dagnino PC, Acero-Pousa I, Zamora-López G, Escrichs A, Erritzoe D, Nutt DJ, Carhart-Harris RL, Sanz Perl Y, Kringelbach ML, Deco G. (2026). \textit{Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.64898/2026.06.12.731811}{doi:10.64898/2026.06.12.731811}.
\item SAIMSARA (2026). \textit{Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA}. SAIMSARA Journal. [published; Crossref]. \href{https://doi.org/10.62487/saimsara7a54f680}{doi:10.62487/saimsara7a54f680}.
\item Labra-Lorenzana Angel, Lima-Sánchez Dania Nimbe, Delaflor-Wagner Christian Alejandro, Martínez-Hernández Diana, Ramos-Jiménez Christian, Toledo-Lozano Christian Gabriel (2026). \textit{Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-Analysis}. Psychiatry International. [published; Crossref]. \href{https://doi.org/10.3390/psychiatryint7030137}{doi:10.3390/psychiatryint7030137}.
\item Theo Tobel, Aidan Cone, Emily M Choquette, McKenna Garland, Micah Johnson, Keller Mink, Caitlin Lynch, Joel Frohlich, Justin Feinstein, Nicco Reggente (2026). \textit{Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-REST in individuals with anxiety and depression}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/6mj8n\_v2}{source link}.
\item Raikkerus H, Bujour A, Kennedy M, Tiihonen J (2026). \textit{The effects of psychedelics on attention deficit and hyperactivity disorder - a systematic review.}. Acta neuropsychiatrica. [published; PubMed]. \href{https://doi.org/10.1017/neu.2026.10088}{doi:10.1017/neu.2026.10088}.
\item Carter D, Reardon I, Swain J, Vando L. (2026). \textit{Prolonged Grief Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 503 Adults}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9839240/v1}{doi:10.21203/rs.3.rs-9839240/v1}.
\item Kelly JR, Sheridan C, Iusan P, Coakley L, Burke L, Brennan C, MacDonald A, Ivers JH, Trepel D, Tormey G, Finnegan M, Young GW, Harkin A (2026). \textit{Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.}. The international journal of neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1093/ijnp/pyag028}{doi:10.1093/ijnp/pyag028}.
\item Pastre M., Pereira F., Gibert T., Giron A., Goemare B., Olié E., Courtet P., Lopez-Castroman J., Conejero I. (2026). \textit{One dose of Psilocybin modulates Brain Activity among Depressive patients: Preliminary Neuroimaging Results from the PSILODAC Study}. European Psychiatry. [published; Crossref]. \href{https://doi.org/10.1192/j.eurpsy.2026.10729}{doi:10.1192/j.eurpsy.2026.10729}.
\item Canady Valerie A. (2026). \textit{Psilocybin shows rapid relief for depression symptoms}. Mental Health Weekly. [published; Crossref]. \href{https://doi.org/10.1002/mhw.34890}{doi:10.1002/mhw.34890}.
\item Ziadi Yosr, Park Taehwan (2026). \textit{EE341 COST-EFFECTIVENESS OF PSILOCYBIN-ASSISTED THERAPY (PAT) FOR PATIENTS WITH TREATMENT-RESISTANT DEPRESSION}. Value in Health. [published; Crossref]. \href{https://doi.org/10.1016/j.jval.2026.03.635}{doi:10.1016/j.jval.2026.03.635}.
\item Patil Shivaputra A., Hunsberger Holly C. (2026). \textit{Psilocybin: Chemical Foundations and Emerging Therapeutic Potential}. Mini-Reviews in Medicinal Chemistry. [published; Crossref]. \href{https://doi.org/10.2174/0113895575429775260119043318}{doi:10.2174/0113895575429775260119043318}.
\item He Z, Wang Y, Chen J, Cheng J, Feng Y, Niu S, Yan J (2026). \textit{Therapeutic effects of psilocybin in major depressive disorder: a systematic review and meta-analysis exploring dose effects.}. European archives of psychiatry and clinical neuroscience. [published; PubMed]. \href{https://doi.org/10.1007/s00406-025-02165-y}{doi:10.1007/s00406-025-02165-y}.
\item Yonezawa Kengo, Hirata Mayuko, Takano Hiroaki, Kusudo Keisuke, Tomiyama Sota, Harada Lisa, Suzuki Kouta, Nutt David J., Uchida Hiroyuki, Tani Hideaki (2026). \textit{Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations}. Psychiatry and Clinical Neurosciences. [published; Crossref]. \href{https://doi.org/10.1111/pcn.70042}{doi:10.1111/pcn.70042}.
\item Sabé M, Grof P, Sackett NB, Tai S, Kryskow P, Bershad A, Turkington D, Buonarroti M, De Pieri M, Baniotopoulos P, Eskinazi M, Böge K, Leucht S, Seragnoli F, Furtado L, Brakha TA, Curtis L, Kirschner M, Kaiser S, Penzenstadler L, Zullino D, Højlund M, Gallo J, Solmi M, Sapienza J, Bosia M, La Torre J (2026). \textit{Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review.}. Schizophrenia research. [published; PubMed]. \href{https://doi.org/10.1016/j.schres.2026.03.003}{doi:10.1016/j.schres.2026.03.003}.
\item Lappan SN, Davis SD (2026). \textit{Suggested Guidelines for Applying a Systemic Lens to Psychedelic-Assisted Psychotherapy.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1177/28314425251404021}{doi:10.1177/28314425251404021}.
\item Miller CWT, Kozak Z (2026). \textit{Hallucinogen-Assisted Psychotherapy for Trauma Disorders: A Bionian Lens.}. Psychodynamic psychiatry. [published; PubMed]. \href{https://doi.org/10.1521/pdps.2026.54.2.308}{doi:10.1521/pdps.2026.54.2.308}.
\item Poppe C, Lyck L, Bechtold L, Repantis D (2026). \textit{Expectations and Motivations for Participation in Clinical Trials Utilizing Psychedelics for Treatment-Resistant Depression: A Qualitative Study.}. Brain and behavior. [published; PubMed]. \href{https://doi.org/10.1002/brb3.71544}{doi:10.1002/brb3.71544}.
\item Rosa WE, Napolitano S, McAndrew N, Jenkins B, Lichtenthal WG, Applebaum AJ, Breitbart W, Agrawal M (2026). \textit{Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1177/28314425251363983}{doi:10.1177/28314425251363983}.
\item Kaczmarek Erica S., Rodrigues Nelson B., Chisamore Noah, Doyle Zoe, Meshkat Shakila, Blainey Marc G., Brudner Ryan, Ali Shaun, Teopiz Kayla M., McIntyre Roger S., Rosenblat Joshua D. (2026). \textit{Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression}. Journal of Affective Disorders. [published; Crossref]. \href{https://doi.org/10.1016/j.jad.2026.121385}{doi:10.1016/j.jad.2026.121385}.
\item Weintraub Marc J., Jeffrey Jessica K., Ichinose Megan C., Bergman R. Lindsey, Shapiro Benjamin, Barnett Gregory, Artin Hewa, Lynn Marc, Salimian Anabel, Grody Shelby, Ramesh Rahul, Eales Lauren, Grob Charles S., Miklowitz David J. (2026). \textit{Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial}. Journal of Affective Disorders. [published; Crossref]. \href{https://doi.org/10.1016/j.jad.2026.121423}{doi:10.1016/j.jad.2026.121423}.
\item Hood Alex, Elkins Gary (2026). \textit{Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysis}. Journal of Psychedelic Studies. [published; Crossref]. \href{https://doi.org/10.1556/2054.2026.00507}{doi:10.1556/2054.2026.00507}.
\item Eskinazi M, Nasserdine R, Cusin RM, Baniotoupoulos P, Saccaro LF, De Pieri M, Corino T, Seragnoli F, Briefer JF, Aboulafia Brakha T, Richard-Lepouriel H, Penzenstadler L, Böge K, Kirchner M, Zullino D, Højlund M, Sapienza J, Bosia M, Catalan A, Vieta E, Solmi M, Sabé M (2026). \textit{Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-026-03657-6}{doi:10.1038/s41380-026-03657-6}.
\item Mertens Lea J., Betzler Felix, Brand Manuela, Evens Ricarda, Jungaberle Andrea, Jungaberle Henrik, Kärtner Laura, Majić Tomislav, Schmitz Christian N., Ströhle Andreas, Scharf Dennis, Spangemacher Moritz, Wolff Max, Assadi Zahra, Bahri Scharif, Becher Lilith, Färber Luca V., Harder Henry, Kirchen Niklas, Kulakova Eugenia, Kunz Linda C., Meijer Andy, Rohrmoser Barbara, Wellek Stefan, Berger Moritz M., Koslowski Michael, Gründer Gerhard (2026). \textit{Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial}. Psychotherapy and Psychosomatics. [published; Crossref]. \href{https://doi.org/10.1159/000552272}{doi:10.1159/000552272}.
\item Emory University (2026). \textit{The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07332143}{source link}.
\item Urban Marvin M., Zillich Lea, Rieser Nathalie M., Herdener Marcus, Spanagel Rainer, Vollenweider Franz X., Preller Katrin H., Meinhardt Marcus W. (2026). \textit{Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder}. Translational Psychiatry. [published; Crossref]. \href{https://doi.org/10.1038/s41398-026-03961-3}{doi:10.1038/s41398-026-03961-3}.
\item Laursen DRT, Salazar J, Jürgens G, Hróbjartsson A (2026). \textit{Active placebo control interventions in pharmacological trials: a scoping review of the development process and a terminological analysis.}. Journal of clinical epidemiology. [published; PubMed]. \href{https://doi.org/10.1016/j.jclinepi.2026.112345}{doi:10.1016/j.jclinepi.2026.112345}.
\item Dallas T Mason (2026). \textit{Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic Potential}. Digital Showcase Research, Scholarship, \& Creative Works (University of Lynchburg). [published; OpenAlex]. \href{https://digitalshowcase.lynchburg.edu/dmscjournal/vol8/iss1/6}{source link}.
\item Rachel N Clark (2026). \textit{The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A New and Promising Approach}. Digital Showcase Research, Scholarship, \& Creative Works (University of Lynchburg). [published; OpenAlex]. \href{https://digitalshowcase.lynchburg.edu/cgi/viewcontent.cgi?article=3694\&context=dmscjournal}{source link}.
\item Caleb Lemus (2026). \textit{Psilocybin-Assisted Therapy in the Management of Anxiety and Depression Among Cancer Patients}. Digital Showcase Research, Scholarship, \& Creative Works (University of Lynchburg). [published; OpenAlex]. \href{https://digitalshowcase.lynchburg.edu/cgi/viewcontent.cgi?article=3713\&context=dmscjournal}{source link}.
\item University of Colorado, Denver (2026). \textit{Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06230757}{source link}.
\item Washington University School of Medicine (2026). \textit{A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07582120}{source link}.
\item University of California, Los Angeles (2026). \textit{Psilocybin-assisted Cognitive Behavioral Therapy for Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05227612}{source link}.
\item Yngwe Hampus, Plavén-Sigray Pontus, Ekman Carl Johan, Henje Eva, Berglund Anders, Tiger Mikael, Beckman Maria, Lundberg Johan (2026). \textit{Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression}. JAMA Network Open. [published; Crossref]. \href{https://doi.org/10.1001/jamanetworkopen.2026.12589}{doi:10.1001/jamanetworkopen.2026.12589}.
\item Alan Davis (2026). \textit{Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07216404}{source link}.
\item University of Calgary (2026). \textit{Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06885996}{source link}.
\item Kosiarski Bartłomiej, Skrzypek Anna, Markowicz Patrycja, Zbrożek Mikołaj, Biłyk Krzysztof, Hutkowski Maciej, Chwostek Zuzanna, Maruchniak Hanna, Marzec Wiktoria, Biedroń Paulina (2026). \textit{Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybin}. Journal of Pre-Clinical and Clinical Research. [published; Crossref]. \href{https://doi.org/10.26444/jpccr/221219}{doi:10.26444/jpccr/221219}.
\item Khadija Kamene (2026). \textit{Treatment-Resistant Depression in the 21st Century: A Scoping Review of Psychedelics and Neuromodulation in Transforming Care}. Premier Journal of Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.70389/pjn.100014}{doi:10.70389/pjn.100014}.
\item Sean M. Viña (2026). \textit{Psychedelic Use and Missed Needed Mental Health Treatment: Gender Differences in Unmet Perceived Need for Care}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives5020014}{doi:10.3390/psychoactives5020014}.
\item Walters CK, Chetty S, Rants’o TA, Gossayn S, Lerotholi LJ. (2026). \textit{Safety and Efficacy of Psilocybin in the Management of Treatment-Resistant Depression: A Systematic Review}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9283280/v1}{doi:10.21203/rs.3.rs-9283280/v1}.
\item Jessie Kim, Liam Lochhead, Cory R. Weissman (2026). \textit{From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical Practice}. Pharmacology Research \& Perspectives. [published; OpenAlex]. \href{https://doi.org/10.1002/prp2.70262}{doi:10.1002/prp2.70262}.
\item University Medical Center Groningen (2026). \textit{The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06782724}{source link}.
\item Reid Matthew, Weisman Eli, Martinez Luis Luna, Coon William, Barrett Frederick (2026). \textit{1080 Psilocybin Elicits Non-Linear Night to Night Changes in Sleep Spectral Power}. SLEEPJ. [published; Crossref]. \href{https://doi.org/10.1093/sleep/zsag091.1079}{doi:10.1093/sleep/zsag091.1079}.
\item Vamvakopoulou IA, Nicholls D, Nutt DJ, Di Simplicio M (2026). \textit{Exploring new avenues: Psychedelic-assisted therapy for young people.}. British journal of clinical pharmacology. [published; PubMed]. \href{https://doi.org/10.1002/bcp.70579}{doi:10.1002/bcp.70579}.
\item Centre for Addiction and Mental Health (2026). \textit{Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05710237}{source link}.
\item Zachar Kinga, Sito Maksymilian, Jurkowski Filip, Wójcik Łukasz, Gawron Natalia, Bojanowski Hubert Tomasz, Dobracka Aleksandra, Marczak Zuzanna, Jarowicz Monika, Czmyr Jędrzej (2026). \textit{Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects - A Narrative Review}. Journal of Education, Health and Sport. [published; Crossref]. \href{https://doi.org/10.12775/jehs.2026.91.70672}{doi:10.12775/jehs.2026.91.70672}.
\item Bart A. Ellenbroek, Gernot Riedel (2026). \textit{Announcement of special issue: ‘Behavioural pharmacology of ketamine and psychedelic drugs’}. Behavioural Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.1097/fbp.0000000000000878}{doi:10.1097/fbp.0000000000000878}.
\item Sunstone Medical (2026). \textit{A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05947383}{source link}.
\item University of North Carolina, Chapel Hill (2026). \textit{Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06303739}{source link}.
\item Stanford University (2026). \textit{A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07479550}{source link}.
\item Lyons T., Spriggs M., Kerkelä L., Rosas F. E., Roseman L., Mediano P. A. M., Timmermann C., Oestreich L., Pagni B. A., Zeifman R. J., Hampshire A., Trender W., Douglass H. M., Girn M., Godfrey K., Kettner H., Sharif F., Espasiano L., Gazzaley A., Wall M. B., Erritzoe D., Nutt D. J., Carhart-Harris R. L. (2026). \textit{Human brain changes after first psilocybin use}. Nature Communications. [published; Crossref]. \href{https://doi.org/10.1038/s41467-026-71962-3}{doi:10.1038/s41467-026-71962-3}.
\item Usona Institute (2026). \textit{A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04353921}{source link}.
\item University of Washington (2026). \textit{A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07565909}{source link}.
\item University of California, Los Angeles (2026). \textit{Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07566104}{source link}.
\item Sayali Ceyda, Weisman Eli, Barrett Frederick (2026). \textit{Effects of Psilocybin Treatment on Cognitive Effort Avoidance in Major Depressive Disorder and Co-Occurring Alcohol Use Disorder}. JoCN Forum. [published; Crossref]. \href{https://doi.org/10.21428/8e6ba8ef.31e358f9}{doi:10.21428/8e6ba8ef.31e358f9}.
\item Lakshmi N Yatham (2026). \textit{Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06943573}{source link}.
\item Poulin Joshua, Viulet Nic, Liu Ashley, MacIntosh Bradley J., Nestor Sean M. (2026). \textit{483. Acute Functional Brain Changes Associated With Psilocybin in Depression and Healthy Adults: A Systematic Review and Coordinate-Based Meta-Analysis}. Biological Psychiatry. [published; Crossref]. \href{https://doi.org/10.1016/j.biopsych.2026.03.717}{doi:10.1016/j.biopsych.2026.03.717}.
\item Greenway KT, Garel N, Dinh-Williams LL, Thibault Lévesque J, Kaelen M, Dagenais-Beaulé V, de la Salle S, Erritzoe D, Looper K, Turecki G, Rej S, Richard-Devantoy S (2026). \textit{The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression.}. The British journal of psychiatry: the journal of mental science. [published; PubMed]. \href{https://doi.org/10.1192/bjp.2025.102}{doi:10.1192/bjp.2025.102}.
\item Viljoen G, Walter H, Bendau A, Koslowski M, Betzler F (2026). \textit{Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251389581}{doi:10.1177/02698811251389581}.
\item Garcia Garcia M, Belahda D, Graux C, Serrand C, Igounenc N, Sergent F, Mura T, Luquiens A (2026). \textit{Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2026.121215}{doi:10.1016/j.jad.2026.121215}.
\item Domi Ana, Lucente Erika, Cadeddu Davide, Bengtsson Niklas, Smedler Erik, Adermark Louise (2026). \textit{Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms}. Neuropharmacology. [published; Crossref]. \href{https://doi.org/10.1016/j.neuropharm.2026.110854}{doi:10.1016/j.neuropharm.2026.110854}.
\item Lewis BR, Reid MJ, Novick AM, Byrne K, Niciu MJ, Fonzo GA, Meyer TD, Feifel D, El-Mallakh RS, Soares J, Suppes T, Barrett FS (2026). \textit{Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251413490}{doi:10.1177/02698811251413490}.
\item Goldy SP, Sepeda ND, Hilbert SN, Bari BA, Garcia-Romeu A, Gukasyan N, Barrett FS, Yaden DB, Nayak SM (2026). \textit{Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2026.117010}{doi:10.1016/j.psychres.2026.117010}.
\item Mertens Lea J., Koslowski Michael, Betzler Felix, Brand Manuela, Evens Ricarda, Kärtner Laura, Jungaberle Andrea, Jungaberle Henrik, Majić Tomislav, Schmitz Christian N., Ströhle Andreas, Scharf Dennis, Spangemacher Moritz, Wolff Max, Assadi Zahra, Bahri Scharif, Becher Lilith, Färber Luca V., Kirchen Niklas, Kulakova Eugenia, Kunz Linda, Meijer Andy, Rohrmoser Barbara, Wellek Stefan, Berger Moritz M., Gründer Gerhard (2026). \textit{Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression}. JAMA Psychiatry. [published; Crossref]. \href{https://doi.org/10.1001/jamapsychiatry.2026.0132}{doi:10.1001/jamapsychiatry.2026.0132}.
\item O'Mahony B, Harrington C, Harkin A, Lally N (2026). \textit{Trip killers: Addressing a critical knowledge gap in psychedelic research.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811261431056}{doi:10.1177/02698811261431056}.
\item Simonsson O, Lyons T, Marks J, Kettner H, Roseman L, Haijen E, Kaelen M, Carhart-Harris R (2026). \textit{Effects of psychedelic use on authoritarian attitudes revisited.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811261443677}{doi:10.1177/02698811261443677}.
\item Hajivalizadeh S, Farahmand K, Kazemzadeh K, Hajivalizadeh G, Shamabadi A (2026). \textit{Pharmacotherapeutic Management of Depression in Patients With Cancer: A Review of Mechanistic and Clinical Evidence.}. Cancer reports (Hoboken, N.J.). [published; PubMed]. \href{https://doi.org/10.1002/cnr2.70587}{doi:10.1002/cnr2.70587}.
\item Beidas Zeina, Ragnhildstveit Anya, Blackman Adam, Anderson Thomas, Fewster Emily, Syed Omer A., Sobolenko Valentyne, Kanca Ismail Kaan, Son Tatiana, Farb Norman, Petranker Rotem (2026). \textit{Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM}. BJPsych Open. [published; Crossref]. \href{https://doi.org/10.1192/bjo.2026.12000}{doi:10.1192/bjo.2026.12000}.
\item University Hospital, Basel, Switzerland (2026). \textit{Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05883540}{source link}.
\item Joshua Woolley, MD, PhD (2026). \textit{A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back Pain}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05351541}{source link}.
\item Magnani L, Ghirotto L, Fesce F, Re T, Tanzi S, Amerio A, Costanza A (2026). \textit{Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review.}. BMJ supportive \& palliative care. [published; PubMed]. \href{https://doi.org/10.1136/spcare-2025-005689}{doi:10.1136/spcare-2025-005689}.
\item Wang H, Li X, Yu F, Wang X (2026). \textit{The Harmonious Dance: A Narrative Review on Psychedelics and Music in Therapeutic Settings.}. Current neuropharmacology. [published; PubMed]. \href{https://doi.org/10.2174/011570159x442471260422110855}{doi:10.2174/011570159x442471260422110855}.
\item Usona Institute (2026). \textit{A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03866174}{source link}.
\item Kyle Greenway (2026). \textit{Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07373535}{source link}.
\item Cahuasqui-Mendoza Deivid Antonio (2026). \textit{Psilocybin as an alternative to conventional treatments: A systematic review}. Gaceta Médica de Caracas. [published; Crossref]. \href{https://doi.org/10.47307/gmc.2026.134.s2.32}{doi:10.47307/gmc.2026.134.s2.32}.
\item University of Colorado, Denver (2026). \textit{Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06430541}{source link}.
\item Khosravi Mohsen, De Berardis Domenico, Tusconi Massimo (2026). \textit{The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes}. Mental Wellness. [published; Crossref]. \href{https://doi.org/10.4081/mw.2026.40}{doi:10.4081/mw.2026.40}.
\item Siti Nashria Rusdhy, Andrian Fajar Kusumadewi, Carla Raymondalexas Marchira, Mustika Suci Mahardikaningrum, Teresa Lalita Wiryarini, Devira Ayu Wulandari (2026). \textit{Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials}. Open Access Indonesian Journal of Medical Reviews. [published; Crossref]. \href{https://doi.org/10.37275/oaijmr.v6i2.883}{doi:10.37275/oaijmr.v6i2.883}.
\item Vipul Janardan, Amit Khanna, Om Prakash, Anadrika Debbarma, SK Mathur (2026). \textit{Psychedelics: Historical Context, Emerging Science, and Future Clinical Frontiers}. Journal of Mental Health Disorders. [published; OpenAlex]. \href{https://doi.org/10.33696/mentalhealth.6.068}{doi:10.33696/mentalhealth.6.068}.
\item Gondi CS, Gnanamony M, Gondi TP, Nersesyan L, Demirkhanyan L (2026). \textit{Psychedelics and Autism Therapy: A Review of Current Research and Future Directions.}. Current issues in molecular biology. [published; PubMed]. \href{https://doi.org/10.3390/cimb48040417}{doi:10.3390/cimb48040417}.
\item Davoudian PA, Jiang Q, Knox CA, Savalia NK, Shao LX, Wilson J, Weiner AM, Chong CW, Liao C, Nothnagel JD, Sakurai T, Kwan AC (2026). \textit{Psilocybin reshapes cortical inhibition through selective interneuron recruitment.}. bioRxiv: the preprint server for biology. [published; PubMed]. \href{https://doi.org/10.64898/2026.04.16.718963}{doi:10.64898/2026.04.16.718963}.
\item Jóźwiak-Bębenista M, Stasiak A, Sienkiewicz M, Kwiatkowski P, Kowalczyk E. (2026). \textit{Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration}. Preprints.org. [preprint; Europe PMC]. \href{https://doi.org/10.20944/preprints202604.1125.v1}{doi:10.20944/preprints202604.1125.v1}.
\item Back Anthony L., McGregor Bonnie A., Thorn Leslie L., Harvey Kalin, Blom Dianna, Callan George, Guy John, Kumar Sameet, Hershberg Rob, Layer Melissa, Levin Jackie, Myers Susanna, Perez Juliana, Salmonson Kathy, Thompson Peter, Whinney Joseph (2026). \textit{A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience}. Frontiers in Public Health. [published; Crossref]. \href{https://doi.org/10.3389/fpubh.2026.1810904}{doi:10.3389/fpubh.2026.1810904}.
\item Section for Affective Disorders; Northern Stockholm Psychiatry (2026). \textit{CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06319378}{source link}.
\item Veysi A, Atanasovski D, Ardalan M, Motamed N, Eriksson E (2026). \textit{Psilocybin elicits a conserved glucocorticoid-responsive gene signature across five 5-HT2A receptor-rich brain regions in rat.}. Acta neuropsychiatrica. [published; PubMed]. \href{https://doi.org/10.1017/neu.2026.10075}{doi:10.1017/neu.2026.10075}.
\item Nikita Sanati Morel, Dea Siggaard Stenbaek, Johan Lundberg, Maria Beckman (2026). \textit{Additional file 1 of Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression}. Figshare. [published; OpenAlex]. \href{https://doi.org/10.6084/m9.figshare.32048850}{doi:10.6084/m9.figshare.32048850}.
\item Morel Nikita Sanati, Stenbaek Dea Siggaard, Lundberg Johan, Beckman Maria (2026). \textit{Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression}. BMC Medical Education. [published; Crossref]. \href{https://doi.org/10.1186/s12909-026-09124-8}{doi:10.1186/s12909-026-09124-8}.
\item Gallardo LM. (2026). \textit{Altered States of Consciousness and the Subconscious Mind: A Comprehensive Comparative Review of Disciplines, Neurobiological Mechanisms, Clinical Applications, and Philosophical Frameworks - Including Life Between Lives and Transpersonal Hypnotherapy}. Preprints.org. [preprint; Europe PMC]. \href{https://doi.org/10.20944/preprints202604.0415.v1}{doi:10.20944/preprints202604.0415.v1}.
\item Singleton S. Parker, Sevchik Brooke L., Lahey Analiese, Cuijpers Pim, Harrer Mathias, Jones Megan T., Nayak Sandeep M., Strain Eric C., Vandekar Simon N., Dworkin Robert H., Scott J. Cobb, Satterthwaite Theodore D. (2026). \textit{A living systematic review, meta-analysis and open-data resource of randomized controlled trials of psilocybin treatment for symptoms of depression}. Nature Mental Health. [published; Crossref]. \href{https://doi.org/10.1038/s44220-026-00630-8}{doi:10.1038/s44220-026-00630-8}.
\item Johns Hopkins University (2026). \textit{Effects of Psilocybin in Obsessive Compulsive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05546658}{source link}.
\item Richmond Linda M. (2026). \textit{MedCheck: FDA Approves Novel Antipsychotic Milsaperidone; Designates Psilocybin Analogue as Breakthrough Therapy for Postpartum Depression, and More!}. Psychiatric News. [published; Crossref]. \href{https://doi.org/10.1176/appi.pn.2026.04.4.3}{doi:10.1176/appi.pn.2026.04.4.3}.
\item Teopiz KM, Le GH, Wong S, McIntyre RS (2026). \textit{The effect of dextromethorphan on reward-related behaviors: A systematic review of preclinical and clinical evidence.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2025.120836}{doi:10.1016/j.jad.2025.120836}.
\item Syed Omer A., Tsang Benjamin, Nestor Sean M., Lipsman Nir, Husain Muhammad Ishrat, Alam Fahad, Giacobbe Peter (2026). \textit{Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis}. Neuroscience \& Biobehavioral Reviews. [published; Crossref]. \href{https://doi.org/10.1016/j.neubiorev.2026.106573}{doi:10.1016/j.neubiorev.2026.106573}.
\item Downar J, Lapenskie J, Anderson K, Parsons G, Polskaia N, Lalumiere G, Lawlor P (2026). \textit{PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial.}. Palliative medicine. [published; PubMed]. \href{https://doi.org/10.1177/02692163261416269}{doi:10.1177/02692163261416269}.
\item Kazdan J, Ladha KS, Husain MI (2026). \textit{Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action.}. Pharmacology research \& perspectives. [published; PubMed]. \href{https://doi.org/10.1002/prp2.70238}{doi:10.1002/prp2.70238}.
\item Marazziti D, Gambini M, Gurrieri R, Russomanno G, Sità G, Pescini E, Digiuseppe FR, Mucci F (2026). \textit{Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations.}. Expert opinion on pharmacotherapy. [published; PubMed]. \href{https://doi.org/10.1080/14656566.2026.2654682}{doi:10.1080/14656566.2026.2654682}.
\item Kenji Hashimoto, Feyza Arıcıoğlu, Mesut Çetin (2026). \textit{Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric Disorders}. Psychiatry and Clinical Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.65801/pcp.3512}{doi:10.65801/pcp.3512}.
\item Sunnybrook Health Sciences Centre (2026). \textit{Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06072898}{source link}.
\item Indiana University (2026). \textit{Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07499583}{source link}.
\item Max Wolff, Samuli Kangaslampi, Richard J. Zeifman, Moritz Spangemacher (2026). \textit{Strong alliance, weak conclusions: Comment on Goodwin et al. (2026) “The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression”}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/8s7xk\_v1}{source link}.
\item Smith Katharine A., Harcourt Edward, Cipriani Andrea (2026). \textit{Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin}. The British Journal of Psychiatry. [published; Crossref]. \href{https://doi.org/10.1192/bjp.2026.10612}{doi:10.1192/bjp.2026.10612}.
\item Catchlove SJ, Oliver K, Savic M, Arunogiri S (2026). \textit{Unlocking 'stuckness' and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic-assisted therapy for substance use and mental health problems.}. Addiction (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1111/add.70403}{doi:10.1111/add.70403}.
\item Federal University of Latin American Integration (2026). \textit{Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06898606}{source link}.
\item Schmidt Malin, Hoffrichter Anne, Davoudi Mahnaz, Horschitz Sandra, Lau Thorsten, Meinhardt Marcus W, Spanagel Rainer, Ladewig Julia, Köhr Georg, Koch Philipp (2026). \textit{Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons}. eLife. [published; Crossref]. \href{https://doi.org/10.7554/elife.104006}{doi:10.7554/elife.104006}.
\item Aly Shah Aziz (2026). \textit{Classic psychedelic medicines for adolescent refractory mental health disease}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2026.00452}{doi:10.1556/2054.2026.00452}.
\item Skalski Piotr, Pękacka-Falkowska Katarzyna, Pluto-Prądzyńska Agnieszka, Owecki Michał K. (2026). \textit{Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD)}. Brain Sciences. [published; Crossref]. \href{https://doi.org/10.3390/brainsci16040358}{doi:10.3390/brainsci16040358}.
\item Medical University of Vienna (2026). \textit{Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07490353}{source link}.
\item Nößler Denis (2026). \textit{Psilocybin, Lp(a), CAC, Niere und Darmkrebs - Evidenz-Quickies KW12}. EvidenzUpdate. [published; Crossref]. \href{https://doi.org/10.69156/quick/2026.03.00011}{doi:10.69156/quick/2026.03.00011}.
\item University of New Mexico (2026). \textit{Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07484906}{source link}.
\item Portes MAM, Bertoglio LJ (2026). \textit{Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2026.2644865}{doi:10.1080/02791072.2026.2644865}.
\item Komarczewska Anna, Kociński Michał, Iglewski Patryk, Pietrasz Michał, Idziński Jakub, Lubomska Anna (2026). \textit{PSILOCYBIN AS AN ADJUNCTIVE TREATMENT FOR DEPRESSION AND PSYCHOLOGICAL DISTRESS IN ONCOLOGY: CURRENT EVIDENCE AND CLINICAL IMPLICATIONS}. International Journal of Innovative Technologies in Social Science. [published; Crossref]. \href{https://doi.org/10.31435/ijitss.1(49).2026.5034}{doi:10.31435/ijitss.1(49).2026.5034}.
\item Farré-Colomés Àlvar, Rublinetska Olga, Soto-Angona Óscar (2026). \textit{Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies}. Discover Mental Health. [published; Crossref]. \href{https://doi.org/10.1007/s44192-026-00384-w}{doi:10.1007/s44192-026-00384-w}.
\item Gustavo Vazquez (2026). \textit{Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06818994}{source link}.
\item Georgia Chlebek (2026). \textit{Hallucinogens for Mood and Anxiety Disorders: A Critical Review of Psychedelic-Assisted Therapies}. ThinkIR: The University of Louisville's Institutional Repository (University of Louisville). [published; OpenAlex]. \href{https://ir.library.louisville.edu/tce/vol3/iss1/11}{source link}.
\item Johns Hopkins University (2026). \textit{Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04123314}{source link}.
\item Sungheetha Akey, Rajesh Sharma R., Aroba Oluwasegun Julius, Mahapatra Sheila, Mahendhiran P. D. (2026). \textit{Explainable AI framework for psilocybin depression treatment optimization}. Frontiers in Computer Science. [published; Crossref]. \href{https://doi.org/10.3389/fcomp.2025.1652190}{doi:10.3389/fcomp.2025.1652190}.
\item Alessandra Linardi, Ariadiny Lima Caetano, Rodrigo Portes Ureshino (2026). \textit{Editorial: Psychedelic substances and neurological diseases: from basics to clinical application}. Frontiers in Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.3389/fphar.2026.1816812}{doi:10.3389/fphar.2026.1816812}.
\item Johns Hopkins University (2026). \textit{Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04620759}{source link}.
\item Crocq MA, Auby P (2026). \textit{The renaissance of research on psychedelics in child and adolescent psychopharmacology.}. Child and adolescent psychiatry and mental health. [published; PubMed]. \href{https://doi.org/10.1186/s13034-026-01069-6}{doi:10.1186/s13034-026-01069-6}.
\item Yale University (2026). \textit{Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06442423}{source link}.
\item Chauhan SB, Akhtar N, Jain C, Singh I (2026). \textit{Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.}. CNS \& neurological disorders drug targets. [published; PubMed]. \href{https://doi.org/10.2174/0118715273434237251212095005}{doi:10.2174/0118715273434237251212095005}.
\item Gregorio GD, Basset S, Manmohan H, Nixon WC, Pogaku A, Zhou J, Sanderson DJ, Lengieza ML, Bocchio M. (2026). \textit{Age moderates the relationship between psychedelics use and mental health in naturalistic settings}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9022170/v1}{doi:10.21203/rs.3.rs-9022170/v1}.
\item Fabiano N, Stubbs B, Lawrence DW, Rosenblat JD, Teixeira PJ, Wong S, Zhou C, Carhart-Harris R (2026). \textit{The combination of exercise and psychedelics for the treatment of major depressive disorder.}. Discover mental health. [published; PubMed]. \href{https://doi.org/10.1007/s44192-026-00408-5}{doi:10.1007/s44192-026-00408-5}.
\item Claydon MDB, Hinchcliffe JK, Bartlett J, Golden CT, Thomas CW, Gilmour G, Mellor JR, Bortolotto ZA, Robinson ESJ. (2026). \textit{Inhibition of cortico-amygdala projections underlies affective bias modification by psilocybin}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.64898/2026.03.02.709133}{doi:10.64898/2026.03.02.709133}.
\item Psyence Australia Pty Ltd (2026). \textit{A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07072728}{source link}.
\item Zeinab Asghari, Gregory Robinson, Marta Gerasymchuk, Esmaeel Ghasemi Gojani, Timur Zanikov, Yasaman Rastamian, Olga Kovalchuk, Igor Kovalchuk* (2026). \textit{THE EFFECT OF PSILOCYBIN AND EUGENOL ON LIPOPOLYSACCHARIDE INDUCED INFLAMMATION IN SMALL AND LARGE INTESTINE OF MICE}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.18796594}{doi:10.5281/zenodo.18796594}.
\item Jorgenson DM, Santos Leon E, Vakkalanka JP, Krispin S, Radke JB (2026). \textit{Psychoactive mushroom edibles: trends and toxicities reported to the United States National Poison Data System®, 2023-2024.}. Clinical toxicology (Philadelphia, Pa.). [published; PubMed]. \href{https://doi.org/10.1080/15563650.2025.2599402}{doi:10.1080/15563650.2025.2599402}.
\item Rached G, Campana A, Fiani D, Nguyen C, Van den Eynde V, Gillman PK, Barnett BS (2026). \textit{Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data.}. CNS drugs. [published; PubMed]. \href{https://doi.org/10.1007/s40263-025-01256-7}{doi:10.1007/s40263-025-01256-7}.
\item Doyle Zoe, Chisamore Noah, Kaczmarek Erica S., Johnson Danica E., Brudner Ryan M., Weiglein Geneva, Blainey Marc G., Bawks Jordan, Riva-Cambrin Jeremy, Sethi Rickinder, McIntyre Roger S., Rosenblat Joshua D. (2026). \textit{Early response to psilocybin in adults with treatment-resistant depression as a predictor for antidepressant efficacy}. General Hospital Psychiatry. [published; Crossref]. \href{https://doi.org/10.1016/j.genhosppsych.2026.01.001}{doi:10.1016/j.genhosppsych.2026.01.001}.
\item Girault N, Quiroga L, Jedrecy S, Bertin S, Djonouma N, Fossati P (2026). \textit{[Perspectives opened up by the physiopathological understanding of psychiatric disorders].}. La Revue du praticien. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/41878960/}{source link}.
\item Khan Faheem Ahmed, Pandupuspitasari Nuruliarizki Shinta, Tencomnao Tewin, Chuchawankul Siriporn (2026). \textit{Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy}. Journal of Affective Disorders. [published; Crossref]. \href{https://doi.org/10.1016/j.jad.2025.120882}{doi:10.1016/j.jad.2025.120882}.
\item Ziadi Yosr, Park Taehwan (2026). \textit{Cost-Effectiveness of Psilocybin-Assisted Therapy Versus Standard of Care for Patients With Treatment-Resistant Depression}. Value in Health Regional Issues. [published; Crossref]. \href{https://doi.org/10.1016/j.vhri.2026.101605}{doi:10.1016/j.vhri.2026.101605}.
\item Ana Deutsch, Luis E. Contreras, Sarah Kratina, Leah M. Mayo (2026). \textit{A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations}. Therapeutic Advances in Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/20451253261433836}{doi:10.1177/20451253261433836}.
\item Zhang J, Lin C, Lv X, Zhao H, Wang X (2026). \textit{Psychedelics and the Extracellular Matrix: Rewiring Neuroplasticity and Metaplasticity for Next-Generation Psychiatric Therapies.}. Biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.biopsych.2026.02.011}{doi:10.1016/j.biopsych.2026.02.011}.
\item C Faria, Diana Dias da Silva, João José Sousa (2026). \textit{Psilocybin-assisted therapy for major depressive disorder: implications for clinical effectiveness, health economics, and regulatory decision-making}. Instituto Politécnico do Porto. [published; OpenAlex]. \href{https://doi.org/10.26537/prpaeh.v4i3.7173}{doi:10.26537/prpaeh.v4i3.7173}.
\item Beaussant Y, Sager Z, Brennan C, Kristan I, Ljuslin M, Mazzola E, Macdonald D, Murphy ME, Nigam K, Rinaldi AD, Sanders J, Schaefer KG, Sholevar R, Summer L, Waliji-Banglawala A, Yudilevich-Espinoza S, Tulsky JA (2026). \textit{Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy.}. BMJ supportive \& palliative care. [published; PubMed]. \href{https://doi.org/10.1136/spcare-2025-005773}{doi:10.1136/spcare-2025-005773}.
\item Gearin A, Docherty J, Sun X, Cheung EH, Tanuseputro P (2026). \textit{Psychedelic therapy and cultural humility.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-026-03913-x}{doi:10.1038/s41398-026-03913-x}.
\item Petranker R, Farb N, Syed O, Li E, Shore D, Anderson T, Blackman A. (2026). \textit{Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-8319478/v1}{doi:10.21203/rs.3.rs-8319478/v1}.
\item Jacobs E, Zahid Z, Hinkle J, Nayak S, Yaden DB (2026). \textit{Psychedelic medicine: mechanisms, evidence, and translation to practice.}. BMJ (Clinical research ed.). [published; PubMed]. \href{https://doi.org/10.1136/bmj-2024-081723}{doi:10.1136/bmj-2024-081723}.
\item Jordan McDowell, Jada Middleton, Alanna Bluett, Alisa Kozachenko, Bayan Attar, Yuvraj Singh Saini, Jennifer Burke, Cayden McPhee, Mutahera Mutahera, Talya Ahmed, Nabila Ibrahim, Gilbert Atukwatsibwe, Sulabha Adhikari, Mohammad Esmaili, Jean-Vital Yambayamba (2026). \textit{Effects of Psilocybin and Select Pharmaceutical Interactions}. MacEwan University Student eJournal. [published; OpenAlex]. \href{https://doi.org/10.31542/bcek6t76}{doi:10.31542/bcek6t76}.
\item Khan Z, Weaver S, Dando RV, Schlag AK, Neill JC, Wainwright V (2026). \textit{Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis.}. Qualitative health research. [published; PubMed]. \href{https://doi.org/10.1177/10497323261419338}{doi:10.1177/10497323261419338}.
\item Yvan Beaussant, MD, MSci (2026). \textit{Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04950608}{source link}.
\item Beidas Z, Ragnhildstveit A, Blackman A, Anderson T, Fewster E, Syed OA, Sobolenko V, Kanca IK, Jaglinska M, Son T, Farb N, Petranker R (2026). \textit{Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial.}. BJPsych open. [published; PubMed]. \href{https://doi.org/10.1192/bjo.2025.10968}{doi:10.1192/bjo.2025.10968}.
\item MycoMedica Life Sciences PBC (2026). \textit{A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07050368}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07405606}{source link}.
\item University of California, Los Angeles (2026). \textit{Psilocybin-Assisted Cognitive Behavioral Therapy for Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07281352}{source link}.
\item Matthew Hicks, Olivia Hicks, Ryan Bradley, Heather Zwickey (2026). \textit{Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2026.00485}{doi:10.1556/2054.2026.00485}.
\item Johnston J, Jones G, Peng S, Yuan P, Yavi M, Kadriu B, Henter I, Quintanilla B, Elkahloun AG, Moaddel R, Schulmann A, Akula N, Kvarta M, McMahon F, Zarate C (2026). \textit{Time-Dependent Effects of Rapid-Acting Antidepressants in iPSC-Derived Neurons from Treatment-Resistant Depression and Healthy Volunteers.}. Research square. [published; PubMed]. \href{https://doi.org/10.21203/rs.3.rs-8733841/v1}{doi:10.21203/rs.3.rs-8733841/v1}.
\item Sarah Shnayder, Gabrielle Agin-Liebes, Troy Hubert, Terence Ching, Jamila Hokanson, Christopher Pittenger, Benjamin Kelmendi, Thomas Adams (2026). \textit{Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/d94hb\_v1}{source link}.
\item Blake Beaton (2026). \textit{Exploring a Decade of Microdosing Research: A Qualitative Meta-synthesis of Microdosing Literature}. Deviant Behavior. [published; OpenAlex]. \href{https://doi.org/10.1080/01639625.2026.2624690}{doi:10.1080/01639625.2026.2624690}.
\item Zen Revista (2026). \textit{Activity-Dependent Neural Rewiring by Psilocybin: A Monosynaptic Rabies Virus Tracing Study}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.18501514}{doi:10.5281/zenodo.18501514}.
\item Hadassah Medical Organization (2026). \textit{Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07079930}{source link}.
\item TRYP Therapeutics (2026). \textit{A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06206265}{source link}.
\item Liu Junhong, Wang Yuanyuan, Xia Ke, Wu Jinfeng, Zheng Danhao, Cai Aoling, Yan Haitao, Su Ruibin (2026). \textit{Acute psilocin increased cortical activity in rat}. Frontiers in Neuroscience. [published; Crossref]. \href{https://doi.org/10.3389/fnins.2026.1593703}{doi:10.3389/fnins.2026.1593703}.
\item Sheida Shadani, Erika Greaves, Zane B. Andrews, Claire J. Foldi (2026). \textit{Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexia}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp026a.0003}{doi:10.61373/pp026a.0003}.
\item Thomas Müller (2026). \textit{Psilocybin wirkt bei therapieresistenter Depression}. DNP - Die Neurologie \& Psychiatrie. [published; OpenAlex]. \href{https://doi.org/10.1007/s15202-025-6636-1}{doi:10.1007/s15202-025-6636-1}.
\item Jorge Encantado, Laura C. Carvalho, Pedro Mota, Catarina Cunha, Albert Garcia-Romeu, Matthew W. Johnson, Pedro J. Teixeira (2026). \textit{Attitudes and perceptions of Portuguese mental health professionals on the therapeutic use of psilocybin and methylenedioxymethamphetamine (MDMA).}. Professional Psychology Research and Practice. [published; OpenAlex]. \href{https://doi.org/10.1037/pro0000664}{doi:10.1037/pro0000664}.
\item Gründer G, Mertens LJ, Jungaberle A, Jungaberle H, Spangemacher M (2026). \textit{Compassionate use of psilocybin for treatment-resistant depression in Germany.}. The lancet. Psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/s2215-0366(25)00277-9}{doi:10.1016/s2215-0366(25)00277-9}.
\item Swainson J, Brietzke E, Khullar A, McIntyre RS, Soares CN (2026). \textit{Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models.}. Canadian journal of psychiatry. Revue canadienne de psychiatrie. [published; PubMed]. \href{https://doi.org/10.1177/07067437251389090}{doi:10.1177/07067437251389090}.
\item Do A, Cloutier L, Hébert-Tremblay L, Thauvin C (2026). \textit{Psilocybin use in bipolar disorder: A comprehensive review.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2025.120485}{doi:10.1016/j.jad.2025.120485}.
\item Wolff M, Kangaslampi S (2026). \textit{Pharmacodynamic biomarker - or psychotherapeutic process? Comment on "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression".}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2025.120637}{doi:10.1016/j.jad.2025.120637}.
\item Ansari M, Elliott SI, Holmes SE, Sanacora G (2026). \textit{Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance.}. Neurologic clinics. [published; PubMed]. \href{https://doi.org/10.1016/j.ncl.2025.08.009}{doi:10.1016/j.ncl.2025.08.009}.
\item Dutton M, Schwenn P, Mitchell J, Hoffmann P, Bailey NW, Fitzgerald PB, Lagopoulos J, Can AT (2026). \textit{Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia's clinical landscape.}. The Australian and New Zealand journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1177/00048674251398677}{doi:10.1177/00048674251398677}.
\item Vollebregt R, Storm AEM, Lucassen PJ, Somers M (2026). \textit{Psychedelic experiences elicited by serotonergic psychedelics: Molecular mechanisms and functional connectivity changes in the brain.}. Neuroscience and biobehavioral reviews. [published; PubMed]. \href{https://doi.org/10.1016/j.neubiorev.2025.106529}{doi:10.1016/j.neubiorev.2025.106529}.
\item Marques MG, Patarroyo-Rodriguez L, Singh B (2026). \textit{Psilocybin and Bipolar Depression: Promise and Prudence.}. CNS drugs. [published; PubMed]. \href{https://doi.org/10.1007/s40263-025-01255-8}{doi:10.1007/s40263-025-01255-8}.
\item Haghdoost F, Bahceci D, Delcourt C, Wijeratne T, Jensen RH, Cincinnato C, Tomlinson S, Wold B, Polito V, Carcel C, Ashraf U, Jenkins B, Petersen AS, Ray JC, Schindler EAD, Tsang B, Gianacas C, Rodgers A (2026). \textit{Patient perspectives on research gaps in cluster headache.}. Headache. [published; PubMed]. \href{https://doi.org/10.1111/head.70031}{doi:10.1111/head.70031}.
\item Halm S (2026). \textit{Psychedelic- and Substance-Assisted Therapies in Global Mental Health: Bridging Cultures, Evidence, and Access.}. Brain and behavior. [published; PubMed]. \href{https://doi.org/10.1002/brb3.71265}{doi:10.1002/brb3.71265}.
\item Kala K, Bederska-Lojewska D, Lazur J, Gasior K, Maslanka A, Szewczyk A, Sulkowska-Ziaja K, Turek J, Szewczyk B, Pilc A, Muszynska B (2026). \textit{Bioactive compounds from Psilocybe cubensis mycelial cultures with transient anxiolytic effects in mice.}. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society. [published; PubMed]. \href{https://doi.org/10.26402/jpp.2026.1.07}{doi:10.26402/jpp.2026.1.07}.
\item McNaughton N, Shadli SM, Beaglehole B, Glue P (2026). \textit{Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.}. Journal of the Royal Society of New Zealand. [published; PubMed]. \href{https://doi.org/10.1002/snz2.70002}{doi:10.1002/snz2.70002}.
\item Anna Maria Komarczewska, Filip Matusiak, Klaudia Brzoza, Michał Kociński, Patryk Iglewski, Michał Pietrasz (2026). \textit{Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects}. Quality in Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/qs.2026.51.68216}{doi:10.12775/qs.2026.51.68216}.
\item Aditi Kanwar, Nitin Jeengar, Pramod Kumar Ashaiya (2026). \textit{Protecting patient autonomy in psychedelic-assisted psychotherapy: a nursing ethics perspective}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.18425838}{doi:10.5281/zenodo.18425838}.
\item H. Knegtering, Thalia Herder, Nynke Boonstra, S. K. Spoelstra (2026). \textit{Psychedelic research and sexuality: opportunities and pitfalls}. The Journal of Sexual Medicine. [published; OpenAlex]. \href{https://doi.org/10.1093/jsxmed/qdag025}{doi:10.1093/jsxmed/qdag025}.
\item Łukasz Deska, Cezary Kosmecki, Dawid Głaz, Natalia Kamińska, Wojciech Sołtys, Magdalena Stolarczyk, Maksymilian Głaz, Mateusz Stronczyński, Aleksandra Jagura-Sukiennik, Julia Wawerska (2026). \textit{PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.1(49).2026.4711}{doi:10.31435/ijitss.1(49).2026.4711}.
\item Adam Wolski, Ewa Szplit, Mikołaj Franciszek Patalong, Roman Cemaga, Mateusz Kubicki, Przemysław Kołodziej, Natalia Bruska, Bartłomiej Błaszkowski, Andrii Bilyk, Katarzyna Więckowska (2026). \textit{Psychedelics in psychiatric treatment: a literature review}. Quality in Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/qs.2026.50.68013}{doi:10.12775/qs.2026.50.68013}.
\item Fernando Mora López, Johynny Solís Solís, Ekaterina Daniela Hernández Baker, Olger Herrera Barboza, David Diaz Polo, Daniela Consumi Cordero (2026). \textit{The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.18375715}{doi:10.5281/zenodo.18375715}.
\item Rishika Scott, James Smith (2026). \textit{The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression}. Emerging Minds Journal for Student Research. [published; OpenAlex]. \href{https://doi.org/10.59973/emjsr.317}{doi:10.59973/emjsr.317}.
\item Tripdatabase (2026). \textit{Does psilocybin help with mental health conditions?}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.18339283}{doi:10.5281/zenodo.18339283}.
\item Jakub Klepacz, Radosław Swędrak, Marzena Swojnóg, Zuzanna Dobrakowska (2026). \textit{THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.1(49).2026.4582}{doi:10.31435/ijitss.1(49).2026.4582}.
\item Florineth, Gianluca Andri, Klima, Isabell, Boeker, Anna Laura, Catzeflis, Polina, Wopfner, Alexander, Denier, Niklaus, Bracht, Tobias, Adorjan, Kristina, Pfammatter, Mario, Müller, Felix, Soravia, Leila Maria (2026). \textit{Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.}. Open Access CRIS of the University of Bern. [published; OpenAlex]. \href{https://doi.org/10.48620/94398}{doi:10.48620/94398}.
\item Xia K, Gao T (2026). \textit{[Clinical application and mechanistic studies of psychedelics for treatment of depression: progress and future challenges].}. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. [published; PubMed]. \href{https://doi.org/10.12122/j.issn.1673-4254.2026.01.01}{doi:10.12122/j.issn.1673-4254.2026.01.01}.
\item Anthony L. Back, Bonnie A. McGregor, Leslie Lazar Thorn, Kelsey K. Baker, T. Gooley, Mendel Kaelen, Kalin Harvey, John M. Guy, Susanna Myers, Juliana Pérez, Peter Thompson, Lindsay Billingsley, Cheryl Sesnon (2026). \textit{Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251413856}{doi:10.1177/28314425251413856}.
\item Theo Tobel, Aidan Cone, Emily M Choquette, McKenna Garland, Micah Johnson, Keller Mink, Caitlin Lynch, Joel Frohlich, Justin Feinstein, Nicco Reggente (2026). \textit{Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-REST}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/6mj8n\_v1}{source link}.
\item Hinchcliffe JK, Thomas CW, Gilmour G, Robinson ES. (2026). \textit{Psilocybin rapidly, but not immediately, reverses reward learning deficits in a durable manner in an inflammatory rat model of depressive symptoms}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.64898/2026.01.14.699553}{doi:10.64898/2026.01.14.699553}.
\item Benjamin Kelmendi, Thomas Adams, Terence Ching, Rachael Grazioplene, Stephen Kichuk, Geena Fram, Prerana Patel, Jeff Eilbott, Elizabeth D’Amico, Sarah Shnayder (2026). \textit{Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/atfum\_v1}{source link}.
\item Sabbah SG, Li S, Wong S, Le GH, Badulescu S, Hawco C, Rosenblat JD, McIntyre RS (2026). \textit{Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2025.120335}{doi:10.1016/j.jad.2025.120335}.
\item Goodwin GM, Aaronson ST, Alvarez O, Carhart-Harris R, Chai-Rees J, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Kirlic N, Licht RW, Marwood L, Meyer TD, Mistry S, Nowakowska A, Páleníček T, Repantis D, Schoevers RA, Simmons H, Somers M, Teoh E, Tsai J, Wahba M, Williams S, Young AH, Young MB, Zisook S, Malievskaia E (2026). \textit{Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2025.120352}{doi:10.1016/j.jad.2025.120352}.
\item Zaynab Khan, Sterre Weaver, Rachael V. Dando, Anne Katrin Schlag, Joanna; id\_orcid 0000-0002-2717-9739 Neill, Verity; id\_orcid 0000-0002-9876-250X Wainwright (2026). \textit{Sense-making around psilocybin in UK women experiencing cancer-related existential distress: An Interpretative Phenomenological Analysis}. Research Explorer (The University of Manchester). [published; OpenAlex]. \href{https://research.manchester.ac.uk/en/publications/6f070f13-96c6-4cc4-9e40-f2837bdb79b3}{source link}.
\item Koch P, Schmidt M, Hoffrichter A, Davoudi M, Horschitz S, Lau T, Meinhardt M, Spanagel R, Ladewig J, Köhr G. (2026). \textit{Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-4242829/v3}{doi:10.21203/rs.3.rs-4242829/v3}.
\item Mitchell J, Neitzke-Spruill L, Mathai DS, Robinson JO, Kavan Z, Averil LA, McGuire AL (2026). \textit{From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care.}. Translational behavioral medicine. [published; PubMed]. \href{https://doi.org/10.1093/tbm/ibag027}{doi:10.1093/tbm/ibag027}.
\item Dallery J, Miller JL, Boissoneault J, Harvey L, Ives L, Knerr A, Blaes S, Ransom MN, Munson M, Gilligan JP, Silverman MH, Guzzo PR, Loeser B (2026). \textit{An open-label pilot study of psilocybin-assisted therapy for binge eating disorder.}. Journal of eating disorders. [published; PubMed]. \href{https://doi.org/10.1186/s40337-025-01508-3}{doi:10.1186/s40337-025-01508-3}.
\item Moshfeghinia R, Mostafavi S, Jazi K, Ghasemi AR, Khosravaninezhad Y, Narayanan S, Ahmadi J, Pasalar M (2026). \textit{The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis.}. BMC psychology. [published; PubMed]. \href{https://doi.org/10.1186/s40359-025-03935-y}{doi:10.1186/s40359-025-03935-y}.
\item Florineth GA, Klima I, Boeker AL, Catzeflis P, Wopfner A, Denier N, Bracht T, Adorjan K, Pfammatter M, Müller F, Soravia LM (2026). \textit{Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.}. JAMA network open. [published; PubMed]. \href{https://doi.org/10.1001/jamanetworkopen.2025.54843}{doi:10.1001/jamanetworkopen.2025.54843}.
\item Federico Durbano, Marco Otto Toscano (2026). \textit{Psychedelic Drugs}. IntechOpen. [published; OpenAlex]. \href{https://www.intechopen.com/books/1004886}{source link}.
\item Rodrigues Paulo Henrique Rodrigues e, Júnior Weliton Rodrigues dos Santos, Araújo Ivan de Sousa, Leony Leonardo Maia, Gomes Fernanda Adélia Almeida Custódio Pires, Junior Tairone Matos de Lima, Moreira Luís Felipe Freitas, Santana Rafael Telles, Santos Manoel Carlos Matos, Silva Roberto de Barros (2026). \textit{COMPARATIVE EFFICACY AND ACCEPTABILITY OF PSILOCYBIN-KETAMINE AND TYPICAL ANTIDEPRESSANTS FOR MAJOR DEPRESSIVE DISORDER MANAGEMENT: A NETWORK META-ANALYSIS}. The Study of Phenomena Related to Health. [published; Crossref]. \href{https://doi.org/10.55905/edicon.978-65-83115-47-8\_8}{doi:10.55905/edicon.978-65-83115-47-8\_8}.
\item Ethan Klukas (2026). \textit{Motivation-based subtypes of psilocybin microdosers}. Open Collections. [published; OpenAlex]. \href{https://doi.org/10.14288/1.0452623}{doi:10.14288/1.0452623}.
\item Mahvash Khan, Muhammad Omar Malik, Sara Sajjad, Muhammad Uzair, Inayat Shah, Muhammad Ismail Bhatti (2026). \textit{COMBINATION OF PSILOCYBIN AND COGNITIVE BEHAVIORAL THERAPY IMPROVES OXYTOCIN LEVELS AND DEPRESSIVE SYMPTOMS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER}. Genetics and Molecular Research. [published; OpenAlex]. \href{https://doi.org/10.4238/e91xh631}{doi:10.4238/e91xh631}.
\item Marta Gómez Álvarez, Javier Calleja-Conde, Víctor Echeverry-Alzate (2026). \textit{Psychedelics and Mental Health: Psilocybin and Depression. A Sistematic Review}. Open Science Framework. [published; OpenAlex]. \href{https://doi.org/10.17605/osf.io/yu3n9}{doi:10.17605/osf.io/yu3n9}.
\item Yosr Ziadi, Taehwan Park (2026). \textit{Cost-Effectiveness of Psilocybin-Assisted Therapy (PAT) for Patients with Treatment-Resistant Depression}. Open MIND. [published; OpenAlex]. \href{https://doi.org/10.17605/osf.io/nrt59}{doi:10.17605/osf.io/nrt59}.
\item Mateus Araújo da Luz, Taynah Pereira Galdino, Lucas Matheus da S. Oliveira, H. Guedes, Anauara Silva, Victor I. Afonso, Suédina M. L. Silva, Antônio G. B. Lima, Marcus V. L. Fook, Maria C. M. Torres (2026). \textit{Optimization of Psilocybin Extraction from Psilocybe cubensis Mushrooms and Characterization of the Fungal Extract}. Journal of the Brazilian Chemical Society. [published; OpenAlex]. \href{https://doi.org/10.21577/0103-5053.20260049}{doi:10.21577/0103-5053.20260049}.
\item Stefan Jerotić, Olga Čolović, Nađa Marić (2026). \textit{Psychedelic-assisted psychotherapy: Clarifying the role of the "psychotherapy"}. Medicinska istrazivanja. [published; OpenAlex]. \href{https://doi.org/10.5937/medi0-62051}{doi:10.5937/medi0-62051}.
\item Maurice Lam, C. Khor, S. Hultin, J. J. Cheung, N. A. Shah (2026). \textit{‘Shroom’ for concern: a case of psychedelic mushroom-induced acute kidney injury}. Internal Medicine Journal. [published; OpenAlex]. \href{https://doi.org/10.1111/imj.70313}{doi:10.1111/imj.70313}.
\item L.J. Mertens, M. Koslowski, F. Betzler, M. Brand, R. Evens, L. Krätner, A. Jungaberle, H. Jungaberle, T. Majić, C.N. Schmitz, A. Ströhle, D. Scharf, M. Spangemacher, M. Wolff, Z. Assadi, B. Scharif, L. Becher, L.V. Färber, N. Kirchen, E. Kulakova, L. Kunz, A. Meijer, B. Rohrmoser, S. Wellek, M. Berger, G. Gründer (2026). \textit{Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE): Results of a randomized active placebo-controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2025.105779}{doi:10.1016/j.nsa.2025.105779}.
\item N. Mcgowan, J. Rucker, R. Yehuda, M. Agrawal, H. Simmons, S. Das, G. Goodwin (2026). \textit{An open-label study of single-dose COMP360 psilocybin for post-traumatic stress disorder: safety, tolerability, and secondary efficacy outcomes}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2025.106821}{doi:10.1016/j.nsa.2025.106821}.
\item L. Puhl, L. Kunz, M. Berger, G. Gründer, L. Mertens, M. Spangemacher (2026). \textit{Relationship between cardiovascular effects and psychedelic experiences under psilocybin in patients with treatment-resistant depression}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2025.106390}{doi:10.1016/j.nsa.2025.106390}.
\item Jensen, Hailey A (2026). \textit{Psilocybin Treatment for Refractory Depression: A Clinical Review}. Digital Commons - Gardner-Webb University (Gardner-Webb University). [published; OpenAlex]. \href{https://digitalcommons.gardner-webb.edu/pa-department-journal-of-medical-science/63}{source link}.
\item Viljoen G, Betzler F (2026). \textit{Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.}. Current topics in behavioral neurosciences. [published; PubMed]. \href{https://doi.org/10.1007/7854\_2024\_534}{doi:10.1007/7854\_2024\_534}.
\item Aghajanian S, Shafiee A, Parvizi Omran S, Rezaei Nejad A, Jafarabady K, Kohandel Gargari O, Rajai S, Mohammadi I, Bahrami Babaheidari T, Bakhtiyari M (2026). \textit{Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811241287542}{doi:10.1177/02698811241287542}.
\item Barstowe A, Kajonius PJ (2026). \textit{Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2024.2424272}{doi:10.1080/02791072.2024.2424272}.
\item Marchi M, Farina R, Rachedi K, Laonigro F, Žuljević MF, Pingani L, Ferrari S, Somers M, Boks MPM, Galeazzi GM (2026). \textit{Psychedelics as an intervention for psychological, existential distress in terminally ill patients: A systematic review and network meta-analysis.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811241303594}{doi:10.1177/02698811241303594}.
\item McGowan NM, Rucker JJ, Yehuda R, Agrawal M, Modlin NL, Simmons H, Tofil-Kaluza A, Das S, Goodwin GM (2026). \textit{Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251362390}{doi:10.1177/02698811251362390}.
\item Marek GJ, Makai-Bölöni S, Umbricht D, Christian EP, Winters J, Dvorak D, Raines S, Hughes ZA, Austin EW, Klein AK, Leong W, Krol FJ, Graaf AJV, Juachon MJ, Otto ME, Borghans LGJM, Jacobs G, Kruegel AC, Sporn J (2026). \textit{A novel psychedelic 5-HT receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251378512}{doi:10.1177/02698811251378512}.
\item Konstantinou GN, Rosenblat J, Hales S, Husain MI, Blumberger DM (2026). \textit{Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety.}. General hospital psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.genhosppsych.2025.12.005}{doi:10.1016/j.genhosppsych.2025.12.005}.
\item Matos ARS, Silva AC, Rego L, Fernandes R, Gonçalves S (2026). \textit{Psilocybin-assisted therapy for individuals with palliative care needs: A systematic review of safety and efficacy.}. Palliative medicine. [published; PubMed]. \href{https://doi.org/10.1177/02692163251383335}{doi:10.1177/02692163251383335}.
\item Maltby CJ, Klein AK, Paschen E, Pinto J, Dvorak D, Hedde JR, Hanks AN, Bianchi M, Hughes ZA (2026). \textit{An exploration of the relationships between the effects of psilocybin on behavior, 5-HT receptor occupancy, and neuroplastic effects in mice.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251395386}{doi:10.1177/02698811251395386}.
\item Moghadam H, Akbari P, Beirami E, Nabavifard S, Ameli A, Valian N (2026). \textit{The Effect of Magic Mushroom (Psilocybe azurescens) on Social Interaction, Anxiety- and Depressive-Like Behaviors in Male Rats; the Role of Neuroinflammation, Oxidative Stress, and Neurotrophic Factors.}. Journal of neuroscience research. [published; PubMed]. \href{https://doi.org/10.1002/jnr.70107}{doi:10.1002/jnr.70107}.
\item Rasheed S, Arif R, Raza AA, Samadi A (2026). \textit{Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder.}. Annals of medicine and surgery (2012). [published; PubMed]. \href{https://doi.org/10.1097/ms9.0000000000004349}{doi:10.1097/ms9.0000000000004349}.
\item Huang Z, Wei X, Wang Y, Tian J, Dong J, Liang B, Lu L, Zhang W (2026). \textit{Single-dose psilocybin promotes cell-type-specific changes of neurons in the orbitofrontal cortex.}. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics. [published; PubMed]. \href{https://doi.org/10.1016/j.neurot.2026.e00841}{doi:10.1016/j.neurot.2026.e00841}.
\item Rasool M, Hannan TM, Imam M (2026). \textit{Magic mushrooms and mood: Exploring psilocybin as a depression treatment.}. JPMA. The Journal of the Pakistan Medical Association. [published; PubMed]. \href{https://doi.org/10.47391/jpma.30858}{doi:10.47391/jpma.30858}.
\item Spiti A, Caldirola D, Perna G (2026). \textit{New Antidepressant Development in the Treatment of Depression.}. Advances in experimental medicine and biology. [published; PubMed]. \href{https://doi.org/10.1007/978-981-95-6872-7\_23}{doi:10.1007/978-981-95-6872-7\_23}.
\item Olivier B, Olivier JDA (2026). \textit{Psychedelics: Future Therapeutics in Major Depression?}. Advances in experimental medicine and biology. [published; PubMed]. \href{https://doi.org/10.1007/978-981-95-6872-7\_25}{doi:10.1007/978-981-95-6872-7\_25}.
\item Shiner B, DuFort V, Peltzman T, Watts BV (2026). \textit{Rural-Urban Disparities in Access to Interventional Psychiatry Treatments among VA Patients.}. Rural mental health. [published; PubMed]. \href{https://doi.org/10.1037/rmh0000333}{doi:10.1037/rmh0000333}.
\item Raza M, Kaur J (2026). \textit{A Promise Without Panacea: Psychedelic-Assisted Therapies in Modern Psychiatry.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.102421}{doi:10.7759/cureus.102421}.
\item Siwek L, Nowocien M, Balajewicz B, Samborska A, Szukalska S, Karczewska M, Lichwala K, Wróblewski K, Wróblewska P (2026). \textit{The Use of Psilocybin in the Treatment of Depressive Disorders: A Narrative Review.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.102694}{doi:10.7759/cureus.102694}.
\item Kirlić N, Atli M, Mistry S, Gold M, Goodwin GM (2026). \textit{The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience: A Retrospective Analysis.}. Journal of clinical psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1097/jcp.0000000000002119}{doi:10.1097/jcp.0000000000002119}.
\item Thuery G, Crossen F, Mc Loone D, Hinds C, Duffy R, Jairaj C, Harkin A, Kelly JR (2026). \textit{Psychedelic therapy and postpartum depression: priorities and prospects.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/20451253251408280}{doi:10.1177/20451253251408280}.
\item Abramsky-Sze S, Marseille E, Matzopoulos R, Morlock R, Lerer L (2026). \textit{Correction: Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2026.1834094}{doi:10.3389/fpsyt.2026.1834094}.
\item Beichmann K, Catzeflis P, Aicher HD, Seragnoli F, Calder A, Amrani A, Hasler G (2026). \textit{Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/20451253261448745}{doi:10.1177/20451253261448745}.
\item Kunal Kumar Sharma (2025). \textit{Psychedelics and neuroanesthesia: A narrative review of converging mechanisms}. Journal of Scientific Innovations in Anesthesiology. [published; OpenAlex]. \href{https://doi.org/10.65929/jsia.2026.1.2.002}{doi:10.65929/jsia.2026.1.2.002}.
\item Aneta Petrušková (2025). \textit{Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity}. OPUS FAU - Online publication system of Friedrich-Alexander-Universität Erlangen-Nürnberg. [published; OpenAlex]. \href{https://doi.org/10.25593/open-fau-2619}{doi:10.25593/open-fau-2619}.
\item Rotem Petranker (2025). \textit{Microdosing Psychedelics to Improve Mood}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05259943}{source link}.
\item Dominiak M, Gędek A, Modrzejewski S, Permoda-Pachuta A, Antosik AZ (2025). \textit{Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.}. Journal of clinical medicine. [published; PubMed]. \href{https://doi.org/10.3390/jcm15010253}{doi:10.3390/jcm15010253}.
\item Sheppard Pratt Health System (2025). \textit{The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05220410}{source link}.
\item University of Chicago (2025). \textit{An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05399498}{source link}.
\item Shadani S, McCoy K, Ong L, Greaves E, Conn K, Andrews ZB, Foldi CJ. (2025). \textit{Psilocybin modulates social behaviour in male and female mice in a time-dependent manner}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.64898/2025.12.18.695064}{doi:10.64898/2025.12.18.695064}.
\item Bukovsky D, Amaev A, Song J, Kyte S, Carmona-Torres E, Ueno F, Deluca V, Strafella AP, Husain MI, Graff-Guerrero A, Gerretsen P (2025). \textit{Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2025.111541}{doi:10.1016/j.pnpbp.2025.111541}.
\item Johnson DE, Meshkat S, Kaczmarek ES, Rabin JS, Brudner RM, Chisamore N, Doyle Z, Bawks J, Riva-Cambrin J, Mansur RB, Lipsitz O, McIntyre RS, Lanctôt KL, Rosenblat JD (2025). \textit{Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2025.111565}{doi:10.1016/j.pnpbp.2025.111565}.
\item Mylène Cheng, Tatiana Aboulafia Brakha, Albert Buchard, Raya Anastasova, Léa Girani, Anna Breitenmoser, Sylvie Alaux, Cédric Mabilais, Caroline Amberger, Federico Seragnoli, Leonice Furtado, Gabriel Thorens, Daniele Zullino, Louise Penzenstadler (2025). \textit{Effects of LSD and Psilocybin on Heart Rate in Patients Receiving Psychedelic Treatment for Depressive and Anxiety Disorders: A Retrospective Observational Study}. Psychology International. [published; OpenAlex]. \href{https://doi.org/10.3390/psycholint8010001}{doi:10.3390/psycholint8010001}.
\item Brar G, Burke T, Gribben AD, Harrington C, Thuery G, Kelly JR (2025). \textit{Psilocybin reporting in media (PRiMe) for the treatment of depression.}. Irish journal of psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/ipm.2025.10142}{doi:10.1017/ipm.2025.10142}.
\item Koning E, Bacchi P, Chaves C, Gomes FA, Brietzke E (2025). \textit{Which Psychotherapy Model Should be Used in Psilocybin Treatment for Depression?}. Trends in psychiatry and psychotherapy. [published; PubMed]. \href{https://doi.org/10.47626/2237-6089-2025-1197}{doi:10.47626/2237-6089-2025-1197}.
\item Sophie Woodruff, Meghan Hibicke, Charles D. Nichols (2025). \textit{Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto Rats}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251393186}{doi:10.1177/28314425251393186}.
\item M. H. M. Wickramasekara, G. D. M. C. Gonapaladeniya (2025). \textit{Psychedelic-Assisted Therapy (Pat): A New Frontier in Mental Health Treatment}. The journal of desk research review and analysis.. [published; OpenAlex]. \href{https://doi.org/10.4038/jdrra.v3i2.87}{doi:10.4038/jdrra.v3i2.87}.
\item Shannon Antoine-Hardy, D’Elia Bonilla (2025). \textit{Exploring Determinants of Psilocybin Acceptance as an Alternative Modality for Major Depressive Disorder: A Pilot Study}. Journal of Complementary and Alternative Medical Research. [published; OpenAlex]. \href{https://doi.org/10.9734/jocamr/2025/v26i11723}{doi:10.9734/jocamr/2025/v26i11723}.
\item Kittur ME, Burgos M LA, Jones BDM, Blumberger DM, Mulsant BH, Rosenblat JD, Husain MI (2025). \textit{Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2025.119952}{doi:10.1016/j.jad.2025.119952}.
\item Jake Hooper, Sarah Williams, Raeghan Mueller, Kent Hutchison (2025). \textit{Age and cannabis co-use are associated with differences in experience and perceived benefits of psilocybin: a retrospective study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/dczw2\_v2}{source link}.
\item Jungwirth J, Westenhöfer S, Aicher H, Provaznikova B, Kronenberg G, Seifritz E, Prinz S, Olbrich S. (2025). \textit{Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-8079137/v1}{doi:10.21203/rs.3.rs-8079137/v1}.
\item Wohlfarth, Gale, Hardy, Susan, Ray, Herman (2025). \textit{Are Magic Mushrooms the Magic to Healing?}. DigitalCommons - Kennesaw State University (Kennesaw State University). [published; OpenAlex]. \href{https://digitalcommons.kennesaw.edu/undergradsymposiumksu/fall2025/fall2025/134}{source link}.
\item Imperial College London (2025). \textit{Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06798636}{source link}.
\item Taslim Uddin, Suma Akter, Kanak Yadab Ghosh (2025). \textit{Psychedelics as neuroplasticity enhancers: Mechanisms, therapeutic applications, and translational challenges}. Advanced Neurology. [published; OpenAlex]. \href{https://doi.org/10.36922/an025410095}{doi:10.36922/an025410095}.
\item NYU Langone Health (2025). \textit{A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05398484}{source link}.
\item Spohn, Kyle (2025). \textit{Magic Mushrooms as Medicine: What the United States Can Learn from Jamaica’s Unregulated Psilocybin Industry as FDA Approval Nears}. eYLS (Yale Law School). [published; OpenAlex]. \href{https://repository.law.miami.edu/umialr/vol57/iss1/7}{source link}.
\item F. Seragnoli (2025). \textit{Psychedelic Assisted Psychotherapy (PAP): the Geneva University Hospital model}. Emerging Trends in Drugs Addictions and Health. [published; OpenAlex]. \href{https://doi.org/10.1016/j.etdah.2025.100256}{doi:10.1016/j.etdah.2025.100256}.
\item S. Fereydouni (2025). \textit{Psilocybin and Neuroplasticity: Mechanisms, Therapeutic Potential, and Future Directions}. Emerging Trends in Drugs Addictions and Health. [published; OpenAlex]. \href{https://doi.org/10.1016/j.etdah.2025.100215}{doi:10.1016/j.etdah.2025.100215}.
\item Buchard A, Seragnoli F, Sabe M, Eskinazi M, Aboulafia T, Furtado L, Briefer J, Roediger E, Penzenstadler L, Zullino D, Thorens G. (2025). \textit{Limited prognostic value of early maladaptive schemas for acute psychedelic experience and symptom improvement}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-8214817/v1}{doi:10.21203/rs.3.rs-8214817/v1}.
\item Aboulafia-Brakha T, Buchard A, Mabilais C, Alaux S, Amberger C, Furtado L, Seragnoli F, Briefer J, Thorens G, Sabé M, Szczesniak L, Iuga R, Zullino D, Penzenstadler L. (2025). \textit{Real-World Effectiveness and Safety of Psychedelic-Assisted Psychotherapy: Outcomes from a Large-Scale Compassionate Use Cohort in Switzerland}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2025.12.01.25341335}{doi:10.1101/2025.12.01.25341335}.
\item Dumenil M, Cordova G, El-Hage W (2025). \textit{[Psilocybin in the setting of treatment-resistant unipolar depression: A case report].}. L'Encephale. [published; PubMed]. \href{https://doi.org/10.1016/j.encep.2025.02.007}{doi:10.1016/j.encep.2025.02.007}.
\item Gillespie CM, Bering JM (2025). \textit{Avoiding Stigma and Sensationalism in Therapeutic Psilocybin Communications: Considerations for Reaching Older Patients.}. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.jagp.2025.07.003}{doi:10.1016/j.jagp.2025.07.003}.
\item Drewko AJ, Habets RLP, Brunt TM (2025). \textit{Above the threshold, beyond the trip: the role of the 5-HT receptor in psychedelic-induced neuroplasticity and antidepressant effects.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-025-03169-9}{doi:10.1038/s41380-025-03169-9}.
\item García-Cabrerizo R, Beruete-Fresnillo I, Bergas-Cladera P, García-Fuster MJ (2025). \textit{Psilocybin as a fast-acting and long-lasting antidepressant for adolescence: Proposing NeuroD1 as a biomarker of its long-term plasticity.}. Biomedicine \& pharmacotherapy = Biomedecine \& pharmacotherapie. [published; PubMed]. \href{https://doi.org/10.1016/j.biopha.2025.118720}{doi:10.1016/j.biopha.2025.118720}.
\item Højlund M, Kafali HY, Kırmızı B, Fusar-Poli P, Correll CU, Cortese S, Sabé M, Fiedorowicz J, Saraf G, Zein J, Berk M, Husain MI, Rosenblat JD, Rubaiyat R, Corace K, Wong S, Hatcher S, Kaluzienski M, Yatham LN, Cipriani A, Gosling CJ, Carhart-Harris R, Tanuseputro P, Myran DT, Fabiano N, Moher D, Mayo LM, Nicholls SG, White T, Prisco M, Radua J, Vieta E, Ladha KS, Katz J, Veroniki AA, Solmi M (2025). \textit{Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.}. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.euroneuro.2025.09.011}{doi:10.1016/j.euroneuro.2025.09.011}.
\item Ferreira J (2025). \textit{Psilocybin reduces comorbid chronic pain and depression in mice.}. Lab animal. [published; PubMed]. \href{https://doi.org/10.1038/s41684-025-01663-9}{doi:10.1038/s41684-025-01663-9}.
\item Kleditzsch N, Gattuso JJ, Hannan AJ, Renoir T (2025). \textit{Acute Blockade of the Serotonin Transporter With Low Doses of Escitalopram Does Not Alter the Behavioural Responses to Acute Psilocybin.}. The European journal of neuroscience. [published; PubMed]. \href{https://doi.org/10.1111/ejn.70351}{doi:10.1111/ejn.70351}.
\item Modlin NL, Williamson V, Goodwin GM, Malievskaia E, Atli M, Elek Z, Gaillard A, Koelpin D, Cleare A, Agrawal M, Yehuda R, Kirlic N, Rucker J (2025). \textit{Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.}. EClinicalMedicine. [published; PubMed]. \href{https://doi.org/10.1016/j.eclinm.2025.103692}{doi:10.1016/j.eclinm.2025.103692}.
\item Liszka P, Ogórek A, Olejnik-Chlewicka KM, Puchalski K, Zasiadła M, Patrzykąt KM, Perediatkiewicz J, Urbański W, Łuczak PM, Brodowski J (2025). \textit{Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.99942}{doi:10.7759/cureus.99942}.
\item Morris Lintong Barimbing, Dian Pritasari Jeger, Made Edwin Sridana (2025). \textit{Efficacy of psilocybin on death anxiety in terminal patients: a narrative review}. Progress in Palliative Care. [published; OpenAlex]. \href{https://doi.org/10.1080/09699260.2026.2657096}{doi:10.1080/09699260.2026.2657096}.
\item University of Texas at Austin (2025). \textit{Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06132178}{source link}.
\item Domżalska M, Kwiatkowska J, Cichoń I, Sokołowska E (2025). \textit{A comparative assessment of the antidepressant efficacy of ketamine, psilocybin, and fluoxetine in a chronic stress model.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-025-29642-7}{doi:10.1038/s41598-025-29642-7}.
\item Charles S. Grob, M.D. (2025). \textit{Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05403086}{source link}.
\item J Pincombe, M.L. Williams, Sean Carruthers, Susan L. Rossell (2025). \textit{Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Disorders: A Scoping Review}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251394012}{doi:10.1177/28314425251394012}.
\item Stacey B. Armstrong, Meghan DellaCrosse, Jaime Fuentes-Balderrama, Rafaelle Lancelotta, Alan K. Davis (2025). \textit{Self-reported improvement in depression, anxiety, and substance use in Spanish-speakers after a memorable psychedelic experience}. Psychedelics. [published; OpenAlex]. \href{https://doi.org/10.1016/j.psyche.2025.100006}{doi:10.1016/j.psyche.2025.100006}.
\item Natoli S, Cuomo A, Marchesini M, Luongo L, Lo Bianco G, Guardamagna VA, Yamaguchi S (2025). \textit{Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists?}. Medical sciences (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/medsci13040277}{doi:10.3390/medsci13040277}.
\item Beersheva Mental Health Center (2025). \textit{A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07183748}{source link}.
\item Beersheva Mental Health Center (2025). \textit{Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04882839}{source link}.
\item Brown KA, Ajibola MI, Medeiros GC, Gould TD (2025). \textit{Synaptic priming: A framework for pharmacotherapy in depression.}. Neuron. [published; PubMed]. \href{https://doi.org/10.1016/j.neuron.2025.09.010}{doi:10.1016/j.neuron.2025.09.010}.
\item Agrawal R, Gillie D, Mungenast A, Chytil M, Engel S, Wu MC, Rasmussen K, Salinas E, Olson DE (2025). \textit{Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.5c00667}{doi:10.1021/acschemneuro.5c00667}.
\item Zeina Beidas, Anya Ragnhildstveit, Adam Blackman, Thomas Anderson, Emily Fewster, Omer Syed, Valentyne Sobolenko, Ismail Kaan Kanca, Magdalena Jaglinska, Tatiana Son (2025). \textit{Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/hmnsw\_v1}{source link}.
\item Meghan DellaCrosse, Shoval Gilead, Rafael Lancelotta, Ana María Ortiz Bernal, Christopher Timmermann, Alan K. Davis (2025). \textit{Qualitative insights into psilocybin and LSD experiences: Enhanced connection and emotion processing reported by Spanish-speaking survey respondents}. Psychedelics. [published; OpenAlex]. \href{https://doi.org/10.1016/j.psyche.2025.100004}{doi:10.1016/j.psyche.2025.100004}.
\item Ellis S, Bostian C, Donnelly A, Feng W, Eisen K, Lean M, Conlan E, Ostacher M, Aaronson S, Suppes T (2025). \textit{Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2025.119655}{doi:10.1016/j.jad.2025.119655}.
\item Gattuso JJ, Kong G, Bezcioglu B, Lu D, Ekwudo MN, Wilson C, Gubert C, Hannan AJ, Renoir T (2025). \textit{Chronic psilocybin administration increases sociability and alters the gut microbiome in male wild-type mice but not in a preclinical model of obsessive-compulsive disorder.}. Neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.neuropharm.2025.110648}{doi:10.1016/j.neuropharm.2025.110648}.
\item Martens MAG, Cunha BG, Erritzoe D, Nutt D, Carhart-Harris R, Harmer CJ (2025). \textit{Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-025-03693-w}{doi:10.1038/s41398-025-03693-w}.
\item Luisina Rodríguez (12333694), Guillermo Morera (22593717), Sandra Lupo (22593720), Danilo Davyt (2738347), Ignacio Carrera (1677175), Gonzalo Hernández Dossi (22593723) (2025). \textit{Novel qNMR Methodto Quantify Psilocybin and Psilocinin Psychedelic Mushrooms}. Figshare. [published; OpenAlex]. \href{https://doi.org/10.1021/acsomega.5c07092.s001}{doi:10.1021/acsomega.5c07092.s001}.
\item Allohverdi SG, Soltanzadeh M, Schmidt A, Charlton CE, Hauke DJ, Karvelis P, Vollenweider FX, Diaconescu AO. (2025). \textit{Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.11.06.687023}{doi:10.1101/2025.11.06.687023}.
\item Milad Soltanzadeh, Zheng Wang, Shona G. Allohverdi, Colleen E. Charlton, André Schmidt, Franz Xaver Vollenweider, Andreea O. Diaconescu (2025). \textit{Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm}. Universität Zürich, ZORA. [published; OpenAlex]. \href{https://doi.org/10.5167/uzh-292276}{doi:10.5167/uzh-292276}.
\item Yale University (2025). \textit{Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03554174}{source link}.
\item University of Washington (2025). \textit{A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05847686}{source link}.
\item Mennenga S, Hanson T, Semple M, Lifshitz D, Flores B, Balducci J, Harker S, Ford A, Lewis C. (2025). \textit{Psilocybin reduces depressive-like behavior and improves cognition in healthy aging mice via epigenetic regulation of plasticity- and immune-related genes}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-7890051/v1}{doi:10.21203/rs.3.rs-7890051/v1}.
\item Aisling McGuigan (2025). \textit{Classic psychedelics may treat depressive disorders, but more evidence and legislative changes are required}. Drugs \& Therapy Perspectives. [published; OpenAlex]. \href{https://doi.org/10.1007/s40267-025-01199-5}{doi:10.1007/s40267-025-01199-5}.
\item Marinis J, Clarke ST, Guerin AA, Guastella AJ, Bedi G (2025). \textit{Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review.}. BJPsych open. [published; PubMed]. \href{https://doi.org/10.1192/bjo.2025.10847}{doi:10.1192/bjo.2025.10847}.
\item Faith Ekoh, Shanice Rerrie, James Angud, Ersilia Mirabelli (2025). \textit{Hormonal Influences on Psilocybin Responsivity Across the Female Lifespan: Toward Personalized Psychedelic-Assisted Therapy}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives4040039}{doi:10.3390/psychoactives4040039}.
\item Thomas Zandonai, Sofia Venturini, Ornella Corazza (2025). \textit{Ketamine and psilocybin for athletes: A therapeutic breakthrough or a slippery slope?}. Performance Enhancement \& Health. [published; OpenAlex]. \href{https://doi.org/10.1016/j.peh.2025.100386}{doi:10.1016/j.peh.2025.100386}.
\item Swieczkowski D, Kwaśny A, Pruc M, Gaca Z, Szarpak L, Cubała WJ (2025). \textit{Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis.}. International journal of psychiatry in medicine. [published; PubMed]. \href{https://doi.org/10.1177/00912174251337572}{doi:10.1177/00912174251337572}.
\item Lashgari NA, Khalaji M, Rana P, Badrabadi F, Rahnama M, Nasoori H, Momeni Roudsari N, Khosravi Nia MM, Shafaroodi H (2025). \textit{Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View.}. Molecular neurobiology. [published; PubMed]. \href{https://doi.org/10.1007/s12035-025-05097-9}{doi:10.1007/s12035-025-05097-9}.
\item Joga R, Yerram S, Patnam JD, Choudhary KK, Varpe P, Raghuvanshi RS, Srivastava S (2025). \textit{Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India.}. Health policy (Amsterdam, Netherlands). [published; PubMed]. \href{https://doi.org/10.1016/j.healthpol.2025.105392}{doi:10.1016/j.healthpol.2025.105392}.
\item Moujaes F, Rieser NM, Belinger L, Herdener M, Zahid Z, Preller KH (2025). \textit{The emotional architecture of the psychedelic brain.}. Trends in cognitive sciences. [published; PubMed]. \href{https://doi.org/10.1016/j.tics.2025.07.006}{doi:10.1016/j.tics.2025.07.006}.
\item Koenig HG (2025). \textit{Psilocybin-assisted psychotherapy, combined antipsychotic and antidepressant treatment for bipolar depression, duration of birth control pill use and risk of depression, handgrip strength and cognitive function, mood disorders in epilepsy, and mental health issues among physicians.}. International journal of psychiatry in medicine. [published; PubMed]. \href{https://doi.org/10.1177/00912174251369880}{doi:10.1177/00912174251369880}.
\item Rahmani S, Crupi R, Riley AL, Davidson T (2025). \textit{The therapeutic use of psychedelic drugs: Legal, policy, and neuroscientific perspectives.}. Pharmacology, biochemistry, and behavior. [published; PubMed]. \href{https://doi.org/10.1016/j.pbb.2025.174087}{doi:10.1016/j.pbb.2025.174087}.
\item Sonda S, Pendin D, Comai S, De Martin S, Manfredi P, Mattarei A (2025). \textit{Emerging mechanisms of psilocybin-induced neuroplasticity.}. Trends in pharmacological sciences. [published; PubMed]. \href{https://doi.org/10.1016/j.tips.2025.08.012}{doi:10.1016/j.tips.2025.08.012}.
\item Hammo A, Wisser S, Cichon J (2025). \textit{Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain.}. Nature neuroscience. [published; PubMed]. \href{https://doi.org/10.1038/s41593-025-02068-0}{doi:10.1038/s41593-025-02068-0}.
\item Hosein MM, Reid MJ, Walser S, Charney S, Fonzo GA, Lewis BR, Yaden DB, Suppes T, Cordner ZA, Barrett FS (2025). \textit{Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds.}. EClinicalMedicine. [published; PubMed]. \href{https://doi.org/10.1016/j.eclinm.2025.103517}{doi:10.1016/j.eclinm.2025.103517}.
\item Blake Beaton (2025). \textit{“It Fueled the Fire to Who I Am Now”: Exploring Motivations for Microdosing Psychedelics}. Journal of Drug Issues. [published; OpenAlex]. \href{https://doi.org/10.1177/00220426251395178}{doi:10.1177/00220426251395178}.
\item d'Andrea G, Chiappini S, Ciavoni L, Tucci R, Martino F, Semeraro FM, Di Battista D, Mosca A, Miuli A, Di Carlo F, Russo M, Di Petta G, Fornaro M, Pettorruso M, Sensi SL, Martinotti G (2025). \textit{Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-025-03654-3}{doi:10.1038/s41398-025-03654-3}.
\item Anna Rose Childress, Ph.D. (2025). \textit{A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06786325}{source link}.
\item Richardson C, Chan C, Macgregor E, Hare C, Hannon B, Black S, Schneider E, Buchman D, Wang S, Rac V, Abrahamyan L, Huszti E, Nissim R, Li M, Zimmermann C, Hapke E, Rosenbaum D, Hales S (2025). \textit{Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial.}. Pilot and feasibility studies. [published; PubMed]. \href{https://doi.org/10.1186/s40814-025-01706-5}{doi:10.1186/s40814-025-01706-5}.
\item James J Gattuso, Bilgenur Bezcioglu, Carey Wilson, Kato Havaux, Anthony J. Hannan, Thibault Renoir (2025). \textit{Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp025i.0044}{doi:10.61373/pp025i.0044}.
\item Li R, Yan H, Chen Y, Liu Y, Tang L, Yu J, Liu J, Wang H, Wang S, Cheng J (2025). \textit{Structure-Guided Design of Novel 5-HT Partial Agonists as Psychedelic Analogues with Antidepressant Effects.}. Journal of medicinal chemistry. [published; PubMed]. \href{https://doi.org/10.1021/acs.jmedchem.5c02045}{doi:10.1021/acs.jmedchem.5c02045}.
\item Farzin H, Koren B, Ferrier H, Sanders JJ, Garel N (2025). \textit{Home-based psilocybin-assisted therapy for a patient with advanced cancer: A case report.}. Palliative \& supportive care. [published; PubMed]. \href{https://doi.org/10.1017/s1478951525100941}{doi:10.1017/s1478951525100941}.
\item Pu Jiang, Cong Lin, Xiaohui Wang (2025). \textit{Psychedelics and time: Exploring altered temporal perception and its implications for consciousness, neuroscience, and therapy}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp025p.0041}{doi:10.61373/pp025p.0041}.
\item special to C EN Mara Johnson-Groh (2025). \textit{Is there more to magic mushrooms than psilocybin?}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-10322-feature2}{doi:10.1021/cen-10322-feature2}.
\item Rongyan Li (11403789), Haohan Yan (22432650), Yujin Chen (1412254), Yangyang Liu (807797), Lingjie Tang (9276407), Jing Yu (81085), Junjun Liu (674159), Huan Wang (109286), Sheng Wang (339979), Jianjun Cheng (646595) (2025). \textit{Structure-GuidedDesign of Novel 5-HT2A Partial Agonists as PsychedelicAnalogues with Antidepressant Effects}. Figshare. [published; OpenAlex]. \href{https://doi.org/10.1021/acs.jmedchem.5c02045.s001}{doi:10.1021/acs.jmedchem.5c02045.s001}.
\item Shadani S, Greaves E, Andrews ZB, Foldi CJ. (2025). \textit{Psilocybin exerts differential effects on social behaviour and inflammation in mice in contexts of activity-based anorexia (ABA)}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.10.14.682467}{doi:10.1101/2025.10.14.682467}.
\item Sha Jin, H.Y. Wang, Xiaohui Wang (2025). \textit{Psychedelics in the context of stress and psychiatric disorders: A new horizon in mental health treatment}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp025v.0038}{doi:10.61373/pp025v.0038}.
\item Razidlo J, Cataldo N, Wenthur CJ (2025). \textit{Psilocybin Enhances Cued Fear Extinction and Extinction Recall in Stress-Naïve, Acutely Stressed, and Chronically Stressed Mice.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.5c00462}{doi:10.1021/acsptsci.5c00462}.
\item Renee Ireland (2025). \textit{Psychedelics in Practice: Science, Safety, and the Future of Healing}. The proceedings of sliit international conference on advancements in science and humanities. [published; OpenAlex]. \href{https://doi.org/10.54389/epsd8792}{doi:10.54389/epsd8792}.
\item Centre Hospitalier St Anne (2025). \textit{Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07210112}{source link}.
\item Domzalska M, Kwiatkowska J, Cichon I, Sokolowska E. (2025). \textit{Towards Novel Antidepressant Strategies: A Comparative Study of Ketamine, Psilocybin, and Fluoxetine in a Chronic Stress Model}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-7269356/v1}{doi:10.21203/rs.3.rs-7269356/v1}.
\item Mackenzie Hancock, Nicole Getz, Shambhu Prasad Adhikari (2025). \textit{Psilocybin-Assisted Therapy for Trauma-Related Disorders: A Scoping Review of a Depression-Dominated Evidence Base with Implications for Intimate Partner Violence-Related PTSD}. Open Science Framework. [published; OpenAlex]. \href{https://doi.org/10.17605/osf.io/ar2s4}{doi:10.17605/osf.io/ar2s4}.
\item M Loganathan, A Saravanakumar, P. Parthiban, G Anandharaj, S Gobika, D Dharshana, Mohamed Safir Ali (2025). \textit{Neurobiological and Therapeutic Potential of Psilocybin in Psychiatric Disorders}. Journal of Pharma Insights and Research.. [published; OpenAlex]. \href{https://doi.org/10.69613/thv1dn30}{doi:10.69613/thv1dn30}.
\item Arif Ersegün Kahraman (2025). \textit{Psilocybin as a Treatment for Depression}. University of Debrecen Electronic Archive. [published; OpenAlex]. \href{https://hdl.handle.net/2437/398317}{source link}.
\item University Hospital, Geneva (2025). \textit{Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07164287}{source link}.
\item Dorczok MC, Mittmann G, Ettl T, Steiner-Hofbauer V (2025). \textit{Psilocybin-assisted psychotherapy in adults with depression - A literature review.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2025.111508}{doi:10.1016/j.pnpbp.2025.111508}.
\item Chisamore N, Kaczmarek ES, Doyle Z, Johnson DE, Weiglein G, Meshkat S, Brudner RM, Blainey MG, Riva-Cambrin J, McIntyre RS, Rosenblat JD (2025). \textit{Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude.}. Canadian journal of psychiatry. Revue canadienne de psychiatrie. [published; PubMed]. \href{https://doi.org/10.1177/07067437251328316}{doi:10.1177/07067437251328316}.
\item Borgogna NC, Owen T, Petrovitch D, Vaughn J, Johnson DAL, Pagano LA, Aita SL, Hill BD (2025). \textit{Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-025-06788-w}{doi:10.1007/s00213-025-06788-w}.
\item Borgogna NC, Owen T, Petrovitch D, Vaughn J, Johnson DAL, Pagano LA, Aita SL, Hill BD (2025). \textit{Correction to: Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-025-06818-7}{doi:10.1007/s00213-025-06818-7}.
\item Pellegrini L, Fineberg NA, O'Connor S, De Souza AMFLP, Godfrey K, Reed S, Peill J, Healy M, Rohani-Shukla C, Lee H, Carhart-Harris R, Robbins TW, Nutt D, Erritzoe D (2025). \textit{Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study.}. Comprehensive psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.comppsych.2025.152619}{doi:10.1016/j.comppsych.2025.152619}.
\item Park D, Lee G, Lee WG, Kim B, Lee Y, Kim JW (2025). \textit{The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-025-03100-2}{doi:10.1038/s41380-025-03100-2}.
\item Jain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, Suomivuori CM, Huang XP, Shub L, DiBerto JF, Kim K, DeLeon C, Krumm BE, Fay JF, Keiser M, Hauser AS, Dror RO, Shoichet B, Gloriam DE, Nichols DE, Roth BL (2025). \textit{The polypharmacology of psychedelics reveals multiple targets for potential therapeutics.}. Neuron. [published; PubMed]. \href{https://doi.org/10.1016/j.neuron.2025.06.012}{doi:10.1016/j.neuron.2025.06.012}.
\item Rosa I, Padula LP, Semeraro F, Marrangone C, Inserra A, De Risio L, Boffa M, Zoratto F, Borgi M, Guidotti R, Lorenzo GD, D'Addario C, Pettorruso M, Martinotti G (2025). \textit{Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2025.116697}{doi:10.1016/j.psychres.2025.116697}.
\item Tap SC, Thomas K, Páleníček T, Stenbæk DS, Oliveira-Maia AJ, van Dalfsen JH, Schoevers RA (2025). \textit{Concomitant use of antidepressants and classic psychedelics: A scoping review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251368360}{doi:10.1177/02698811251368360}.
\item Bonniwell EM, Alabdali R, Hennessey JJ, McKee JL, Cavalco NG, Lammers JC, Moore EJ, Franchini L, Orlandi C, McCorvy JD (2025). \textit{Serotonin 5-HT Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.5c00647}{doi:10.1021/acschemneuro.5c00647}.
\item Sabé M, Seragnoli F, Penzenstadler L, Thorens G (2025). \textit{[Role of psychedelics in psychiatry: a true therapeutic revolution or a trend?].}. La Revue du praticien. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/41575100/}{source link}.
\item Anneliese McConnell, Wei He, Harry McConnell, Sandro Sprendei, Paul F. Sowman (2025). \textit{3642 Down the rabbit hole: case reports of a hallucinogen-induced disorder of neuroperception}. Poster Abstracts. [published; OpenAlex]. \href{https://doi.org/10.1136/bmjno-2025-anzan.170}{doi:10.1136/bmjno-2025-anzan.170}.
\item Stefania Chiappini, Clara Cavallotto, Andrea Miuli, Giacomo d’Andrea, Alessio Mosca, Carlotta Marrangone, Rita Allegretti, Serena Panichella, Antonio d'Attilio, Giovanna Mammarella, Luca Persico, Alessia Santeusanio, Gianfranco Tamagnini, Mauro Pettorruso, Giovanni Martinotti (2025). \textit{Novel perspectives for glutamatergic strategies, psychedelics and antipsychotic augmentation in Treatment Resistant Depression: A narrative review}. Clinical Neuropsychopharmacology and Addiction. [published; OpenAlex]. \href{https://doi.org/10.53941/cna.2025.100006}{doi:10.53941/cna.2025.100006}.
\item Healing Advocacy Fund (2025). \textit{Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07189988}{source link}.
\item Matthew Halma, R. Levy, Joseph Varón (2025). \textit{With great power comes great responsibility: Promise and caution in the new psychedelic renaissance}. Brain Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.dscb.2025.100286}{doi:10.1016/j.dscb.2025.100286}.
\item Knock E, Siefried KJ, Bedi G, Albert S, Day RO, Ezard N, Ross M, Liknaitzky P, Brett J (2025). \textit{Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study.}. Addiction (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1111/add.70187}{doi:10.1111/add.70187}.
\item Benjamin R. Lewis (22279166), John Hendrick (22279169), Kevin Byrne (1610821), Madeleine Odette (22279172), Chaorong Wu (8444343), Eric L. Garland (4666660) (2025). \textit{S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial}. Figshare. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pmed.1004519.s001}{doi:10.1371/journal.pmed.1004519.s001}.
\item Beaglehole B, Manuel J (2025). \textit{Reappraisal of the hype and hope offered by psilocybin treatment of depression.}. The New Zealand medical journal. [published; PubMed]. \href{https://doi.org/10.26635/6965.7138}{doi:10.26635/6965.7138}.
\item Lopez, Alissa A, Salloum, Ihsan, Lopez-Alvarenga, Juan C (2025). \textit{Efficacy of Psychedelics Therapy Across Psychiatric Disorders: An Umbrella Review of Meta-Analyses}. ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley). [published; OpenAlex]. \href{https://scholarworks.utrgv.edu/colloquium/2025/talks/1}{source link}.
\item Emma M. Bonniwell (14267047), Rana Alabdali (22241286), Joseph J. Hennessey (22241289), John L. McKee (22179170), Natalie G. Cavalco (20388684), Josie C. Lammers (22241292), Ethan J. Moore (22241295), Luca Franchini (10578054), Cesare Orlandi (204175), John D. McCorvy (1416910) (2025). \textit{Serotonin 5-HT2C Receptor SignalingAnalysis Reveals Psychedelic Biased Agonism}. Figshare. [published; OpenAlex]. \href{https://doi.org/10.1021/acschemneuro.5c00647.s001}{doi:10.1021/acschemneuro.5c00647.s001}.
\item Kargbo RB (2025). \textit{Therapeutic Divergence in 5-HTA Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome.}. ACS medicinal chemistry letters. [published; PubMed]. \href{https://doi.org/10.1021/acsmedchemlett.5c00475}{doi:10.1021/acsmedchemlett.5c00475}.
\item King's College London (2025). \textit{Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07164755}{source link}.
\item Alan K. Davis, Meghan DellaCrosse, Nathan D. Sepeda, Adam W. Levin, Mary P Cosimano, Hillary Shaub, Washington Taylor, Peter M. Gooch, Shoval Gilead, Skylar J. Gaughan, Stacey B. Armstrong, Frederick S. Barrett (2025). \textit{Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2025.00461}{doi:10.1556/2054.2025.00461}.
\item Andrade FRT, Buchborn T, Thalheimer G, Meinhardt MW, Joca S, de Almeida RMM (2025). \textit{Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence.}. Acta neuropsychiatrica. [published; PubMed]. \href{https://doi.org/10.1017/neu.2025.10039}{doi:10.1017/neu.2025.10039}.
\item Kaylee Reid, Daniel Kot, Argel Aguilar-Valles (2025). \textit{Therapeutic Effects of Psychedelics and their Non-Hallucinogenic Analogs on Depressive-Like Behaviour}. Carleton undergraduate journal of science.. [published; OpenAlex]. \href{https://doi.org/10.22215/cujs.v5i1.5286}{doi:10.22215/cujs.v5i1.5286}.
\item Gregor Hasler (2025). \textit{Gregor Hasler: Three Guiding Questions - How do psychedelics shape the brain? How can they heal psychiatric disorders such as depression and PTSD? How can we ensure their safe and responsible use?}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp025k.0032}{doi:10.61373/pp025k.0032}.
\item Kerem Kemal Soylemez, Emma Marie de Boo, Aysil Susuzlu, Joanne Lusher (2025). \textit{Neuroplasticity and Neuro-Generation: The Promise of Psychedelics in Dementia Care}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives4030031}{doi:10.3390/psychoactives4030031}.
\item Khyber Medical University Peshawar (2025). \textit{Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06746441}{source link}.
\item Chris Simms (2025). \textit{We may know why psilocybin helps treat mental health conditions}. The New Scientist. [published; OpenAlex]. \href{https://doi.org/10.1016/s0262-4079(25)01446-0}{doi:10.1016/s0262-4079(25)01446-0}.
\item M Mercier, Cédric Mabilais, Vasileios Chytas, Leonice Furtado, Federico Seragnoli, Albert Buchard, Tatiana Aboulafia Brakha, Gabriel Thorens, Daniele Zullino, Louise Penzenstadler (2025). \textit{Psilocybin-Assisted Psychotherapy for Chronic Somatoform Pain Disorder: A Case Report}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives4030030}{doi:10.3390/psychoactives4030030}.
\item Anna Blazhkova, Magdalena Czaja, Hanna Sitka, Sven Solisch, Anna Susłow, Ewa Szczęsna (2025). \textit{PSYCHEDELICS IN PSYCHIATRY - OVERVIEW OF PSILOCYBIN RESEARCH}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.3(47).2025.3650}{doi:10.31435/ijitss.3(47).2025.3650}.
\item Sudhakaran G, Chakraborty S, Aung San, Bharti SAK, Csaba V, Valan Arasu M, Namasivayam SKR, Arockiaraj J. (2025). \textit{Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review}. Curr Microbiol. [published; Europe PMC]. \href{https://europepmc.org/article/AGR/IND609227368}{source link}.
\item Keller MR, McKinney MG, Sen AK, Guagliardo FG, Hellwarth EB, Islam KN, Kaplan NA, Gibbons WJ, Kemmerly GE, Meers C, Wang X, Jones JA (2025). \textit{Psilocybin biosynthesis enhancement through gene source optimization.}. Metabolic engineering. [published; PubMed]. \href{https://doi.org/10.1016/j.ymben.2025.04.003}{doi:10.1016/j.ymben.2025.04.003}.
\item Blanton AM, Parikh P, Zhou S, Mohamed M, Ufret-Vincenty RL, Mancini R (2025). \textit{Self-inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms.}. American journal of ophthalmology case reports. [published; PubMed]. \href{https://doi.org/10.1016/j.ajoc.2025.102359}{doi:10.1016/j.ajoc.2025.102359}.
\item Brudner RM, Kaczmarek E, Blainey MG, Schulz-Quach C, Meshkat S, Doyle Z, Lipsitz O, Offman H, Sethi R, Weiglein G, McIntyre RS, Rosenblat JD (2025). \textit{Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251346697}{doi:10.1177/02698811251346697}.
\item Nadeem Z, Parker S, McGovern H, Sebben B, Oestreich LK (2025). \textit{Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers.}. The Australian and New Zealand journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1177/00048674251346679}{doi:10.1177/00048674251346679}.
\item Cherup NP, Finan PH (2025). \textit{Psilocybin as a psychophysical adaptogen in chronic pain rehabilitation.}. The journal of pain. [published; PubMed]. \href{https://doi.org/10.1016/j.jpain.2025.105507}{doi:10.1016/j.jpain.2025.105507}.
\item Lewis BR, Hendrick J, Byrne K, Odette M, Wu C, Garland EL (2025). \textit{Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial.}. PLoS medicine. [published; PubMed]. \href{https://doi.org/10.1371/journal.pmed.1004519}{doi:10.1371/journal.pmed.1004519}.
\item David Nutt, David Erritzøe, Anne Katrin Schlag, David Luke, Deborah C. Mash, Hiroyuki Uchida, Jacob S. Aday, James Rucker, Liliana Galindo, Mark Sweeney, Matthew X. Lowe, Oliver Davis, Plinio Ferreira, Rayyan Zafar, Robin Carhart-Harris, Tadeusz Hawrot, Joanna C. Neill (2025). \textit{A lexicon for psychedelic research and treatment}. Drug Science Policy and Law. [published; OpenAlex]. \href{https://doi.org/10.1177/20503245251380511}{doi:10.1177/20503245251380511}.
\item Askariyan K, Joghataei MT, Dehghan S, Nohesara S, Riahi Pour L, Mohammadi MH, Ahmadirad N (2025). \textit{An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2025.111461}{doi:10.1016/j.pnpbp.2025.111461}.
\item Avanceña ALV, Vuong L, Kahn JG, Marseille E (2025). \textit{Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-025-03556-4}{doi:10.1038/s41398-025-03556-4}.
\item Andres-Olivera P, de la Iglesia J, Dominguez-Alvarez E, Soto’Gonzalez P, Rodriguez C, Munaiz-Cossio C, Gonzalez-Bolaños R, Brito-Rey R, Marín-Lorenzo C, Arribas-Simon B. (2025). \textit{Psilocybin: Systematic review of its use in the treatment of depression}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC12436869}{source link}.
\item Elise C. Tarbi, Skye A. Miner, Kabir Nigam, Zachary Sager, Justin J. Sanders, Michael Ljuslin, Benjamin Guérin, Kimberly Roddy, James A. Tulsky, Manish Agrawal, Yvan Beaussant (2025). \textit{“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251370303}{doi:10.1177/28314425251370303}.
\item Zeifman R, Danias G, Agin-Liebes G, Pagni B, Kettner H, Bhat V, Ross S, Erritzoe D, Carhart-Harris R (2025). \textit{Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-Compassion.}. Research square. [published; PubMed]. \href{https://doi.org/10.21203/rs.3.rs-7420529/v1}{doi:10.21203/rs.3.rs-7420529/v1}.
\item Centre Hospitalier Universitaire de Nīmes (2025). \textit{Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression: a Pilot Clinical Neuroimaging Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06650800}{source link}.
\item COMPASS Pathways (2025). \textit{A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05733546}{source link}.
\item Singleton SP, Sevchik BL, Lahey A, Cuijpers P, Harrer M, Jones MT, Nayak SM, Strain EC, Vandekar SN, Dworkin RH, Scott JC, Satterthwaite TD. (2025). \textit{Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2025.08.13.25333530}{doi:10.1101/2025.08.13.25333530}.
\item Repple J, Bayas M, Möser C, Kobayashi NF, Reif A (2025). \textit{Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action.}. Biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.biopsych.2025.02.903}{doi:10.1016/j.biopsych.2025.02.903}.
\item Silczuk A, Madejek RJ, Koweszko T, Mularczyk-Tomczewska P, Adamska E, Gujski M, Szulc A (2025). \textit{Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment.}. Medical science monitor: international medical journal of experimental and clinical research. [published; PubMed]. \href{https://doi.org/10.12659/msm.948302}{doi:10.12659/msm.948302}.
\item Fernández-Borkel T, Borkel LF, Rojas-Hernández J, Hernández-Álvarez E, Quintana-Hernández DJ, Ponti LG, Henríquez-Hernández LA (2025). \textit{The Causal Role of Consciousness in Psychedelic Therapy for Treatment-Resistant Depression: Hypothesis and Proposal.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.5c00445}{doi:10.1021/acsptsci.5c00445}.
\item Trevor R. Norman (2025). \textit{The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression?}. Exploration of neuroscience. [published; OpenAlex]. \href{https://doi.org/10.37349/en.2025.1006105}{doi:10.37349/en.2025.1006105}.
\item Argel Aguilar-Valles, Dhiral Kot, Victor Lewis, Gianfilippo Coppola (2025). \textit{544. MOLECULAR AND CELLULAR MECHANISMS OF THE LONG-LASTING EFFECTS OF PSYCHEDELICS AND THEIR NON-HALLUCINOGENIC DERIVATIVES}. The International Journal of Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1093/ijnp/pyaf052.363}{doi:10.1093/ijnp/pyaf052.363}.
\item Guy M. Goodwin (2025). \textit{670. CAN WE RE-MEDICALISE THE PSYCHEDELIC EXPERIENCE?}. The International Journal of Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1093/ijnp/pyaf052.159}{doi:10.1093/ijnp/pyaf052.159}.
\item G Martinotti, C Cavallotto, G D'Andrea, A D'Attilio, G Mammarella, F Zoratto, M Pettorruso (2025). \textit{631. PSILOCYBIN AND KETANSERIN VS RTMS IN TREATMENT-RESISTANT DEPRESSION: ENHANCING TOLERABILITY BY MITIGATING PSYCHEDELIC EFFECTS}. The international journal of neuropsychopharmacology. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC12359594}{source link}.
\item S Meikle, O Carter, P Liknaitzky, L Johansen, R Iyer, N Strauss, M Williams, D Castle, S Rossell (2025). \textit{229. PSILOCYBIN WITH PSYCHOTHERAPEUTIC SUPPORT FOR TREATMENT-RESISTANT DEPRESSION: A PILOT CLINICAL TRIAL}. The international journal of neuropsychopharmacology. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC12359778}{source link}.
\item S Kasper (2025). \textit{597. ARE SIDE EFFECTS NECESSARY FOR ANTIDEPRESSIVE TREATMENT: THE PSILOCYBIN EXPERIENCE}. The international journal of neuropsychopharmacology. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC12359505}{source link}.
\item Hashimoto K (2025). \textit{Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?}. European archives of psychiatry and clinical neuroscience. [published; PubMed]. \href{https://doi.org/10.1007/s00406-024-01770-7}{doi:10.1007/s00406-024-01770-7}.
\item Swieczkowski D, Kwaśny A, Sadko K, Pruc M, Gaca Z, Szarpak L, Cubała WJ (2025). \textit{Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2025.116559}{doi:10.1016/j.psychres.2025.116559}.
\item Berkovitch L, Fauvel B, Preller KH, Gaillard R (2025). \textit{Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans.}. Neuroscience and biobehavioral reviews. [published; PubMed]. \href{https://doi.org/10.1016/j.neubiorev.2025.106239}{doi:10.1016/j.neubiorev.2025.106239}.
\item Vinarcsik L, Smoller C, Grossberg G (2025). \textit{Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.}. Drugs \& aging. [published; PubMed]. \href{https://doi.org/10.1007/s40266-025-01221-5}{doi:10.1007/s40266-025-01221-5}.
\item Bayes A (2025). \textit{Australia's psychedelic experiment: reflections from a psychiatrist clinical researcher.}. Australasian psychiatry: bulletin of Royal Australian and New Zealand College of Psychiatrists. [published; PubMed]. \href{https://doi.org/10.1177/10398562251347890}{doi:10.1177/10398562251347890}.
\item Adebo M, Bonnet M, Laouej O, Defaix C, McGowan JC, Butlen-Ducuing F, David DJ, Poupon E, Tritschler L, Gardier AM (2025). \textit{Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms.}. Fundamental \& clinical pharmacology. [published; PubMed]. \href{https://doi.org/10.1111/fcp.70038}{doi:10.1111/fcp.70038}.
\item Hughes B, Mirza S, Ponamala M, Sagaser J, Paredes R, Hematillake N, Tailor C, Khan R, Pemminati S (2025). \textit{Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.90425}{doi:10.7759/cureus.90425}.
\item Fernandes-Nascimento MH, Viana-Ferreira K, Negrão AB (2025). \textit{Overview and Specificity of Psilocybin Use in the Treatment of Mental Disorders:.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2024.0031}{doi:10.1089/psymed.2024.0031}.
\item Hiroe Tani (2025). \textit{577. CLINICAL EVIDENCE AND APPLICATIONS OF PSYCHEDELICS FOR MENTAL ILLNESSES}. The International Journal of Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1093/ijnp/pyaf052.377}{doi:10.1093/ijnp/pyaf052.377}.
\item Cheung K, Brodie M, Chang SL, Deschamps P, Fallu JS, Farzin H, Hébert J, Stephan JF, Dorval M, Joly Y, P3A Study Group (2025). \textit{Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians' Concerns.}. The Journal of law, medicine \& ethics: a journal of the American Society of Law, Medicine \& Ethics. [published; PubMed]. \href{https://doi.org/10.1017/jme.2025.10109}{doi:10.1017/jme.2025.10109}.
\item Ciszowski K, Ziaja A, Niedzielska-Andres E, Pomierny-Chamioło L (2025). \textit{Natural hallucinogens of fungal and animal origin: action and potentialapplications - a narrative review.}. Folia medica Cracoviensia. [published; PubMed]. \href{https://doi.org/10.24425/fmc.2025.156119}{doi:10.24425/fmc.2025.156119}.
\item Heidi Allen, B. Stott (2025). \textit{Preparing Social Work for Psychedelic-Assisted Therapy}. Social Work. [published; OpenAlex]. \href{https://doi.org/10.1093/sw/swaf031}{doi:10.1093/sw/swaf031}.
\item Barbara Anna Zapalska, Antonina Teresa Witkowska, Anna Cukrowska, Artur Galus (2025). \textit{Psilocybin-assisted treatment of depression}. Medical Science. [published; OpenAlex]. \href{https://doi.org/10.54905/disssi.v29i161.e110ms3657}{doi:10.54905/disssi.v29i161.e110ms3657}.
\item Luquiens A, Belahda D, Graux C, Igounenc N, Serrand C, Rochefort P, Mura T, Sergent F (2025). \textit{Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial.}. Addiction (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1111/add.70152}{doi:10.1111/add.70152}.
\item Emory University (2025). \textit{The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05506982}{source link}.
\item Cioe PA, Stang GS, Azam D, Dugal S (2025). \textit{"I've learned that I'm open-minded to this possibility": A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke.}. Addiction science \& clinical practice. [published; PubMed]. \href{https://doi.org/10.1186/s13722-025-00563-0}{doi:10.1186/s13722-025-00563-0}.
\item Urban MM, Zillich L, Rieser NM, Herdener M, Vollenweider FX, Spanagel R, Preller KH, Meinhardt MW. (2025). \textit{Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use Disorder}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.07.18.664368}{doi:10.1101/2025.07.18.664368}.
\item Michael-Paul Schallmo, Sophia Jungers, Ranji Varghese, Kathryn R. Cullen, Michael D. Evans, Jessica L. Nielson, Link Swanson (2025). \textit{Stronger visual surround suppression under psilocybin: A psychophysical and EEG pilot study}. Journal of Vision. [published; OpenAlex]. \href{https://doi.org/10.1167/jov.25.9.2091}{doi:10.1167/jov.25.9.2091}.
\item Sudhakaran G, Chakraborty S, Kumar A, Bharti SAK, Csaba V, Valan Arasu M, Namasivayam SKR, Arockiaraj J (2025). \textit{Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review.}. Current microbiology. [published; PubMed]. \href{https://doi.org/10.1007/s00284-025-04379-8}{doi:10.1007/s00284-025-04379-8}.
\item Miyuan Zhang (21677016), Haojiang Zhai (21677019), Longwei Yang (21677022), Haohong Li (5164970), Xiaohui Wang (19899) (2025). \textit{The Medial PrefrontalCortex Modulates Psychedelic-likeEffects of Psilocin}. Figshare. [published; OpenAlex]. \href{https://doi.org/10.1021/acsptsci.5c00324.s001}{doi:10.1021/acsptsci.5c00324.s001}.
\item Balazs Szigeti (2025). \textit{An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/97cqx\_v1}{source link}.
\item Yutong Song (2025). \textit{Explore the effect of psilocybin on depression and anxiety}. Arts Culture and Language. [published; OpenAlex]. \href{https://doi.org/10.61173/rcg8me57}{doi:10.61173/rcg8me57}.
\item Szigeti B. (2025). \textit{An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/97cqx\_v1}{doi:10.31234/osf.io/97cqx\_v1}.
\item Ahmed KE, Abu Nasrieh D, Banihani HA, Obaidat MF, Mazzawi T, Al-Tarawneh AK, Bani Mustafa R, Al Kayed Z (2025). \textit{Exploring Jordanian Physicians' and Medical Students' Perspectives on Ketamine and Psychedelic-Assisted Therapies: An Insight from the Middle East.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2025.2526403}{doi:10.1080/02791072.2025.2526403}.
\item Mark Haden, Sarah A. Paschall, Birgitta Woods (2025). \textit{Beyond prohibition: A public health analysis of naturalistic psychedelic use}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2025.00450}{doi:10.1556/2054.2025.00450}.
\item Tolle HM, Luppi AI, Lawn T, Roseman L, Nutt D, Carhart-Harris RL, Mediano PAM. (2025). \textit{Accurate and Interpretable Prediction of Antidepressant Treatment Response from Receptor-informed Neuroimaging}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.07.02.662710}{doi:10.1101/2025.07.02.662710}.
\item Rahbarnia A, Li Z, Fletcher PJ (2025). \textit{Effects of psilocybin, the 5-HT receptor agonist TCB-2, and the 5-HT receptor antagonist M100907 on visual attention in male mice in the continuous performance test.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-023-06474-9}{doi:10.1007/s00213-023-06474-9}.
\item Atiq MA, Baker MR, Voort JLV, Vargas MV, Choi DS (2025). \textit{Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-024-06599-5}{doi:10.1007/s00213-024-06599-5}.
\item Kolasa M, Nikiforuk A, Korlatowicz A, Solich J, Potasiewicz A, Dziedzicka-Wasylewska M, Bugno R, Hogendorf A, Bojarski A, Faron-Górecka A (2025). \textit{Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-024-06644-3}{doi:10.1007/s00213-024-06644-3}.
\item Bradley ER, Sakai K, Fernandes-Osterhold G, Szigeti B, Ludwig C, Ostrem JL, Tanner CM, Bock MA, Llerena K, Finley PR, O'Donovan A, Zuzuarregui JRP, Busby Z, McKernan A, Penn AD, Wang ACC, Rosen RC, Woolley JD (2025). \textit{Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/s41386-025-02097-0}{doi:10.1038/s41386-025-02097-0}.
\item Swieczkowski D, Kwaśny A, Pruc M, Gaca Z, Szarpak L, Cubała WJ (2025). \textit{Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis.}. Pharmacopsychiatry. [published; PubMed]. \href{https://doi.org/10.1055/a-2529-7029}{doi:10.1055/a-2529-7029}.
\item Harding R, Singer N, Wall MB, Hendler T, Erritzoe D, Nutt D, Carhart-Harris R, Roseman L (2025). \textit{Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-025-03035-8}{doi:10.1038/s41380-025-03035-8}.
\item Syed OA, Petranker R, Tsang B (2025). \textit{The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field.}. Neuroscience and biobehavioral reviews. [published; PubMed]. \href{https://doi.org/10.1016/j.neubiorev.2025.106204}{doi:10.1016/j.neubiorev.2025.106204}.
\item Chen MJQ, Chen-Li D, Chisamore N, Husain MI, Di Vincenzo JD, Mansur RB, Phan L, Johnson D, McIntyre RS, Rosenblat JD (2025). \textit{Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2025.116532}{doi:10.1016/j.psychres.2025.116532}.
\item Cummins BR, Billac GB, Nichols DE, Nichols CD (2025). \textit{5-HT receptors: Pharmacology and functional selectivity.}. Pharmacological reviews. [published; PubMed]. \href{https://doi.org/10.1016/j.pharmr.2025.100059}{doi:10.1016/j.pharmr.2025.100059}.
\item Harding R, Singer N, Wall MB, Hendler T, Erritzoe D, Nutt D, Carhart-Harris R, Roseman L (2025). \textit{Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-025-03066-1}{doi:10.1038/s41380-025-03066-1}.
\item Calnan M, Blest-Hopley G, Busch C, Adams M, Ruffell SGD, Piper T, Roseman L, Kettner H, Carhart-Harris R (2025). \textit{Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings.}. Brain and behavior. [published; PubMed]. \href{https://doi.org/10.1002/brb3.70660}{doi:10.1002/brb3.70660}.
\item Hieronymus F, López E, Werin Sjögren H, Lundberg J (2025). \textit{Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis.}. JAMA network open. [published; PubMed]. \href{https://doi.org/10.1001/jamanetworkopen.2025.24119}{doi:10.1001/jamanetworkopen.2025.24119}.
\item Brown Rodney, Hamilton Niall M., Mallon Connor, Stevenson James, Faley Michael T., Kargbo Robert B., Sherwood Alexander M., Upeandran Balasubramaniam (2025). \textit{Synthesis of Psilocin, Psilocybin and 5-MeO-DMT Succinate, All Labelled With Carbon-14 at the Indole 2-Position}. Journal of Labelled Compounds and Radiopharmaceuticals. [published; Crossref]. \href{https://doi.org/10.1002/jlcr.4155}{doi:10.1002/jlcr.4155}.
\item Schuman HDM, Savard C, Mina R, Barkova S, Conradi HSW, Deleemans JM, Carlson LE (2025). \textit{Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis.}. Current oncology (Toronto, Ont.). [published; PubMed]. \href{https://doi.org/10.3390/curroncol32070380}{doi:10.3390/curroncol32070380}.
\item Mathieu Fradet (2025). \textit{Increasing the Evaluation and Reporting Rigor of Psychotherapy Interventions in Treatments Involving Psychedelics}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives4030021}{doi:10.3390/psychoactives4030021}.
\item Nayiri Barton (2025). \textit{Evaluating Psilocybin as a Treatment for Neuropsychiatric Symptoms in Parkinson’s Disease}. Global Journal of Medical Research. [published; OpenAlex]. \href{https://doi.org/10.34257/gjmravol25is1pg1}{doi:10.34257/gjmravol25is1pg1}.
\item Paul Okugo Imoh, Aderonke Ajiboye, Tahir Kolawole Balogun, Amina Catherine Ijiga, Toyosi Motilola Olola, Emmanuel Oluwasayomi Ahmadu (2025). \textit{Exploring the integration of psychedelic-assisted therapy and digital mental health interventions in trauma recovery for underserved adults with high-functioning autism}. Magna Scientia Advanced Research and Reviews. [published; OpenAlex]. \href{https://doi.org/10.30574/msarr.2025.14.1.0079}{doi:10.30574/msarr.2025.14.1.0079}.
\item Koolen M, Wirsching A, Krediet E, van Elk M (2025). \textit{Assessing the Attitudes of Dutch Mental Health Care Professionals Toward Psychedelic-Assisted Psychotherapy: A Cross-Sectional Exploratory Study.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2025.2508156}{doi:10.1080/02791072.2025.2508156}.
\item Czopek A, Jończyk J, Fryc M, Kluzik D, Zagórska A (2025). \textit{Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.5c00152}{doi:10.1021/acschemneuro.5c00152}.
\item Agrawal M, Roddy K, Jenkins B, Leeks C, Emanuel E (2025). \textit{Long-term benefits of single-dose psilocybin in depressed patients with cancer.}. Cancer. [published; PubMed]. \href{https://doi.org/10.1002/cncr.35889}{doi:10.1002/cncr.35889}.
\item Erkizia-Santamaría I, Horrillo I, Martínez-Álvarez N, Pérez-Martínez D, Rivero G, Erdozain AM, Meana JJ, Ortega JE (2025). \textit{Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-025-03421-4}{doi:10.1038/s41398-025-03421-4}.
\item Jensen AA, Cecchi CR, Hibicke M, Bach AH, Kaadt E, Märcher-Rørsted E, Nichols CD, Elfving B, Kristensen JL (2025). \textit{The Selective Serotonin 5-HT Receptor Agonist ()-3-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)piperidine (LPH-5) Induces Persistent and Robust Antidepressant-Like Effects in Rodents.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.5c00208}{doi:10.1021/acsptsci.5c00208}.
\item Stephen Ross (2025). \textit{Stephen Ross: Psychedelic-assisted therapies for difficult-to-treat psychiatric and medical disorders}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp025k.0017}{doi:10.61373/pp025k.0017}.
\item Luke Lanham, Alistair R. McTaggart, James R. Falconer (2025). \textit{Is there mush-room to improve the environmental sustainability of psilocybin production?}. Journal of CO2 Utilization. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jcou.2025.103137}{doi:10.1016/j.jcou.2025.103137}.
\item Erkizia-Santamaría I, Martínez-Álvarez N, Salinas-Novoa L, Meana JJ, Ortega JE (2025). \textit{Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice.}. The international journal of neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1093/ijnp/pyaf035}{doi:10.1093/ijnp/pyaf035}.
\item Matthew Hicks (2025). \textit{Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06372197}{source link}.
\item National University of Natural Medicine (2025). \textit{Optimizing Microdosing and Meditation}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06560658}{source link}.
\item Frautschi PC, Singh AP, Stowe NA, Grady SM, Zahid Z, Banks MI, Yu JJ (2025). \textit{Effects of Psilocybin on Mouse Brain Microstructure.}. AJNR. American journal of neuroradiology. [published; PubMed]. \href{https://doi.org/10.3174/ajnr.a8634}{doi:10.3174/ajnr.a8634}.
\item Kolasa M, Nikiforuk A, Korlatowicz A, Solich J, Potasiewicz A, Dziedzicka-Wasylewska M, Bugno R, Hogendorf A, Bojarski A, Faron-Górecka A (2025). \textit{Correction to: Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-024-06654-1}{doi:10.1007/s00213-024-06654-1}.
\item Jungwirth J, von Rotz R, Dziobek I, Vollenweider FX, Preller KH (2025). \textit{Psilocybin increases emotional empathy in patients with major depression.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-024-02875-0}{doi:10.1038/s41380-024-02875-0}.
\item Becker AM, Humbert-Droz M, Mueller L, Jelušić A, Tolev A, Straumann I, Avedisian I, Erne L, Thomann J, Luethi D, Grünblatt E, Meyer Zu Schwabedissen H, Liechti ME (2025). \textit{Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial.}. Clinical pharmacology and therapeutics. [published; PubMed]. \href{https://doi.org/10.1002/cpt.3618}{doi:10.1002/cpt.3618}.
\item Umbacia MA, Leon MX, Quintero JM, Castro LM, Paez V, Dodd S, Bustos RH (2025). \textit{Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being.}. Expert opinion on emerging drugs. [published; PubMed]. \href{https://doi.org/10.1080/14728214.2025.2488786}{doi:10.1080/14728214.2025.2488786}.
\item Fonzo GA, Doss MK, Nemeroff CB (2025). \textit{There's More Than One Way to Bring Health Back: Divergent Effects of Psilocybin and Escitalopram Treatment on Emotional Brain Function in Depression.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20250247}{doi:10.1176/appi.ajp.20250247}.
\item Karthiyayini B, Kalyani NN, Gowdhami B, Muthuselvam M, Dharumadurai D (2025). \textit{Characterization and Identification of an Antimicrobial Compound Psilocybin from Psychedelic Mushroom.}. Indian journal of microbiology. [published; PubMed]. \href{https://doi.org/10.1007/s12088-024-01396-2}{doi:10.1007/s12088-024-01396-2}.
\item Mathew A, Dongre R, Kim SH, Turner J, Mathew A, Cherryholmes E, Mehrinfar M, Kamprath S (2025). \textit{The Clinical Applications of Psilocybin Therapies and Post-COVID Syndrome: A Comprehensive Narrative Review.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.86659}{doi:10.7759/cureus.86659}.
\item Joseph K, Collins J, Genovese T, Maxwell M, Lieberman JA, Osten P. (2025). \textit{Converging pathways: shared brain circuitry engaged by monoaminergic antidepressants, ketamine and psilocybin}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.05.26.655791}{doi:10.1101/2025.05.26.655791}.
\item Abboud A, Schiebrel C, Nahhas RW, Durkin S, Hua K, Redding H, Gainer D (2025). \textit{Patients' Attitudes Toward Hallucinogenic and Non-Hallucinogenic Psilocybin for Mental Health Treatment.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2025.2511752}{doi:10.1080/02791072.2025.2511752}.
\item University Hospital, Basel, Switzerland (2025). \textit{Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06796361}{source link}.
\item Palmer C, Ferber AT, Greenwald BD (2025). \textit{The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review.}. Brain sciences. [published; PubMed]. \href{https://doi.org/10.3390/brainsci15060572}{doi:10.3390/brainsci15060572}.
\item Hooper J, Williams S, Mueller R, Hutchison K. (2025). \textit{Age and cannabis co-use moderate experience and perceived benefits of psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/dczw2\_v1}{doi:10.31234/osf.io/dczw2\_v1}.
\item Jake Hooper, Sarah Williams, Raeghan Mueller, Kent Hutchison (2025). \textit{Age and cannabis co-use moderate experience and perceived benefits of psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/dczw2\_v1}{source link}.
\item Schäfer T, Sherwood A, Kirkland T, Krüger T, Worbs J, Kniemeyer O, Gressler M, Hoffmeister D (2025). \textit{In Vitro Psilocybin Synthesis by Co-Immobilized Enzymes.}. Chemistry (Weinheim an der Bergstrasse, Germany). [published; PubMed]. \href{https://doi.org/10.1002/chem.202501037}{doi:10.1002/chem.202501037}.
\item Basedow LA, Lottes L, Falkenberg I, Vogelbacher C, Yildiz C. (2025). \textit{Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatments}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/6hjkm\_v1}{doi:10.31234/osf.io/6hjkm\_v1}.
\item Lukas A. Basedow, Lynn Lottes, Irina Falkenberg, Christoph Vogelbacher, Cüneyt Yildiz (2025). \textit{Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatments}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/6hjkm\_v1}{source link}.
\item Icahn School of Medicine at Mount Sinai (2025). \textit{Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06592833}{source link}.
\item Ong Jennifer A. (2025). \textit{Psychedelic-assisted psychotherapy and its potential to manage demoralization: A brief exploration of an alternative approach to end of life care}. Advances in Complementary and Integrative Medicine. [published; Crossref]. \href{https://doi.org/10.70462/acim.2025.1.001}{doi:10.70462/acim.2025.1.001}.
\item Wang H, Wang X (2025). \textit{Exploring the Role of Psychedelics in Modulating Ego and Treating Neuropsychiatric Disorders.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.5c00247}{doi:10.1021/acschemneuro.5c00247}.
\item Michael A. Wheeler (2025). \textit{Michael A. Wheeler: Psychedelics and neuroimmune circuits-what a strange trip, indeed}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp025k.0011}{doi:10.61373/pp025k.0011}.
\item Wang Z, Robbins B, Zhuang R, Bruggen Rv, Sandini T, Li X, Zhang Y. (2025). \textit{Psilocybin Mitigates Behavioral Despair and Cognitive Impairment in Treatment-resistant Depression Model using Wistar Kyoto Rats}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-5493661/v1}{doi:10.21203/rs.3.rs-5493661/v1}.
\item Hannes Kettner (2025). \textit{Psychedelic therapy as relational medicine: psychosocial mechanisms in clinical and naturalistic contexts}. Open MIND. [published; OpenAlex]. \href{https://doi.org/10.25560/125300}{doi:10.25560/125300}.
\item Anna Lasch, Timo Schweikert, Eva Dora, Theresa Kolb, Hanne Lilian Schurig, Andreas Walther (2025). \textit{Psilocybin-gestützte Therapie von Depression, Angst und Suchtstörungen: Neurobiologische Grundlagen und klinische Anwendung}. Nervenheilkunde. [published; OpenAlex]. \href{https://doi.org/10.1055/a-2517-1621}{doi:10.1055/a-2517-1621}.
\item Menon V, Ramamurthy P, Venu S, Andrade C (2025). \textit{Randomized Controlled Trials of Psilocybin-Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis.}. Acta psychiatrica Scandinavica. [published; PubMed]. \href{https://doi.org/10.1111/acps.13778}{doi:10.1111/acps.13778}.
\item Liebnau J, Betzler F, Kerber A (2025). \textit{Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811241312866}{doi:10.1177/02698811241312866}.
\item Ghaznavi S, Richter SG (2025). \textit{Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges.}. Drugs. [published; PubMed]. \href{https://doi.org/10.1007/s40265-025-02172-2}{doi:10.1007/s40265-025-02172-2}.
\item Falchi-Carvalho M, Palhano-Fontes F, Wießner I, Barros H, Bolcont R, Laborde S, Ruschi B Silva S, Montanini D, C Barbosa D, Teixeira E, Florence-Vilela R, Almeida R, K A de Macedo R, Arichelle F, J Pantrigo É, V Costa-Macedo J, da Cruz Nunes JA, de Araújo Costa Neto LA, Nunes Ferreira LF, Dantas Corrêa L, da Costa Bezerra RB, Arcoverde E, Galvão-Coelho N, B Araujo D (2025). \textit{Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/s41386-025-02091-6}{doi:10.1038/s41386-025-02091-6}.
\item Weintraub MJ, Miklowitz DJ, Jeffrey JK (2025). \textit{Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder.}. Journal of psychiatric practice. [published; PubMed]. \href{https://doi.org/10.1097/pra.0000000000000853}{doi:10.1097/pra.0000000000000853}.
\item Acero VP, Flatt TA, Gooch PM, Gaughan SJ, Levin AW, Davis AK (2025). \textit{From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs.}. Expert review of clinical pharmacology. [published; PubMed]. \href{https://doi.org/10.1080/17512433.2025.2515866}{doi:10.1080/17512433.2025.2515866}.
\item Kit A, Conway K, Makarowski S, O'Regan G, Allen J, Shultz SR, Bodnar TS, Christie BR (2025). \textit{Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?}. Neurobiology of stress. [published; PubMed]. \href{https://doi.org/10.1016/j.ynstr.2025.100732}{doi:10.1016/j.ynstr.2025.100732}.
\item Sevander Saara Susan, Rissanen Marja-Liisa Susan (2025). \textit{The benefits and harm of psychedelics in the treatment of patients with mental health and substance abuse disorders: an integrative literature review}. Health, environment and sustainable development: interdisciplinary approach. [published; Crossref]. \href{https://doi.org/10.59476/hesdia.v0i1.700}{doi:10.59476/hesdia.v0i1.700}.
\item Denise C. Vidot, Amrit Baral, Bria-Necole Diggs, Ranya Marrakchi El Fellah, Kylee Krivijanski, Albert Garcia-Romeu, Winston De La Haye, Clarence Locklear, Girardin Jean-Louis (2025). \textit{0391 Racial/Ethnic Differences in Psychedelic Use and Sleep Satisfaction: Preliminary Findings from the Herbal Heart Study}. SLEEP. [published; OpenAlex]. \href{https://doi.org/10.1093/sleep/zsaf090.0391}{doi:10.1093/sleep/zsaf090.0391}.
\item Penzenstadler L, Baudois S, Lingenberg A, Catalano Chiuvé S, Tomkova E, Fleury V (2025). \textit{[Treatment with psychedelics: potential benefits in Parkinson's disease].}. Revue medicale suisse. [published; PubMed]. \href{https://doi.org/10.53738/revmed.2025.21.915.47180}{doi:10.53738/revmed.2025.21.915.47180}.
\item Kerem Kemal Soylemez, Emma Marie de Boo, Joanne Lusher (2025). \textit{Regulatory Challenges of Integrating Psychedelics into Mental Health Sector}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives4020011}{doi:10.3390/psychoactives4020011}.
\item Lapid MI, Pagali SR, Randall AL, Donovan KA, Bronars CA, Gauthier TA, Bock J, Lim SD, Carey EC, Sokolowski E, Ulrich AM, Hassett LC, Kung S, Whitford KJ, Olivier KR, D'Andre SD (2025). \textit{Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review.}. Palliative \& supportive care. [published; PubMed]. \href{https://doi.org/10.1017/s147895152500032x}{doi:10.1017/s147895152500032x}.
\item Kevin Boehnke (2025). \textit{A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With Fibromyalgia}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05128162}{source link}.
\item Beesley VL, Kennedy TJ, Maccallum F, Ross M, Harvey R, Rossell SL, Sarris J, Perkins D, Neale RE, Bennett-Levy J, Johnson S, Beebe H, Roset N, Strobel J, Parker S (2025). \textit{Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement.}. BMJ open. [published; PubMed]. \href{https://doi.org/10.1136/bmjopen-2024-095992}{doi:10.1136/bmjopen-2024-095992}.
\item Orly Lipsitz, Joshua D. Rosenblat (2025). \textit{194. Improving Workplace and Psychosocial Function in Treatment-Resistant Depression: Exploratory Outcomes From an Open-Label Feasibility Trial of Psilocybin-Assisted Psychotherapy}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2025.02.431}{doi:10.1016/j.biopsych.2025.02.431}.
\item Erica Kaczmarek, Nelson B. Rodrigues, Noah Chisamore, Zoe Doyle, Roger S. McIntyre, Rodrigo B. Mansur, Joshua D. Rosenblat (2025). \textit{187. Changes in Symptoms of Anhedonia With Psilocybin-Assisted Psychotherapy: A Secondary Analysis of a Randomized Clinical Trial for Treatment-Resistant Depression}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2025.02.424}{doi:10.1016/j.biopsych.2025.02.424}.
\item Danica E. Johnson, Erica Kaczmarek, Noah Chisamore, Orly Lipitz, Zoe Doyle, Rodrigo B. Mansur, Roger S. McIntyre, Joshua D. Rosenblat (2025). \textit{186. Assessing Cognitive Outcomes in Treatment-Resistant Depression Following Psilocybin-Assisted Psychotherapy}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2025.02.423}{doi:10.1016/j.biopsych.2025.02.423}.
\item Xue Zhang, Emily Zhai, Claire Bertrand, Sara Ellis, Isabelle Wydler, Anna J. Donnelly, Trisha Suppes, Leanne M. Williams (2025). \textit{166. Dynamic Mediodorsal Thalamus Activity Predicts and Reflects Longitudinal Treatment Outcomes in Psilocybin Therapy for Treatment-Resistant Depression}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2025.02.403}{doi:10.1016/j.biopsych.2025.02.403}.
\item University of Otago (2025). \textit{Psilocybin-assisted Interpersonal Therapy for Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05581797}{source link}.
\item Omidian H, Omidian A (2025). \textit{The Emergence of Psilocybin in Psychiatry and Neuroscience.}. Pharmaceuticals (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/ph18040555}{doi:10.3390/ph18040555}.
\item Lu OD, White K, Raymond K, Liu C, Klein AS, Green N, Vaillancourt S, Gallagher A, Shindy L, Li A, Wallquist K, Li R, Zou M, Casey AB, Cameron LP, Pomrenze MB, Sohal V, Kheirbek MA, Gomez AM, Lammel S, Heifets BD, Malenka R (2025). \textit{A multi-institutional investigation of psilocybin's effects on mouse behavior.}. bioRxiv: the preprint server for biology. [published; PubMed]. \href{https://doi.org/10.1101/2025.04.08.647810}{doi:10.1101/2025.04.08.647810}.
\item Jennifer Jones (2025). \textit{Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimization}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2025.1565852}{doi:10.3389/fpsyt.2025.1565852}.
\item Kurkova V, Winkler O, Greenshaw A, Jetly R, Swainson J, Lodewyk K, Saghafi P, Dennett E, Burback L (2025). \textit{Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2025.111333}{doi:10.1016/j.pnpbp.2025.111333}.
\item Bysiek A, Wojtas A, Szpręgiel I, Wawrzczak-Bargieła A, Maćkowiak M, Gołembiowska K (2025). \textit{The effect of low-dose psilocybin on brain neurotransmission and rat behavior.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2025.111347}{doi:10.1016/j.pnpbp.2025.111347}.
\item Sean M. Viña (2025). \textit{Minorities’ diminished psychedelic returns: Depression, suicide, distress, and serious mental illness}. Drug Science Policy and Law. [published; OpenAlex]. \href{https://doi.org/10.1177/20503245251337357}{doi:10.1177/20503245251337357}.
\item Sutherland I, Ho MF, Croarkin PE (2025). \textit{Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor.}. Journal of child and adolescent psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1089/cap.2024.0082}{doi:10.1089/cap.2024.0082}.
\item Irrmischer M, Puxty D, Yıldırım BO, Deijen JB, Engelbregt H (2025). \textit{Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-024-06733-3}{doi:10.1007/s00213-024-06733-3}.
\item Kim SH, Yang S, Jung J, Choi J, Kang M, Joo JY (2025). \textit{Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning-Based Advanced Perspectives.}. Advanced science (Weinheim, Baden-Wurttemberg, Germany). [published; PubMed]. \href{https://doi.org/10.1002/advs.202413786}{doi:10.1002/advs.202413786}.
\item Huang Z, Yao Y, Di R, Zhang J, Pan Y, Liu G (2025). \textit{De Novo Biosynthesis of Antidepressant Psilocybin in Escherichia coli.}. Microbial biotechnology. [published; PubMed]. \href{https://doi.org/10.1111/1751-7915.70135}{doi:10.1111/1751-7915.70135}.
\item Schenberg EE (2025). \textit{From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice.}. Pharmacology research \& perspectives. [published; PubMed]. \href{https://doi.org/10.1002/prp2.70097}{doi:10.1002/prp2.70097}.
\item Mimms C, Sotelo K, Khaliq AS (2025). \textit{Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.82532}{doi:10.7759/cureus.82532}.
\item Turkia M. (2025). \textit{Ayahuasca in the treatment of the consequences of chronic childhood sexual abuse in a religious community}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/mzkyv\_v1}{doi:10.31234/osf.io/mzkyv\_v1}.
\item Mika Turkia (2025). \textit{Ayahuasca in the treatment of the consequences of chronic childhood sexual abuse in a religious community}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/mzkyv\_v1}{source link}.
\item Meng C, Guo W, Xiao C, Wen Y, Zhu X, Zhang Q, Liang Y, Li H, Xu S, Qiu Y, Chen H, Lin WJ, Wu B (2025). \textit{Structural basis for psilocybin biosynthesis.}. Nature communications. [published; PubMed]. \href{https://doi.org/10.1038/s41467-025-58239-x}{doi:10.1038/s41467-025-58239-x}.
\item Henry J, Giribaldi B, Nutt DJ, Erritzoe D, Carhart-Harris R, Lyons T. (2025). \textit{The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2025.03.17.25324123}{doi:10.1101/2025.03.17.25324123}.
\item Portes MAM, Werle I, Bertoglio LJ (2025). \textit{Is there a place for psychedelics in sports practice?}. Acta neuropsychiatrica. [published; PubMed]. \href{https://doi.org/10.1017/neu.2025.13}{doi:10.1017/neu.2025.13}.
\item de Deus JL, Maia JM, Soriano RN, Amorim MR, Branco LGS (2025). \textit{Psychedelics in neuroinflammation: Mechanisms and therapeutic potential.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2025.111278}{doi:10.1016/j.pnpbp.2025.111278}.
\item Centre Hospitalier Universitaire de Nīmes (2025). \textit{Psilocybin in Alcohol Use Disorder With Comorbid Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06235411}{source link}.
\item University of Washington (2025). \textit{A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05163496}{source link}.
\item Meyer TD, Ibrahim M, Vale LN, Soares JC (2025). \textit{Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2024.12.044}{doi:10.1016/j.jad.2024.12.044}.
\item Farinha-Ferreira M, Miranda-Lourenço C, Galipeau C, Lenkei Z, Sebastião AM (2025). \textit{Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner.}. Neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.neuropharm.2024.110280}{doi:10.1016/j.neuropharm.2024.110280}.
\item Gattuso JJ, Wilson C, Li S, Hannan AJ, Renoir T (2025). \textit{Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin.}. European journal of pharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.ejphar.2025.177304}{doi:10.1016/j.ejphar.2025.177304}.
\item Valentin Yurievich Skryabin (2025). \textit{The renaissance of psychedelics in modern psychiatry: a new breakthrough or the myth of a “magic bullet”?}. Neurology Bulletin. [published; OpenAlex]. \href{https://doi.org/10.17816/nb639991}{doi:10.17816/nb639991}.
\item Bobak L, Dorney I, Kovacevich A, Barnett BS (2025). \textit{Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2025.2478097}{doi:10.1080/02791072.2025.2478097}.
\item Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (2025). \textit{Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT00302744}{source link}.
\item Dr Hafiz Shafique Ahmad, Muhammad Waqar Ali, Usman Ul Haq (2025). \textit{PSYCHEDELIC PHARMACOLOGY IN PSYCHIATRY: THE MECHANISMS AND THERAPEUTIC POTENTIAL OF PSILOCYBIN, MDMA, AND LSD IN MENTAL HEALTH DISORDERS}. Journal of medical \& health sciences review.. [published; OpenAlex]. \href{https://doi.org/10.62019/r713mw08}{doi:10.62019/r713mw08}.
\item Quah S, Glick C, Roseman L, Pasquini L, Carhart-Harris R, Saggar M. (2025). \textit{Revealing Changes in Linear and Nonlinear Functional Connectivity After Psilocybin and Escitalopram Treatment in Patients with Depression}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.03.05.641592}{doi:10.1101/2025.03.05.641592}.
\item Michał Orzechowski, Joanna Orzechowska, Paulina Fijałek, Jan Karczmarz, Aleksandra Paprocka, Marika Gutowska, Agnieszka Kosińska, Urszula Świrk, Wiktoria Belcarz, Katarzyna Kalinowska (2025). \textit{Risks of using psilocybin in treatment of treatment-resistant depression}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2025.79.58319}{doi:10.12775/jehs.2025.79.58319}.
\item University Hospital, Basel, Switzerland (2025). \textit{Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05523401}{source link}.
\item Aicher HD, Müller F, Gasser P (2025). \textit{Further education in psychedelic-assisted therapy - experiences from Switzerland.}. BMC medical education. [published; PubMed]. \href{https://doi.org/10.1186/s12909-025-06871-y}{doi:10.1186/s12909-025-06871-y}.
\item Craig, Danny R, Blalock, Eric M. (2025). \textit{Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?}. UKnowledge (University of Kentucky). [published; OpenAlex]. \href{https://uknowledge.uky.edu/jpns/vol2/iss1/1}{source link}.
\item Barnett BS, Mauney EE, King F (2025). \textit{Psychedelic-assisted therapy: An overview for the internist.}. Cleveland Clinic journal of medicine. [published; PubMed]. \href{https://doi.org/10.3949/ccjm.92a.24032}{doi:10.3949/ccjm.92a.24032}.
\item Goodwin GM, Nowakowska A, Atli M, Dunlop BW, Feifel D, Hellerstein DJ, Marwood L, Shabir Z, Mistry S, Stansfield SC, Teoh E, Tsai J, Young MB, Malievskaia E (2025). \textit{Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder.}. The Journal of clinical psychiatry. [published; PubMed]. \href{https://doi.org/10.4088/jcp.24m15449}{doi:10.4088/jcp.24m15449}.
\item Sabé M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L, Richard-Lepouriel H, Penzenstadler L, Seragnoli F, Thorens G, Zullino D, Preller K, Böge K, Leucht S, Correll CU, Solmi M, Kaiser S, Kirschner M (2025). \textit{Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-024-02800-5}{doi:10.1038/s41380-024-02800-5}.
\item Høgsted ES, Beliveau V, Ozenne B, Madsen MK, Svarer C, Dam VH, Johansen A, Fisher P, Knudsen GM, Frokjaer VG, Sankar A (2025). \textit{Consistent evidence that brain serotonin 2A receptor binding is positively associated with personality-based risk markers of depression.}. The British journal of psychiatry: the journal of mental science. [published; PubMed]. \href{https://doi.org/10.1192/bjp.2024.143}{doi:10.1192/bjp.2024.143}.
\item Dutcher EG, Krystal AD (2025). \textit{Treatment Expectancies and Psilocybin vs Escitalopram for Depression.}. JAMA psychiatry. [published; PubMed]. \href{https://doi.org/10.1001/jamapsychiatry.2024.4387}{doi:10.1001/jamapsychiatry.2024.4387}.
\item Goodwin GM, Aaronson ST, Alvarez O, Carhart-Harris R, Chai-Rees J, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Kirlic N, Licht RW, Marwood L, Meyer TD, Mistry S, Nowakowska A, Páleníček T, Repantis D, Schoevers RA, Simmons H, Somers M, Teoh E, Tsai J, Wahba M, Williams S, Young AH, Young MB, Zisook S, Malievskaia E (2025). \textit{The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2024.12.061}{doi:10.1016/j.jad.2024.12.061}.
\item Fleury V, Tomkova E, Catalano Chiuvé S, Penzenstadler L (2025). \textit{Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report.}. Journal of Parkinson's disease. [published; PubMed]. \href{https://doi.org/10.1177/1877718x241312604}{doi:10.1177/1877718x241312604}.
\item Petrušková A, Guhathakurta D, Akdaş EY, Perelló-Amorós B, Frischknecht R, Weiss EM, Páleníček T, Fejtová A (2025). \textit{Serotonergic Psychedelics Rapidly Modulate Evoked Glutamate Release in Cultured Cortical Neurons.}. Journal of neurochemistry. [published; PubMed]. \href{https://doi.org/10.1111/jnc.70020}{doi:10.1111/jnc.70020}.
\item Somers M, Scheepers FE (2025). \textit{Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20240121}{doi:10.1176/appi.ajp.20240121}.
\item Belitzky E, Ravani Carvalho LV, Taylor M, Ortiz CN, Baum L, Fiellin DA, Lustberg MB (2025). \textit{Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy.}. Cancer medicine. [published; PubMed]. \href{https://doi.org/10.1002/cam4.70586}{doi:10.1002/cam4.70586}.
\item Meshkat S, Kaczmarek E, Doyle Z, Brudner RM, Gomes FA, Blainey MG, Weiglein G, McIntyre RS, Mansur RB, Rosenblat JD (2025). \textit{Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2024.0032}{doi:10.1089/psymed.2024.0032}.
\item Dino F (2025). \textit{A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.80707}{doi:10.7759/cureus.80707}.
\item Serretti A (2025). \textit{Anhedonia: Current and future treatments.}. PCN reports: psychiatry and clinical neurosciences. [published; PubMed]. \href{https://doi.org/10.1002/pcn5.70088}{doi:10.1002/pcn5.70088}.
\item Petrovitch D, Hosford S, Littlefield AK, Austin-Robillard H. (2025). \textit{Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/26tz7\_v1}{doi:10.31234/osf.io/26tz7\_v1}.
\item Dan Petrovitch, Samuel Hosford, Andrew K. Littlefield, Heather Austin-Robillard (2025). \textit{Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/26tz7\_v1}{source link}.
\item Kargbo RB (2025). \textit{Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring.}. ACS medicinal chemistry letters. [published; PubMed]. \href{https://doi.org/10.1021/acsmedchemlett.5c00031}{doi:10.1021/acsmedchemlett.5c00031}.
\item Lucido MJ, Dunlop BW (2025). \textit{Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges.}. Brain sciences. [published; PubMed]. \href{https://doi.org/10.3390/brainsci15020161}{doi:10.3390/brainsci15020161}.
\item Shannon Hughes, Lucia Terpak, Reilly Capps, Pam Peters, Nicole Lilly, Dylan Rivard (2025). \textit{Psilocybin mushroom stewardship: A qualitative inquiry into practices and priorities of “underground” psilocybin mushroom practitioners}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2025.00375}{doi:10.1556/2054.2025.00375}.
\item de Miranda AS, C B Toscano E, Venna VR, Graeff FG, Teixeira AL (2025). \textit{Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches.}. Expert opinion on drug discovery. [published; PubMed]. \href{https://doi.org/10.1080/17460441.2025.2460674}{doi:10.1080/17460441.2025.2460674}.
\item Mori-Kreiner A, Aggarwal A, Bordoloi M (2025). \textit{Hallucinogen-Persisting Perception Disorder in a 16-Year-Old Adolescent.}. Psychopharmacology bulletin. [published; PubMed]. \href{https://doi.org/10.64719/pb.4525}{doi:10.64719/pb.4525}.
\item Daisuke Ibi, Rika Takaba, Keisuke Yoshida, Takayoshi Mamiya, Shinji Kitagaki, Masayuki Hiramatsu (2025). \textit{BEHAVIORAL ANALYSES OF ANTIDEPRESSANT-LIKE EFFECT OF SEROTONERGIC PSYCHEDELICS IN MICE}. The International Journal of Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1093/ijnp/pyae059.584}{doi:10.1093/ijnp/pyae059.584}.
\item Jérémie Richard, Sandeep M. Nayak, Nathan D. Sepeda, Albert Garcia-Romeu (2025). \textit{Latent Class Analysis of Changes in Substance Use and Depressive Symptoms following Naturalistic Psilocybin Use: Results from a Prospective Longitudinal Survey}. Drug and Alcohol Dependence. [published; OpenAlex]. \href{https://doi.org/10.1016/j.drugalcdep.2024.112184}{doi:10.1016/j.drugalcdep.2024.112184}.
\item *Leonard Lerer, Katherine Spear, Jeet Varia, Cecily Keim, Alex Buko, Karin Blakolmer, Bernard Lerer (2025). \textit{BEHAVIORAL PHENOTYPING AND METABOLOMIC COMPARISON OF CHEMICALLY SYNTHESIZED PSILOCYBIN AND PSYCHEDELIC MUSHROOM EXTRACT IN A ZEBRAFISH DEPRESSION MODEL}. The international journal of neuropsychopharmacology. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC11815225}{source link}.
\item Rebecca Harding, Natalie Ertl, Rayyan Zafar (2025). \textit{ASSOCIATIONS BETWEEN ESCITALOPRAM AND PSILOCYBIN THERAPY AND BRAIN RESTING-STATE FUNCTIONAL CONNECTIVITY IN MAJOR DEPRESSIVE DISORDER}. The international journal of neuropsychopharmacology. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC11814992}{source link}.
\item Jones G, Lowe MX, Nayak S, Sepeda N, Kettner H, Carhart-Harris R, Jackson H, Garcia-Romeu A (2025). \textit{Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2024.10.058}{doi:10.1016/j.jad.2024.10.058}.
\item Rogge K, Wagner TJ, Hoffmeister D, Rupp B, Werten S (2025). \textit{Substrate recognition by the 4-hydroxytryptamine kinase PsiK in psilocybin biosynthesis.}. FEBS letters. [published; PubMed]. \href{https://doi.org/10.1002/1873-3468.15042}{doi:10.1002/1873-3468.15042}.
\item Freitas RR, Gotsis ES, Gallo AT, Fitzgibbon BM, Bailey NW, Fitzgerald PB (2025). \textit{The safety of psilocybin-assisted psychotherapy: A systematic review.}. The Australian and New Zealand journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1177/00048674241289024}{doi:10.1177/00048674241289024}.
\item Geller J, Whitney E (2025). \textit{Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma.}. Current psychiatry reports. [published; PubMed]. \href{https://doi.org/10.1007/s11920-024-01577-2}{doi:10.1007/s11920-024-01577-2}.
\item Swieczkowski D, Kwaśny A, Pruc M, Gaca Z, Szarpak L, Cubała WJ (2025). \textit{Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2024.116337}{doi:10.1016/j.psychres.2024.116337}.
\item Louie E, Towers E, Morse AR, Watt J, Bryant Z, Haber P, Morley K (2025). \textit{The Acceptability of Psychedelic-Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour.}. International journal of mental health nursing. [published; PubMed]. \href{https://doi.org/10.1111/inm.70010}{doi:10.1111/inm.70010}.
\item Shaughnessy AF (2025). \textit{Among Psychedelics, Only Psilocybin Has Demonstrated Benefit to Treat Depression.}. American family physician. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/39964936/}{source link}.
\item Central Institute of Mental Health, Mannheim (2025). \textit{A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04670081}{source link}.
\item Melani A, Bonaso M, Biso L, Zucchini B, Conversano C, Scarselli M (2025). \textit{Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications.}. Pharmaceuticals (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/ph18010130}{doi:10.3390/ph18010130}.
\item Ellis S, Bostian C, Feng W, Fischer E, Schwartz G, Eisen K, Lean M, Conlan E, Ostacher M, Aaronson S, Suppes T (2025). \textit{Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2024.09.133}{doi:10.1016/j.jad.2024.09.133}.
\item Li JR, Chiang KT, Kao YC, Yu CL, Yang FC, Liang CS, Hsu TW (2025). \textit{The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2024.10.016}{doi:10.1016/j.jad.2024.10.016}.
\item Amin Sharifan (2025). \textit{What are the benefits and harms of classical psychedelics (psilocybin and LSD) for treating anxiety, depression, and existential distress in people with life-threatening diseases?}. Cochrane Clinical Answers. [published; OpenAlex]. \href{https://doi.org/10.1002/cca.4512}{doi:10.1002/cca.4512}.
\item Valerie A. Canady (2025). \textit{Study finds encouraging results in psilocybin treatment for TRD patients}. Mental Health Weekly. [published; OpenAlex]. \href{https://doi.org/10.1002/mhw.34292}{doi:10.1002/mhw.34292}.
\item Wang Z, Robbins B, Zhuang R, Sandini T, van Bruggen R, Li XM, Zhang Y (2025). \textit{Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar rats.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2024.111243}{doi:10.1016/j.pnpbp.2024.111243}.
\item Erkizia-Santamaría I, Horrillo I, Meana JJ, Ortega JE (2025). \textit{Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2025.111249}{doi:10.1016/j.pnpbp.2025.111249}.
\item Constantino JL, van Dalfsen JH, Massetti S, Kamphuis J, Schoevers RA (2025). \textit{Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2025.111251}{doi:10.1016/j.pnpbp.2025.111251}.
\item Destoop M, Mohr P, Butlen F, Kéri P, Samochowiec J, De Picker L, Fiorillo A, Kuypers KPC, Dom G (2025). \textit{Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper.}. European psychiatry: the journal of the Association of European Psychiatrists. [published; PubMed]. \href{https://doi.org/10.1192/j.eurpsy.2024.1806}{doi:10.1192/j.eurpsy.2024.1806}.
\item Eduardo d’Avila Lins Lacerda, Bianca Medeiros Ferraz da Nóbrega, Yasmin Mesquita Dias Franca Gadelha, Liliane Reis Teixeira, Manolo Altieri Espinar, Bruna Trigueiro Carlini, Gabriel Santa Cruz Lins, Anthonielly Leinat Lima, Isabel Azevedo, Paulo Heinrich Soares Bomtempo (2025). \textit{PSYCHEDELICS IN THE TREATMENT OF MENTAL DISORDERS}. Health and Society. [published; OpenAlex]. \href{https://doi.org/10.51249/hs.v5i01.2377}{doi:10.51249/hs.v5i01.2377}.
\item Zhang M, Yang Y, Yang Z, Wen X, Zhang C, Xiao P, Wang Y, Sun J, Wang H, Wang X (2025). \textit{Structural insights into tryptamine psychedelics: The role of hydroxyl indole ring site in 5-HT receptor activation and psychedelic-like activity.}. European journal of medicinal chemistry. [published; PubMed]. \href{https://doi.org/10.1016/j.ejmech.2024.117049}{doi:10.1016/j.ejmech.2024.117049}.
\item Socoró Garrigosa M, Sanz Perl Y, Kringelbach ML, Carhart-Harris R, Vohryzek J, Deco G. (2025). \textit{Perturbing whole-brain models of brain hierarchy: an application for depression following pharmacological treatment}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.01.01.631011}{doi:10.1101/2025.01.01.631011}.
\item Papp N, Gonda X (2025). \textit{[Psychedelics and pyschodelic-associated psychotherapies - Who is PAP for after all?].}. Psychiatria Hungarica: A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/42412648/}{source link}.
\item Machado Henrique Tofoli Vieira, Seixas Geovana Mendes de, Silva Luis Gustavo Alves, Brito Mariana Duarte Garcia, Castro Giovanna Miziara (2025). \textit{Alternative therapy for neurological and psychiatric disorders using psilocybin}. São Paulo Medical Journal. [published; Crossref]. \href{https://doi.org/10.5327/1516-3180.cpn.1123}{doi:10.5327/1516-3180.cpn.1123}.
\item Kostić Marina D., Nedić Jana, Dragojević Jovana S., Divac Vera M. (2025). \textit{In Silico Evaluation of Tryptamine-Derived Schiff Bases as Modulators of the Serotonin 5-HT₂A Receptor}. Book of Proceedings. [published; Crossref]. \href{https://doi.org/10.46793/iccbikg25.477k}{doi:10.46793/iccbikg25.477k}.
\item Madison M. H. Simounet, Joy Drinnon (2025). \textit{Attitudes Towards Psilocybin: A General Population’s Opinions on Psilocybin and Psilocybin-Assisted Therapies}. Psi Chi Journal of Psychological Research. [published; OpenAlex]. \href{https://doi.org/10.24839/2325-7342.jn30.4.345}{doi:10.24839/2325-7342.jn30.4.345}.
\item Rebecca Harding, Natalie Ertl, Rabia Zafar, Magnus Wall, Rajkanya Das, David Erritzøe, David Nutt, Robin Carhart-Harris (2025). \textit{Effects of escitalopram and psilocybin therapy on mesolimbic resting-state functional connectivity in depression}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2025.105421}{doi:10.1016/j.nsa.2025.105421}.
\item Friederike Klein (2025). \textit{Therapieresistente Depression: Studie zur Psilocybin-augmentierten Psychotherapie nicht erfolgreich}. InFo Neurologie + Psychiatrie. [published; OpenAlex]. \href{https://doi.org/10.1007/s15005-024-4209-z}{doi:10.1007/s15005-024-4209-z}.
\item Mile Jevtić (2025). \textit{The effects of psychedelics on neuroplasticity: A review of current research and the possibility of therapeutic application in psychiatry}. Engrami. [published; OpenAlex]. \href{https://doi.org/10.5937/engrami47-57385}{doi:10.5937/engrami47-57385}.
\item Joshua Woolley, MD, PhD (2025). \textit{Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04932434}{source link}.
\item Bahji A, Lunsky I, Gutierrez G, Vazquez G (2025). \textit{Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2023.2278586}{doi:10.1080/02791072.2023.2278586}.
\item Shah FI, Shehzadi S, Akram F, Haq IU, Javed B, Sabir S, Kazim Y, Ashfaq S (2025). \textit{Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy.}. Molecular biotechnology. [published; PubMed]. \href{https://doi.org/10.1007/s12033-023-00994-7}{doi:10.1007/s12033-023-00994-7}.
\item Humphreys K, Todd Korthuis P, Stjepanović D, Hall W (2025). \textit{Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money.}. Annual review of psychology. [published; PubMed]. \href{https://doi.org/10.1146/annurev-psych-020124-023532}{doi:10.1146/annurev-psych-020124-023532}.
\item Negrine JJ, Puljević C, Ferris J, Liknaitzky P, Perlman C, Piatkowski T (2025). \textit{Australian psychologists' attitudes towards psychedelic-assisted therapy and training following a world-first drug down-scheduling.}. Drug and alcohol review. [published; PubMed]. \href{https://doi.org/10.1111/dar.13973}{doi:10.1111/dar.13973}.
\item Richardson E, Patterson R, Meltzer-Brody S, McClure R, Tow A (2025). \textit{Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression.}. Annual review of medicine. [published; PubMed]. \href{https://doi.org/10.1146/annurev-med-050423-095712}{doi:10.1146/annurev-med-050423-095712}.
\item Kirlić N, Lennard-Jones M, Atli M, Malievskaia E, Modlin NL, Peck SK, Gaillard A, Goodwin GM, Koelpin D (2025). \textit{Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20230884}{doi:10.1176/appi.ajp.20230884}.
\item Fonzo GA, Wolfgang AS, Barksdale BR, Krystal JH, Carpenter LL, Kraguljac NV, Grzenda A, McDonald WM, Widge AS, Rodriguez CI, Nemeroff CB (2025). \textit{Psilocybin: From Psychiatric Pariah to Perceived Panacea.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20230682}{doi:10.1176/appi.ajp.20230682}.
\item Ramaekers JG, Reckweg JT, Mason NL (2025). \textit{Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20230890}{doi:10.1176/appi.ajp.20230890}.
\item Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, Lauterbach M, Suppes T, Sackeim HA (2025). \textit{Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20231063}{doi:10.1176/appi.ajp.20231063}.
\item Wolfgang AS, McClair VL, Schnurr PP, Holtzheimer PE, Woolley JD, Stauffer CS, Wolf RC, States LJ, Benedek DM, Capaldi VF, Bradley J, Fuller MA, Smyth MJ, Hermes EDA, Tenhula W, Wiechers IR (2025). \textit{Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20240751}{doi:10.1176/appi.ajp.20240751}.
\item Pagni BA, Zeifman RJ, Mennenga SE, Carrithers BM, Goldway N, Bhatt S, O'Donnell KC, Ross S, Bogenschutz MP (2025). \textit{Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20230887}{doi:10.1176/appi.ajp.20230887}.
\item Manzano-Nunez R, Gomez DA, Toledo-Mendoza C, Perez-Otero M, Matilla IL, Prats C, Perez-Lopez E, Pardo H, Díaz-Pellicer P, De La Torre-Fornell R, Aldea AM (2025). \textit{Exploring Psychedelics Pharmacology: A Scoping Review Charting the Course of Psilocybin Pharmacokinetics.}. Clinical neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1097/wnf.0000000000000617}{doi:10.1097/wnf.0000000000000617}.
\item Lewis BR, Hendrick J, Byrne K, Odette M, Wu C, Garland EL (2025). \textit{Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial.}. medRxiv: the preprint server for health sciences. [published; PubMed]. \href{https://doi.org/10.1101/2024.12.31.24319806}{doi:10.1101/2024.12.31.24319806}.
\item Bires J (2025). \textit{Existing evidence for the use of psychedelics in patients with cancer and other serious illness: A narrative review.}. Journal of psychosocial oncology. [published; PubMed]. \href{https://doi.org/10.1080/07347332.2025.2482917}{doi:10.1080/07347332.2025.2482917}.
\item Zhu X, Zhang C, Hellerstein D, Feusner JD, Wheaton MG, Gomez GJ, Schneier F (2025). \textit{Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder.}. Psychedelics. [published; PubMed]. \href{https://doi.org/10.61373/pp024r.0028}{doi:10.61373/pp024r.0028}.
\item Totomanova I, Haijen ECHM, Hurks PPM, Ramaekers JG, Kuypers KPC (2025). \textit{Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry?}. International review of neurobiology. [published; PubMed]. \href{https://doi.org/10.1016/bs.irn.2025.03.002}{doi:10.1016/bs.irn.2025.03.002}.
\item Wingert AM, Agnorelli C, Peill J, Reed S, Nutt DJ, Erritzoe D (2025). \textit{Serotonergic psychedelics for depression: A comprehensive overview.}. International review of neurobiology. [published; PubMed]. \href{https://doi.org/10.1016/bs.irn.2025.04.009}{doi:10.1016/bs.irn.2025.04.009}.
\item Tap S, Bostoen T, Breeksema J, Schoevers R (2025). \textit{Psychedelics for the treatment of end-of-life distress in patients with a life-threatening disease.}. International review of neurobiology. [published; PubMed]. \href{https://doi.org/10.1016/bs.irn.2025.03.001}{doi:10.1016/bs.irn.2025.03.001}.
\item Perez GM, Rosenberg BM, Xu W, Oathes DJ (2025). \textit{Brain changes associated with depression treatment: a meta-analysis.}. NeuroImage. Clinical. [published; PubMed]. \href{https://doi.org/10.1016/j.nicl.2025.103874}{doi:10.1016/j.nicl.2025.103874}.
\item Kinderlehrer DA (2025). \textit{Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.}. Neuropsychiatric disease and treatment. [published; PubMed]. \href{https://doi.org/10.2147/ndt.s500337}{doi:10.2147/ndt.s500337}.
\item Silva F, Butlen-Ducuing F, Guizzaro L, Balabanov P (2025). \textit{A review of psychedelics trials completed in depression, informed by European regulatory perspectives.}. Neuroscience applied. [published; PubMed]. \href{https://doi.org/10.1016/j.nsa.2025.105516}{doi:10.1016/j.nsa.2025.105516}.
\item Junges LH, Müller-Santos M (2025). \textit{Exploring the biocatalysis of psilocybin and other tryptamines: Enzymatic pathways, synthetic strategies, and industrial implications.}. Biotechnology progress. [published; PubMed]. \href{https://doi.org/10.1002/btpr.3513}{doi:10.1002/btpr.3513}.
\item Abramsky-Sze S, Marseille E, Matzopoulos R, Morlock R, Lerer L (2025). \textit{Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2025.1508811}{doi:10.3389/fpsyt.2025.1508811}.
\item Mauney E, King F, Burton-Murray H, Kuo B (2025). \textit{Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome.}. Journal of clinical gastroenterology. [published; PubMed]. \href{https://doi.org/10.1097/mcg.0000000000002149}{doi:10.1097/mcg.0000000000002149}.
\item Kratina S, Strike C, Schwartz R, Nayfeh A, Jopling S, Lo C, Rush B (2025). \textit{A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life.}. PloS one. [published; PubMed]. \href{https://doi.org/10.1371/journal.pone.0318343}{doi:10.1371/journal.pone.0318343}.
\item Hooper JF, Gyongyosi EL, Hutchison KE, Mueller RL (2025). \textit{Aesthetic quality of psychedelic experience is linked to insight and psychological outcomes.}. Frontiers in psychology. [published; PubMed]. \href{https://doi.org/10.3389/fpsyg.2025.1533055}{doi:10.3389/fpsyg.2025.1533055}.
\item Roseby W, Kettner H, Roseman L, Spriggs MJ, Lyons T, Peill J, Giribaldi B, Erritzoe D, Nutt DJ, Carhart-Harris RL (2025). \textit{Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies.}. Frontiers in psychology. [published; PubMed]. \href{https://doi.org/10.3389/fpsyg.2025.1580663}{doi:10.3389/fpsyg.2025.1580663}.
\item Modlin NL, Williamson V, Maggio C, Stubley J, Kirlic N, Cleare A, Rucker J (2025). \textit{Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/20451253251342319}{doi:10.1177/20451253251342319}.
\item De Gasperi R, Perez Garcia G, Gama Sosa MA, Perez GM, Abutarboush R, Kawoos U, Hof PR, Zhu CW, Ahlers ST, Elder GA (2025). \textit{Serotonin 5-HT2A receptor expression is chronically decreased in the anterior cerebral cortex of male rats following repetitive low-level blast exposure.}. Frontiers in neurology. [published; PubMed]. \href{https://doi.org/10.3389/fneur.2025.1594335}{doi:10.3389/fneur.2025.1594335}.
\item Marek J, Domek-Gumprecht M, Macionga A, Szafoni S, Więckiewicz G (2025). \textit{PolDrugs 2025: results of the third edition of the nationwide study on psychoactive substance use in the context of psychiatry and harm reduction.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2025.1591658}{doi:10.3389/fpsyt.2025.1591658}.
\item Barnett BS, Koons CJ, Van den Eynde V, Gillman PK, Bodkin JA (2025). \textit{Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2024.2368617}{doi:10.1080/02791072.2024.2368617}.
\item Małgorzata W, Kopczyk R, Gerlach A, Rymaszewska J (2025). \textit{Therapeutic and legal aspects of psilocybin in cancer-related depression.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2025.1591864}{doi:10.3389/fpsyt.2025.1591864}.
\item Adeyinka D, Forsyth D, Currie S, Faraone N (2025). \textit{Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models.}. Frontiers in systems neuroscience. [published; PubMed]. \href{https://doi.org/10.3389/fnsys.2025.1585367}{doi:10.3389/fnsys.2025.1585367}.
\item Blest-Hopley G, Pasculli G, Ruffell SGD, Tsang W, Emmanuel O, Pate KM, Kettner H, Roseman L, Erritzoe D, Carhart-Harris R (2025). \textit{Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2025.1594307}{doi:10.3389/fpsyt.2025.1594307}.
\item Thaoboonruang N, Lohitnavy M, Lohitnavy O (2025). \textit{Pharmacokinetics of Psilocybin, a Tryptamine Alkaloid in Magic Mushroom (): A Systematic Review.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2024.2399128}{doi:10.1080/02791072.2024.2399128}.
\item Hultgren J, Hafsteinsson MH, Brulin JG (2025). \textit{A dose of therapy with psilocybin - A meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy.}. General hospital psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.genhosppsych.2025.07.020}{doi:10.1016/j.genhosppsych.2025.07.020}.
\item Ross ML, Iyer R, Williams ML, Boughey M, O'Callaghan C, Hiscock R, Dwyer J (2025). \textit{Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial.}. General hospital psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.genhosppsych.2025.08.001}{doi:10.1016/j.genhosppsych.2025.08.001}.
\item Wong S, Meckling G, Fabiano N, Lee S, Jones BDM, Shorr R, Dargel A, Davis AK, Fiedorowicz JG, Solmi M, Rosenblat JD, Mulsant BH, Blumberger DM, Husain MI (2025). \textit{Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/20451253251372449}{doi:10.1177/20451253251372449}.
\item Wierzbicka M, Kopczyk R, Gerlach A, Rymaszewska J (2025). \textit{Correction: Therapeutic and legal aspects of psilocybin in cancer-related depression.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2025.1698185}{doi:10.3389/fpsyt.2025.1698185}.
\item Hooper JF, Ellingson JM, Hutchison KE (2025). \textit{Preliminary validation and refinement of the psychedelic aesthetic experience questionnaire.}. Frontiers in psychology. [published; PubMed]. \href{https://doi.org/10.3389/fpsyg.2025.1648968}{doi:10.3389/fpsyg.2025.1648968}.
\item Meikle S, Carter O, Liknaitzky P, Johansen L, Iyer R, Strauss N, Williams M, Castle D, Rossell SL (2025). \textit{Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/20451253251377187}{doi:10.1177/20451253251377187}.
\item Wong S, Jones BDM, Thiyagarajah MT, Sabbah SG, Thompson C, Solmi M, Umer M, Zrenner C, Voineskos D, Rosenblat JD, Mulsant BH, Blumberger DM, Husain MI (2025). \textit{Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/20451253251384513}{doi:10.1177/20451253251384513}.
\item Havlik JL, Isaac S, Raman P, Tran N, Hidalgo K, Suppes T (2025). \textit{Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders.}. Journal of clinical psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1097/jcp.0000000000002095}{doi:10.1097/jcp.0000000000002095}.
\item Beaussant Y, Tarbi E, Nigam K, Miner S, Sager Z, Sanders J, Ljuslin M, Guérin B, Sholevar R, Roddy K, Tulsky JA, Agrawal M (2025). \textit{Set and setting in psilocybin-assisted therapy: A qualitative study of patients with cancer and depression.}. General hospital psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.genhosppsych.2025.10.010}{doi:10.1016/j.genhosppsych.2025.10.010}.
\item Afsharnia S, Liang V, Lunsky Y, Orsini AP, Tint A, Lin HY (2025). \textit{Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey.}. PLOS mental health. [published; PubMed]. \href{https://doi.org/10.1371/journal.pmen.0000514}{doi:10.1371/journal.pmen.0000514}.
\item Sobieraj J, Sleziak J, Szyszka M, Błażejewska M, Łukańko K, Soczomska P, Bodziony K, Piotrowski P (2025). \textit{Self-administered complementary and alternative methods of treating mental disorders among students in Wrocław: a cross-sectional study.}. Frontiers in public health. [published; PubMed]. \href{https://doi.org/10.3389/fpubh.2025.1734137}{doi:10.3389/fpubh.2025.1734137}.
\item Khalaud Naseeb Alhajry, Zahra Mohammed Sukairi, Hamidah Abdullah Lajami, Safiah Anber Bin Ali Ibrahim, Nawal Obaid Alanazi, Eman Ali Alsafwani, Ashwag Saad Hnif Albishi, Nada Naser Alomi, Zahrh Ahmed Ali Al-Hamadah, Anwar Mehdaf Akash Alrowaly (2024). \textit{Psychedelic-Assisted Therapy: The Emerging Role of the Psychiatric-Mental Health Nurse}. Saudi Journal of Medicine and Public Health. [published; OpenAlex]. \href{https://doi.org/10.64483/20251153}{doi:10.64483/20251153}.
\item Mohammad Ali, Urbah Viqar (2024). \textit{Treatment-Resistant Depression: A Comprehensive Insight of Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Psychedelic-Assisted Psychotherapy}. Annals of Punjab Medical College. [published; OpenAlex]. \href{https://doi.org/10.29054/apmc/2024.1658}{doi:10.29054/apmc/2024.1658}.
\item Muniz, John Marco D.F. (2024). \textit{Comparative Efficacy of Hallucinogens in Treating Mood Disorders Through a Meta-Analysis of Symptom Reduction, Dosage, and Duration}. Journal of International Crisis and Risk Communication Research. [published; OpenAlex]. \href{https://stars.library.ucf.edu/hut2024/268}{source link}.
\item Spangemacher M, Mertens LJ, Färber LV, Jungaberle A, Jungaberle H, Gründer G (2024). \textit{Psilocybin as a Disease-Modifying Drug-A Salutogenic Approach in Psychiatry.}. Deutsches Arzteblatt international. [published; PubMed]. \href{https://doi.org/10.3238/arztebl.m2024.0224}{doi:10.3238/arztebl.m2024.0224}.
\item García-Cabrerizo R, Beruete-Fresnillo I, García-Fuster MJ. (2024). \textit{Characterizing psilocybin as an antidepressant for adolescence in male and female rats}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.12.20.629571}{doi:10.1101/2024.12.20.629571}.
\item Barnett JH, Todd KT, Benetatos J, Rabichow BE, Gibson KA, Olney KC, Fryer JD. (2024). \textit{Psilocybin causes sex, time, and dose dependent alterations in brain signaling pathways}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.12.16.628764}{doi:10.1101/2024.12.16.628764}.
\item Kargbo RB (2024). \textit{Advances in Psychedelic Therapeutics: Novel Prodrugs and Derivatives for Enhanced Mental Health Treatment.}. ACS medicinal chemistry letters. [published; PubMed]. \href{https://doi.org/10.1021/acsmedchemlett.4c00519}{doi:10.1021/acsmedchemlett.4c00519}.
\item Wahba M, Hayes C, Kletter M, McAllister-Williams RH (2024). \textit{Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience.}. BJPsych open. [published; PubMed]. \href{https://doi.org/10.1192/bjo.2024.768}{doi:10.1192/bjo.2024.768}.
\item Christopher L. Robinson, Pawan Solanki, S Snyder, Adam Amir, Antje M. Barreveld, Rory Vu Mather, Ivo H. Cerda, Michael Motoc, Harman Chopra, R. Jason Yong, Joel Castellanos, Timothy Furnish, Alan D. Kaye, Vwaire Orhurhu, Trent Emerick (2024). \textit{Chronic pain education: past, present, and future of psychedelics for the management of chronic pain}. Pain Medicine. [published; OpenAlex]. \href{https://doi.org/10.1093/pm/pnae124}{doi:10.1093/pm/pnae124}.
\item Shinozuka K, Jerotic K, Mediano P, Zhao AT, Preller KH, Carhart-Harris R, Kringelbach ML (2024). \textit{Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-024-03187-1}{doi:10.1038/s41398-024-03187-1}.
\item Back AL, Freeman-Young TK, Morgan L, Sethi T, Baker KK, Myers S, McGregor BA, Harvey K, Tai M, Kollefrath A, Thomas BJ, Sorta D, Kaelen M, Kelmendi B, Gooley TA (2024). \textit{Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.}. JAMA network open. [published; PubMed]. \href{https://doi.org/10.1001/jamanetworkopen.2024.49026}{doi:10.1001/jamanetworkopen.2024.49026}.
\item Jeffrey JK, Weintraub MJ, Grob CS (2024). \textit{Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution.}. Journal of the American Academy of Child and Adolescent Psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.jaac.2024.03.021}{doi:10.1016/j.jaac.2024.03.021}.
\item Hinkle JT, Graziosi M, Nayak SM, Yaden DB (2024). \textit{Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.}. JAMA psychiatry. [published; PubMed]. \href{https://doi.org/10.1001/jamapsychiatry.2024.2546}{doi:10.1001/jamapsychiatry.2024.2546}.
\item Li G, Facchini PJ (2024). \textit{New frontiers in the biosynthesis of psychoactive specialized metabolites.}. Current opinion in plant biology. [published; PubMed]. \href{https://doi.org/10.1016/j.pbi.2024.102626}{doi:10.1016/j.pbi.2024.102626}.
\item Behera HK, Joga R, Yerram S, Karnati P, Mergu T, Gandhi K, M S, Nathiya D, Singh RP, Srivastava S, Kumar S (2024). \textit{Exploring the regulatory framework of psychedelics in the US \& Europe.}. Asian journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.ajp.2024.104242}{doi:10.1016/j.ajp.2024.104242}.
\item Meshkat S, Tello-Gerez TJ, Gholaminezhad F, Dunkley BT, Reichelt AC, Erritzoe D, Vermetten E, Zhang Y, Greenshaw A, Burback L, Winkler O, Jetly R, Mayo LM, Bhat V (2024). \textit{Impact of psilocybin on cognitive function: A systematic review.}. Psychiatry and clinical neurosciences. [published; PubMed]. \href{https://doi.org/10.1111/pcn.13741}{doi:10.1111/pcn.13741}.
\item Szpręgiel I, Bysiek A (2024). \textit{Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.}. Pharmacological reports: PR. [published; PubMed]. \href{https://doi.org/10.1007/s43440-024-00660-y}{doi:10.1007/s43440-024-00660-y}.
\item Marwood L, Croal M, Mistry S, Simmons H, Tsai J, Young MB, Goodwin GM (2024). \textit{The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.}. Journal of psychiatric research. [published; PubMed]. \href{https://doi.org/10.1016/j.jpsychires.2024.10.009}{doi:10.1016/j.jpsychires.2024.10.009}.
\item Collins HM (2024). \textit{Psychedelics for the Treatment of Obsessive-Compulsive Disorder: Efficacy and Proposed Mechanisms.}. The international journal of neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1093/ijnp/pyae057}{doi:10.1093/ijnp/pyae057}.
\item de Jonge D, van der Meer PB, Kramers C, Schellekens A (2024). \textit{Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need.}. Current psychiatry reports. [published; PubMed]. \href{https://doi.org/10.1007/s11920-024-01567-4}{doi:10.1007/s11920-024-01567-4}.
\item Scala M, Fabbri C, Fusar-Poli P, Di Lorenzo G, Ferrara M, Amerio A, Fusar-Poli L, Pichiecchio A, Asteggiano C, Menchetti M, De Ronchi D, MNESYS - Mood and Psychosis Sub-Project (Spoke 5), Fanelli G, Serretti A (2024). \textit{The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges.}. CNS spectrums. [published; PubMed]. \href{https://doi.org/10.1017/s1092852924002268}{doi:10.1017/s1092852924002268}.
\item Fradet M, Kelly CM, Donnelly AJ, Suppes T (2024). \textit{Psilocybin and hallucinogenic mushrooms.}. CNS spectrums. [published; PubMed]. \href{https://doi.org/10.1017/s1092852924002487}{doi:10.1017/s1092852924002487}.
\item Ehrenkranz R, Agrawal M, Penberthy JK, Yaden DB (2024). \textit{Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.}. International review of psychiatry (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1080/09540261.2024.2357668}{doi:10.1080/09540261.2024.2357668}.
\item Terao I, Kodama W (2024). \textit{Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta-analyses of randomized controlled trials.}. PCN reports: psychiatry and clinical neurosciences. [published; PubMed]. \href{https://doi.org/10.1002/pcn5.70042}{doi:10.1002/pcn5.70042}.
\item Arman Fard, Allison Cohen (2024). \textit{Exploring Psychotherapeutic Benefits of Psilocybin and Psychedelics In Controlled Medical Settings}. Journal of Student Research. [published; OpenAlex]. \href{https://doi.org/10.47611/jsrhs.v13i4.7602}{doi:10.47611/jsrhs.v13i4.7602}.
\item Morris SL (2024). \textit{A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient.}. Clinical psychopharmacology and neuroscience: the official scientific journal of the Korean College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.9758/cpn.24.1180}{doi:10.9758/cpn.24.1180}.
\item Ben-Tal T, Pogodin I, Botvinnik A, Lifschytz T, Heresco-Levy U, Lerer B. (2024). \textit{Synergistic Behavioral and Neuroplastic Effects of Psilocybin-NMDAR Modulator Administration}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.11.28.625811}{doi:10.1101/2024.11.28.625811}.
\item Adams DR, Allen H, Nicol GE, Cabassa LJ (2024). \textit{Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science.}. Translational behavioral medicine. [published; PubMed]. \href{https://doi.org/10.1093/tbm/ibae053}{doi:10.1093/tbm/ibae053}.
\item TRYP Therapeutics (2024). \textit{A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05035927}{source link}.
\item Raj Nashikkar, Kavita Mane, Rajendra Patil (2024). \textit{Psilocybin Fungi Unveiled: Morphological Characteristics and Pharmacological Potentials}. International Journal for Research in Applied Science and Engineering Technology. [published; OpenAlex]. \href{https://doi.org/10.22214/ijraset.2024.65160}{doi:10.22214/ijraset.2024.65160}.
\item Wang E, Mathai DS, Gukasyan N, Nayak S, Garcia-Romeu A (2024). \textit{Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-024-78736-1}{doi:10.1038/s41598-024-78736-1}.
\item Kargbo RB (2024). \textit{Expanding the Therapeutic Horizons of Psilocybin in Mental Health.}. ACS medicinal chemistry letters. [published; PubMed]. \href{https://doi.org/10.1021/acsmedchemlett.4c00488}{doi:10.1021/acsmedchemlett.4c00488}.
\item University of Utah (2024). \textit{PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related Burnout}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05557643}{source link}.
\item Pasquini L, Vohryzek J, Escrichs A, Sanz Perl Y, Ponce-Alvarez A, Idesis S, Girn M, Roseman L, Mitchell JM, Gazzaley A, Kringelbach M, Nutt DJ, Lyons T, Carhart-Harris RL, Deco G. (2024). \textit{Long-term effects of psilocybin on dynamic and effectivity connectivity of fronto-striatal-thalamic circuits}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.11.06.622302}{doi:10.1101/2024.11.06.622302}.
\item Gribben A, Burke T, Harrington C, Husein A, Murnane KS, Hendricks PS, Tobin K, Ivers JH, Thuery G, Harkin A, Kelly JR (2024). \textit{Amid magic and menace: psychiatrists' attitudes to psilocybin therapy.}. Irish journal of psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/ipm.2024.49}{doi:10.1017/ipm.2024.49}.
\item Cristiano Chaves, Rafael G. dos Santos, Serdar Dursun, Massimo Tusconi, Mauro Giovanni Carta, Elisa Brietzke, Jaime E. C. Hallak (2024). \textit{Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2024.1485337}{doi:10.3389/fpsyt.2024.1485337}.
\item Swanson LR, Jungers S, Varghese R, Cullen KR, Evans MD, Nielson JL, Schallmo MP (2024). \textit{Enhanced visual contrast suppression during peak psilocybin effects: Psychophysical results from a pilot randomized controlled trial.}. Journal of vision. [published; PubMed]. \href{https://doi.org/10.1167/jov.24.12.5}{doi:10.1167/jov.24.12.5}.
\item Shao LX, Liao C, Davoudian PA, Savalia NK, Jiang Q, Wojtasiewicz C, Tan D, Nothnagel JD, Liu RJ, Woodburn SC, Bilash OM, Kim H, Che A, Kwan AC (2024). \textit{Pyramidal cell types and 5-HT receptors are essential for psilocybin's lasting drug action.}. bioRxiv: the preprint server for biology. [published; PubMed]. \href{https://doi.org/10.1101/2024.11.02.621692}{doi:10.1101/2024.11.02.621692}.
\item Lamia Özgör (2024). \textit{Psilocybin-unterstützte Psychotherapie reduziert Ängste und Depressionen}. InFo Hämatologie + Onkologie. [published; OpenAlex]. \href{https://doi.org/10.1007/s15004-024-0785-9}{doi:10.1007/s15004-024-0785-9}.
\item Kim A, Halton B, Shah A, Seecof OM, Ross S (2024). \textit{Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review.}. Annals of palliative medicine. [published; PubMed]. \href{https://doi.org/10.21037/apm-24-35}{doi:10.21037/apm-24-35}.
\item Zhen Z, Sun X, Yuan S, Zhang J (2024). \textit{Psychoactive substances for the treatment of neuropsychiatric disorders.}. Asian journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.ajp.2024.104193}{doi:10.1016/j.ajp.2024.104193}.
\item Janevska S, Weiser S, Huang Y, Lin J, Hoefgen S, Jojić K, Barber AE, Schäfer T, Fricke J, Hoffmeister D, Regestein L, Valiante V, Kufs JE (2024). \textit{Optimized psilocybin production in tryptophan catabolism-repressed fungi.}. Microbial biotechnology. [published; PubMed]. \href{https://doi.org/10.1111/1751-7915.70039}{doi:10.1111/1751-7915.70039}.
\item Reid MJ, Kettner H, Blanken TF, Weiss B, Carhart-Harris R (2024). \textit{Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action.}. Current psychiatry reports. [published; PubMed]. \href{https://doi.org/10.1007/s11920-024-01539-8}{doi:10.1007/s11920-024-01539-8}.
\item Forte V, Shaughnessy AF, Kurotschka PK (2024). \textit{[Depression and effectiveness of psychedelics: high-dose psilocybin has shown benefits in improving symptoms.].}. Recenti progressi in medicina. [published; PubMed]. \href{https://doi.org/10.1701/4365.43590}{doi:10.1701/4365.43590}.
\item Petridis PD, Grinband J, Agin-Liebes G, Kinslow CJ, Zeifman RJ, Bogenschutz MP, Griffiths RR, Ross S (2024). \textit{Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer.}. Nature. Mental health. [published; PubMed]. \href{https://doi.org/10.1038/s44220-024-00331-0}{doi:10.1038/s44220-024-00331-0}.
\item Wahba M, Hayes C, Kletter M, McAllister-Williams RH (2024). \textit{Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: Case report and thematic analysis of one participant's experience}. BJPsych Open. [published; OpenAlex]. \href{https://openalex.org/W7139416359}{source link}.
\item Imperial College London (2024). \textit{Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03429075}{source link}.
\item Fleury S, Nautiyal KM. (2024). \textit{The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.10.18.618582}{doi:10.1101/2024.10.18.618582}.
\item Hooper J, Gyongyosi E, Hutchison K, Mueller R. (2024). \textit{Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/u9yeg\_v1}{doi:10.31234/osf.io/u9yeg\_v1}.
\item Hooper J, Gyongyosi E, Hutchison K, Mueller R. (2024). \textit{Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/u9yeg}{doi:10.31234/osf.io/u9yeg}.
\item Jake Hooper, Emily Gyongyosi, Kent Hutchison, Raeghan Mueller (2024). \textit{Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/u9yeg\_v1}{source link}.
\item Hannah Douglass (2024). \textit{The therapeutic potential and mechanisms of action of psilocybin-assisted therapy in anorexia nervosa treatment}. Open MIND. [published; OpenAlex]. \href{https://doi.org/10.25560/118978}{doi:10.25560/118978}.
\item Morgan Justin, Kerry Watrin (2024). \textit{Does psilocybin reduce symptoms of depression in adults with major depressive disorder or life-threatening cancer?}. Evidence-Based Practice. [published; OpenAlex]. \href{https://doi.org/10.1097/ebp.0000000000002281}{doi:10.1097/ebp.0000000000002281}.
\item Pincombe J, Williams M, Carruthers S, Rossell S. (2024). \textit{Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/ga9p2}{doi:10.31234/osf.io/ga9p2}.
\item Jennifer Pincombe, Martin Williams, Sean Carruthers, Susan Rossell (2024). \textit{Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/ga9p2\_v1}{source link}.
\item Dahan JDC, Dadiomov D, Bostoen T, Dahan A (2024). \textit{Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome.}. Npj mental health research. [published; PubMed]. \href{https://doi.org/10.1038/s44184-024-00091-w}{doi:10.1038/s44184-024-00091-w}.
\item Dimy Fluyau, Vasanth Kattalai Kailasam, Neelambika Revadigar (2024). \textit{Rapid and Prolonged Antidepressant and Antianxiety Effects of Psychedelics and 3,4-Methylenedioxy-methamphetamine-A Systematic Review and Meta-Analysis}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives3040029}{doi:10.3390/psychoactives3040029}.
\item Schenberg EE. (2024). \textit{From efficacy to effectiveness: evaluating psychedelic randomised controlled trials for trustworthy evidence-based policy and practice.}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/uxhv7}{doi:10.31234/osf.io/uxhv7}.
\item Schenberg EE. (2024). \textit{From efficacy to effectiveness: evaluating psychedelic randomised controlled trials for trustworthy evidence-based policy and practice.}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/uxhv7\_v1}{doi:10.31234/osf.io/uxhv7\_v1}.
\item Conn K, Milton LK, Huang K, Munguba H, Ruuska J, Lemus MB, Greaves E, Homman-Ludiye J, Oldfield BJ, Foldi CJ (2024). \textit{Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-024-02575-9}{doi:10.1038/s41380-024-02575-9}.
\item Nadeem Z, Parker S, McGovern H, Oestreich LK (2024). \textit{Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia.}. The Australian and New Zealand journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1177/00048674241261779}{doi:10.1177/00048674241261779}.
\item Gomez-Escolar A, Folch-Sanchez D, Stefaniuk J, Swithenbank Z, Nisa A, Braddick F, Idrees Chaudhary N, van der Meer PB, Batalla A (2024). \textit{Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.}. CNS drugs. [published; PubMed]. \href{https://doi.org/10.1007/s40263-024-01101-3}{doi:10.1007/s40263-024-01101-3}.
\item Madden K, Flood B, Young Shing D, Ade-Conde M, Kashir I, Mark M, MacKillop J, Bhandari M, Adili A (2024). \textit{Psilocybin for clinical indications: A scoping review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811241269751}{doi:10.1177/02698811241269751}.
\item Yang X, Kuang W (2024). \textit{Letter to editor regarding "Psilocybin-assisted therapy for depression: A systematic review and meta-analysis".}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2024.116136}{doi:10.1016/j.psychres.2024.116136}.
\item Najib J (2024). \textit{The role of psilocybin in depressive disorders.}. Current medical research and opinion. [published; PubMed]. \href{https://doi.org/10.1080/03007995.2024.2396536}{doi:10.1080/03007995.2024.2396536}.
\item Calder AE, Rausch B, Liechti ME, Holze F, Hasler G (2024). \textit{Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811241278873}{doi:10.1177/02698811241278873}.
\item Erritzoe D, Barba T, Greenway KT, Murphy R, Martell J, Giribaldi B, Timmermann C, Murphy-Beiner A, Jones MB, Nutt D, Weiss B, Carhart-Harris R (2024). \textit{Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.}. EClinicalMedicine. [published; PubMed]. \href{https://doi.org/10.1016/j.eclinm.2024.102799}{doi:10.1016/j.eclinm.2024.102799}.
\item Fisher EL, Smith R, Conn K, Corcoran AW, Milton LK, Hohwy J, Foldi CJ (2024). \textit{Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-024-03103-7}{doi:10.1038/s41398-024-03103-7}.
\item Carlos Henrique Marchiori, Marco Vinícios de Oliveira Santana, Klebert de Paula Malheiros (2024). \textit{The Action on Psilocybin in Neural Plasticity, Brain Reorganization and Cognitive Enhancement}. Middle East Research Journal of Biological Sciences. [published; OpenAlex]. \href{https://doi.org/10.36348/merjbs.2024.v04i05.001}{doi:10.36348/merjbs.2024.v04i05.001}.
\item Allohverdi S, Soltanzadeh M, Schmidt A, Charlton C, Hauke D, Karvelis P, Vollenweider F, Diaconescu A. (2024). \textit{Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-4492873/v1}{doi:10.21203/rs.3.rs-4492873/v1}.
\item University of California, San Francisco (2024). \textit{An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05065294}{source link}.
\item Abe Y, Sugiura Y, Maeda R, Taira S, Yoshida K, Ibi D, Moritoh S, Hashimoto K, Yagishita S, Tanaka KF. (2024). \textit{Distinct classes of antidepressants commonly act to shape pallidal structure and function in mice}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.09.23.614626}{doi:10.1101/2024.09.23.614626}.
\item Larsen K, Lindberg U, Ozenne B, McCulloch DE, Armand S, Madsen MK, Johansen A, Stenbæk DS, Knudsen GM, Fisher PM. (2024). \textit{Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2024.09.19.24313958}{doi:10.1101/2024.09.19.24313958}.
\item Armstrong SB, Davis AK (2024). \textit{Psychedelic research at a crossroads.}. Science (New York, N.Y.). [published; PubMed]. \href{https://doi.org/10.1126/science.adt1024}{doi:10.1126/science.adt1024}.
\item University Hospital, Ghent (2024). \textit{Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06378229}{source link}.
\item Danielle B Rodrigues (2024). \textit{Use of Psilocybin in the Treatment of Mental Disorders: Systematic Review of Clinal Trials}. Journal of Complementary Medicine \& Alternative Healthcare. [published; OpenAlex]. \href{https://doi.org/10.19080/jcmah.2024.13.555852}{doi:10.19080/jcmah.2024.13.555852}.
\item Syed F. Rab, Charles L. Raison, Elliot Marseille (2024). \textit{An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp024r.0025}{doi:10.61373/pp024r.0025}.
\item Schipper S, Nigam K, Schmid Y, Piechotta V, Ljuslin M, Beaussant Y, Schwarzer G, Boehlke C (2024). \textit{Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.}. The Cochrane database of systematic reviews. [published; PubMed]. \href{https://doi.org/10.1002/14651858.cd015383.pub2}{doi:10.1002/14651858.cd015383.pub2}.
\item Arnim Quante (2024). \textit{Einmalig Psilocybin: antidepressive Effekte}. PSYCH up2date. [published; OpenAlex]. \href{https://doi.org/10.1055/a-2185-5208}{doi:10.1055/a-2185-5208}.
\item Gattuso JJ, Wilson C, Hannan AJ, Renoir T (2024). \textit{Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review.}. Journal of neurochemistry. [published; PubMed]. \href{https://doi.org/10.1111/jnc.16017}{doi:10.1111/jnc.16017}.
\item Jackson ES, Goldway N, Gerlach-Houck H, Gold ND (2024). \textit{Stutterers' experiences on classic psychedelics: A preliminary self-report study.}. Journal of fluency disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jfludis.2024.106062}{doi:10.1016/j.jfludis.2024.106062}.
\item Jacobs DS, Bogachuk AP, Le Moing CL, Moghaddam B (2024). \textit{Effects of psilocybin on uncertain punishment learning.}. Neurobiology of learning and memory. [published; PubMed]. \href{https://doi.org/10.1016/j.nlm.2024.107954}{doi:10.1016/j.nlm.2024.107954}.
\item Guo Q, Guo L, Wang Y, Shang S (2024). \textit{Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2024.116018}{doi:10.1016/j.psychres.2024.116018}.
\item Jungwirth J, Bavato F, Quednow BB (2024). \textit{[Psychedelic and dissociative agents in psychiatry: challenges in the treatment].}. Der Nervenarzt. [published; PubMed]. \href{https://doi.org/10.1007/s00115-024-01727-0}{doi:10.1007/s00115-024-01727-0}.
\item Federico S, Geo M, Entela M, Bachmann S, Elisa R, Silvio C, Zoë D, Louise P, Gabriel T, Joël B, Daniele Z (2024). \textit{Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report.}. Clinical case reports. [published; PubMed]. \href{https://doi.org/10.1002/ccr3.9305}{doi:10.1002/ccr3.9305}.
\item Treviranus GRS (2024). \textit{Rapidly Trading Down Depression's 3 Pillars to 5HT3-Receptors Through ECT or Psilocybin?}. Psychiatria Danubina. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/39378462/}{source link}.
\item Amany E. Ayad (2024). \textit{G33 Psychedelic drugs for the treatment of chronic pain: is ketamine included?}. Ask the expert - Psychedelic substances. [published; OpenAlex]. \href{https://doi.org/10.1136/rapm-2024-esra.582}{doi:10.1136/rapm-2024-esra.582}.
\item Hsu TW, Tsai CK, Kao YC, Thompson T, Carvalho AF, Yang FC, Tseng PT, Hsu CW, Yu CL, Tu YK, Liang CS (2024). \textit{Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.}. BMJ (Clinical research ed.). [published; PubMed]. \href{https://doi.org/10.1136/bmj-2023-078607}{doi:10.1136/bmj-2023-078607}.
\item Emiliano Loria, Elisabetta Lalumera, Ambra D’Imperio (2024). \textit{Psilocybin, moralization and psychotherapy: a scoping review and a case report}. Philosophical Psychology. [published; OpenAlex]. \href{https://doi.org/10.1080/09515089.2024.2389962}{doi:10.1080/09515089.2024.2389962}.
\item Doğancan Sönmez, Aslı Enzel Koç (2024). \textit{Psilocybin in the Treatment of Mental Disorders}. DergiPark (Istanbul University). [published; OpenAlex]. \href{https://doi.org/10.30708/mantar.1535344}{doi:10.30708/mantar.1535344}.
\item Jim Weil (2024). \textit{Tripping on Utopia: Margaret Mead, the Cold War, and the troubled birth of psychedelic science By BenjaminBreen. New York: Grand Central Publishing, 2024. 384 pp.}. American Anthropologist. [published; OpenAlex]. \href{https://doi.org/10.1111/aman.28009}{doi:10.1111/aman.28009}.
\item Salvetti G, Saccenti D, Moro AS, Lamanna J, Ferro M (2024). \textit{Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials.}. Brain sciences. [published; PubMed]. \href{https://doi.org/10.3390/brainsci14080829}{doi:10.3390/brainsci14080829}.
\item Rodolfo Myronn de Melo Rodrigues (2024). \textit{Psilocybin-assisted psychotherapy: Advancements, challenges, and future directions for treating resistant depression}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp024c.0022}{doi:10.61373/pp024c.0022}.
\item Sheppard Pratt Health System (2024). \textit{An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04433858}{source link}.
\item Brugmann University Hospital (2024). \textit{Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy \& (Neuro)Cognitive Mechanisms}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06160232}{source link}.
\item Gustavo Deco, Yonatan Sanz Perl, Samuel Johnson, Niamh Bourke, Robin Carhart-Harris, Morten L. Kringelbach (2024). \textit{Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression}. Nature Mental Health. [published; OpenAlex]. \href{https://doi.org/10.1038/s44220-024-00298-y}{doi:10.1038/s44220-024-00298-y}.
\item Sarah Jane Palmer (2024). \textit{Insights into the efficacy of psilocybin in treating depression and other disorders}. British Journal of Neuroscience Nursing. [published; OpenAlex]. \href{https://doi.org/10.12968/bjnn.2024.0046}{doi:10.12968/bjnn.2024.0046}.
\item Nutt D, Crome I, Young AH (2024). \textit{Is it now time to prepare psychiatry for a psychedelic future?}. The British journal of psychiatry: the journal of mental science. [published; PubMed]. \href{https://doi.org/10.1192/bjp.2024.76}{doi:10.1192/bjp.2024.76}.
\item Aday JS, Horton D, Fernandes-Osterhold G, O'Donovan A, Bradley ER, Rosen RC, Woolley JD (2024). \textit{Psychedelic-assisted psychotherapy: where is the psychotherapy research?}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-024-06620-x}{doi:10.1007/s00213-024-06620-x}.
\item Chisamore N, Johnson D, Chen MJQ, Offman H, Chen-Li D, Kaczmarek ES, Doyle Z, McIntyre RS, Rosenblat JD (2024). \textit{Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.}. Journal of psychiatric research. [published; PubMed]. \href{https://doi.org/10.1016/j.jpsychires.2024.05.051}{doi:10.1016/j.jpsychires.2024.05.051}.
\item Appiani FJ, Caroff SN (2024). \textit{The cyclical revival of psychedelics in psychiatric treatment.}. Current medical research and opinion. [published; PubMed]. \href{https://doi.org/10.1080/03007995.2024.2368725}{doi:10.1080/03007995.2024.2368725}.
\item Korthuis PT, Hoffman K, Wilson-Poe AR, Luoma JB, Bazinet A, Pertl K, Morgan DL, Cook RR, Bielavitz S, Myers R, Wolf RC, McCarty D, Stauffer CS (2024). \textit{Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811241257839}{doi:10.1177/02698811241257839}.
\item Kaiserman A, Vanderjist L, Kornreich C (2024). \textit{CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS.}. Psychiatria Danubina. [published; PubMed]. \href{https://doi.org/10.24869/psyd.2024.174}{doi:10.24869/psyd.2024.174}.
\item V Suresh, Jitendra Lakhani, R Balaraman (2024). \textit{Psilocybin - A Drug to be Considered for the Treatment of Anxiety and Depression in Cancer Patients}. Journal of Natural Remedies. [published; OpenAlex]. \href{https://doi.org/10.18311/jnr/2024/35676}{doi:10.18311/jnr/2024/35676}.
\item Claire Walker, Timothy Piatkowski, Jason Ferris, Emma Davies, Monica J. Barratt, Adam Winstock, Cheneal Puljević (2024). \textit{From chaos to kaleidoscope: Exploring factors in psychedelic self-treatment for mental health conditions}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811241265762}{doi:10.1177/02698811241265762}.
\item Washington University School of Medicine (2024). \textit{Psilocybin for the Treatment of Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05675800}{source link}.
\item Bader H, Farraj H, Maghnam J, Abu Omar Y (2024). \textit{Investigating the therapeutic efficacy of psilocybin in advanced cancer patients: A comprehensive review and meta-analysis.}. World journal of clinical oncology. [published; PubMed]. \href{https://doi.org/10.5306/wjco.v15.i7.908}{doi:10.5306/wjco.v15.i7.908}.
\item de la Salle S, Kettner H, Thibault Lévesque J, Garel N, Dames S, Patchett-Marble R, Rej S, Gloeckler S, Erritzoe D, Carhart-Harris R, Greenway KT (2024). \textit{Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-024-66817-0}{doi:10.1038/s41598-024-66817-0}.
\item Zarankin M, Pellegrini MS, Zenteno F (2024). \textit{[Psilocybin fungi microdose treatment in major depressive disorder: a case report].}. Vertex (Buenos Aires, Argentina). [published; PubMed]. \href{https://doi.org/10.53680/vertex.v35i164.544}{doi:10.53680/vertex.v35i164.544}.
\item DeBattista C, Schatzberg AF (2024). \textit{The Black Book of Psychotropic Dosing and Monitoring.}. Psychopharmacology bulletin. [published; PubMed]. \href{https://doi.org/10.64719/pb.4493}{doi:10.64719/pb.4493}.
\item Hussein El Bourji, Aziz Farhat, Zahi Hamdan, Ritvij Satodiya, Rashmi Shukla, Samer El Hayek (2024). \textit{Psilocybin in the Management of Substance Use Disorders: A Summary ofCurrent Evidence}. Current Psychopharmacologye. [published; OpenAlex]. \href{https://doi.org/10.2174/0122115560288779240628043307}{doi:10.2174/0122115560288779240628043307}.
\item Poulin JM, Bigford GE, Lanctôt KL, Giacobbe P, Schaffer A, Sinyor M, Rabin JS, Masellis M, Singnurkar A, Pople CB, Lipsman N, Husain MI, Rosenblat JD, Cao X, MacIntosh BJ, Nestor SM (2024). \textit{Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.}. Trials. [published; PubMed]. \href{https://doi.org/10.1186/s13063-024-08268-6}{doi:10.1186/s13063-024-08268-6}.
\item Lauren Gorfinkel, Julia M. Bujno, Claire Walsh, Dvora Shmulewitz, Deborah S. Hasin (2024). \textit{Lifetime Depression and Psilocybin Mushroom Use in U.S. Adults, 2008-2019}. Drug and Alcohol Dependence. [published; OpenAlex]. \href{https://doi.org/10.1016/j.drugalcdep.2023.110267}{doi:10.1016/j.drugalcdep.2023.110267}.
\item Korkmaz ND, Cikrikcili U, Akan M, Yucesan E (2024). \textit{Psychedelic therapy in depression and substance use disorders.}. The European journal of neuroscience. [published; PubMed]. \href{https://doi.org/10.1111/ejn.16421}{doi:10.1111/ejn.16421}.
\item Fang Q, Chan VKY, Chan SSM, Jiao Y, Wang J, Li X (2024). \textit{Efficacy and safety of psilocybin on treatment-resistant depression: A systematic review and meta-analysis.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2024.115960}{doi:10.1016/j.psychres.2024.115960}.
\item Ramos L, Vicente SG (2024). \textit{The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review.}. Journal of clinical and experimental neuropsychology. [published; PubMed]. \href{https://doi.org/10.1080/13803395.2024.2363343}{doi:10.1080/13803395.2024.2363343}.
\item Hanstein AP, Felchlin C (2024). \textit{Treating Anxiety and Depression With Psilocybin Therapy.}. Radiologic technology. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/39079732/}{source link}.
\item Nauman Ashraf (2024). \textit{IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?}. Journal of Pakistan Psychiatric Society. [published; OpenAlex]. \href{https://doi.org/10.63050/jpps.21.02.935}{doi:10.63050/jpps.21.02.935}.
\item Parker C, Wood BM (2024). \textit{At the Forefront: Social Workers' Role in Psilocybin Treatment for Depression and Substance Misuse.}. Social work. [published; PubMed]. \href{https://doi.org/10.1093/sw/swae019}{doi:10.1093/sw/swae019}.
\item Fluyau D, Kailasam VK, Revadigar N. (2024). \textit{Rapid and prolonged antidepressant and antianxiety effects of psilocybin, lysergic acid diethylamide, ayahuasca, and 3, 4-methylenedioxy-methamphetamine. A systematic review and meta-analysis of randomized controlled trials}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2024.06.17.24308787}{doi:10.1101/2024.06.17.24308787}.
\item Bryson N, Alexander R, Asnis-Alibozek A, Ehlers MD (2024). \textit{RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-,-diisopropyltryptamine.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.4c00058}{doi:10.1021/acschemneuro.4c00058}.
\item Torrado Pacheco A, Moghaddam B (2024). \textit{Licit use of illicit drugs for treating depression: the pill and the process.}. The Journal of clinical investigation. [published; PubMed]. \href{https://doi.org/10.1172/jci180217}{doi:10.1172/jci180217}.
\item Le GH, Wong S, Badulescu S, Au H, Di Vincenzo JD, Gill H, Phan L, Rhee TG, Ho R, Teopiz KM, Kwan ATH, Rosenblat JD, Mansur RB, McIntyre RS (2024). \textit{Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2024.03.165}{doi:10.1016/j.jad.2024.03.165}.
\item Linda M. Richmond (2024). \textit{Psychedelics’ Use as Medicine Hits Significant Roadblock}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.07.7.54}{doi:10.1176/appi.pn.2024.07.7.54}.
\item University of Sydney (2024). \textit{A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06444243}{source link}.
\item Dan Petrovitch, Sean M. Mitchell, Jason Van Allen, Andrew K. Littlefield (2024). \textit{Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/adnpg\_v1}{source link}.
\item Ouliana Panova, Nichols D.E, Shoichet B.K, Lyu J, Georgios Skiniotis, Che T, Roth B.L, DiBerto J.F, Daniel Wacker, Robertson M.J, Kami Kim, Krumm B.E, Seven A.B (2024). \textit{Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor}. UNC Libraries. [published; OpenAlex]. \href{https://doi.org/10.17615/yb2v-ca64}{doi:10.17615/yb2v-ca64}.
\item Haniff ZR, Bocharova M, Mantingh T, Rucker JJ, Velayudhan L, Taylor DM, Young AH, Aarsland D, Vernon AC, Thuret S (2024). \textit{Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.}. Pharmacology \& therapeutics. [published; PubMed]. \href{https://doi.org/10.1016/j.pharmthera.2024.108641}{doi:10.1016/j.pharmthera.2024.108641}.
\item Lasch A, Schweikert T, Dora E, Kolb T, Schurig HL, Walther A (2024). \textit{[Psilocybin-Assisted Treatment of Depression, Anxiety and Substance use Disorders: Neurobiological Basis and Clinical Application].}. Fortschritte der Neurologie-Psychiatrie. [published; PubMed]. \href{https://doi.org/10.1055/a-2046-5202}{doi:10.1055/a-2046-5202}.
\item Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, Lauterbach M, Sackeim HA, Suppes T (2024). \textit{Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.}. JAMA psychiatry. [published; PubMed]. \href{https://doi.org/10.1001/jamapsychiatry.2023.4685}{doi:10.1001/jamapsychiatry.2023.4685}.
\item Szigeti B, Weiss B, Rosas FE, Erritzoe D, Nutt D, Carhart-Harris R (2024). \textit{Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.}. Psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/s0033291723003653}{doi:10.1017/s0033291723003653}.
\item Haniff Z, Bocharova M, Mantingh T, Rucker J, Velayudhan L, Taylor D, Young A, Aarsland D, Vernon A, Thuret S. (2024). \textit{Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases}. Pharmacology \& therapeutics. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC11847495}{source link}.
\item Fried EI, Cristea IA, Naudet F (2024). \textit{Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety.}. JAMA psychiatry. [published; PubMed]. \href{https://doi.org/10.1001/jamapsychiatry.2024.0420}{doi:10.1001/jamapsychiatry.2024.0420}.
\item Aaronson ST, van der Vaart A, Sackeim HA (2024). \textit{Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety-Reply.}. JAMA psychiatry. [published; PubMed]. \href{https://doi.org/10.1001/jamapsychiatry.2024.0423}{doi:10.1001/jamapsychiatry.2024.0423}.
\item Agor D, Knettel BA, Daici K, Meanley S (2024). \textit{The Intersection of Mental Health and Sexual and Gender Minority Identities for Older Adults Living with Human Immunodeficiency Virus: A Narrative Review.}. The Nursing clinics of North America. [published; PubMed]. \href{https://doi.org/10.1016/j.cnur.2024.01.005}{doi:10.1016/j.cnur.2024.01.005}.
\item DiRenzo D, Barrett FS, Perin J, Darrah E, Christopher-Stine L, Griffiths RR (2024). \textit{Impact of Psilocybin on Peripheral Cytokine Production.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0039}{doi:10.1089/psymed.2023.0039}.
\item Wang SM, Kim S, Choi WS, Lim HK, Woo YS, Pae CU, Bahk WM (2024). \textit{Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials.}. Clinical psychopharmacology and neuroscience: the official scientific journal of the Korean College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.9758/cpn.23.1134}{doi:10.9758/cpn.23.1134}.
\item Hoyer D. (2024). \textit{On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.}. Authorea Preprints. [preprint; Europe PMC]. \href{https://doi.org/10.22541/au.171648613.31141136/v1}{doi:10.22541/au.171648613.31141136/v1}.
\item Bhagavan C, Glue P, Evans W, Reynolds L, Turner T, King C, Russell BR, Morunga E, Mills JL, Layton G, Menkes DB (2024). \textit{Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.}. Trials. [published; PubMed]. \href{https://doi.org/10.1186/s13063-024-08174-x}{doi:10.1186/s13063-024-08174-x}.
\item Fisher EL, Smith R, Corcoran AW, Milton LK, Conn K, Hohwy J, Foldi CJ. (2024). \textit{Psilocybin increases optimistic engagement over time: computational modelling of behavior in rats}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.05.16.594614}{doi:10.1101/2024.05.16.594614}.
\item Harari R, Chatterjee I, Getselter D, Elliott E (2024). \textit{Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor.}. iScience. [published; PubMed]. \href{https://doi.org/10.1016/j.isci.2024.109686}{doi:10.1016/j.isci.2024.109686}.
\item Shunichiro Ikeda, Toshihiko Kinoshita (2024). \textit{Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens}. Psychiatry and Clinical Neurosciences Reports. [published; OpenAlex]. \href{https://doi.org/10.1002/pcn5.196}{doi:10.1002/pcn5.196}.
\item Mateusz Pawlicki, Aleksandra Kłos, Karol Stachyrak, Dawid Mika, Bartosz Mazur, Kamila Turek, Maciej Lambach, Anna Gregułą, Aleksandra Mazurek, Wiktoria Wilanowska (2024). \textit{Psilocybin as a new way for depression treatment}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2024.68.50168}{doi:10.12775/jehs.2024.68.50168}.
\item Copa D, Erritzoe D, Giribaldi B, Nutt D, Carhart-Harris R, Tagliazucchi E (2024). \textit{Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2024.02.089}{doi:10.1016/j.jad.2024.02.089}.
\item Terri D’Arrigo (2024). \textit{Calls to Poison Centers Involving Psilocybin Rising in Youth}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.06.6.2}{doi:10.1176/appi.pn.2024.06.6.2}.
\item M Ro Rsted E, Jensen AA, Smits G, Frydenvang K, Kristensen JL (2024). \textit{Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT Receptor Agonists.}. Journal of medicinal chemistry. [published; PubMed]. \href{https://doi.org/10.1021/acs.jmedchem.4c00082}{doi:10.1021/acs.jmedchem.4c00082}.
\item Nova Mentis Life Science Corp (2024). \textit{An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult Patients}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05832255}{source link}.
\item British Medical Journal Publishing Group (2024). \textit{EXPRESSION OF CONCERN: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.}. BMJ (Clinical research ed.). [published; PubMed]. \href{https://doi.org/10.1136/bmj.q1025}{doi:10.1136/bmj.q1025}.
\item Brancaccio Hanna (2024). \textit{Efficacy of Psilocybin in the Treatment of Substance and Alcohol Use Disorders}. Research Posters. [published; Crossref]. \href{https://doi.org/10.31986/issn.2689-0690\_rdw.stratford\_research\_day.149\_2024}{doi:10.31986/issn.2689-0690\_rdw.stratford\_research\_day.149\_2024}.
\item Nicholas A Kerna, Kevin D. Pruitt, N.D. Victor Carsrud, Kyle Kadivi, Dabeluchi C. Ngwu, Hilary M. Holets, John V. Flores, Ijeoma Nnake, Cornelius I. Azi, Joseph Anderson, Fatimah A. Olunlade, Uzoamaka Nwokorie (2024). \textit{From Venerable Cultural Practices to Modern Psychological Solutions: Enter Entheogens into Mainstream Medicine}. European Journal of Arts Humanities and Social Sciences. [published; OpenAlex]. \href{https://doi.org/10.59324/ejahss.2024.1(3).10}{doi:10.59324/ejahss.2024.1(3).10}.
\item Takaba R, Ibi D, Yoshida K, Hosomi E, Kawase R, Kitagawa H, Goto H, Achiwa M, Mizutani K, Maeda K, González-Maeso J, Kitagaki S, Hiramatsu M (2024). \textit{Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice.}. Naunyn-Schmiedeberg's archives of pharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00210-023-02778-x}{doi:10.1007/s00210-023-02778-x}.
\item Holze F, Singh N, Liechti ME, D'Souza DC (2024). \textit{Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.}. Biological psychiatry. Cognitive neuroscience and neuroimaging. [published; PubMed]. \href{https://doi.org/10.1016/j.bpsc.2024.01.007}{doi:10.1016/j.bpsc.2024.01.007}.
\item Erritzoe D, Barba T, Spriggs MJ, Rosas FE, Nutt DJ, Carhart-Harris R (2024). \textit{Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811241237870}{doi:10.1177/02698811241237870}.
\item Yao Y, Guo D, Lu TS, Liu FL, Huang SH, Diao MQ, Li SX, Zhang XJ, Kosten TR, Shi J, Bao YP, Lu L, Han Y (2024). \textit{Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2024.115886}{doi:10.1016/j.psychres.2024.115886}.
\item Peill J, Marguilho M, Erritzoe D, Barba T, Greenway KT, Rosas F, Timmermann C, Carhart-Harris R (2024). \textit{Psychedelics and the 'inner healer': Myth or mechanism?}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811241239206}{doi:10.1177/02698811241239206}.
\item De Giorgi R, Ede R (2024). \textit{Psilocybin for depression.}. BMJ (Clinical research ed.). [published; PubMed]. \href{https://doi.org/10.1136/bmj.q798}{doi:10.1136/bmj.q798}.
\item Metaxa AM, Clarke M (2024). \textit{Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.}. BMJ (Clinical research ed.). [published; PubMed]. \href{https://doi.org/10.1136/bmj-2023-078084}{doi:10.1136/bmj-2023-078084}.
\item Ruan Y, Yuan R, He J, Jiang Y, Chu S, Chen N (2024). \textit{New perspective on sustained antidepressant effect: focus on neurexins regulating synaptic plasticity.}. Cell death discovery. [published; PubMed]. \href{https://doi.org/10.1038/s41420-024-01974-9}{doi:10.1038/s41420-024-01974-9}.
\item Bellman V (2024). \textit{Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon.}. Cancers. [published; PubMed]. \href{https://doi.org/10.3390/cancers16091702}{doi:10.3390/cancers16091702}.
\item Terri D’Arrigo (2024). \textit{MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and More}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.05.5.1}{doi:10.1176/appi.pn.2024.05.5.1}.
\item Section for Affective Disorders; Northern Stockholm Psychiatry (2024). \textit{The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04630964}{source link}.
\item Sarosh Nawaz, Abdulaziz Mohammed Althwanay, Esraa M. AlEdani MB Ch B, Harleen Kaur, Malik Kasapoglu, Rajesh Yadavalli, Ann Kashmer Yu (2024). \textit{Therapeutics Uses of Psychedelics in patients with psychiatric disorders A Systematic Review}. Journal For International Medical Graduates. [published; OpenAlex]. \href{https://doi.org/10.56570/jimgs.v1i1.155}{doi:10.56570/jimgs.v1i1.155}.
\item Sloshower J, Zeifman RJ, Guss J, Krause R, Safi-Aghdam H, Pathania S, Pittman B, D'Souza DC (2024). \textit{Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-024-58318-x}{doi:10.1038/s41598-024-58318-x}.
\item Daniel Meling, Rebecca Ehrenkranz, Sandeep M. Nayak, Helena Aicher, Xaver Funk, Michiel van Elk, Marianna Graziosi, Prisca R. Bauer, Milan Scheidegger, David B. Yaden (2024). \textit{Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives3020014}{doi:10.3390/psychoactives3020014}.
\item Erika Dyck (2024). \textit{Who will staff the psychedelic resurgence?}. Open Access Government. [published; OpenAlex]. \href{https://doi.org/10.56367/oag-042-10690}{doi:10.56367/oag-042-10690}.
\item López E, Yngwe H, Beckman M, Tiger M, Hieronymus F, Lundberg J (2024). \textit{[Psychedelic psychiatry].}. Lakartidningen. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/38572715/}{source link}.
\item J. S. Seo (2024). \textit{Current situation regarding psychedelics and magic mushroom in Korea}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2024.1695}{doi:10.1192/j.eurpsy.2024.1695}.
\item Eva Maria Schindowski, Franz X. Vollenweider (2024). \textit{Fallbeispiele zur Therapie der rezidivierenden Depression mit Psilocybin}. Nervenheilkunde. [published; OpenAlex]. \href{https://doi.org/10.1055/a-2283-0221}{doi:10.1055/a-2283-0221}.
\item Kim P. C. Kuypers (2024). \textit{Microdosing psychedelics in the treatment of ADHD and comorbid disorders}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2024.44}{doi:10.1192/j.eurpsy.2024.44}.
\item Rucker JJ (2024). \textit{Evidence versus expectancy: the development of psilocybin therapy.}. BJPsych bulletin. [published; PubMed]. \href{https://doi.org/10.1192/bjb.2023.28}{doi:10.1192/bjb.2023.28}.
\item Kelly TJ, Bonniwell EM, Mu L, Liu X, Hu Y, Friedman V, Yu H, Su W, McCorvy JD, Liu QS (2024). \textit{Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/s41386-023-01744-8}{doi:10.1038/s41386-023-01744-8}.
\item Beaussant Y, Tarbi E, Nigam K, Miner S, Sager Z, Sanders JJ, Ljuslin M, Guérin B, Thambi P, Tulsky JA, Agrawal M (2024). \textit{Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis.}. Cancer. [published; PubMed]. \href{https://doi.org/10.1002/cncr.35024}{doi:10.1002/cncr.35024}.
\item Thrul J, Kozak Z, Carducci MA, Garcia-Romeu A, Yaden DB (2024). \textit{Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer.}. Cancer. [published; PubMed]. \href{https://doi.org/10.1002/cncr.35127}{doi:10.1002/cncr.35127}.
\item Agrawal M, Richards W, Beaussant Y, Shnayder S, Ameli R, Roddy K, Stevens N, Richards B, Schor N, Honstein H, Jenkins B, Bates M, Thambi P (2024). \textit{Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder.}. Cancer. [published; PubMed]. \href{https://doi.org/10.1002/cncr.35010}{doi:10.1002/cncr.35010}.
\item Wong S, Kwan ATH, Teopiz KM, Le GH, Meshkat S, Ho R, d'Andrea G, Cao B, Di Vincenzo JD, Rosenblat JD, McIntyre RS (2024). \textit{A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2024.01.142}{doi:10.1016/j.jad.2024.01.142}.
\item Yerubandi A, Thomas JE, Bhuiya NMMA, Harrington C, Villa Zapata L, Caballero J (2024). \textit{Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis.}. JAMA network open. [published; PubMed]. \href{https://doi.org/10.1001/jamanetworkopen.2024.5960}{doi:10.1001/jamanetworkopen.2024.5960}.
\item Laabi S, LeMmon C, Vogel C, Chacon M, Jimenez VM (2024). \textit{Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights.}. International immunopharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.intimp.2024.111753}{doi:10.1016/j.intimp.2024.111753}.
\item Hudspeth J, Rogge K, Dörner S, Müll M, Hoffmeister D, Rupp B, Werten S (2024). \textit{Methyl transfer in psilocybin biosynthesis.}. Nature communications. [published; PubMed]. \href{https://doi.org/10.1038/s41467-024-46997-z}{doi:10.1038/s41467-024-46997-z}.
\item David Nutt (2024). \textit{Psychedelics: reconnecting the brain to heal the mind}. The Biochemist. [published; OpenAlex]. \href{https://doi.org/10.1042/bio\_2023\_156}{doi:10.1042/bio\_2023\_156}.
\item Shreyasee Das, Rahul Shil (2024). \textit{Psychedelic Drugs: A Mind-expanding Hallucinogens}. Indian Journal of Behavioural Sciences. [published; OpenAlex]. \href{https://doi.org/10.55229/ijbs.v27i1.13}{doi:10.55229/ijbs.v27i1.13}.
\item Adrian Preda (2024). \textit{Psychedelic Renaissance: Evidence and Culture}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.04.4.39}{doi:10.1176/appi.pn.2024.04.4.39}.
\item Hoener S, Wolfgang A, Nissan D, Howe E (2024). \textit{Ethical considerations for psychedelic-assisted therapy in military clinical settings.}. Journal of medical ethics. [published; PubMed]. \href{https://doi.org/10.1136/jme-2023-108943}{doi:10.1136/jme-2023-108943}.
\item Natalie Ertl, Matthew B. Wall (2024). \textit{Scanning the new frontier of mental health: psychedelic brain imaging}. The Biochemist. [published; OpenAlex]. \href{https://doi.org/10.1042/bio\_2023\_171}{doi:10.1042/bio\_2023\_171}.
\item Ben Seal (2024). \textit{Psychedelic drugs and the law: What’s next?}. Knowable Magazine. [published; OpenAlex]. \href{https://doi.org/10.1146/knowable-031424-2}{doi:10.1146/knowable-031424-2}.
\item Aaronson ST, Kozak Z (2024). \textit{New evidence for flexible psilocybin dosing in patients with treatment-resistant depression.}. Med (New York, N.Y.). [published; PubMed]. \href{https://doi.org/10.1016/j.medj.2024.01.014}{doi:10.1016/j.medj.2024.01.014}.
\item Rosenblat JD, Meshkat S, Doyle Z, Kaczmarek E, Brudner RM, Kratiuk K, Mansur RB, Schulz-Quach C, Sethi R, Abate A, Ali S, Bawks J, Blainey MG, Brietzke E, Cronin V, Danilewitz J, Dhawan S, Di Fonzo A, Di Fonzo M, Drzadzewski P, Dunlop W, Fiszter H, Gomes FA, Grewal S, Leon-Carlyle M, McCallum M, Mofidi N, Offman H, Riva-Cambrin J, Schmidt J, Smolkin M, Quinn JM, Zumrova A, Marlborough M, McIntyre RS (2024). \textit{Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.}. Med (New York, N.Y.). [published; PubMed]. \href{https://doi.org/10.1016/j.medj.2024.01.005}{doi:10.1016/j.medj.2024.01.005}.
\item Brandon Weiss, Leor Roseman, Bruna Giribaldi, David Nutt, Robin Carhart-Harris, David Erritzøe (2024). \textit{Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder}. International Journal of Mental Health and Addiction. [published; OpenAlex]. \href{https://doi.org/10.1007/s11469-024-01253-9}{doi:10.1007/s11469-024-01253-9}.
\item Velit-Salazar MR, Shiroma PR, Cherian E (2024). \textit{A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder.}. Brain sciences. [published; PubMed]. \href{https://doi.org/10.3390/brainsci14030248}{doi:10.3390/brainsci14030248}.
\item Henning Hintzsche (2024). \textit{Psilocybin zur Behandlung depressiver Erkrankungen}. BIOspektrum. [published; OpenAlex]. \href{https://doi.org/10.1007/s12268-024-2157-2}{doi:10.1007/s12268-024-2157-2}.
\item Sekssaoui M, Bockaert J, Marin P, Bécamel C (2024). \textit{Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT receptor the unique player?}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/s41386-024-01794-6}{doi:10.1038/s41386-024-01794-6}.
\item Strickland JC, Garcia-Romeu A, Johnson MW (2024). \textit{The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0046}{doi:10.1089/psymed.2023.0046}.
\item Barnett BS, Arakelian M, Beebe D, Ontko J, Riegal C, Siu WO, Weleff J, Pope HG (2024). \textit{American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A7-Year Follow-Up Survey.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0036}{doi:10.1089/psymed.2023.0036}.
\item Hibicke M, Billac G, Nichols CD (2024). \textit{Preadministration of Lorazepam Reduces Efficacy and Longevity of Antidepressant-Like Effect from a Psychedelic.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0037}{doi:10.1089/psymed.2023.0037}.
\item Watford T, Masood N (2024). \textit{Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review.}. Clinical psychopharmacology and neuroscience: the official scientific journal of the Korean College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.9758/cpn.23.1120}{doi:10.9758/cpn.23.1120}.
\item Funk D, Araujo J, Slassi M, Lanthier J, Atkinson J, Feng D, Lau W, Lê A, Higgins GA (2024). \textit{Effect of a single psilocybin treatment on Fos protein expression in male rat brain.}. Neuroscience. [published; PubMed]. \href{https://doi.org/10.1016/j.neuroscience.2024.01.001}{doi:10.1016/j.neuroscience.2024.01.001}.
\item Frautschi PC, Singh AP, Stowe NA, Yu JJ (2024). \textit{Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain.}. AJNR. American journal of neuroradiology. [published; PubMed]. \href{https://doi.org/10.3174/ajnr.a8118}{doi:10.3174/ajnr.a8118}.
\item Hernandez-Leon A, Escamilla-Orozco RI, Tabal-Robles AR, Martínez-Vargas D, Romero-Bautista L, Escamilla-Soto G, González-Romero OS, Torres-Valencia M, González-Trujano ME (2024). \textit{Antidepressant- and anxiolytic-like activities and acute toxicity evaluation of the Psilocybe cubensis mushroom in experimental models in mice.}. Journal of ethnopharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.jep.2023.117415}{doi:10.1016/j.jep.2023.117415}.
\item Timmermann C, Zeifman RJ, Erritzoe D, Nutt DJ, Carhart-Harris RL (2024). \textit{Effects of DMT on mental health outcomes in healthy volunteers.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-024-53363-y}{doi:10.1038/s41598-024-53363-y}.
\item Barba T, Kettner H, Radu C, Peill JM, Roseman L, Nutt DJ, Erritzoe D, Carhart-Harris R, Giribaldi B (2024). \textit{Psychedelics and sexual functioning: a mixed-methods study.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-023-49817-4}{doi:10.1038/s41598-023-49817-4}.
\item Breeksema JJ, Niemeijer A, Krediet E, Karsten T, Kamphuis J, Vermetten E, van den Brink W, Schoevers R (2024). \textit{Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-024-53188-9}{doi:10.1038/s41598-024-53188-9}.
\item Thomas Müller (2024). \textit{Psilocybin gegen Depressionen}. CME. [published; OpenAlex]. \href{https://doi.org/10.1007/s11298-023-3754-y}{doi:10.1007/s11298-023-3754-y}.
\item Borissova A, Rucker JJ (2024). \textit{The development of psilocybin therapy for treatment-resistant depression: an update.}. BJPsych bulletin. [published; PubMed]. \href{https://doi.org/10.1192/bjb.2023.25}{doi:10.1192/bjb.2023.25}.
\item Videira NB, Nair V, Paquet V, Calhoun D (2024). \textit{The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits.}. Journal of applied toxicology: JAT. [published; PubMed]. \href{https://doi.org/10.1002/jat.4533}{doi:10.1002/jat.4533}.
\item Phil Wolfson, Gita Vaid (2024). \textit{Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective-a new and evolving approach}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2024.1209419}{doi:10.3389/fpsyt.2024.1209419}.
\item Massachusetts General Hospital (2024). \textit{The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05381974}{source link}.
\item Payal Ghosh, Debjeet Sur (2024). \textit{Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists}. Current Psychiatry Research and Reviews. [published; OpenAlex]. \href{https://doi.org/10.2174/0126660822258502231120074036}{doi:10.2174/0126660822258502231120074036}.
\item Javier González-Maeso (2024). \textit{Psychedelics for mental health: a biochemical perspective}. The Biochemist. [published; OpenAlex]. \href{https://doi.org/10.1042/bio\_2023\_161}{doi:10.1042/bio\_2023\_161}.
\item Kelsey Klute, Lou Lukas, Soonjo Hwang, Yeongjin Gwon, Mridula Krishnan, Jean L. Grem, Sunil R. Hingorani, Jody Koenig Kellas (2024). \textit{Abstract C001: A pilot study of palliadelic treatment with psilocybin to reduce psychological distress and improve quality of life in patients with advanced pancreatic adenocarcinoma}. Cancer Research. [published; OpenAlex]. \href{https://doi.org/10.1158/1538-7445.panca2023-c001}{doi:10.1158/1538-7445.panca2023-c001}.
\item Marc J. Weintraub, David J. Miklowitz (2024). \textit{How should psychotherapy proceed when adjoined with psychedelics?}. World Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1002/wps.21170}{doi:10.1002/wps.21170}.
\item Kaadt E, Søkilde R, Hansen H, Raval N, Lundgaard L, Just J, Knudsen G, Elfving B. (2024). \textit{MicroRNAs underlying the antidepressant effect of psilocybin - Establishing an nCounter pipeline for microRNA-quantification in the pig brain}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-3787179/v1}{doi:10.21203/rs.3.rs-3787179/v1}.
\item Swanson L, Jungers S, Varghese R, Cullen KR, Evans MD, Nielson J, Schallmo M. (2024). \textit{Enhanced visual contrast suppression during peak psilocybin effects: A psychophysical study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/5rm62}{doi:10.31234/osf.io/5rm62}.
\item Link Swanson, Sophia Jungers, Ranji Varghese, Kathryn R. Cullen, Michael D Evans, Jessica L. Nielson, Michael-Paul Schallmo (2024). \textit{Enhanced visual contrast suppression during peak psilocybin effects: A psychophysical study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/5rm62\_v1}{source link}.
\item Duan W, Cao D, Wang S, Cheng J (2024). \textit{Serotonin 2A Receptor (5-HTR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants.}. Chemical reviews. [published; PubMed]. \href{https://doi.org/10.1021/acs.chemrev.3c00375}{doi:10.1021/acs.chemrev.3c00375}.
\item Hinchcliffe JK, Stuart SA, Wood CM, Bartlett J, Kamenish K, Arban R, Thomas CW, Selimbeyoglu A, Hurley S, Hengerer B, Gilmour G, Robinson ESJ (2024). \textit{Rapid-acting antidepressant drugs modulate affective bias in rats.}. Science translational medicine. [published; PubMed]. \href{https://doi.org/10.1126/scitranslmed.adi2403}{doi:10.1126/scitranslmed.adi2403}.
\item Huang Z, Wei X, Wang Y, Tian J, Dong J, Liang B, Lu L, Zhang W. (2024). \textit{Psilocybin Promotes Cell-Type-Specific Changes in the Orbitofrontal Cortex Revealed by Single-Nucleus RNA-seq}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.01.07.573163}{doi:10.1101/2024.01.07.573163}.
\item Vanderijst L, Hever F, Buot A, Dauré C, Benoit J, Hanak C, Veeser J, Morgiève M, Campanella S, Kornreich C, Mallet L, Leys C, Noël X. (2024). \textit{Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-3829237/v1}{doi:10.21203/rs.3.rs-3829237/v1}.
\item Verneri Pellinen (2024). \textit{Psilocybin as a treatment for psychiatric disorders: a review of the literature}. Työväentutkimus Vuosikirja. [published; OpenAlex]. \href{http://hdl.handle.net/10138/575808}{source link}.
\item Barajas, Carlos (2024). \textit{Psilocybin’s Role in Major Depressive Disorder: A Scoping Review}. Digital Commons - George Fox University (George Fox University). [published; OpenAlex]. \href{https://digitalcommons.georgefox.edu/dmsc/31}{source link}.
\item R.S. Treviranus, Gottfried (2024). \textit{RAPIDLY TRADING DOWN DEPRESSION'S3 PILLARS TO 5HT3-RECEPTORS THROUGH ECT OR PSILOCYBIN?}. University of Zagreb University Computing Centre (SRCE). [published; OpenAlex]. \href{https://doi.org/10.24869/psyd.2024.134}{doi:10.24869/psyd.2024.134}.
\item Bridget Verhaaren (2024). \textit{Panini and Psilocybin}. Dialogue A Journal of Mormon Thought. [published; OpenAlex]. \href{https://doi.org/10.5406/15549399.57.4.08}{doi:10.5406/15549399.57.4.08}.
\item Matthew B. Young, J. Chai-Rees, Anna Nowakowska, Jeng-Yu Tsai, Guy M. Goodwin (2024). \textit{Changes in positive and negative affect in participants with treatment-resistant depression following COMP360 psilocybin treatment}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2024.104163}{doi:10.1016/j.nsa.2024.104163}.
\item Thomas Barba, David Erritzøe, Kyle T. Greenway, Rinki Murphy, John Martell, Christopher Timmermann, Ashleigh Murphy-Beiner, Bruna Giribaldi, Michelle Baker Jones, Brandon Weiss, Robin Carhart-Harris (2024). \textit{Psilocybin vs Escitalopram for depression: 6-month follow-up}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2024.104377}{doi:10.1016/j.nsa.2024.104377}.
\item C. Schmitz, Hana Adolphi, Michael Frank, E. Seeger, Maciej Musiał, Moritz Spangemacher, Michael Koslowski, Lea J. Mertens, Florian Schlagenhauf, Gerhard Gründer (2024). \textit{Neural effects of psilocybin-treatment in patients with treatment-resistant depression}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2024.105028}{doi:10.1016/j.nsa.2024.105028}.
\item Watford Tessa (2024). \textit{The Therapeutic Potential of Psilocybin for Depression}. Scientia. [published; Crossref]. \href{https://doi.org/10.33548/scientia1082}{doi:10.33548/scientia1082}.
\item Prosenjit Ghosh, Avinash Desousa (2024). \textit{Psychedelics: The New Kid on the Block}. Annals of Indian Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.4103/aip.aip\_195\_23}{doi:10.4103/aip.aip\_195\_23}.
\item Agata Korlatowicz, Katarzyna Latocha, Paulina Pabian, Ryszard Bugno, Adam S. Hogendorf, Tamás Kovács, Andrzej J. Bojarski, Zoltán V. Varga, Agata Faron-Górecka (2024). \textit{Exploring the molecular basis of treatment-resistant depression: Discoveries from a rat model and psilocybin therapy}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2024.104020}{doi:10.1016/j.nsa.2024.104020}.
\item Dominic Sisti (2024). \textit{Introduction to the Special Section on Psychedelics Research and Treatment}. Perspectives in biology and medicine. [published; OpenAlex]. \href{https://doi.org/10.1353/pbm.2024.a919714}{doi:10.1353/pbm.2024.a919714}.
\item N. Hewitt, J. Chai-Rees, Megan Croal, S. Mistry, Jeng-Yu Tsai, Matthew B. Young, Guy M. Goodwin (2024). \textit{Investigational COMP360 psilocybin treatment for treatment-resistant depression: assessing altered states of consciousness}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2024.104391}{doi:10.1016/j.nsa.2024.104391}.
\item Low F, Earleywine M (2024). \textit{Educational Materials and Image Induction Increase Treatment Credibility.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2022.2154722}{doi:10.1080/02791072.2022.2154722}.
\item Weiss B, Ginige I, Shannon L, Giribaldi B, Murphy-Beiner A, Murphy R, Baker-Jones M, Martell J, Nutt DJ, Carhart-Harris RL, Erritzoe D (2024). \textit{Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.}. Psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/s0033291723001514}{doi:10.1017/s0033291723001514}.
\item Weiss B, Ginige I, Shannon L, Giribaldi B, Murphy-Beiner A, Murphy R, Baker-Jones M, Martell J, Nutt DJ, Carhart-Harris RL, Erritzoe D (2024). \textit{Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression - CORRIGENDUM.}. Psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/s0033291723002039}{doi:10.1017/s0033291723002039}.
\item Heresco-Levy U, Lerer B (2024). \textit{Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-023-02312-8}{doi:10.1038/s41380-023-02312-8}.
\item Nutt DJ, Peill JM, Weiss B, Godfrey K, Carhart-Harris RL, Erritzoe D (2024). \textit{Psilocybin and Other Classic Psychedelics in Depression.}. Current topics in behavioral neurosciences. [published; PubMed]. \href{https://doi.org/10.1007/7854\_2023\_451}{doi:10.1007/7854\_2023\_451}.
\item Nogueira GN, Vasconcelos MMA, Souza FGM, Bisol LW (2024). \textit{Is there credible evidence to assert psilocybin-assisted therapy for depression?}. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.euroneuro.2023.11.003}{doi:10.1016/j.euroneuro.2023.11.003}.
\item Schenberg EE, King F, da Fonseca JE, Roseman L (2024). \textit{Is Poorly Assisted Psilocybin Treatment an Increasing Risk?}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20230664}{doi:10.1176/appi.ajp.20230664}.
\item Earleywine M, De Leo J, Bhayana D, Rajanna B, Scott K (2024). \textit{Psilocybin Without Psychotherapy: A Cart Without a Horse?}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20230572}{doi:10.1176/appi.ajp.20230572}.
\item Goodwin GM, Malievskaia E, Fonzo GA, Nemeroff CB (2024). \textit{Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20230905}{doi:10.1176/appi.ajp.20230905}.
\item Bouchet L, Sager Z, Yrondi A, Nigam KB, Anderson BT, Ross S, Petridis PD, Beaussant Y (2024). \textit{Older adults in psychedelic-assisted therapy trials: A systematic review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231215420}{doi:10.1177/02698811231215420}.
\item Ibi D (2024). \textit{[Up-to-Date on clinical and preclinical studies of psilocybin therapy].}. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. [published; PubMed]. \href{https://doi.org/10.1254/fpj.24007}{doi:10.1254/fpj.24007}.
\item Olivier B, Olivier JDA (2024). \textit{Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD).}. Advances in experimental medicine and biology. [published; PubMed]. \href{https://doi.org/10.1007/978-981-97-4402-2\_3}{doi:10.1007/978-981-97-4402-2\_3}.
\item Armand S, Larsen K, Madsen MK, Ozenne B, Preller KH, Knudsen GM, Stenbæk DS, Fisher PM (2024). \textit{Amygdala response to emotional faces following acute administration of psilocybin in healthy individuals.}. Neuroscience applied. [published; PubMed]. \href{https://doi.org/10.1016/j.nsa.2023.103934}{doi:10.1016/j.nsa.2023.103934}.
\item E-Wen McCulloch D, Liechti ME, Kuypers KP, Nutt D, Lundberg J, Stenbæk DS, Goodwin GM, Gründer G, Butlen-Ducuing F, Haberkamp M, Thirstrup S, Knudsen GM (2024). \textit{Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects.}. Neuroscience applied. [published; PubMed]. \href{https://doi.org/10.1016/j.nsa.2024.103938}{doi:10.1016/j.nsa.2024.103938}.
\item Modlin NL, Creed M, Sarang M, Maggio C, Rucker JJ, Williamson V (2024). \textit{Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions.}. Neuropsychiatric disease and treatment. [published; PubMed]. \href{https://doi.org/10.2147/ndt.s432537}{doi:10.2147/ndt.s432537}.
\item Fang S, Yang X, Zhang W (2024). \textit{Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2024.1359088}{doi:10.3389/fpsyt.2024.1359088}.
\item Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS (2024). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.}. American journal of therapeutics. [published; PubMed]. \href{https://doi.org/10.1097/mjt.0000000000001727}{doi:10.1097/mjt.0000000000001727}.
\item Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS (2024). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.}. American journal of therapeutics. [published; PubMed]. \href{https://doi.org/10.1097/mjt.0000000000001724}{doi:10.1097/mjt.0000000000001724}.
\item Çatal Y, Northoff G (2024). \textit{Where do the symptoms come from in depression? Topography and dynamics matter.}. Brain communications. [published; PubMed]. \href{https://doi.org/10.1093/braincomms/fcae067}{doi:10.1093/braincomms/fcae067}.
\item Levin AW, Lancelotta R, Sepeda ND, Gukasyan N, Nayak S, Wagener TL, Barrett FS, Griffiths RR, Davis AK (2024). \textit{The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder.}. PloS one. [published; PubMed]. \href{https://doi.org/10.1371/journal.pone.0300501}{doi:10.1371/journal.pone.0300501}.
\item Straumann I, Holze F, Becker AM, Ley L, Halter N, Liechti ME (2024). \textit{Safety pharmacology of acute psilocybin administration in healthy participants.}. Neuroscience applied. [published; PubMed]. \href{https://doi.org/10.1016/j.nsa.2024.104060}{doi:10.1016/j.nsa.2024.104060}.
\item Xu M, Kiss AJ, Jones JA, McMurray MS, Shi H (2024). \textit{Effect of oral tryptamines on the gut microbiome of rats-a preliminary study.}. PeerJ. [published; PubMed]. \href{https://doi.org/10.7717/peerj.17517}{doi:10.7717/peerj.17517}.
\item Wang CK, Kim G, Aleksandrova LR, Panenka WJ, Barr AM (2024). \textit{A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2024.1387158}{doi:10.3389/fphar.2024.1387158}.
\item Szafoni S, Gręblowski P, Grabowska K, Więckiewicz G (2024). \textit{Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2024.1406888}{doi:10.3389/fpsyt.2024.1406888}.
\item Lee HJ, Tsang VW, Chai BS, Lin MC, Howard A, Uy C, Elefante JO (2024). \textit{Psilocybin's Potential Mechanisms in the Treatment of Depression: A Systematic Review.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2023.2223195}{doi:10.1080/02791072.2023.2223195}.
\item Zheng S, Ma R, Yang Y, Li G (2024). \textit{Psilocybin for the treatment of Alzheimer's disease.}. Frontiers in neuroscience. [published; PubMed]. \href{https://doi.org/10.3389/fnins.2024.1420601}{doi:10.3389/fnins.2024.1420601}.
\item Do A, Michaud V, Stephan JF, Moreau M, Benoît É, Bérubé FA, Bibaud-De Serres A, Taillefer A, Vincent P (2024). \textit{Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2024.1394962}{doi:10.3389/fpsyt.2024.1394962}.
\item VanderZwaag B, Garcia-Romeu A, Garcia-Barrera MA (2024). \textit{Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/20451253241264812}{doi:10.1177/20451253241264812}.
\item Chen MH, Cheng SL, Kao YC, Tseng PT, Hsu CW, Yu CL, Yang FC, Thompson T, Hsu TW, Liang CS (2024). \textit{The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2024.1439347}{doi:10.3389/fpsyt.2024.1439347}.
\item Li LJ, Mo Y, Shi ZM, Huang XB, Ning YP, Wu HW, Yang XH, Zheng W (2024). \textit{Psilocybin for major depressive disorder: a systematic review of randomized controlled studies.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2024.1416420}{doi:10.3389/fpsyt.2024.1416420}.
\item Kim K, Yusuf A, Sud A, Persaud N, Kirubarajan A, Moller M, Lloyd T, O'Neill B (2024). \textit{Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada.}. PloS one. [published; PubMed]. \href{https://doi.org/10.1371/journal.pone.0309911}{doi:10.1371/journal.pone.0309911}.
\item Verheijen Marcha C.T. (2023). \textit{Psilocybin Therapy for Depression: A Review of Current Molecular Knowledge}. Journal of the Netherlands Society of Toxicology. [published; Crossref]. \href{https://doi.org/10.61833/jnst.2024.0002}{doi:10.61833/jnst.2024.0002}.
\item Karolina Wąsik, Sebastian Tomaszuk, Magda Wojtuś (2023). \textit{Psilocybin - new remedy for patients with psychiatric disorders? Critical analysis of the current state of knowledge}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2023.50.01.005}{doi:10.12775/jehs.2023.50.01.005}.
\item Tianran Liu (2023). \textit{The Therapeutic Effect and Potential Application of Psilocybin}. Highlights in Science Engineering and Technology. [published; OpenAlex]. \href{https://doi.org/10.54097/3cfwjn09}{doi:10.54097/3cfwjn09}.
\item Danias G, Appel J (2023). \textit{Public Interest in Psilocybin and Psychedelic Therapy in the Context of the COVID-19 Pandemic: Google Trends Analysis.}. JMIR formative research. [published; PubMed]. \href{https://doi.org/10.2196/43850}{doi:10.2196/43850}.
\item Poulin JM, Bigford GE, Lanctot KL, Giacobbe P, Schaffer A, Sinyor M, Rabin JS, Masellis M, Singnurkar A, Pople CB, Lipsman N, MacIntosh BJ, Nestor SM. (2023). \textit{Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, proof-of-principle, placebo-controlled and crossover, neuroimaging trial in depression}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-3474764/v1}{doi:10.21203/rs.3.rs-3474764/v1}.
\item Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS. (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/byms6}{doi:10.31234/osf.io/byms6}.
\item Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS. (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/a8xwk}{doi:10.31234/osf.io/a8xwk}.
\item Multidisciplinary Association for Psychedelic Studies (2023). \textit{Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT00979693}{source link}.
\item Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D. Beutler, Kirsten Cherian, Viviana D. Evans, Chelsey Fasano, Owen S. Muir (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/byms6\_v1}{source link}.
\item Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D. Beutler, Kirsten Cherian, Viviana D. Evans, Chelsey Fasano, Owen S. Muir (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/a8xwk\_v1}{source link}.
\item Wojtas A, Gołembiowska K (2023). \textit{Molecular and Medical Aspects of Psychedelics.}. International journal of molecular sciences. [published; PubMed]. \href{https://doi.org/10.3390/ijms25010241}{doi:10.3390/ijms25010241}.
\item Jingxuan Chen (2023). \textit{Application of psilocybin in mental health disorders}. Theoretical and Natural Science. [published; OpenAlex]. \href{https://doi.org/10.54254/2753-8818/21/20230859}{doi:10.54254/2753-8818/21/20230859}.
\item Du Y, Li Y, Zhao X, Yao Y, Wang B, Zhang L, Wang G (2023). \textit{Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity.}. Chinese medical journal. [published; PubMed]. \href{https://doi.org/10.1097/cm9.0000000000002647}{doi:10.1097/cm9.0000000000002647}.
\item Kolbman N, Liu T, Guzzo P, Gilligan J, Mashour GA, Vanini G, Pal D (2023). \textit{Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain.}. Current biology: CB. [published; PubMed]. \href{https://doi.org/10.1016/j.cub.2023.10.016}{doi:10.1016/j.cub.2023.10.016}.
\item Conn K, Milton L, Huang K, Munguba H, Ruuska J, Lemus M, Greaves E, Homman-Ludiye J, Oldfield B, Foldi C. (2023). \textit{Psilocybin prevents activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2023.12.12.571374}{doi:10.1101/2023.12.12.571374}.
\item Ivana Turek (2023). \textit{Psychotropics: A scientific, regulatory, and public view on the medicinal uses of cannabinoids and psilocybin}. Medical Writing. [published; OpenAlex]. \href{https://doi.org/10.56012/tsen2260}{doi:10.56012/tsen2260}.
\item McCrone P, Fisher H, Knight C, Harding R, Schlag AK, Nutt DJ, Neill JC (2023). \textit{Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model.}. Psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/s0033291723001411}{doi:10.1017/s0033291723001411}.
\item Crowe M, Manuel J, Carlyle D, Lacey C (2023). \textit{Psilocybin-assisted psychotherapy for treatment-resistant depression: Which psychotherapy?}. International journal of mental health nursing. [published; PubMed]. \href{https://doi.org/10.1111/inm.13214}{doi:10.1111/inm.13214}.
\item Śladowska K, Kawalec P, Brzostek T, Pilc A (2023). \textit{Potential use of psilocybin drugs in the treatment of depression.}. Expert opinion on emerging drugs. [published; PubMed]. \href{https://doi.org/10.1080/14728214.2023.2264180}{doi:10.1080/14728214.2023.2264180}.
\item Wsół A (2023). \textit{Cardiovascular safety of psychedelic medicine: current status and future directions.}. Pharmacological reports: PR. [published; PubMed]. \href{https://doi.org/10.1007/s43440-023-00539-4}{doi:10.1007/s43440-023-00539-4}.
\item Kolasa M, Faron-Górecka A (2023). \textit{Preclinical models of treatment-resistant depression: challenges and perspectives.}. Pharmacological reports: PR. [published; PubMed]. \href{https://doi.org/10.1007/s43440-023-00542-9}{doi:10.1007/s43440-023-00542-9}.
\item Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST (2023). \textit{Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.}. Drug discovery today. [published; PubMed]. \href{https://doi.org/10.1016/j.drudis.2023.103818}{doi:10.1016/j.drudis.2023.103818}.
\item Holas P, Kamińska J (2023). \textit{Mindfulness meditation and psychedelics: potential synergies and commonalities.}. Pharmacological reports: PR. [published; PubMed]. \href{https://doi.org/10.1007/s43440-023-00551-8}{doi:10.1007/s43440-023-00551-8}.
\item Chruścicka-Smaga B, Machaczka A, Szewczyk B, Pilc A (2023). \textit{Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.}. Pharmacological reports: PR. [published; PubMed]. \href{https://doi.org/10.1007/s43440-023-00547-4}{doi:10.1007/s43440-023-00547-4}.
\item Wojtas A (2023). \textit{The possible place for psychedelics in pharmacotherapy of mental disorders.}. Pharmacological reports: PR. [published; PubMed]. \href{https://doi.org/10.1007/s43440-023-00550-9}{doi:10.1007/s43440-023-00550-9}.
\item Boudreau E, Orlowski K (2023). \textit{Psilocybin therapy to reduce depression following a terminal diagnosis.}. JAAPA: official journal of the American Academy of Physician Assistants. [published; PubMed]. \href{https://doi.org/10.1097/01.jaa.0000994952.07847.2d}{doi:10.1097/01.jaa.0000994952.07847.2d}.
\item Carter S, Packard G, Coghlan C, George JR, Brown AJ, Ching THW, Julian J, Maples-Keller JL (2023). \textit{Perceptions of psychedelic-assisted therapy among Black Americans.}. Journal of mood and anxiety disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.xjmad.2023.100023}{doi:10.1016/j.xjmad.2023.100023}.
\item Weintraub MJ, Jeffrey JK, Grob CS, Ichinose MC, Bergman RL, Cooper ZD, Miklowitz DJ (2023). \textit{Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0018}{doi:10.1089/psymed.2023.0018}.
\item Apex Labs Ltd. (2023). \textit{A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06141876}{source link}.
\item Tahlia R. Harrison (2023). \textit{Altered stakes: Identifying gaps in the informed consent process for psychedelic-assisted therapy trials}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2023.00267}{doi:10.1556/2054.2023.00267}.
\item Danelle Jones (2023). \textit{Psychedelic Integration: Psychotherapy for non-ordinary states of consciousness}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2023.00306}{doi:10.1556/2054.2023.00306}.
\item Schoeller F, Jain A, Adrien V, Maes P, Reggente N. (2023). \textit{Aesthetic Chills Mitigate Maladaptive Cognition In Depression}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-3582420/v1}{doi:10.21203/rs.3.rs-3582420/v1}.
\item COMPASS Pathways (2023). \textit{The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04739865}{source link}.
\item Omer A. Syed, Benjamin Tsang (2023). \textit{Managing expectations with psychedelic microdosing}. npj Mental Health Research. [published; OpenAlex]. \href{https://doi.org/10.1038/s44184-023-00044-9}{doi:10.1038/s44184-023-00044-9}.
\item Elizabeth Sugiarto, Rebecca Leung, Jamie Yuen (2023). \textit{Pharmacists’ perspectives on psilocybin in Canada}. JAPhA Practice Innovations. [published; OpenAlex]. \href{https://doi.org/10.1016/j.japhpi.2023.100003}{doi:10.1016/j.japhpi.2023.100003}.
\item Cameron LP, Benetatos J, Lewis V, Bonniwell EM, Jaster AM, Moliner R, Castrén E, McCorvy JD, Palner M, Aguilar-Valles A (2023). \textit{Beyond the 5-HT Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.}. The Journal of neuroscience: the official journal of the Society for Neuroscience. [published; PubMed]. \href{https://doi.org/10.1523/jneurosci.1384-23.2023}{doi:10.1523/jneurosci.1384-23.2023}.
\item 7450 Summit Cir, Davison, MI48423, Sarah Naher (2023). \textit{The Potential Therapeutic Benefits and Safety of Psychedelics in the Treatment of Mental Health Conditions: A Systematic Review}. Journal of Sociology Psychology \& Religious Studies. [published; OpenAlex]. \href{https://doi.org/10.53819/81018102t4217}{doi:10.53819/81018102t4217}.
\item Van Der Walt J, Parker R (2023). \textit{LSD and psilocybin for chronic nociplastic pain: A narrative review of the literature supporting the use of classic psychedelic agents in chronic pain.}. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. [published; PubMed]. \href{https://doi.org/10.7196/samj.2023.v113i11.814}{doi:10.7196/samj.2023.v113i11.814}.
\item Gray JC, Murphy M, Carter SE, Johnson MW, Wolfgang AS, Roy MJ, Maples-Keller JL (2023). \textit{Beliefs and Perceived Barriers Regarding Psychedelic-assisted Therapy in a Pilot Study of Service Members and Veterans With a History of Traumatic Brain Injury.}. Military medicine. [published; PubMed]. \href{https://doi.org/10.1093/milmed/usac400}{doi:10.1093/milmed/usac400}.
\item Perez N, Langlest F, Mallet L, De Pieri M, Sentissi O, Thorens G, Seragnoli F, Zullino D, Kirschner M, Kaiser S, Solmi M, Sabé M (2023). \textit{Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies.}. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.euroneuro.2023.07.011}{doi:10.1016/j.euroneuro.2023.07.011}.
\item Mason NL, Szabo A, Kuypers KPC, Mallaroni PA, de la Torre Fornell R, Reckweg JT, Tse DHY, Hutten NRPW, Feilding A, Ramaekers JG (2023). \textit{Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study.}. Brain, behavior, and immunity. [published; PubMed]. \href{https://doi.org/10.1016/j.bbi.2023.09.004}{doi:10.1016/j.bbi.2023.09.004}.
\item Malikowska-Racia N, Koniewski M, Golebiowska J, Popik P (2023). \textit{Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231205692}{doi:10.1177/02698811231205692}.
\item Haikazian S, Chen-Li DCJ, Johnson DE, Fancy F, Levinta A, Husain MI, Mansur RB, McIntyre RS, Rosenblat JD (2023). \textit{Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2023.115531}{doi:10.1016/j.psychres.2023.115531}.
\item Raj P, Rauniyar S, Sapkale B (2023). \textit{Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.48719}{doi:10.7759/cureus.48719}.
\item Kratina S, Lo C, Schwartz R, Strike C, Jopling S, Nayfeh A, Rush B. (2023). \textit{A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/4gfyd}{doi:10.31234/osf.io/4gfyd}.
\item Sarah Kratina, Chris Lo, Robert Schwartz, Carol Strike, Sydney Jopling, Ayah Nayfeh, Brian Rush (2023). \textit{A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/4gfyd\_v1}{source link}.
\item Natasha Biscoe, Amanda Bonson, Max Slavin, Walter Busuttil, Deirdre MacManus, Andrew T. Cox, Dominic Murphy (2023). \textit{Psilocybin-assisted psychotherapy for the treatment of PTSD in UK armed forces veterans: A feasibility study protocol}. European Journal of Trauma \& Dissociation. [published; OpenAlex]. \href{https://doi.org/10.1016/j.ejtd.2023.100359}{doi:10.1016/j.ejtd.2023.100359}.
\item Lucia Carbajal, Tessa E. Moore, R. H. Barry Sample, Joseph Nelson (2023). \textit{Is psilocybin effective for treatment of depression?}. Evidence-Based Practice. [published; OpenAlex]. \href{https://doi.org/10.1097/ebp.0000000000002021}{doi:10.1097/ebp.0000000000002021}.
\item Ian B. Hickie, Allan H. Young, F. Markus Leweke (2023). \textit{Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?}. Research Directions Depression. [published; OpenAlex]. \href{https://doi.org/10.1017/dep.2023.21}{doi:10.1017/dep.2023.21}.
\item Payman Baharmand, Amardeep Kambo (2023). \textit{Assessing Metro Vancouver Residents’ Knowledge and Opinions of Psilocybin}. BCIT Environmental Public Health Journal. [published; OpenAlex]. \href{https://doi.org/10.47339/ephj.2023.229}{doi:10.47339/ephj.2023.229}.
\item Kargbo RB (2023). \textit{Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential.}. ACS medicinal chemistry letters. [published; PubMed]. \href{https://doi.org/10.1021/acsmedchemlett.3c00390}{doi:10.1021/acsmedchemlett.3c00390}.
\item Anna Douglas, Daniel Staas, Anna Hampton, Kylie Burns, F. Suter (2023). \textit{Psilocybin, Depression, and Synaptogenesis: Insights into the Field’s Past, Present, and Future}. Georgetown Scientific Research Journal. [published; OpenAlex]. \href{https://doi.org/10.48091/gsr.v3i2.62}{doi:10.48091/gsr.v3i2.62}.
\item Shinozuka K, Jerotic K, Mediano P, Zhao AT, Preller KH, Carhart-Harris R, Kringelbach ML. (2023). \textit{Synergistic, Multi-level Understanding of Psychedelics: Three Systematic Reviews and Meta-analyses of Their Pharmacology, Neuroimaging and Phenomenology}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2023.10.06.561183}{doi:10.1101/2023.10.06.561183}.
\item Robert H. Dworkin, Michael McDermott, Sandeep M. Nayak, Eric C. Strain (2023). \textit{Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?}. Clinical Pharmacology \& Therapeutics. [published; OpenAlex]. \href{https://doi.org/10.1002/cpt.3050}{doi:10.1002/cpt.3050}.
\item Donegan CJ, Daldegan-Bueno D, Sumner R, Menkes D, Evans W, Hoeh N, Sundram F, Reynolds L, Ponton R, Cavadino A, Smith T, Roop P, Allen N, Abeysinghe B, Svirskis D, Forsyth A, Bansal M, Muthukumaraswamy S (2023). \textit{An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).}. Pilot and feasibility studies. [published; PubMed]. \href{https://doi.org/10.1186/s40814-023-01399-8}{doi:10.1186/s40814-023-01399-8}.
\item Chloé Galipeau, Miguel Farinha-Ferreira, Jean-Charles Mariani, Samuel Diebolt, Louis Barthe, Renata Santos, Zsolt Lenkei, Ana M. Sebastião (2023). \textit{UNRAVELLING THE ROLE OF5-HT2AR ACTIVATION IN THE LONG-LASTING BEHAVIORAL EFFECTS OF PSILOCYBIN}. IBRO Neuroscience Reports. [published; OpenAlex]. \href{https://doi.org/10.1016/j.ibneur.2023.08.1116}{doi:10.1016/j.ibneur.2023.08.1116}.
\item Aneta Petrušková, Eva-Maria Weiss, Debarpan Guhathakurta, Enes Yağız Akdaş, Bartomeu Perelló, Renato Frischknecht, Tomáš Páleníček, Anna Fejtová (2023). \textit{MODULATION OF SYNAPTIC FUNCTION AND NEURONAL NETWORK ACTIVITY BY SEROTONERGIC PSYCHEDELICS}. IBRO Neuroscience Reports. [published; OpenAlex]. \href{https://doi.org/10.1016/j.ibneur.2023.08.608}{doi:10.1016/j.ibneur.2023.08.608}.
\item Ines Erkizia-Santamaría, J. Javier Meana, Igor Horrillo, Jorge E. Ortega (2023). \textit{PSILOCYBIN EXERTS ANTIDEPRESSANT EFFECTS IN A CHRONIC UNPREDICTABLE MILD STRESS (CUMS) ANIMAL MODEL}. IBRO Neuroscience Reports. [published; OpenAlex]. \href{https://doi.org/10.1016/j.ibneur.2023.08.1097}{doi:10.1016/j.ibneur.2023.08.1097}.
\item Tomáš Páleníček, Tereza Klučková, M. Nikolič, Čestmír Vejmola, Filip Tylš, Vojtěch Viktorin, Jiřı́ Horáček, Martin Brunovský (2023). \textit{DOES THE PHENOMENOLOGY OF THE PSILOCYBIN EXPERIENCE PREDICT LONG-TERM EFFECTS ON MOOD AND WELL-BEING IN HEALTHY VOLUNTEERS?}. IBRO Neuroscience Reports. [published; OpenAlex]. \href{https://doi.org/10.1016/j.ibneur.2023.08.1240}{doi:10.1016/j.ibneur.2023.08.1240}.
\item Müller T. (2023). \textit{Psilocybin kann offenbar Depressionen lindern.}. MMW Fortschritte der Medizin. [published; Europe PMC]. \href{https://doi.org/10.1007/s15006-023-3025-6}{doi:10.1007/s15006-023-3025-6}.
\item Brown O (2023). \textit{Letter to the editor on "Increased low-frequency brain responses to music after psilocybin therapy for depression".}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2023.05.088}{doi:10.1016/j.jad.2023.05.088}.
\item Wolfgang AS, Hoge CW (2023). \textit{Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.}. Current psychiatry reports. [published; PubMed]. \href{https://doi.org/10.1007/s11920-023-01446-4}{doi:10.1007/s11920-023-01446-4}.
\item University of New Mexico (2023). \textit{Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT01534494}{source link}.
\item Wojtas A, Bysiek A, Wawrzczak-Bargiela A, Maćkowiak M, Gołembiowska K. (2023). \textit{Limbic System Response to Psilocybin and Ketamine Administration in Rats: A Neurochemical and Behavioral Study}. Preprints.org. [preprint; Europe PMC]. \href{https://doi.org/10.20944/preprints202309.1649.v1}{doi:10.20944/preprints202309.1649.v1}.
\item Mitch Earleywine, Maha N. Mian, Joseph A. De Leo (2023). \textit{Expectancies for Subjective and Antidepressant Effects in Psilocybin Users}. Journal of Humanistic Psychology. [published; OpenAlex]. \href{https://doi.org/10.1177/00221678231194798}{doi:10.1177/00221678231194798}.
\item Guy M. Goodwin (2023). \textit{The psychedelic experience and treatment-resistant depression}. World Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1002/wps.21140}{doi:10.1002/wps.21140}.
\item Heal DJ, Smith SL, Belouin SJ, Henningfield JE (2023). \textit{Psychedelics: Threshold of a Therapeutic Revolution.}. Neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.neuropharm.2023.109610}{doi:10.1016/j.neuropharm.2023.109610}.
\item Lawrence Canale, Dhvanit Raval, Preet Chatha, Katie Penn, Claudia Weber, Catherine Stout, Jeremy Weleff (2023). \textit{Classic Psychedelics for the Treatment of Depressive Disorders: An Update for Psychiatrists in Training}. American Journal of Psychiatry Residents Journal. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.ajp-rj.2023.190103}{doi:10.1176/appi.ajp-rj.2023.190103}.
\item Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, Kakar R, Hassman M, Trivedi RP, Robison R, Gukasyan N, Nayak SM, Hu X, O'Donnell KC, Kelmendi B, Sloshower J, Penn AD, Bradley E, Kelly DF, Mletzko T, Nicholas CR, Hutson PR, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis MC, Nelson-Douthit C, Wilson S, Brown C, Linton W, Ross S, Griffiths RR (2023). \textit{Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.}. JAMA. [published; PubMed]. \href{https://doi.org/10.1001/jama.2023.14530}{doi:10.1001/jama.2023.14530}.
\item Wall MB, Harding R, Zafar R, Rabiner EA, Nutt DJ, Erritzoe D (2023). \textit{Neuroimaging in psychedelic drug development: past, present, and future.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-023-02271-0}{doi:10.1038/s41380-023-02271-0}.
\item Ezeaka Udoka C., Kim Hye Ji J., Laprairie Robert B. (2023). \textit{Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models}. Current Topics in Medicinal Chemistry. [published; Crossref]. \href{https://doi.org/10.2174/1568026623666230705151922}{doi:10.2174/1568026623666230705151922}.
\item White CM, Weisman N, Dalo J (2023). \textit{Psychedelics for Patients With Cancer: A Comprehensive Literature Review.}. The Annals of pharmacotherapy. [published; PubMed]. \href{https://doi.org/10.1177/10600280221144055}{doi:10.1177/10600280221144055}.
\item Lewis BR, Garland EL, Byrne K, Durns T, Hendrick J, Beck A, Thielking P (2023). \textit{HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer.}. Journal of pain and symptom management. [published; PubMed]. \href{https://doi.org/10.1016/j.jpainsymman.2023.06.006}{doi:10.1016/j.jpainsymman.2023.06.006}.
\item Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, O'Keane V, Peck SK, Simmons H, Sisa C, Stansfield SC, Tsai J, Williams S, Malievskaia E (2023). \textit{Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/s41386-023-01648-7}{doi:10.1038/s41386-023-01648-7}.
\item Szigeti B, Phillips LD, Nutt D (2023). \textit{Bayesian analysis of real-world data as evidence for drug approval: Remembering Sir Michael Rawlins.}. British journal of clinical pharmacology. [published; PubMed]. \href{https://doi.org/10.1111/bcp.15841}{doi:10.1111/bcp.15841}.
\item Jahanabadi S, Amiri S, Karkeh-Abadi M, Razmi A (2023). \textit{Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters.}. Fitoterapia. [published; PubMed]. \href{https://doi.org/10.1016/j.fitote.2023.105620}{doi:10.1016/j.fitote.2023.105620}.
\item Simonsson O, Carlbring P, Carhart-Harris R, Davis AK, Nutt DJ, Griffiths RR, Erritzoe D, Goldberg SB (2023). \textit{Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2023.115349}{doi:10.1016/j.psychres.2023.115349}.
\item Sharma P, Nguyen QA, Matthews SJ, Carpenter E, Mathews DB, Patten CA, Hammond CJ (2023). \textit{Psilocybin history, action and reaction: A narrative clinical review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231190858}{doi:10.1177/02698811231190858}.
\item Garakani A, Alexander JL, Sumner CR, Pine JH, Gross LS, Raison CL, Aaronson ST, Baron DA (2023). \textit{Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.}. Journal of psychiatric practice. [published; PubMed]. \href{https://doi.org/10.1097/pra.0000000000000729}{doi:10.1097/pra.0000000000000729}.
\item Bhuiya NMA, Jacobs RJ, Wang K, Sun Y, Nava B, Sampiere L, Yerubandi A, Caballero J (2023). \textit{Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.45169}{doi:10.7759/cureus.45169}.
\item Pagán AF, Lex C, Soares JC, Meyer TD (2023). \textit{Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter?}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0022}{doi:10.1089/psymed.2023.0022}.
\item Herrmann Z, Levin AW, Cole SP, Slabaugh S, Barnett B, Penn A, Jain R, Raison C, Rajanna B, Jain S (2023). \textit{Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0030}{doi:10.1089/psymed.2023.0030}.
\item Xuehan Du (2023). \textit{Pharmacology and Therapeutic Effects of Psilocybin}. Highlights in Science Engineering and Technology. [published; OpenAlex]. \href{https://doi.org/10.54097/hset.v65i.11331}{doi:10.54097/hset.v65i.11331}.
\item Justyna Woźniak, Rafał BOGACZ, Magdalena Gaik, Ewa URAM, Inga MAGDA, Karol Womperski, Magdalena OSUCH (2023). \textit{use of psilocybin in the treatment of psychiatric disorders - review}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2023.43.01.009}{doi:10.12775/jehs.2023.43.01.009}.
\item Nick Zagorski (2023). \textit{Australia Legalizes Psychedelics for Use in Depression, PTSD Therapy}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.09.9.20}{doi:10.1176/appi.pn.2023.09.9.20}.
\item Thase ME (2023). \textit{Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy.}. The Journal of clinical psychiatry. [published; PubMed]. \href{https://doi.org/10.4088/jcp.mulmdd3048sho}{doi:10.4088/jcp.mulmdd3048sho}.
\item Jordan A (2023). \textit{Emerging Perspectives in Addiction Psychiatry.}. The Journal of clinical psychiatry. [published; PubMed]. \href{https://doi.org/10.4088/jcp. muladx3048sho}{doi:10.4088/jcp. muladx3048sho}.
\item Anna Jaremek, Joanna Kępa, Norbert Kandefer, Michał Wyszkowski, Aleksandra Grabarczyk, Anna Pawlak, Sylwia Grad, Małgorzata Gregorek, Paweł Gregorek (2023). \textit{Psilocybin's Emerging Role in Combating Depressive Disorder}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2023.40.01.011}{doi:10.12775/jehs.2023.40.01.011}.
\item Yaniv D, Ramondetta LM, Cohen L, Amit M (2023). \textit{Psilocybin-assisted psychotherapy for cancer-related anxiety and depression.}. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. [published; PubMed]. \href{https://doi.org/10.1136/ijgc-2023-004659}{doi:10.1136/ijgc-2023-004659}.
\item Pilozzi A, Foster S, Mischoulon D, Fava M, Huang X (2023). \textit{A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression.}. International journal of molecular sciences. [published; PubMed]. \href{https://doi.org/10.3390/ijms241512513}{doi:10.3390/ijms241512513}.
\item Ibrahim IB, Videbech P, Straszek SPV (2023). \textit{[Not Available].}. Ugeskrift for laeger. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/37615227/}{source link}.
\item Moritz Spangemacher (2023). \textit{Psilocybin und Funktionalität bei Depression}. InFo Neurologie + Psychiatrie. [published; OpenAlex]. \href{https://doi.org/10.1007/s15005-023-3336-2}{doi:10.1007/s15005-023-3336-2}.
\item Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, Berk M (2023). \textit{Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy.}. CNS spectrums. [published; PubMed]. \href{https://doi.org/10.1017/s1092852922000888}{doi:10.1017/s1092852922000888}.
\item Crowe M, Manuel J, Carlyle D, Lacey C (2023). \textit{Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis.}. International journal of mental health nursing. [published; PubMed]. \href{https://doi.org/10.1111/inm.13127}{doi:10.1111/inm.13127}.
\item Zia FZ, Baumann MH, Belouin SJ, Dworkin RH, Ghauri MH, Hendricks PS, Henningfield JE, Lanier RK, Ross S, Berger A (2023). \textit{Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.}. Neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.neuropharm.2023.109528}{doi:10.1016/j.neuropharm.2023.109528}.
\item Zeifman RJ, Wagner AC, Monson CM, Carhart-Harris RL (2023). \textit{How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2023.04.105}{doi:10.1016/j.jad.2023.04.105}.
\item Jing X, Hoeh NR, Menkes DB (2023). \textit{Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.}. Palliative \& supportive care. [published; PubMed]. \href{https://doi.org/10.1017/s147895152300069x}{doi:10.1017/s147895152300069x}.
\item Chen T, Cheng L, Ma J, Yuan J, Pi C, Xiong L, Chen J, Liu H, Tang J, Zhong Y, Zhang X, Liu Z, Zuo Y, Shen H, Wei Y, Zhao L (2023). \textit{Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants.}. Pharmacological research. [published; PubMed]. \href{https://doi.org/10.1016/j.phrs.2023.106837}{doi:10.1016/j.phrs.2023.106837}.
\item Brain and Cognition Discovery Foundation (2023). \textit{The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05029466}{source link}.
\item Husain MI, Blumberger DM, Castle DJ, Ledwos N, Fellows E, Jones BDM, Ortiz A, Kloiber S, Wang W, Rosenblat JD, Mulsant BH (2023). \textit{Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.}. BJPsych open. [published; PubMed]. \href{https://doi.org/10.1192/bjo.2023.535}{doi:10.1192/bjo.2023.535}.
\item Goodwin G, Marwood L, Mistry S, Nowakowska A, Simmons H, Tsai J, Williams S, Young M, Malievskaia E. (2023). \textit{Improvement in Depression Symptoms Measured by Montgomery-Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology-Self Rated Items after Randomised Double-blind COMP360 Psilocybin Therapy for Treatment-resistant Depression}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC10595939}{source link}.
\item Kuypers K. (2023). \textit{Psychedelics for depression: from neurobiology to treatment}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC10417770}{source link}.
\item Ramírez González J, Fernández Márquez I, Ferreiro González S, Ruíz E. (2023). \textit{The therapeutic potential of psilocybin in depression resistant to psychotropic drugs}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC10479004}{source link}.
\item Lin M, Lee H, Tsang V, Chai B, Howard A, Uy C, Elefante J. (2023). \textit{Systematic Review on the Mechanisms of Action of Psilocybin in the Treatment of Depression}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC10434693}{source link}.
\item Venugopal Kaden L. (2023). \textit{Psilocybin Therapy for Major Depressive Disorder: A Systematic Review}. Undergraduate Research in Natural and Clinical Science and Technology Journal. [published; Crossref]. \href{https://doi.org/10.26685/urncst.489}{doi:10.26685/urncst.489}.
\item Nicolas Garel, Julien Thibault Lévesque, Dasha A. Sandra, Justin Lessard-Wajcer, Elizaveta Solomonova, Michael Lifshitz, Stéphane Richard-Devantoy, Kyle T. Greenway (2023). \textit{Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings}. Frontiers in Human Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.3389/fnhum.2023.1200393}{doi:10.3389/fnhum.2023.1200393}.
\item Jorge Valdiviezo-Oña, Lizbeth Toscano-Molina, Juan Fernando Chávez, Jonathan Elias Herrera Criollo, Clara Paz (2023). \textit{Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping review}. Advances in Mental Health. [published; OpenAlex]. \href{https://doi.org/10.1080/18387357.2023.2235030}{doi:10.1080/18387357.2023.2235030}.
\item Nogrady B (2023). \textit{Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics.}. BMJ (Clinical research ed.). [published; PubMed]. \href{https://doi.org/10.1136/bmj.p1599}{doi:10.1136/bmj.p1599}.
\item Takaba R, Ibi D, Yoshida K, Hosomi E, Kawase R, Kitagawa H, Goto H, Achiwa M, Mizutani K, Maede K, González-Maeso J, Kitagaki S, Hiramatsu M (2023). \textit{Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice.}. Research square. [published; PubMed]. \href{https://doi.org/10.21203/rs.3.rs-3138705/v1}{doi:10.21203/rs.3.rs-3138705/v1}.
\item Tetem J, Fischmann T, Möller TJ. (2023). \textit{Psychoactive substances in psychotherapy - A vision for the future? - A systematic review on Psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/ztyxh}{doi:10.31234/osf.io/ztyxh}.
\item Cybin Therapeutics Inc. (2023). \textit{Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05594667}{source link}.
\item Jenny Tetem, Tamara Fischmann, Tim Julian Möller (2023). \textit{Psychoactive substances in psychotherapy - A vision for the future? - A systematic review on Psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/ztyxh\_v1}{source link}.
\item Sloshower J, Skosnik PD, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D'Souza DC (2023). \textit{Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231154852}{doi:10.1177/02698811231154852}.
\item Feduccia A, Agin-Liebes G, Price CM, Grinsell N, Paradise S, Rabin DM (2023). \textit{The need for establishing best practices and gold standards in psychedelic medicine.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2023.03.083}{doi:10.1016/j.jad.2023.03.083}.
\item Weiss B, Erritzoe D, Giribaldi B, Nutt DJ, Carhart-Harris RL (2023). \textit{A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231167848}{doi:10.1177/02698811231167848}.
\item Rossell SL, Meikle SE, Williams ML, Castle DJ (2023). \textit{Why didn't the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder?}. The Australian and New Zealand journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1177/00048674231172691}{doi:10.1177/00048674231172691}.
\item Keramatian K, Chakrabarty T, DuBow A, Saraf G, Yatham LN (2023). \textit{New Pharmacologic Approaches to the Treatment of Bipolar Depression.}. Drugs. [published; PubMed]. \href{https://doi.org/10.1007/s40265-023-01872-x}{doi:10.1007/s40265-023-01872-x}.
\item Gukasyan N, Griffiths RR, Yaden DB, Antoine DG, Nayak SM (2023). \textit{Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231179910}{doi:10.1177/02698811231179910}.
\item Haridy R (2023). \textit{Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.}. Nature. [published; PubMed]. \href{https://doi.org/10.1038/d41586-023-02093-8}{doi:10.1038/d41586-023-02093-8}.
\item Skosnik PD, Sloshower J, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D'Souza DC (2023). \textit{Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231179800}{doi:10.1177/02698811231179800}.
\item Hovmand OR, Poulsen ED, Arnfred S, Storebø OJ (2023). \textit{Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231180276}{doi:10.1177/02698811231180276}.
\item Halucenex Life Sciences Inc. (2023). \textit{Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05243329}{source link}.
\item Terri D’Arrigo (2023). \textit{Experts Offer Tips on Talking With Patients About Psychedelics}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.07.7.51}{doi:10.1176/appi.pn.2023.07.7.51}.
\item Cheung K, Patch K, Earp BD, Yaden DB (2023). \textit{Psychedelics, Meaningfulness, and the "Proper Scope" of Medicine: Continuing the Conversation.}. Cambridge quarterly of healthcare ethics: CQ: the international journal of healthcare ethics committees. [published; PubMed]. \href{https://doi.org/10.1017/s0963180123000270}{doi:10.1017/s0963180123000270}.
\item Wulff AB, Nichols CD, Thompson SM (2023). \textit{Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.}. Neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.neuropharm.2023.109504}{doi:10.1016/j.neuropharm.2023.109504}.
\item Romain Nardou, Edward J. Sawyer, Young Jun Song, M. F. Wilkinson, Yasmin Padovan-Hernandez, Júnia L. de Deus, Noelle Wright, Carine Lama, Sehr Faltin, Loyal A. Goff, Genevieve Stein-O’Brien, Gül Dölen (2023). \textit{Psychedelics reopen the social reward learning critical period}. Nature. [published; OpenAlex]. \href{https://doi.org/10.1038/s41586-023-06204-3}{doi:10.1038/s41586-023-06204-3}.
\item Kevin Herkenham (2023). \textit{A regulatory framework review of Schedule I psychedelics in the United States}. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. [published; OpenAlex]. \href{https://doi.org/10.1002/jac5.1841}{doi:10.1002/jac5.1841}.
\item Turkia M. (2023). \textit{Self-treatment of parental neglect-induced mixed anxiety and depressive disorder with psilocybin - A retrospective case study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/qyce5}{doi:10.31234/osf.io/qyce5}.
\item Mika Turkia (2023). \textit{The treatment of abandonment anxiety with MDMA and LSD}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/pw2tf\_v1}{source link}.
\item Mika Turkia (2023). \textit{Self-treatment of parental neglect-induced mixed anxiety and depressive disorder with psilocybin - A retrospective case study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/qyce5\_v1}{source link}.
\item Wall MB, Demetriou L, Giribaldi B, Roseman L, Ertl N, Erritzoe D, Nutt DJ, Carhart-Harris RL. (2023). \textit{Reduced brain responsiveness to emotional stimuli with escitalopram but not psilocybin therapy for depression}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2023.05.29.23290667}{doi:10.1101/2023.05.29.23290667}.
\item Tooba Noor, Areej Shakil, Aimen Waqar Khan, Syeda Mahrukh Fatima Zaidi, Hussain Sohail Rangwala, Burhanuddin Sohail Rangwala (2023). \textit{Psilocybin therapy: A novel approach to treating depression}. International Journal of Surgery Global Health. [published; OpenAlex]. \href{https://doi.org/10.1097/gh9.0000000000000175}{doi:10.1097/gh9.0000000000000175}.
\item Irvine W, Tyler M, Delgoda R (2023). \textit{In silico characterization of the psilocybin biosynthesis pathway.}. Computational biology and chemistry. [published; PubMed]. \href{https://doi.org/10.1016/j.compbiolchem.2023.107854}{doi:10.1016/j.compbiolchem.2023.107854}.
\item Agrawal M, Emanuel E, Richards B, Richards W, Roddy K, Thambi P (2023). \textit{Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder.}. JAMA oncology. [published; PubMed]. \href{https://doi.org/10.1001/jamaoncol.2023.0351}{doi:10.1001/jamaoncol.2023.0351}.
\item Kamal S, Jha MK, Radhakrishnan R (2023). \textit{Role of Psychedelics in Treatment-Resistant Depression.}. The Psychiatric clinics of North America. [published; PubMed]. \href{https://doi.org/10.1016/j.psc.2023.02.004}{doi:10.1016/j.psc.2023.02.004}.
\item Gold ND, Podrebarac SK, White LA, Marini C, Simon NM, Mittelman MS, Ross S, Bogenschutz MP, Petridis PD (2023). \textit{Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2022.0011}{doi:10.1089/psymed.2022.0011}.
\item Manish Agrawal, Sarah Shnayder, Heather Honstein, Ezekiel Emanuel, Paul Thambi (2023). \textit{Long term efficacy of psilocybin in patients with cancer and major depressive disorder (MDD).}. Journal of Clinical Oncology. [published; OpenAlex]. \href{https://doi.org/10.1200/jco.2023.41.16\_suppl.12021}{doi:10.1200/jco.2023.41.16\_suppl.12021}.
\item Combat Stress (2023). \textit{Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05876481}{source link}.
\item Qasim S, Zaheer Z, Jawad MY, Shad MU (2023). \textit{Neurobiological Correlates of Psilocybin Response in Depression.}. The primary care companion for CNS disorders. [published; PubMed]. \href{https://doi.org/10.4088/pcc.22r03419}{doi:10.4088/pcc.22r03419}.
\item University of Wisconsin, Madison (2023). \textit{Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04842045}{source link}.
\item Fonseka LN, Woo BK (2023). \textit{Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review.}. World journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.5498/wjp.v13.i5.182}{doi:10.5498/wjp.v13.i5.182}.
\item Raithatha SA, Hagel JM, Matinkhoo K, Yu L, Press D, Cook SG, Sharma G, D D, Jensen G, Lee JB, Cai C, Gallant J, Bains JS, Tucker JE, Facchini PJ. (2023). \textit{Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2023.05.16.540994}{doi:10.1101/2023.05.16.540994}.
\item Chirag Ambaliya, Dimple Gupta, Ashok Vala, Krupa Mukeshbhai Unadkat (2023). \textit{THE THERAPEUTIC POTENTIAL OF PSYCHEDELICS FOR MENTAL HEALTH DISORDERS: A REVIEW OF CURRENT EVIDENCE}. PARIPEX-INDIAN JOURNAL OF RESEARCH. [published; OpenAlex]. \href{https://doi.org/10.36106/paripex/6712845}{doi:10.36106/paripex/6712845}.
\item University of Wisconsin, Madison (2023). \textit{A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05467761}{source link}.
\item THORENS G, PENZENSTADLER l, FURTADO LCDC, SERAGNOLI F, ROTHEN S, MABILAIS C, ZULLINO D. (2023). \textit{Exposure therapy under psilocybin for general anxiety disorder and claustrophobia}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-2859973/v1}{doi:10.21203/rs.3.rs-2859973/v1}.
\item Więckiewicz G, Marek J, Stokłosa I, Szafoni S, Pluta S, Smukowska K, Żebrowska G, Stokłosa M, Gorczyca P, Pudlo R (2023). \textit{The Need for Psychiatric Treatment among Polish Users of Psychoactive Substances Is Increasing: This and Other Results from the Newest PolDrugs Survey.}. Medicina (Kaunas, Lithuania). [published; PubMed]. \href{https://doi.org/10.3390/medicina59050908}{doi:10.3390/medicina59050908}.
\item Johns Hopkins University (2023). \textit{Effects of Psilocybin in Anorexia Nervosa}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04052568}{source link}.
\item Goodwin GM, Croal M, Marwood L, Malievskaia E (2023). \textit{Unblinding and demand characteristics in the treatment of depression.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2023.02.030}{doi:10.1016/j.jad.2023.02.030}.
\item Rosenblat JD, Leon-Carlyle M, Ali S, Husain MI, McIntyre RS (2023). \textit{Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20220835}{doi:10.1176/appi.ajp.20220835}.
\item Ibi D (2023). \textit{[Contribution of serotonin 5-HT receptor to antidepressant effect of serotonergic psychedelics].}. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. [published; PubMed]. \href{https://doi.org/10.1254/fpj.22141}{doi:10.1254/fpj.22141}.
\item Schneier FR, Feusner J, Wheaton MG, Gomez GJ, Cornejo G, Naraindas AM, Hellerstein DJ (2023). \textit{Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.}. Journal of psychiatric research. [published; PubMed]. \href{https://doi.org/10.1016/j.jpsychires.2023.03.031}{doi:10.1016/j.jpsychires.2023.03.031}.
\item Eric N. Kramer, Kalyn Reddy, Bryan Shapiro (2023). \textit{A suicide attempt following psilocybin ingestion in a patient with no prior psychiatric history}. Psychiatry Research Case Reports. [published; OpenAlex]. \href{https://doi.org/10.1016/j.psycr.2023.100118}{doi:10.1016/j.psycr.2023.100118}.
\item COMPASS Pathways (2023). \textit{The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03775200}{source link}.
\item Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Lennard-Jones MR, Licht RW, Marwood L, Mistry S, Páleníček T, Redjep O, Repantis D, Schoevers RA, Septimus B, Simmons HJ, Soares JC, Somers M, Stansfield SC, Stuart JR, Tadley HH, Thiara NK, Tsai J, Wahba M, Williams S, Winzer RI, Young AH, Young MB, Zisook S, Malievskaia E (2023). \textit{Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2023.01.108}{doi:10.1016/j.jad.2023.01.108}.
\item Xi Zhu, David J. Hellerstein, Jamie D. Feusner, Michael G. Wheaton, Gloria Gómez, Franklin R. Schneier (2023). \textit{347. Changes in Resting State Functional Connectivity After Psilocybin for Body Dysmorphic Disorder}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2023.02.587}{doi:10.1016/j.biopsych.2023.02.587}.
\item Scott Aaronson, Tammy Miller, Samuel Rudow, MacKenzie Forbes, Audrey Shoultz, Trisha Suppes (2023). \textit{96. An Open Label Study of Synthetic Psilocybin in Bipolar Type II Depression}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2023.02.336}{doi:10.1016/j.biopsych.2023.02.336}.
\item Julia Mertens L. (2023). \textit{Psilocybin zeigt Wirkung bei Depression.}. MMW Fortschritte der Medizin. [published; Europe PMC]. \href{https://doi.org/10.1007/s15006-023-2540-9}{doi:10.1007/s15006-023-2540-9}.
\item Lyes M, Yang KH, Castellanos J, Furnish T (2023). \textit{Microdosing psilocybin for chronic pain: a case series.}. Pain. [published; PubMed]. \href{https://doi.org/10.1097/j.pain.0000000000002778}{doi:10.1097/j.pain.0000000000002778}.
\item VanderZwaag J, Halvorson T, Dolhan K, Šimončičová E, Ben-Azu B, Tremblay MÈ (2023). \textit{The Missing Piece? A Case for Microglia's Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics.}. Neurochemical research. [published; PubMed]. \href{https://doi.org/10.1007/s11064-022-03772-0}{doi:10.1007/s11064-022-03772-0}.
\item Kelly DF, Heinzerling K, Sharma A, Gowrinathan S, Sergi K, Mallari RJ (2023). \textit{Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology.}. Neurosurgery. [published; PubMed]. \href{https://doi.org/10.1227/neu.0000000000002275}{doi:10.1227/neu.0000000000002275}.
\item Modlin NL, Miller TM, Rucker JJ, Kirlic N, Lennard-Jones M, Schlosser D, Aaronson ST (2023). \textit{Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2023.01.077}{doi:10.1016/j.jad.2023.01.077}.
\item Dawood Hristova JJ, Pérez-Jover V (2023). \textit{Psychotherapy with Psilocybin for Depression: Systematic Review.}. Behavioral sciences (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/bs13040297}{doi:10.3390/bs13040297}.
\item Gattuso JJ, Perkins D, Ruffell S, Lawrence AJ, Hoyer D, Jacobson LH, Timmermann C, Castle D, Rossell SL, Downey LA, Pagni BA, Galvão-Coelho NL, Nutt D, Sarris J (2023). \textit{Default Mode Network Modulation by Psychedelics: A Systematic Review.}. The international journal of neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1093/ijnp/pyac074}{doi:10.1093/ijnp/pyac074}.
\item Optimi Health Corporation (2023). \textit{Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05252598}{source link}.
\item Zanikov T, Gerasymchuk M, Ghasemi Gojani E, Robinson GI, Asghari S, Groves A, Haselhorst L, Nandakumar S, Stahl C, Cameron M, Li D, Rodriguez-Juarez R, Snelling A, Hudson D, Fiselier A, Kovalchuk O, Kovalchuk I (2023). \textit{The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice.}. Molecules (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/molecules28062624}{doi:10.3390/molecules28062624}.
\item New York State Psychiatric Institute (2023). \textit{Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04656301}{source link}.
\item Turkia M. (2023). \textit{Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD-A retrospective case study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/wupvy}{doi:10.31234/osf.io/wupvy}.
\item Turkia M. (2023). \textit{Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin-A retrospective case study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/t6k9b}{doi:10.31234/osf.io/t6k9b}.
\item Mika Turkia (2023). \textit{Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD-A retrospective case study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/wupvy\_v1}{source link}.
\item Mika Turkia (2023). \textit{Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin-A retrospective case study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/t6k9b\_v1}{source link}.
\item Steven W. Cotten, Frederick G. Strathmann, Frederick S. Barrett, Laura Labay, James Mullally, Alexander M. Sherwood, Frank Wiegand (2023). \textit{Psychedelics for Medicinal Use: How Will This Alter the Collective Laboratory Consciousness?}. Clinical Chemistry. [published; OpenAlex]. \href{https://doi.org/10.1093/clinchem/hvad016}{doi:10.1093/clinchem/hvad016}.
\item Kalkman HO (2023). \textit{Inhibition of Microglial GSK3β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles.}. Biomedicines. [published; PubMed]. \href{https://doi.org/10.3390/biomedicines11030806}{doi:10.3390/biomedicines11030806}.
\item Shi En Kim (2023). \textit{How psychedelics spark neuronal growth}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-10108-scicon1}{doi:10.1021/cen-10108-scicon1}.
\item Emmerich N, Humphries B (2023). \textit{Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist's Training?}. Cambridge quarterly of healthcare ethics: CQ: the international journal of healthcare ethics committees. [published; PubMed]. \href{https://doi.org/10.1017/s0963180123000099}{doi:10.1017/s0963180123000099}.
\item Lazur J, Hnatyk K, Kała K, Sułkowska-Ziaja K, Muszyńska B (2023). \textit{Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review.}. Antioxidants (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/antiox12030623}{doi:10.3390/antiox12030623}.
\item Nayak SM, Bari BA, Yaden DB, Spriggs MJ, Rosas FE, Peill JM, Giribaldi B, Erritzoe D, Nutt DJ, Carhart-Harris R (2023). \textit{A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2022.0002}{doi:10.1089/psymed.2022.0002}.
\item Kisely S, Connor M, Somogyi AA, Siskind D (2023). \textit{A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders.}. The Australian and New Zealand journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1177/00048674221083868}{doi:10.1177/00048674221083868}.
\item Schmidt C, Wolff M, Gründer G, Jungaberle H (2023). \textit{[Attitudes of Mental Health Experts Towards Psilocybin].}. Fortschritte der Neurologie-Psychiatrie. [published; PubMed]. \href{https://doi.org/10.1055/a-1846-1161}{doi:10.1055/a-1846-1161}.
\item McTaggart AR, James TY, Slot JC, Barlow C, Fechner N, Shuey LS, Drenth A (2023). \textit{Genome sequencing progenies of magic mushrooms (Psilocybe subaeruginosa) identifies tetrapolar mating and gene duplications in the psilocybin pathway.}. Fungal genetics and biology: FG \& B. [published; PubMed]. \href{https://doi.org/10.1016/j.fgb.2022.103769}{doi:10.1016/j.fgb.2022.103769}.
\item Zohairi F, Khandelia H, Hakami Zanjani AA (2023). \textit{Interaction of psychedelic tryptamine derivatives with a lipid bilayer.}. Chemistry and physics of lipids. [published; PubMed]. \href{https://doi.org/10.1016/j.chemphyslip.2023.105279}{doi:10.1016/j.chemphyslip.2023.105279}.
\item Jha MK, Mathew SJ (2023). \textit{Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20230025}{doi:10.1176/appi.ajp.20230025}.
\item Hibicke M, Kramer HM, Nichols CD (2023). \textit{A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2022.0012}{doi:10.1089/psymed.2022.0012}.
\item Aday JS, Skiles Z, Eaton N, Fredenburg L, Pleet M, Mantia J, Bradley ER, Fernandes-Osterhold G, Woolley JD (2023). \textit{Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2022.0004}{doi:10.1089/psymed.2022.0004}.
\item Østergaard SD, Hieronymus F (2023). \textit{Psilocybin for Treatment-Resistant Depression.}. The New England journal of medicine. [published; PubMed]. \href{https://doi.org/10.1056/nejmc2215459}{doi:10.1056/nejmc2215459}.
\item Jacques Ambrose, J.S. Zabinski (2023). \textit{Psychedelic Renaissance: Clinical Health Justice, Patient Safety, and Equity Need to Be Put First}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.03.3.43}{doi:10.1176/appi.pn.2023.03.3.43}.
\item Ashish Sarangi, Omotola Akinkunmi (2023). \textit{Psychedelics for the Neuropsychiatric Symptoms of Alzheimer's disease}. American Journal of Geriatric Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jagp.2022.12.201}{doi:10.1016/j.jagp.2022.12.201}.
\item Shnayder S, Ameli R, Sinaii N, Berger A, Agrawal M (2023). \textit{Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2022.11.046}{doi:10.1016/j.jad.2022.11.046}.
\item Jeffery Heilman (2023). \textit{The History, Legalization and Potentials of Psilocybin-Assisted Psychotherapy}. Journal of Scientific Exploration. [published; OpenAlex]. \href{https://doi.org/10.31275/20222633}{doi:10.31275/20222633}.
\item Gonda X, Dome P, Neill JC, Tarazi FI (2023). \textit{Novel antidepressant drugs: Beyond monoamine targets.}. CNS spectrums. [published; PubMed]. \href{https://doi.org/10.1017/s1092852921000791}{doi:10.1017/s1092852921000791}.
\item Ko K, Kopra EI, Cleare AJ, Rucker JJ (2023). \textit{Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2022.09.168}{doi:10.1016/j.jad.2022.09.168}.
\item Burmester DR, Madsen MK, Szabo A, Aripaka SS, Stenbæk DS, Frokjaer VG, Elfving B, Mikkelsen JD, Knudsen GM, Fisher PM (2023). \textit{Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation.}. Comprehensive psychoneuroendocrinology. [published; PubMed]. \href{https://doi.org/10.1016/j.cpnec.2022.100163}{doi:10.1016/j.cpnec.2022.100163}.
\item Cameron LP, Patel SD, Vargas MV, Barragan EV, Saeger HN, Warren HT, Chow WL, Gray JA, Olson DE (2023). \textit{5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.2c00718}{doi:10.1021/acschemneuro.2c00718}.
\item von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jäncke L, Preller KH, Vollenweider FX (2023). \textit{Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.}. EClinicalMedicine. [published; PubMed]. \href{https://doi.org/10.1016/j.eclinm.2022.101809}{doi:10.1016/j.eclinm.2022.101809}.
\item von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jäncke L, Preller KH, Vollenweider FX (2023). \textit{Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.}. EClinicalMedicine. [published; PubMed]. \href{https://doi.org/10.1016/j.eclinm.2023.101841}{doi:10.1016/j.eclinm.2023.101841}.
\item Rucker JJ (2023). \textit{Psilocybin therapy for depression. A good trip?}. Journal of mental health (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1080/09638237.2023.2183492}{doi:10.1080/09638237.2023.2183492}.
\item Jennings Hernandez (2023). \textit{Plant Medicine Healing! Discovering the Roots of Psychedelic-Assisted Therapy in Mental Health}. Advances in Research. [published; OpenAlex]. \href{https://doi.org/10.9734/air/2023/v24i1931}{doi:10.9734/air/2023/v24i1931}.
\item Washington University School of Medicine (2023). \textit{SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05601648}{source link}.
\item Benjamin R. Lewis, Kevin Byrne, John Hendrick, Eric L. Garland, Paul Thielking, Anna C. Beck (2023). \textit{Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2022.00222}{doi:10.1556/2054.2022.00222}.
\item Dragana Marković, Eleonora Čapelja (2023). \textit{Therapeutic potential of psilocybin: a promising agent in treating major depressive disorder}. AIDASCO Reviews. [published; OpenAlex]. \href{https://doi.org/10.59783/aire.2023.15}{doi:10.59783/aire.2023.15}.
\item Mann JJ (2023). \textit{Is psilocybin an effective antidepressant and what is its Mechanism of action?}. Cell reports. Medicine. [published; PubMed]. \href{https://doi.org/10.1016/j.xcrm.2022.100906}{doi:10.1016/j.xcrm.2022.100906}.
\item Gukasyan N (2023). \textit{On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression.}. Med (New York, N.Y.). [published; PubMed]. \href{https://doi.org/10.1016/j.medj.2022.12.003}{doi:10.1016/j.medj.2022.12.003}.
\item Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G, Tirelli E, Pucci M, Ribaudo G, Oselladore E, Premoli M, Gianoncelli A, Uberti DL, Memo M (2023). \textit{The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.}. International journal of molecular sciences. [published; PubMed]. \href{https://doi.org/10.3390/ijms24021329}{doi:10.3390/ijms24021329}.
\item Torrado Pacheco A, Olson RJ, Garza G, Moghaddam B (2023). \textit{Acute psilocybin enhances cognitive flexibility in rats.}. bioRxiv: the preprint server for biology. [published; PubMed]. \href{https://doi.org/10.1101/2023.01.09.523291}{doi:10.1101/2023.01.09.523291}.
\item Sidsel Andersen (2023). \textit{Et psykoanalytisk og et postmoderne perspektiv på selv/egoopløsning i en psykedelisk kontekst}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/f26ce\_v1}{source link}.
\item Ines Erkizia-Santamaría, Guadalupe Rivero, Igor Horrillo, J. Javier Meana, Jorge E. Ortega (2023). \textit{Psilocybin rescues depressive phenotype and modulates serotonin-2A and glucocorticoid receptor mRNA expression in brain cortex of a stress animal model}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2023.102452}{doi:10.1016/j.nsa.2023.102452}.
\item Guy M. Goodwin, Lindsey Marwood, S. Mistry, Anna Nowakowska, Zainib Shabir, H. Clifton Simmons, E.K. Teoh, Jeng-Yu Tsai, E. Malievskaia (2023). \textit{The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a long-term observational follow-up study}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2023.102906}{doi:10.1016/j.nsa.2023.102906}.
\item Agata Machaczka, Jane Turek, Dorota Bederska-Łojewska, Bartłomiej Pochwat, Łukasz Gąsior, Bernadeta Szewczyk, Andrzej Pilc (2023). \textit{Effect of co-administration of low doses of psilocybin and mGluR2/3 antagonist LY341495 in chronic restraint stress model of depression}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2023.102939}{doi:10.1016/j.nsa.2023.102939}.
\item Miriam L. Navarro, Alberte Wollesen Breum, Annette Johansen, Brice Ozenne, Vibe G. Frøkjær, Gitte M. Knudsen (2023). \textit{Change in whole blood BDNF after escitalopram or psilocybin intervention in patients with depression and healthy controls}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2023.103646}{doi:10.1016/j.nsa.2023.103646}.
\item Adriana D’Arienzo, Giorgio Samorini (2023). \textit{Italian psychedelic therapies of the past century: An historical overview}. Drug Science Policy and Law. [published; OpenAlex]. \href{https://doi.org/10.1177/20503245231179687}{doi:10.1177/20503245231179687}.
\item O. Shahar, A. Botvinik, T. Lifschytz, B. Lerer (2023). \textit{Therapeutic mechanism of psilocybin in the treatment of depression and other psychiatric disorders.}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2023.101067}{doi:10.1016/j.nsa.2023.101067}.
\item Nadiia Omelchenko, Anton Kurapov (2023). \textit{Psychedelic-Assisted Therapy and Meditative Experience as Factors of Personal Change}. Bulletin of Taras Shevchenko National University of Kyiv Psychology. [published; OpenAlex]. \href{https://doi.org/10.17721/bpsy.2023.1(17).8}{doi:10.17721/bpsy.2023.1(17).8}.
\item John R. Rossiter (2023). \textit{Psychedelic Drug Therapy for Mental Disorders?}. Open Journal of Medical Psychology. [published; OpenAlex]. \href{https://doi.org/10.4236/ojmp.2023.123010}{doi:10.4236/ojmp.2023.123010}.
\item Hodge AT, Sukpraprut-Braaten S, Narlesky M, Strayhan RC (2023). \textit{The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2022.2044096}{doi:10.1080/02791072.2022.2044096}.
\item Earleywine M, Low F, Altman BR, De Leo J (2023). \textit{How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression?}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2022.2047842}{doi:10.1080/02791072.2022.2047842}.
\item Knudsen GM (2023). \textit{Sustained effects of single doses of classical psychedelics in humans.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/s41386-022-01361-x}{doi:10.1038/s41386-022-01361-x}.
\item Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenway KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V (2023). \textit{The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.}. Canadian journal of psychiatry. Revue canadienne de psychiatrie. [published; PubMed]. \href{https://doi.org/10.1177/07067437221111371}{doi:10.1177/07067437221111371}.
\item Calder AE, Hasler G (2023). \textit{Towards an understanding of psychedelic-induced neuroplasticity.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/s41386-022-01389-z}{doi:10.1038/s41386-022-01389-z}.
\item Jones GM (2023). \textit{Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811221127304}{doi:10.1177/02698811221127304}.
\item Shukuroglou M, Roseman L, Wall M, Nutt D, Kaelen M, Carhart-Harris R (2023). \textit{Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811221125354}{doi:10.1177/02698811221125354}.
\item Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J (2023). \textit{Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811221131997}{doi:10.1177/02698811221131997}.
\item Meccia J, Lopez J, Bagot RC (2023). \textit{Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-022-06297-0}{doi:10.1007/s00213-022-06297-0}.
\item Kotoula V, Evans JW, Punturieri C, Johnson SC, Zarate CA (2023). \textit{Functional MRI markers for treatment-resistant depression: Insights and challenges.}. Progress in brain research. [published; PubMed]. \href{https://doi.org/10.1016/bs.pbr.2023.04.001}{doi:10.1016/bs.pbr.2023.04.001}.
\item Chen MH, Tu PC, Su TP (2023). \textit{Next generation antidepressants with novel mechanisms for treatment resistant depression.}. Progress in brain research. [published; PubMed]. \href{https://doi.org/10.1016/bs.pbr.2023.02.005}{doi:10.1016/bs.pbr.2023.02.005}.
\item Ahmed H, Mushahid H, Arshad T (2023). \textit{UNCOVERING THE UNTAPPED POTENTIAL OF PSILOCYBIN THERAPY IN ALLEVIATING CANCER-RELATED DEPRESSION: AN URGENT CALL TO RE-EVALUATE TREATMENT STRATEGIES.}. Psychiatria Danubina. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/37992112/}{source link}.
\item Edelsohn GA, Sisti D (2023). \textit{Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment.}. Perspectives in biology and medicine. [published; PubMed]. \href{https://doi.org/10.1353/pbm.2023.0007}{doi:10.1353/pbm.2023.0007}.
\item IsHak WW, Garcia P, Pearl R, Dang J, William C, Totlani J, Danovitch I (2023). \textit{The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials.}. Innovations in clinical neuroscience. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/37387703/}{source link}.
\item Liu J, Wang Y, Xia K, Wu J, Zheng D, Cai A, Yan H, Su R (2023). \textit{Acute psilocybin increased cortical activities in rats.}. Frontiers in neuroscience. [published; PubMed]. \href{https://doi.org/10.3389/fnins.2023.1168911}{doi:10.3389/fnins.2023.1168911}.
\item Schindler EAD, Hendricks PS (2023). \textit{Adapting psychedelic medicine for headache and chronic pain disorders.}. Expert review of neurotherapeutics. [published; PubMed]. \href{https://doi.org/10.1080/14737175.2023.2246655}{doi:10.1080/14737175.2023.2246655}.
\item Kozak Z, Johnson MW, Aaronson ST (2023). \textit{Assessing potential of psilocybin for depressive disorders.}. Expert opinion on investigational drugs. [published; PubMed]. \href{https://doi.org/10.1080/13543784.2023.2273493}{doi:10.1080/13543784.2023.2273493}.
\item Herrmann Z, Earleywine M, De Leo J, Slabaugh S, Kenny T, Rush AJ (2023). \textit{Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2022.2125467}{doi:10.1080/02791072.2022.2125467}.
\item Kalfas M, Taylor RH, Tsapekos D, Young AH (2023). \textit{Psychedelics for treatment resistant depression: are they game changers?}. Expert opinion on pharmacotherapy. [published; PubMed]. \href{https://doi.org/10.1080/14656566.2023.2281582}{doi:10.1080/14656566.2023.2281582}.
\item Nayak SM, Jackson H, Sepeda ND, Mathai DS, So S, Yaffe A, Zaki H, Brasher TJ, Lowe MX, Jolly DRP, Barrett FS, Griffiths RR, Strickland JC, Johnson MW, Jackson H, Garcia-Romeu A (2023). \textit{Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2023.1199642}{doi:10.3389/fpsyt.2023.1199642}.
\item Halim HJ, Burk BG, Fargason RE, Birur B (2023). \textit{Manic episode following psilocybin use in a man with bipolar II disorder: a case report.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2023.1221131}{doi:10.3389/fpsyt.2023.1221131}.
\item Acero VP, Cribas ES, Browne KD, Rivellini O, Burrell JC, O'Donnell JC, Das S, Cullen DK (2023). \textit{Bedside to bench: the outlook for psychedelic research.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2023.1240295}{doi:10.3389/fphar.2023.1240295}.
\item Ko K, Carter B, Cleare AJ, Rucker JJ (2023). \textit{Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis.}. Neuropsychiatric disease and treatment. [published; PubMed]. \href{https://doi.org/10.2147/ndt.s426193}{doi:10.2147/ndt.s426193}.
\item Escamilla R, González-Trujano ME, González Mariscal JM, Torres-Valencia JM, Guzmán-González H, Vega JL, Loizaga-Velder A (2023). \textit{A Proposal to Study the Safety and Efficacy of in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2023.2246459}{doi:10.1080/02791072.2023.2246459}.
\item Marseille E, Stauffer CS, Agrawal M, Thambi P, Roddy K, Mithoefer M, Bertozzi SM, Kahn JG (2023). \textit{Group psychedelic therapy: empirical estimates of cost-savings and improved access.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2023.1293243}{doi:10.3389/fpsyt.2023.1293243}.
\item Munafò A, Arillotta D, Mannaioni G, Schifano F, Bernardini R, Cantarella G (2022). \textit{Psilocybin for Depression: From Credibility to Feasibility, What's Missing?}. Pharmaceuticals (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/ph16010068}{doi:10.3390/ph16010068}.
\item Vanessa Eveline VLAIC, Andreea ONA (2022). \textit{The Potential of Psilocybe Genus Fungi to Treat Depression and Some Addictions}. Hop and Medicinal Plants. [published; OpenAlex]. \href{https://doi.org/10.15835/hpm.v30i1-2.14453}{doi:10.15835/hpm.v30i1-2.14453}.
\item Nick Zagorski (2022). \textit{Depression Improves Following Single Dose of Psilocybin}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.01.1.50}{doi:10.1176/appi.pn.2023.01.1.50}.
\item Bradshaw AJ, Backman TA, Ramírez-Cruz V, Forrister DL, Winter JM, Guzmán-Dávalos L, Furci G, Stamets P, Dentinger BTM (2022). \textit{DNA Authentication and Chemical Analysis of Mushrooms Reveal Widespread Misdeterminations in Fungaria and Inconsistencies in Metabolites.}. Applied and environmental microbiology. [published; PubMed]. \href{https://doi.org/10.1128/aem.01498-22}{doi:10.1128/aem.01498-22}.
\item Schäfer T, Kramer K, Werten S, Rupp B, Hoffmeister D (2022). \textit{Characterization of the Gateway Decarboxylase for Psilocybin Biosynthesis.}. Chembiochem: a European journal of chemical biology. [published; PubMed]. \href{https://doi.org/10.1002/cbic.202200551}{doi:10.1002/cbic.202200551}.
\item Pędzich BD, Medrano M, Buckinx A, Smolders I, De Bundel D (2022). \textit{Psychedelic-Induced Serotonin 2A Receptor Downregulation Does Not Predict Swim Stress Coping in Mice.}. International journal of molecular sciences. [published; PubMed]. \href{https://doi.org/10.3390/ijms232315284}{doi:10.3390/ijms232315284}.
\item Kelly JR, Baker A, Babiker M, Burke L, Brennan C, O'Keane V (2022). \textit{The psychedelic renaissance: the next trip for psychiatry?}. Irish journal of psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/ipm.2019.39}{doi:10.1017/ipm.2019.39}.
\item Barber G, Nemeroff CB, Siegel S (2022). \textit{A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.22010073}{doi:10.1176/appi.ajp.22010073}.
\item Dooper Marten (2022). \textit{Fast and sustained effect of 2 administrations of psilocybin on depression}. Medicom Conference Report ECNP 2022. [published; Crossref]. \href{https://doi.org/10.55788/0629715f}{doi:10.55788/0629715f}.
\item NWTraumatherapies (2022). \textit{NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05042466}{source link}.
\item Guss J, Krause R, Sloshower J. (2022). \textit{Manuel de Yale pour la Thérapie de la Dépression Assistée par la Psilocybine}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/r96tc}{doi:10.31234/osf.io/r96tc}.
\item Jeffrey Guss, Robert Krause, Jordan Sloshower (2022). \textit{Manuel de Yale pour la Thérapie de la Dépression Assistée par la Psilocybine}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/r96tc\_v1}{source link}.
\item NYU Langone Health (2022). \textit{A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT02061293}{source link}.
\item Jefferson SJ, Gregg I, Dibbs M, Liao C, Wu H, Davoudian PA, Sprouse JS, Sherwood AM, Kaye AP, Pittenger C, Kwan AC. (2022). \textit{5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2022.11.03.515044}{doi:10.1101/2022.11.03.515044}.
\item Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E (2022). \textit{Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.}. The New England journal of medicine. [published; PubMed]. \href{https://doi.org/10.1056/nejmoa2206443}{doi:10.1056/nejmoa2206443}.
\item Madras BK (2022). \textit{Psilocybin in Treatment-Resistant Depression.}. The New England journal of medicine. [published; PubMed]. \href{https://doi.org/10.1056/nejme2210975}{doi:10.1056/nejme2210975}.
\item Iacobucci G (2022). \textit{Psilocybin reduces symptoms in treatment resistant depression, trial results show.}. BMJ (Clinical research ed.). [published; PubMed]. \href{https://doi.org/10.1136/bmj.o2623}{doi:10.1136/bmj.o2623}.
\item Hamna Raheel, Unaiza Naeem, Asim Shaikh, Omer Ahmed Shaikh (2022). \textit{The psychedelic renaissance: can psilocybin possibly combat depression?}. International Journal of Surgery Global Health. [published; OpenAlex]. \href{https://doi.org/10.1097/gh9.0000000000000089}{doi:10.1097/gh9.0000000000000089}.
\item Mason N, Szabo A, Kuypers K, Mallaroni P, de la Torre Fornell R, Reckweg J, Tse D, Hutten N, Feilding A, Ramaekers J. (2022). \textit{Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2022.10.31.22281688}{doi:10.1101/2022.10.31.22281688}.
\item Raut SB, Marathe PA, van Eijk L, Eri R, Ravindran M, Benedek DM, Ursano RJ, Canales JJ, Johnson LR (2022). \textit{Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.}. Pharmacology \& therapeutics. [published; PubMed]. \href{https://doi.org/10.1016/j.pharmthera.2022.108195}{doi:10.1016/j.pharmthera.2022.108195}.
\item Berens N, Kim SY (2022). \textit{Rapid-Response Treatments for Depression and Requests for Physician-Assisted Death: An Ethical Analysis.}. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.jagp.2022.07.003}{doi:10.1016/j.jagp.2022.07.003}.
\item Watts R, Kettner H, Geerts D, Gandy S, Kartner L, Mertens L, Timmermann C, Nour MM, Kaelen M, Nutt D, Carhart-Harris R, Roseman L (2022). \textit{The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-022-06187-5}{doi:10.1007/s00213-022-06187-5}.
\item Irizarry R, Winczura A, Dimassi O, Dhillon N, Minhas A, Larice J (2022). \textit{Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.31796}{doi:10.7759/cureus.31796}.
\item Gukasyan N, Griffiths RR, Yaden DB, Antoine D, Nayak SM. (2022). \textit{Serotonergic antidepressant use is associated with weaker psilocybin effects}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/2zys9}{doi:10.31234/osf.io/2zys9}.
\item Natalie Gukasyan, Roland R. Griffiths, David Bryce Yaden, Denis Antoine, Sandeep M Nayak (2022). \textit{Serotonergic antidepressant use is associated with weaker psilocybin effects}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/2zys9\_v1}{source link}.
\item Sheppard Pratt Health System (2022). \textit{The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04433845}{source link}.
\item Natalie Gukasyan (2022). \textit{19.3 Psilocybin-Assisted Therapy for MDD: Current Evidence and Clinical Considerations}. Journal of the American Academy of Child \& Adolescent Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jaac.2022.07.664}{doi:10.1016/j.jaac.2022.07.664}.
\item Meyer TD, Meir P, Lex C, Soares JC (2022). \textit{Magic Mushrooms - an exploratory look at how mental health professionals feel and think about Psilocybin.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2022.114727}{doi:10.1016/j.psychres.2022.114727}.
\item Pilc A, Machaczka A, Kawalec P, Smith JL, Witkin JM (2022). \textit{Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.}. Expert opinion on drug discovery. [published; PubMed]. \href{https://doi.org/10.1080/17460441.2022.2111415}{doi:10.1080/17460441.2022.2111415}.
\item Prouzeau D, Conejero I, Voyvodic PL, Becamel C, Abbar M, Lopez-Castroman J (2022). \textit{Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.}. Current psychiatry reports. [published; PubMed]. \href{https://doi.org/10.1007/s11920-022-01361-0}{doi:10.1007/s11920-022-01361-0}.
\item Pochwat B, Krupa AJ, Siwek M, Szewczyk B (2022). \textit{New investigational agents for the treatment of major depressive disorder.}. Expert opinion on investigational drugs. [published; PubMed]. \href{https://doi.org/10.1080/13543784.2022.2113376}{doi:10.1080/13543784.2022.2113376}.
\item Barber GS, Aaronson ST (2022). \textit{The Emerging Field of Psychedelic Psychotherapy.}. Current psychiatry reports. [published; PubMed]. \href{https://doi.org/10.1007/s11920-022-01363-y}{doi:10.1007/s11920-022-01363-y}.
\item Odland AU, Kristensen JL, Andreasen JT (2022). \textit{Animal Behavior in Psychedelic Research.}. Pharmacological reviews. [published; PubMed]. \href{https://doi.org/10.1124/pharmrev.122.000590}{doi:10.1124/pharmrev.122.000590}.
\item Dupuis D, Veissière S (2022). \textit{Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos?}. Transcultural psychiatry. [published; PubMed]. \href{https://doi.org/10.1177/13634615221131465}{doi:10.1177/13634615221131465}.
\item Goel DB, Zilate S (2022). \textit{Potential Therapeutic Effects of Psilocybin: A Systematic Review.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.30214}{doi:10.7759/cureus.30214}.
\item Dougherty RF, Clarke P, Alti M, Kuc J, Schlosser D, Dunlop BW, Hellerstein DJ, Aaronson ST, Zisook S, Young AH, Carhart-Harris R, Goodwin G, Ryslik GA. (2022). \textit{Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/kh3cx}{doi:10.31234/osf.io/kh3cx}.
\item Robert F. Dougherty, Patrick Clarke, Merve Alti, Joanna Kuc, Danielle Schlosser, Boadie W. Dunlop, David J. Hellerstein, Scott T. Aaronson, Sidney Zisook, Allan H Young (2022). \textit{Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/kh3cx\_v1}{source link}.
\item Psiuk D, Nowak EM, Dycha N, Łopuszańska U, Kurzepa J, Samardakiewicz M (2022). \textit{Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.}. International journal of molecular sciences. [published; PubMed]. \href{https://doi.org/10.3390/ijms231911450}{doi:10.3390/ijms231911450}.
\item Michael Eisenstein (2022). \textit{The psychedelic escape from depression}. Nature. [published; OpenAlex]. \href{https://doi.org/10.1038/d41586-022-02872-9}{doi:10.1038/d41586-022-02872-9}.
\item Jaster AM, Younkin J, Cuddy T, de la Fuente Revenga M, Poklis JL, Dozmorov MG, González-Maeso J (2022). \textit{Differences across sexes on head-twitch behavior and 5-HT receptor signaling in C57BL/6J mice.}. Neuroscience letters. [published; PubMed]. \href{https://doi.org/10.1016/j.neulet.2022.136836}{doi:10.1016/j.neulet.2022.136836}.
\item COMPASS Pathways (2022). \textit{Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04519957}{source link}.
\item Vohryzek J, Cabral J, Lord L, Fernandes H, Roseman L, Nutt D, Carhart-Harris R, Deco G, Kringelbach M. (2022). \textit{Brain dynamics predictive of response to psilocybin for treatment-resistant depression}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-2060381/v1}{doi:10.21203/rs.3.rs-2060381/v1}.
\item da Costa SC, Oesterle T, Rummans TA, Richelson E, Gold M (2022). \textit{Psychedelic drugs for psychiatric disorders.}. Journal of the neurological sciences. [published; PubMed]. \href{https://doi.org/10.1016/j.jns.2022.120332}{doi:10.1016/j.jns.2022.120332}.
\item Kavita Golia (2022). \textit{Psilocybin as a healer}. Consciousness Spirituality \& Transpersonal Psychology. [published; OpenAlex]. \href{https://doi.org/10.53074/cstp.2022.37}{doi:10.53074/cstp.2022.37}.
\item Stoliker D, Novelli L, Vollenweider FX, Egan GF, Preller KH, Razi A. (2022). \textit{Effective connectivity of emotion and cognition under psilocybin}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2022.09.06.22279626}{doi:10.1101/2022.09.06.22279626}.
\item Doss MK, Barrett FS, Corlett PR (2022). \textit{Skepticism about Recent Evidence That Psilocybin "Liberates" Depressed Minds.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.2c00461}{doi:10.1021/acschemneuro.2c00461}.
\item Barba T, Buehler S, Kettner H, Radu C, Cunha BG, Nutt DJ, Erritzoe D, Roseman L, Carhart-Harris R (2022). \textit{Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.}. BJPsych open. [published; PubMed]. \href{https://doi.org/10.1192/bjo.2022.565}{doi:10.1192/bjo.2022.565}.
\item special to C EN Attabey Rodríguez Benítez (2022). \textit{Psychedelics’ binding depends on receptor mutations}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-10031-scicon6}{doi:10.1021/cen-10031-scicon6}.
\item Mitch Earleywine, Zachary Herrmann (2022). \textit{Psychedelics for Psychiatric Disorders: Promise, Not Panacea}. Psychiatric Annals. [published; OpenAlex]. \href{https://doi.org/10.3928/00485713-20220810-01}{doi:10.3928/00485713-20220810-01}.
\item Girala N. (2022). \textit{Psychopathological descriptive model of hallucinogenic/psychedelic drugs effect in the treatment of depression and addictions}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9567945}{source link}.
\item National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Neuroscience and Nervous System Disorders. (2022). \textit{Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop}. National Academies Press (US), Washington (DC). [published; Europe PMC]. \href{https://europepmc.org/article/MED/36049038}{source link}.
\item Shah K, Trivedi C, Kamrai D, Akbar M, Tankersley W. (2022). \textit{Association of Psilocybin Use in Adolescents with Major Depressive Episode}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9563652}{source link}.
\item Lehto RH, Miller M, Sender J (2022). \textit{The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research.}. Journal of holistic nursing: official journal of the American Holistic Nurses' Association. [published; PubMed]. \href{https://doi.org/10.1177/08980101211039086}{doi:10.1177/08980101211039086}.
\item Nguyen TQT, Lund FW, Zanjani AAH, Khandelia H (2022). \textit{Magic mushroom extracts in lipid membranes.}. Biochimica et biophysica acta. Biomembranes. [published; PubMed]. \href{https://doi.org/10.1016/j.bbamem.2022.183957}{doi:10.1016/j.bbamem.2022.183957}.
\item Johannesdottir A, Sigurdsson E (2022). \textit{[The use of psilocybin for treatment-resistant depression].}. Laeknabladid. [published; PubMed]. \href{https://doi.org/10.17992/lbl.2022.09.706}{doi:10.17992/lbl.2022.09.706}.
\item Kurtz JS, Patel NA, Gendreau JL, Yang C, Brown N, Bui N, Picton B, Harris M, Hatter M, Beyer R, Sahyouni R, Diaz-Aguilar LD, Castellanos J, Schuster N, Abraham ME (2022). \textit{The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.29167}{doi:10.7759/cureus.29167}.
\item Nutt D. (2022). \textit{Psychedelic Psychiatry}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9565852}{source link}.
\item Graham Zoe (2022). \textit{‘Shrooms for the Blues: Psilocybin to alleviate difficult-to-treat depression}. Journal of High School Science. [published; Crossref]. \href{https://doi.org/10.64336/001c.37945}{doi:10.64336/001c.37945}.
\item Neşe Devenot, Trey Conner, Richard Doyle (2022). \textit{Dark Side of the Shroom: Erasing Indigenous and Counterculture Wisdoms with Psychedelic Capitalism, and the Open Source Alternative}. Anthropology of Consciousness. [published; OpenAlex]. \href{https://doi.org/10.1111/anoc.12154}{doi:10.1111/anoc.12154}.
\item Yao S, Wei C, Lin H, Zhang P, Liu Y, Deng Y, Huang Q, Xie B (2022). \textit{Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in Mushroom via Amino Acid Metabolism Pathways.}. Journal of fungi (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/jof8080870}{doi:10.3390/jof8080870}.
\item Brian Peacock (2022). \textit{A-118 Psychedelic Interventions for Neuropsychological Conditions}. Archives of Clinical Neuropsychology. [published; OpenAlex]. \href{https://doi.org/10.1093/arclin/acac060.118}{doi:10.1093/arclin/acac060.118}.
\item Terri D’Arrigo (2022). \textit{Med Check: Psilocybin for OCD, Nuplazid Vote, and More}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2022.08.8.2}{doi:10.1176/appi.pn.2022.08.8.2}.
\item Rosa WE, Sager Z, Miller M, Bernstein I, Doerner Rinaldi A, Addicott K, Ljuslin M, Adrian C, Back AL, Beachy J, Bossis AP, Breitbart WS, Cosimano MP, Fischer SM, Guss J, Knighton E, Phelps J, Richards BD, Richards WA, Tulsky JA, Williams MT, Beaussant Y (2022). \textit{Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.}. Journal of palliative medicine. [published; PubMed]. \href{https://doi.org/10.1089/jpm.2022.0036}{doi:10.1089/jpm.2022.0036}.
\item Jairaj C, Rucker JJ (2022). \textit{Postpartum depression: A role for psychedelics?}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811221093793}{doi:10.1177/02698811221093793}.
\item Nygart VA, Pommerencke LM, Haijen E, Kettner H, Kaelen M, Mortensen EL, Nutt DJ, Carhart-Harris RL, Erritzoe D (2022). \textit{Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811221101061}{doi:10.1177/02698811221101061}.
\item Golden CT, Chadderton P (2022). \textit{Psilocybin reduces low frequency oscillatory power and neuronal phase-locking in the anterior cingulate cortex of awake rodents.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-022-16325-w}{doi:10.1038/s41598-022-16325-w}.
\item University of California, San Diego (2022). \textit{Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04661514}{source link}.
\item Lenz Claudius, Dörner Sebastian, Trottmann Felix, Hertweck Christian, Sherwood Alexander, Hoffmeister Dirk (2022). \textit{Assessment of Bioactivity-Modulating Pseudo-Ring Formation in Psilocin and Related Tryptamines}. ChemBioChem. [published; Crossref]. \href{https://doi.org/10.1002/cbic.202200183}{doi:10.1002/cbic.202200183}.
\item Bosch OG, Halm S, Seifritz E (2022). \textit{Psychedelics in the treatment of unipolar and bipolar depression.}. International journal of bipolar disorders. [published; PubMed]. \href{https://doi.org/10.1186/s40345-022-00265-5}{doi:10.1186/s40345-022-00265-5}.
\item Vohryzek J, Cabral J, Lord L, Fernandes HM, Roseman L, Nutt DJ, Carhart-Harris RL, Deco G, Kringelbach ML. (2022). \textit{Brain dynamics predictive of response to psilocybin for treatment-resistant depression}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2022.06.30.497950}{doi:10.1101/2022.06.30.497950}.
\item Sherif MA, Khalil MZ, Shukla R, Brown JC, Carpenter LL. (2022). \textit{Synapses, predictions, and prediction errors: a neocortical computational study of MDD using the temporal memory algorithm of HTM}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2022.06.29.498015}{doi:10.1101/2022.06.29.498015}.
\item Gokul Raj (2022). \textit{Psychedelic use in India, its pattern and personal significance - findings from an online survey}. Indian Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry\_447\_21}{doi:10.4103/indianjpsychiatry.indianjpsychiatry\_447\_21}.
\item Nayak SM, Bari BA, Yaden DB, Spriggs MJ, Rosas F, Peill JM, Giribaldi B, Erritzoe D, Nutt D, Carhart-Harris R. (2022). \textit{A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/sb5ur}{doi:10.31234/osf.io/sb5ur}.
\item Fradkin D (2022). \textit{Psilocybin: A brief overview for psychiatric mental health nurse practitioners.}. Perspectives in psychiatric care. [published; PubMed]. \href{https://doi.org/10.1111/ppc.12888}{doi:10.1111/ppc.12888}.
\item Kozlowska U, Nichols C, Wiatr K, Figiel M (2022). \textit{From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders.}. Journal of neurochemistry. [published; PubMed]. \href{https://doi.org/10.1111/jnc.15509}{doi:10.1111/jnc.15509}.
\item Slocum ST, DiBerto JF, Roth BL (2022). \textit{Molecular insights into psychedelic drug action.}. Journal of neurochemistry. [published; PubMed]. \href{https://doi.org/10.1111/jnc.15540}{doi:10.1111/jnc.15540}.
\item Saeger HN, Olson DE (2022). \textit{Psychedelic-inspired approaches for treating neurodegenerative disorders.}. Journal of neurochemistry. [published; PubMed]. \href{https://doi.org/10.1111/jnc.15544}{doi:10.1111/jnc.15544}.
\item Köck P, Froelich K, Walter M, Lang U, Dürsteler KM (2022). \textit{A systematic literature review of clinical trials and therapeutic applications of ibogaine.}. Journal of substance abuse treatment. [published; PubMed]. \href{https://doi.org/10.1016/j.jsat.2021.108717}{doi:10.1016/j.jsat.2021.108717}.
\item Sakurai H, Yonezawa K, Tani H, Mimura M, Bauer M, Uchida H (2022). \textit{Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.}. Pharmacopsychiatry. [published; PubMed]. \href{https://doi.org/10.1055/a-1714-9097}{doi:10.1055/a-1714-9097}.
\item Gill H, Puramat P, Patel P, Gill B, Marks CA, Rodrigues NB, Castle D, Cha DS, Mansur RB, Rosenblat JD, McIntyre RS (2022). \textit{The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2022.114577}{doi:10.1016/j.psychres.2022.114577}.
\item Smausz R, Neill J, Gigg J (2022). \textit{Neural mechanisms underlying psilocybin's therapeutic potential - the need for preclinical in vivo electrophysiology.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811221092508}{doi:10.1177/02698811221092508}.
\item Sandeep M Nayak, Bilal A Bari, David Bryce Yaden, Meg J Spriggs, Fernando Rosas, Joseph M Peill, Bruna Giribaldi, David Erritzoe, David Nutt, Robin Carhart-Harris (2022). \textit{A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/sb5ur\_v1}{source link}.
\item Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow, Kalin Harvey, Paul Stamets, Eesmyal Santos-Brault, Kim P.C. Kuypers, Zach Walsh (2022). \textit{Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls}. VIUspace. [published; OpenAlex]. \href{https://doi.org/10.25316/ir-20556}{doi:10.25316/ir-20556}.
\item Wake Network, Inc. (2022). \textit{Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04989972}{source link}.
\item Wall M, Harding R, Zafar R, Rabiner EA, Nutt D, Erritzoe D. (2022). \textit{Neuroimaging in psychedelic drug development: Past, present, and future}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/xwu4j}{doi:10.31234/osf.io/xwu4j}.
\item Matthew B. Wall, Rebecca Harding, Rayyan Zafar, Eugenii A. Rabiner, David Nutt, David Erritzoe (2022). \textit{Neuroimaging in psychedelic drug development: Past, present, and future}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/xwu4j\_v1}{source link}.
\item J Schneider, JP Cooper, S Davies, K Beltran (2022). \textit{MSR20 Challenges in the Development of Economic Evaluations for Psychedelics in Treatment of Depression}. Value in Health. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jval.2022.04.1227}{doi:10.1016/j.jval.2022.04.1227}.
\item Annie M. McCartney, H. T. McGovern, Alexander De Foe (2022). \textit{Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2022.00211}{doi:10.1556/2054.2022.00211}.
\item Anthony Principe (2022). \textit{Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin}. SURG Journal. [published; OpenAlex]. \href{https://doi.org/10.21083/surg.v14i1.6870}{doi:10.21083/surg.v14i1.6870}.
\item Kaushal Shah, C. Trivedi, D. Kamrai, M. Akbar, W. Tankersley (2022). \textit{Association of Psilocybin Use in Adolescents with Major Depressive Episode}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2022.837}{doi:10.1192/j.eurpsy.2022.837}.
\item Corrigan K, Haran M, McCandliss C, McManus R, Cleary S, Trant R, Kelly Y, Ledden K, Rush G, O'Keane V, Kelly JR (2022). \textit{Psychedelic perceptions: mental health service user attitudes to psilocybin therapy.}. Irish journal of medical science. [published; PubMed]. \href{https://doi.org/10.1007/s11845-021-02668-2}{doi:10.1007/s11845-021-02668-2}.
\item Bender D, Hellerstein DJ (2022). \textit{Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-021-06049-6}{doi:10.1007/s00213-021-06049-6}.
\item Miceli McMillan R, Jordens C (2022). \textit{Psychedelic-assisted psychotherapy for the treatment of major depression: a synthesis of phenomenological explanations.}. Medicine, health care, and philosophy. [published; PubMed]. \href{https://doi.org/10.1007/s11019-022-10070-7}{doi:10.1007/s11019-022-10070-7}.
\item van Amsterdam J, van den Brink W (2022). \textit{The therapeutic potential of psilocybin: a systematic review.}. Expert opinion on drug safety. [published; PubMed]. \href{https://doi.org/10.1080/14740338.2022.2047929}{doi:10.1080/14740338.2022.2047929}.
\item Jaster AM, Elder H, Marsh SA, de la Fuente Revenga M, Negus SS, González-Maeso J (2022). \textit{Effects of the 5-HT receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-022-06092-x}{doi:10.1007/s00213-022-06092-x}.
\item Sarparast A, Thomas K, Malcolm B, Stauffer CS (2022). \textit{Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-022-06083-y}{doi:10.1007/s00213-022-06083-y}.
\item McClure-Begley TD, Roth BL (2022). \textit{The promises and perils of psychedelic pharmacology for psychiatry.}. Nature reviews. Drug discovery. [published; PubMed]. \href{https://doi.org/10.1038/s41573-022-00421-7}{doi:10.1038/s41573-022-00421-7}.
\item Adams AM, Anas NA, Sen AK, Hinegardner-Hendricks JD, O'Dell PJ, Gibbons WJ, Flower JE, McMurray MS, Jones JA (2022). \textit{Development of an -based norbaeocystin production platform and evaluation of behavioral effects in rats.}. Metabolic engineering communications. [published; PubMed]. \href{https://doi.org/10.1016/j.mec.2022.e00196}{doi:10.1016/j.mec.2022.e00196}.
\item van den Berg M, Magaraggia I, Schreiber R, Hillhouse TM, Porter JH (2022). \textit{How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-022-06106-8}{doi:10.1007/s00213-022-06106-8}.
\item Husain MI, Umer M, Mulsant BH (2022). \textit{Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?}. Expert opinion on drug safety. [published; PubMed]. \href{https://doi.org/10.1080/14740338.2022.2063274}{doi:10.1080/14740338.2022.2063274}.
\item Rossi GN, Hallak JEC, Bouso Saiz JC, Dos Santos RG (2022). \textit{Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.}. Expert opinion on drug safety. [published; PubMed]. \href{https://doi.org/10.1080/14740338.2022.2066650}{doi:10.1080/14740338.2022.2066650}.
\item Inouye A, Wolfgang A (2022). \textit{3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.26402}{doi:10.7759/cureus.26402}.
\item Manish Agrawal, Paul Thambi, Sarah Shnayder (2022). \textit{The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder.}. Journal of Clinical Oncology. [published; OpenAlex]. \href{https://doi.org/10.1200/jco.2022.40.16\_suppl.12097}{doi:10.1200/jco.2022.40.16\_suppl.12097}.
\item Richard Karel (2022). \textit{Psilocybin-Assisted Therapy Found to Improve Depression, Offer Other Benefits}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2022.06.6.30}{doi:10.1176/appi.pn.2022.06.6.30}.
\item Mahmood D, Alenezi SK, Anwar MJ, Azam F, Qureshi KA, Jaremko M (2022). \textit{New Paradigms of Old Psychedelics in Schizophrenia.}. Pharmaceuticals (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/ph15050640}{doi:10.3390/ph15050640}.
\item National Institute of Mental Health, Czech Republic (2022). \textit{Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05383313}{source link}.
\item Andrew Hodge, Suporn Sukpraprut-Braaten, Robert Strayhan (2022). \textit{The Efficacy of Psilocybin in the Treatment of Depression andAnxiety: A Meta-Analysis}. Current Psychiatry Research and Reviews. [published; OpenAlex]. \href{https://doi.org/10.2174/2666082218666220513142002}{doi:10.2174/2666082218666220513142002}.
\item Johansen L, Liknaitzky P, Nedeljkovic M, Mastin-Purcell L, Murray G (2022). \textit{The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol.}. Systematic reviews. [published; PubMed]. \href{https://doi.org/10.1186/s13643-022-01930-7}{doi:10.1186/s13643-022-01930-7}.
\item Stein CA, Penn A, Van Hope S, Dorsen CG, Mangini M (2022). \textit{The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.}. Journal of midwifery \& women's health. [published; PubMed]. \href{https://doi.org/10.1111/jmwh.13371}{doi:10.1111/jmwh.13371}.
\item Sotille R, Singh H, Weisman A, Vida T (2022). \textit{Unraveling the Mysteries of Mental Illness With Psilocybin.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.25414}{doi:10.7759/cureus.25414}.
\item Claudia Schwarz-Plaschg (2022). \textit{Socio-psychedelic imaginaries: envisioning and building legal psychedelic worlds in the United States}. European Journal of Futures Research. [published; OpenAlex]. \href{https://doi.org/10.1186/s40309-022-00199-2}{doi:10.1186/s40309-022-00199-2}.
\item University of Zurich (2022). \textit{Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy in Major Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03715127}{source link}.
\item Manoj Doss, Frederick Streeter Barrett, Philip R. Corlett (2022). \textit{Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/a25wb\_v1}{source link}.
\item Scott Aaronson, Tammy Miller, Samuel Rudow, MacKenzie Forbes, Trisha Suppes (2022). \textit{P388. Open Label Psilocybin Administration in Severely Treatment Resistant Depression}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2022.02.624}{doi:10.1016/j.biopsych.2022.02.624}.
\item Lowe H, Toyang N, Steele B, Grant J, Ali A, Gordon L, Ngwa W (2022). \textit{Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.}. Molecules (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/molecules27082520}{doi:10.3390/molecules27082520}.
\item Lemos Martins Sofia, Machado Brito-da-Costa Andreia, Madureira-Carvalho Áurea, Dinis-Oliveira Ricardo Jorge, Dias da Silva Diana (2022). \textit{Psylocybin and Psilocin as new tools to fight depression: an overview of the Pharmacodynamic and pharmacokinetic mechanisms}. RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia. [published; Crossref]. \href{https://doi.org/10.51126/revsalus.v4isup.271}{doi:10.51126/revsalus.v4isup.271}.
\item Antonia Kuhn, Matthias F. Melzig (2022). \textit{Psilocybe mexicana R. Heim - Mexikanischer Kahlkopf}. Zeitschrift für Phytotherapie. [published; OpenAlex]. \href{https://doi.org/10.1055/a-1540-9907}{doi:10.1055/a-1540-9907}.
\item Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Grünblatt E, Liechti ME (2022). \textit{Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.}. Clinical pharmacology and therapeutics. [published; PubMed]. \href{https://doi.org/10.1002/cpt.2487}{doi:10.1002/cpt.2487}.
\item Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R (2022). \textit{Increased global integration in the brain after psilocybin therapy for depression.}. Nature medicine. [published; PubMed]. \href{https://doi.org/10.1038/s41591-022-01744-z}{doi:10.1038/s41591-022-01744-z}.
\item Michael Avissar, Adrian Jacques H. Ambrose (2022). \textit{Demystifying Psychedelic Treatments in Psychiatry: Is Ego Dissolution the Solution?}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2022.04.4.35}{doi:10.1176/appi.pn.2022.04.4.35}.
\item Pearson C, Siegel J, Gold JA (2022). \textit{Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.}. Journal of the neurological sciences. [published; PubMed]. \href{https://doi.org/10.1016/j.jns.2021.120096}{doi:10.1016/j.jns.2021.120096}.
\item Meade E, Hehir S, Rowan N, Garvey M (2022). \textit{Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.}. Journal of fungi (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/jof8030290}{doi:10.3390/jof8030290}.
\item Smedfors G, Glotfelty E, Kalani N, Hjelle CP, Horntvedt O, Wellfelt K, Brodin A, von Kieseritzky F, Olson L, Karlsson T. (2022). \textit{Psilocybin Combines Rapid Synaptogenic And Anti-Inflammatory Effects In Vitro}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-1321542/v1}{doi:10.21203/rs.3.rs-1321542/v1}.
\item Bethany Halford﻿ (2022). \textit{Rediscovering psychedelics}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-10009-cover}{doi:10.1021/cen-10009-cover}.
\item Gass P, Vasilescu AN, Inta D (2022). \textit{[Rapid-acting antidepressants-neurobiological mechanisms of action].}. Der Nervenarzt. [published; PubMed]. \href{https://doi.org/10.1007/s00115-021-01225-7}{doi:10.1007/s00115-021-01225-7}.
\item Elman I, Pustilnik A, Borsook D (2022). \textit{Beating pain with psychedelics: Matter over mind?}. Neuroscience and biobehavioral reviews. [published; PubMed]. \href{https://doi.org/10.1016/j.neubiorev.2021.12.005}{doi:10.1016/j.neubiorev.2021.12.005}.
\item Gründer G, Brand M, Kärtner L, Scharf D, Schmitz C, Spangemacher M, Mertens LJ (2022). \textit{[Are psychedelics fast acting antidepressant agents?].}. Der Nervenarzt. [published; PubMed]. \href{https://doi.org/10.1007/s00115-021-01255-1}{doi:10.1007/s00115-021-01255-1}.
\item Bates N, Bello JK, Osazuwa-Peters N, Sullivan MD, Scherrer JF (2022). \textit{Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer.}. Current treatment options in oncology. [published; PubMed]. \href{https://doi.org/10.1007/s11864-022-00954-4}{doi:10.1007/s11864-022-00954-4}.
\item Thomas Christopher W., Blanco-Duque Cristina, Bréant Benjamin J., Goodwin Guy M., Sharp Trevor, Bannerman David M., Vyazovskiy Vladyslav V. (2022). \textit{Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice}. Translational Psychiatry. [published; Crossref]. \href{https://doi.org/10.1038/s41398-022-01846-9}{doi:10.1038/s41398-022-01846-9}.
\item Wall MB, Lam C, Ertl N, Kaelen M, Roseman L, Nutt DJ, Carhart-Harris RL. (2022). \textit{Increased low-frequency brain responses to music after psilocybin therapy for depression}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2022.02.13.480302}{doi:10.1101/2022.02.13.480302}.
\item Kargbo RB, Sherwood AM, Meisenheimer P, Lenoch K, Abebe S (2022). \textit{Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD).}. ACS omega. [published; PubMed]. \href{https://doi.org/10.1021/acsomega.1c06708}{doi:10.1021/acsomega.1c06708}.
\item Yu CL, Liang CS, Yang FC, Tu YK, Hsu CW, Carvalho AF, Stubbs B, Thompson T, Tsai CK, Yeh TC, Yang SN, Shin JI, Chu CS, Tseng PT, Su KP (2022). \textit{Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis.}. Journal of clinical medicine. [published; PubMed]. \href{https://doi.org/10.3390/jcm11040938}{doi:10.3390/jcm11040938}.
\item Coppola M, Bevione F, Mondola R (2022). \textit{Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?}. Journal of xenobiotics. [published; PubMed]. \href{https://doi.org/10.3390/jox12010004}{doi:10.3390/jox12010004}.
\item Bethany Halford﻿ (2022). \textit{Hallucinogen chemistry guides antidepressant drug discovery}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-10005-leadcon}{doi:10.1021/cen-10005-leadcon}.
\item Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR (2022). \textit{Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811211073759}{doi:10.1177/02698811211073759}.
\item Ziff S, Stern B, Lewis G, Majeed M, Gorantla VR (2022). \textit{Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.21944}{doi:10.7759/cureus.21944}.
\item James Bailey Sanford (2022). \textit{Psychedelics hold promise for primary care research}. Family Practice. [published; OpenAlex]. \href{https://doi.org/10.1093/fampra/cmac009}{doi:10.1093/fampra/cmac009}.
\item Jurriaan F. M. Strous (2022). \textit{Psilocybine vergeleken met escitalopram bij depressie}. Pure Amsterdam UMC. [published; OpenAlex]. \href{https://pure.amsterdamumc.nl/en/publications/b99a8d48-a871-49d6-978c-969dd09a6dae}{source link}.
\item Strous JFM (2022). \textit{[Psilocybin compared with escitalopram for depression].}. Nederlands tijdschrift voor geneeskunde. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/35138714/}{source link}.
\item Ellen Saikku (2022). \textit{Classic psychedelics in the treatment of depression: mechanisms of action and the role of therapy}. Työväentutkimus Vuosikirja. [published; OpenAlex]. \href{http://hdl.handle.net/10138/606412}{source link}.
\item A. Wojtas, A. Bysiek, Z. Szych, M. Herian, K. Gołembiowska (2022). \textit{Neurochemical properties of psilocybin in comparison to ketamine in vivo}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2022.100408}{doi:10.1016/j.nsa.2022.100408}.
\item K. Šíchová, K. Chona, Lucie Olejníková Ladislavová, T. Páleníček (2022). \textit{The role of psilocybin in memory consolidation in the animal model}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2022.100953}{doi:10.1016/j.nsa.2022.100953}.
\item Daisuke Ibi (2022). \textit{Investigation of the neural network responsible for antidepressant effect of serotonergic psychedelics}. Proceedings for Annual Meeting of The Japanese Pharmacological Society. [published; OpenAlex]. \href{https://doi.org/10.1254/jpssuppl.96.0\_4-b-s43-2}{doi:10.1254/jpssuppl.96.0\_4-b-s43-2}.
\item Jeff Tarrant (2022). \textit{SPECIAL ISSUE: Do Biofeedback, Neurofeedback, and Neuromeditation Have a Role in Psychedelic-Assisted Therapies?}. Biofeedback. [published; OpenAlex]. \href{https://doi.org/10.5298/1081-5937-50.03.03}{doi:10.5298/1081-5937-50.03.03}.
\item Daisuke Ibi (2022). \textit{Investigation of neuronal basis underlying antidepressant effect of serotonergic psychedelics}. Proceedings for Annual Meeting of The Japanese Pharmacological Society. [published; OpenAlex]. \href{https://doi.org/10.1254/jpssuppl.95.0\_3-s35-1}{doi:10.1254/jpssuppl.95.0\_3-s35-1}.
\item Friederike Holze, Laura Ley, F. Müller, V. Nimmy, Anne Eckert, Matthias E. Liechti (2022). \textit{Comparison of subjective, autonomic, and endocrine effects of LSD and psilocybin in healthy subjects}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2022.100075}{doi:10.1016/j.nsa.2022.100075}.
\item G. Goodwin, Scott T. Aaronson, Boadie W. Dunlop, D. Feifel, David J. Hellerstein, L. Marwood, S. Mistry, Metten Somers, S.C. Stansfield, J. Tsai, S. Williams, Allan H. Young, Sidney Zisook, E. Malievskaia (2022). \textit{The efficacy of COMP360 psilocybin therapy in treatment-resistant depression: exploratory results from a phase IIb randomised controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2022.100213}{doi:10.1016/j.nsa.2022.100213}.
\item G.M. Goodwin, Scott T. Aaronson, Boadie W. Dunlop, David Feifel, David J. Hellerstein, N. Hewitt, L. Marwood, S. Mistry, Metten Somers, S.C. Stansfield, J. Tsai, S. Williams, Antony Young, Sidney Zisook, E. Malievskaia (2022). \textit{The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2022.100511}{doi:10.1016/j.nsa.2022.100511}.
\item Teixeira PJ, Johnson MW, Timmermann C, Watts R, Erritzoe D, Douglass H, Kettner H, Carhart-Harris RL (2022). \textit{Psychedelics and health behaviour change.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811211008554}{doi:10.1177/02698811211008554}.
\item Leger RF, Unterwald EM (2022). \textit{Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811211044688}{doi:10.1177/02698811211044688}.
\item Li NX, Hu YR, Chen WN, Zhang B (2022). \textit{Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2021.09.041}{doi:10.1016/j.jad.2021.09.041}.
\item Liechti ME, Holze F (2022). \textit{Dosing Psychedelics and MDMA.}. Current topics in behavioral neurosciences. [published; PubMed]. \href{https://doi.org/10.1007/7854\_2021\_270}{doi:10.1007/7854\_2021\_270}.
\item Ling S, Ceban F, Lui LMW, Lee Y, Teopiz KM, Rodrigues NB, Lipsitz O, Gill H, Subramaniapillai M, Mansur RB, Lin K, Ho R, Rosenblat JD, Castle D, McIntyre RS (2022). \textit{Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.}. CNS drugs. [published; PubMed]. \href{https://doi.org/10.1007/s40263-021-00877-y}{doi:10.1007/s40263-021-00877-y}.
\item Agin-Liebes G, Davis AK (2022). \textit{Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.}. Current topics in behavioral neurosciences. [published; PubMed]. \href{https://doi.org/10.1007/7854\_2021\_282}{doi:10.1007/7854\_2021\_282}.
\item Schimmers N, Breeksema JJ, Smith-Apeldoorn SY, Veraart J, van den Brink W, Schoevers RA (2022). \textit{Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-021-06027-y}{doi:10.1007/s00213-021-06027-y}.
\item Sousa TR, Rema J, Machado S, Novais F (2022). \textit{Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.}. Current topics in medicinal chemistry. [published; PubMed]. \href{https://doi.org/10.2174/1568026621666211201145800}{doi:10.2174/1568026621666211201145800}.
\item Sarris J, Pinzon Rubiano D, Day K, Galvão-Coelho NL, Perkins D (2022). \textit{Psychedelic medicines for mood disorders: current evidence and clinical considerations.}. Current opinion in psychiatry. [published; PubMed]. \href{https://doi.org/10.1097/yco.0000000000000759}{doi:10.1097/yco.0000000000000759}.
\item Marschall J, Fejer G, Lempe P, Prochazkova L, Kuchar M, Hajkova K, van Elk M (2022). \textit{Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811211050556}{doi:10.1177/02698811211050556}.
\item Yaden DB, Nayak SM, Gukasyan N, Anderson BT, Griffiths RR (2022). \textit{The Potential of Psychedelics for End of Life and Palliative Care.}. Current topics in behavioral neurosciences. [published; PubMed]. \href{https://doi.org/10.1007/7854\_2021\_278}{doi:10.1007/7854\_2021\_278}.
\item Jones GM, Nock MK (2022). \textit{Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811211066714}{doi:10.1177/02698811211066714}.
\item Rucker JJ, Marwood L, Ajantaival RJ, Bird C, Eriksson H, Harrison J, Lennard-Jones M, Mistry S, Saldarini F, Stansfield S, Tai SJ, Williams S, Weston N, Malievskaia E, Young AH (2022). \textit{The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811211064720}{doi:10.1177/02698811211064720}.
\item Strickland JC, Johnson MW (2022). \textit{Human behavioral pharmacology of psychedelics.}. Advances in pharmacology (San Diego, Calif.). [published; PubMed]. \href{https://doi.org/10.1016/bs.apha.2021.10.003}{doi:10.1016/bs.apha.2021.10.003}.
\item Khan AJ, Bradley E, O'Donovan A, Woolley J (2022). \textit{Psilocybin for Trauma-Related Disorders.}. Current topics in behavioral neurosciences. [published; PubMed]. \href{https://doi.org/10.1007/7854\_2022\_366}{doi:10.1007/7854\_2022\_366}.
\item Sekula AD, Downey L, Puspanathan P (2022). \textit{Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy.}. Frontiers in psychology. [published; PubMed]. \href{https://doi.org/10.3389/fpsyg.2022.813746}{doi:10.3389/fpsyg.2022.813746}.
\item Mertens LJ, Koslowski M, Betzler F, Evens R, Gilles M, Jungaberle A, Jungaberle H, Majić T, Ströhle A, Wolff M, Wellek S, Gründer G (2022). \textit{Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.}. Neuroscience applied. [published; PubMed]. \href{https://doi.org/10.1016/j.nsa.2022.100104}{doi:10.1016/j.nsa.2022.100104}.
\item Raison CL, Jain R, Penn AD, Cole SP, Jain S (2022). \textit{Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2022.831092}{doi:10.3389/fpsyt.2022.831092}.
\item Matzopoulos R, Morlock R, Morlock A, Lerer B, Lerer L (2022). \textit{Corrigendum: Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2022.877390}{doi:10.3389/fpsyt.2022.877390}.
\item Pots W, Chakhssi F (2022). \textit{Psilocybin-Assisted Compassion Focused Therapy for Depression.}. Frontiers in psychology. [published; PubMed]. \href{https://doi.org/10.3389/fpsyg.2022.812930}{doi:10.3389/fpsyg.2022.812930}.
\item Hayes C, Wahba M, Watson S (2022). \textit{Will psilocybin lose its magic in the clinical setting?}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/20451253221090822}{doi:10.1177/20451253221090822}.
\item Vorobyeva N, Kozlova AA (2022). \textit{Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2022.927984}{doi:10.3389/fphar.2022.927984}.
\item Lyons A (2022). \textit{Self-administration of Psilocybin in the Setting of Treatment-resistant Depression.}. Innovations in clinical neuroscience. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/36204170/}{source link}.
\item Ko K, Knight G, Rucker JJ, Cleare AJ (2022). \textit{Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2022.917199}{doi:10.3389/fpsyt.2022.917199}.
\item Kuburi S, Di Passa AM, Tassone VK, Mahmood R, Lalovic A, Ladha KS, Dunlop K, Rizvi S, Demchenko I, Bhat V (2022). \textit{Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review.}. Chronic stress (Thousand Oaks, Calif.). [published; PubMed]. \href{https://doi.org/10.1177/24705470221115342}{doi:10.1177/24705470221115342}.
\item López-Arnau R, Camarasa J, Carbó ML, Nadal-Gratacós N, Puigseslloses P, Espinosa-Velasco M, Urquizu E, Escubedo E, Pubill D (2022). \textit{3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2022.990405}{doi:10.3389/fpsyt.2022.990405}.
\item Altman BR, Earleywine M, De Leo J (2022). \textit{Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2021.2020382}{doi:10.1080/02791072.2021.2020382}.
\item Ledwos N, Rosenblat JD, Blumberger DM, Castle DJ, McIntyre RS, Mulsant BH, Husain MI (2022). \textit{A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.}. Journal of clinical psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1097/jcp.0000000000001608}{doi:10.1097/jcp.0000000000001608}.
\item Balon R (2022). \textit{Are Magic Mushrooms Really Magic?: Psilocybin in the Treatment of Depression.}. Journal of clinical psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1097/jcp.0000000000001610}{doi:10.1097/jcp.0000000000001610}.
\item Paganin W, Signorini S, Leccese V, Sciarretta A (2022). \textit{[Treatment-resistant depression. From classification to new therapies.].}. Rivista di psichiatria. [published; PubMed]. \href{https://doi.org/10.1708/3922.39072}{doi:10.1708/3922.39072}.
\item Marseille E, Bertozzi S, Kahn JG (2022). \textit{The economics of psychedelic-assisted therapies: A research agenda.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2022.1025726}{doi:10.3389/fpsyt.2022.1025726}.
\item DellaCrosse M, Pleet M, Morton E, Ashtari A, Sakai K, Woolley J, Michalak E (2022). \textit{"A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use.}. PloS one. [published; PubMed]. \href{https://doi.org/10.1371/journal.pone.0279073}{doi:10.1371/journal.pone.0279073}.
\item Husain MI, Ledwos N, Fellows E, Baer J, Rosenblat JD, Blumberger DM, Mulsant BH, Castle DJ (2022). \textit{Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2022.1076459}{doi:10.3389/fpsyt.2022.1076459}.
\item University Hospital, Basel, Switzerland (2021). \textit{LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03153579}{source link}.
\item Johns Hopkins University (2021). \textit{Effects of Psilocybin in Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03181529}{source link}.
\item Louk J. M. J. Vanderschuren, Paul Willner, Emily M. Jutkiewicz, Bart Ellenbroek (2021). \textit{Announcement of two special issues: behavioural pharmacology of synaptopathies and psychedelic drugs}. Behavioural Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.1097/fbp.0000000000000662}{doi:10.1097/fbp.0000000000000662}.
\item Lea J. Mertens, Michael Koslowski, Felix Betzler, Ricarda Evens, Maria Gilles, Andrea Jungaberle, Henrik Jungaberle, Tomislav Majić, Max Wolff, Andreas Ströhle, Stefan Wellek, Gerhard Gründer (2021). \textit{P.0421 Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - study design, rationale and current status}. European Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.euroneuro.2021.10.394}{doi:10.1016/j.euroneuro.2021.10.394}.
\item Matthew B. Wall, Cynthia Lam, Natalie Ertl, Mendel Kaelen, Leor Roseman, David Nutt, Robin Carhart-Harris (2021). \textit{P.0885 The effect of psilocybin therapy for depression on low-frequency brain activity in response to music}. European Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.euroneuro.2021.10.741}{doi:10.1016/j.euroneuro.2021.10.741}.
\item Sara Penedos, Caio Freitas Ramos, María José López Miguel, Márcio José Martins Alves, Luciana Campos Paulino, Adriano Valério S. Azevêdo, M. Magalhães, L. Moreno, N. Ribeiro, Inês Fonseca, Ana Margarida Romão Franco, Luís Madruga, A. Gamito (2021). \textit{P.0729 Highlights of psychedelic history and current research on psilocybin application for treatment of depression - a comprehensive literature review}. European Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.euroneuro.2021.10.797}{doi:10.1016/j.euroneuro.2021.10.797}.
\item Perkins D, Sarris J, Rossell S, Bonomo Y, Forbes D, Davey C, Hoyer D, Loo C, Murray G, Hood S, Schubert V, Galvão-Coelho NL, O'Donnell M, Carter O, Liknaitzky P, Williams M, Siskind D, Penington D, Berk M, Castle D (2021). \textit{Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.}. The Australian and New Zealand journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1177/0004867421998785}{doi:10.1177/0004867421998785}.
\item Gibbons WJ, McKinney MG, O'Dell PJ, Bollinger BA, Jones JA (2021). \textit{Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?}. Bioengineered. [published; PubMed]. \href{https://doi.org/10.1080/21655979.2021.1987090}{doi:10.1080/21655979.2021.1987090}.
\item Rucker J, Jafari H, Mantingh T, Bird C, Modlin NL, Knight G, Reinholdt F, Day C, Carter B, Young A (2021). \textit{Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial.}. BMJ open. [published; PubMed]. \href{https://doi.org/10.1136/bmjopen-2021-056091}{doi:10.1136/bmjopen-2021-056091}.
\item Linda M. Richmond (2021). \textit{Marijuana, Hallucinogen Use Reach Historic Levels Among Young Adults}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2021.11.29}{doi:10.1176/appi.pn.2021.11.29}.
\item David J. Hellerstein, Kevin A. Sabet, Jeffrey A. Lieberman (2021). \textit{Psychedelic Drugs for Mental Disorders and Human Potential: Placebo or Panacea}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2021.12.14}{doi:10.1176/appi.pn.2021.12.14}.
\item Rootman JM, Kryskow P, Harvey K, Stamets P, Santos-Brault E, Kuypers KPC, Polito V, Bourzat F, Walsh Z (2021). \textit{Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-021-01811-4}{doi:10.1038/s41598-021-01811-4}.
\item Graham F (2021). \textit{Daily briefing: Largest trial shows psilocybin is effective to treat depression.}. Nature. [published; PubMed]. \href{https://doi.org/10.1038/d41586-021-03413-6}{doi:10.1038/d41586-021-03413-6}.
\item Karim Ashraf ElAgamy (2021). \textit{Psychedelics and their therapeutic effects}. University of Debrecen Electronic Archive. [published; OpenAlex]. \href{http://hdl.handle.net/2437/336821}{source link}.
\item Doss MK, Považan M, Rosenberg MD, Sepeda ND, Davis AK, Finan PH, Smith GS, Pekar JJ, Barker PB, Griffiths RR, Barrett FS (2021). \textit{Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-021-01706-y}{doi:10.1038/s41398-021-01706-y}.
\item Aleksandrova LR, Phillips AG (2021). \textit{Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics.}. Trends in pharmacological sciences. [published; PubMed]. \href{https://doi.org/10.1016/j.tips.2021.08.003}{doi:10.1016/j.tips.2021.08.003}.
\item Dee Dee Goldpaugh (2021). \textit{Finding the divine within: exploring the role of the sacred in psychedelic integration therapy for sexual trauma and dysfunction}. Sexual \& Relationship Therapy. [published; OpenAlex]. \href{https://doi.org/10.1080/14681994.2021.1994138}{doi:10.1080/14681994.2021.1994138}.
\item Maryland Oncology Hematology, PA (2021). \textit{The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04593563}{source link}.
\item Ryan Cross﻿ (2021). \textit{Delix to synthesize psychedelic drugs}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-09936-buscon3}{doi:10.1021/cen-09936-buscon3}.
\item Fogg C, Michaels TI, de la Salle S, Jahn ZW, Williams MT (2021). \textit{Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.}. Experimental and clinical psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1037/pha0000490}{doi:10.1037/pha0000490}.
\item Zeiss R, Gahr M, Graf H (2021). \textit{Rediscovering Psilocybin as an Antidepressive Treatment Strategy.}. Pharmaceuticals (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/ph14100985}{doi:10.3390/ph14100985}.
\item Alison Knopf (2021). \textit{Psilocybin: Next to treat depression, OCD and nicotine addiction}. Alcoholism \& Drug Abuse Weekly. [published; OpenAlex]. \href{https://doi.org/10.1002/adaw.33204}{doi:10.1002/adaw.33204}.
\item Matthias Forstmann, Christina Sagioglou (2021). \textit{New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances}. European Psychologist. [published; OpenAlex]. \href{https://doi.org/10.1027/1016-9040/a000447}{doi:10.1027/1016-9040/a000447}.
\item Dan Cătălin Oprea, Loretta Epure, Vasile Chiriță, Adrian Cantemir (2021). \textit{The therapeutical role of psychedelic drugs in treatment of mental disorders}. Bulletin of Integrative Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.36219/bpi.2021.3.09}{doi:10.36219/bpi.2021.3.09}.
\item Benjamin R. Lewis, Kevin Byrne (2021). \textit{Is MDD the right target for early-stage psychedelic-assisted therapy trials?}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2021.00180}{doi:10.1556/2054.2021.00180}.
\item Tehseen Noorani, Jonny Martell (2021). \textit{New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2021.727050}{doi:10.3389/fpsyt.2021.727050}.
\item Gonçalo Cotovio, Ana Maia, Ana Velosa, Carolina Seybert, Albino J. Oliveira-Maia (2021). \textit{Treating Major Depression Disorder with Psychedelics: A Potential Therapeutic Application for Psilocybin?}. Revista Portuguesa de Psiquiatria e Saúde Mental. [published; OpenAlex]. \href{https://doi.org/10.51338/rppsm.2021.v7.i3.241}{doi:10.51338/rppsm.2021.v7.i3.241}.
\item Magaraggia I, Kuiperes Z, Schreiber R (2021). \textit{Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach.}. Neurobiology of learning and memory. [published; PubMed]. \href{https://doi.org/10.1016/j.nlm.2021.107467}{doi:10.1016/j.nlm.2021.107467}.
\item Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR (2021). \textit{Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.}. Pharmacopsychiatry. [published; PubMed]. \href{https://doi.org/10.1055/a-1524-2794}{doi:10.1055/a-1524-2794}.
\item Kverno KS, Mangano E (2021). \textit{Treatment-Resistant Depression: Approaches to Treatment.}. Journal of psychosocial nursing and mental health services. [published; PubMed]. \href{https://doi.org/10.3928/02793695-20210816-01}{doi:10.3928/02793695-20210816-01}.
\item Wiley JF, Bei B (2021). \textit{Psilocybin for Depression.}. The New England journal of medicine. [published; PubMed]. \href{https://doi.org/10.1056/nejmc2108082}{doi:10.1056/nejmc2108082}.
\item Ryan Cross﻿ (2021). \textit{Beckley raises funds for psychedelic drugs}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-09930-buscon17}{doi:10.1021/cen-09930-buscon17}.
\item Frederico Marques Silveira, Amanda Pereira Mendes, Mayara Rodrigues dos Santos, Júlia Ramos Cerchi, IRIS TIYONO TAVARES UMEDA, Breno Basílio de Melo, Luiza Elena Casaburi, Mateus Nóbrega Oliveira, Douglas Reis Abdalla (2021). \textit{Use of alternative therapy with Psilocybin in oncologic patients with depression and/or anxiety disorders - integrative review}. Research Society and Development. [published; OpenAlex]. \href{https://doi.org/10.33448/rsd-v10i10.19297}{doi:10.33448/rsd-v10i10.19297}.
\item Peixoto C, Santos F, Rego D, Medeiros H. (2021). \textit{Psychedelics and psychiatric disorders: A emerging role}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9470409}{source link}.
\item Torres S. (2021). \textit{Psychedelics: A new era of treatment?}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9475866}{source link}.
\item Fraga A, Esteves-Sousa D, Facucho-Oliveira J, Albuquerque M, Costa M, Dos Santos P, Moura N, Moutinho A. (2021). \textit{Effects of psilocybin-assisted therapy on treatment-resistant depression}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9480034}{source link}.
\item Descalço N, Medeiros A, Santos C, Borges G. (2021). \textit{Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9476072}{source link}.
\item Wayne Hall, Michael Farrell (2021). \textit{What can we learn from the history of research on psychedelic drugs in the addictions?}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.15560}{doi:10.1111/add.15560}.
\item Więckiewicz G, Stokłosa I, Piegza M, Gorczyca P, Pudlo R (2021). \textit{Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review.}. Pharmaceuticals (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/ph14080793}{doi:10.3390/ph14080793}.
\item Markus Weih (2021). \textit{Mit Psilocybin gegen Depression}. InFo Neurologie + Psychiatrie. [published; OpenAlex]. \href{https://doi.org/10.1007/s15005-021-2012-7}{doi:10.1007/s15005-021-2012-7}.
\item Berkovitch L, Roméo B, Karila L, Gaillard R, Benyamina A (2021). \textit{[Efficacy of psychedelics in psychiatry, a systematic review of the literature].}. L'Encephale. [published; PubMed]. \href{https://doi.org/10.1016/j.encep.2020.12.002}{doi:10.1016/j.encep.2020.12.002}.
\item Psiuk D, Nowak E, Cholewa K, Łopuszańska U, Samardakiewicz M (2021). \textit{The Potential Role of Serotonergic Hallucinogens in Depression Treatment.}. Life (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/life11080765}{doi:10.3390/life11080765}.
\item Borroto-Escuela DO, Ambrogini P, Narvaez M, Di Liberto V, Beggiato S, Ferraro L, Fores-Pons R, Alvarez-Contino JE, Lopez-Salas A, Mudò G, Díaz-Cabiale Z, Fuxe K (2021). \textit{Serotonin Heteroreceptor Complexes and Their Integration of Signals in Neurons and Astroglia-Relevance for Mental Diseases.}. Cells. [published; PubMed]. \href{https://doi.org/10.3390/cells10081902}{doi:10.3390/cells10081902}.
\item Nick Zagorski (2021). \textit{Psychedelic Therapy Hits Another Milestone, But Caution Urged}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2021.7.14}{doi:10.1176/appi.pn.2021.7.14}.
\item King's College London (2021). \textit{A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04959253}{source link}.
\item Watts R. (2021). \textit{Psilocybin for Depression: The ACE Model Manual}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/5x2bu}{doi:10.31234/osf.io/5x2bu}.
\item Marta Kaczmarczyk, Rosalind Watts (2021). \textit{Psilocybin for Depression: The ACE Model Manual}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/5x2bu\_v1}{source link}.
\item Mertens LJ, Preller KH (2021). \textit{Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.}. Pharmacopsychiatry. [published; PubMed]. \href{https://doi.org/10.1055/a-1341-1907}{doi:10.1055/a-1341-1907}.
\item Earleywine M, Ueno LF, Mian MN, Altman BR (2021). \textit{Cannabis-induced oceanic boundlessness.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881121997099}{doi:10.1177/0269881121997099}.
\item Siegel AN, Meshkat S, Benitah K, Lipsitz O, Gill H, Lui LMW, Teopiz KM, McIntyre RS, Rosenblat JD (2021). \textit{Registered clinical studies investigating psychedelic drugs for psychiatric disorders.}. Journal of psychiatric research. [published; PubMed]. \href{https://doi.org/10.1016/j.jpsychires.2021.05.019}{doi:10.1016/j.jpsychires.2021.05.019}.
\item Coppola M, Bevione F, Mondola R. (2021). \textit{Psilocybin for Treating Psychiatric Disorders: Is it a Psychonaut Legend or a Promising Therapeutic Perspective?}. Preprints.org. [preprint; Europe PMC]. \href{https://doi.org/10.20944/preprints202106.0682.v1}{doi:10.20944/preprints202106.0682.v1}.
\item McCartney A, McGovern H, De Foe A. (2021). \textit{Psychedelic Assisted Therapy for Major Depressive Disorder: A Review}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/9kuhs}{doi:10.31234/osf.io/9kuhs}.
\item Annie McCartney, Hugh McGovern, Alexander De Foe (2021). \textit{Psychedelic Assisted Therapy for Major Depressive Disorder: A Review}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/9kuhs\_v1}{source link}.
\item Sarah-Catherine Rodan, Phillip Aouad, Iain S. McGregor, Sarah Maguire (2021). \textit{Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa}. OBM Neurobiology. [published; OpenAlex]. \href{https://doi.org/10.21926/obm.neurobiol.2102102}{doi:10.21926/obm.neurobiol.2102102}.
\item Corrigan A, Burchill E, Pelton L, Marrocu A, Mazzoleni A, Shackshaft L. (2021). \textit{Psilocybin: the magic medicine for depression?}. BJPsych open. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC8770735}{source link}.
\item Amber Elyse Corrigan, Ella Burchill, Lucy Pelton, Alessia Marrocu, Adele Mazzoleni, Lydia Shackshaft (2021). \textit{Psilocybin: the magic medicine for depression?}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2021.456}{doi:10.1192/bjo.2021.456}.
\item Chao YS, Horton J. (2021). \textit{Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders}. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON). [published; Europe PMC]. \href{https://europepmc.org/article/MED/36170470}{source link}.
\item Kelly JR, Crockett MT, Alexander L, Haran M, Baker A, Burke L, Brennan C, O'Keane V (2021). \textit{Psychedelic science in post-COVID-19 psychiatry.}. Irish journal of psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/ipm.2020.94}{doi:10.1017/ipm.2020.94}.
\item Daws R, Timmerman C, Giribaldi B, Sexton J, Wall M, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R. (2021). \textit{Decreased brain modularity after psilocybin therapy for depression.}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-513323/v1}{doi:10.21203/rs.3.rs-513323/v1}.
\item Evan Lewis-Healey, Ruben Eero Laukkonen, Michiel van Elk (2021). \textit{Future Directions for Clinical Psilocybin Research: The Relaxed Symptom Network}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.1037/pne0000290}{doi:10.1037/pne0000290}.
\item Lewis-Healey E, Laukkonen RE, van Elk M. (2021). \textit{Future Directions for Clinical Psilocybin Research: The Relaxed Symptom Network}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/q3ymd}{doi:10.31234/osf.io/q3ymd}.
\item Wayne Hall (2021). \textit{The need for publicly funded research on therapeutic use of psychedelic drugs}. World Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1002/wps.20847}{doi:10.1002/wps.20847}.
\item Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L (2021). \textit{The Therapeutic Potential of Psilocybin.}. Molecules (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/molecules26102948}{doi:10.3390/molecules26102948}.
\item Forstmann M, Sagioglou C. (2021). \textit{New insights into the clinical and nonclinical effects of psychedelic substances: an integrative review}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/2489x}{doi:10.31234/osf.io/2489x}.
\item Matthias Forstmann, Christina Sagioglou (2021). \textit{New insights into the clinical and nonclinical effects of psychedelic substances: an integrative review}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/2489x\_v1}{source link}.
\item Fabiana Venancio Santana Silva, Alexandre Libanio Silva Reis, Amanda Prazeres Costa, Maria Carolaine Souza da Silva, Rafaela da Conceição de Lemos, Elisângela Marcionilo Da Conceição, Joyce Kelly Soares da Silva, Carlos Alberto Tiburcio Valeriano, David Filipe de Santana (2021). \textit{A utilização terapêutica da psilocibina como coadjuvante no tratamento do transtorno depressivo maior: uma revisão narrativa de literatura / The therapeutic use of psilocybin as an adjunct in the treatment of major depressive disorder: a narrative literature review}. Brazilian Journal of Health Review. [published; OpenAlex]. \href{https://doi.org/10.34119/bjhrv4n3-012}{doi:10.34119/bjhrv4n3-012}.
\item Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2021). \textit{Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.}. JAMA psychiatry. [published; PubMed]. \href{https://doi.org/10.1001/jamapsychiatry.2020.3285}{doi:10.1001/jamapsychiatry.2020.3285}.
\item Reynolds CF (2021). \textit{Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression-Quo Vadis?}. JAMA psychiatry. [published; PubMed]. \href{https://doi.org/10.1001/jamapsychiatry.2020.2901}{doi:10.1001/jamapsychiatry.2020.2901}.
\item Davis AK, Griffiths RR (2021). \textit{Errors in a Response Rate and in Effect Sizes in Study of Psilocybin-Assisted Therapy for Major Depressive Disorder.}. JAMA psychiatry. [published; PubMed]. \href{https://doi.org/10.1001/jamapsychiatry.2020.4638}{doi:10.1001/jamapsychiatry.2020.4638}.
\item Romeo B, Hermand M, Pétillion A, Karila L, Benyamina A (2021). \textit{Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review.}. Journal of psychiatric research. [published; PubMed]. \href{https://doi.org/10.1016/j.jpsychires.2021.03.002}{doi:10.1016/j.jpsychires.2021.03.002}.
\item Bird CIV, Modlin NL, Rucker JJH (2021). \textit{Psilocybin and MDMA for the treatment of trauma-related psychopathology.}. International review of psychiatry (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1080/09540261.2021.1919062}{doi:10.1080/09540261.2021.1919062}.
\item University of Zurich (2021). \textit{Characterization of Altered Waking States of Consciousness in Healthy Humans}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03853577}{source link}.
\item Katrin H. Preller (2021). \textit{Altered Prediction-Error Processing May Underlie Psilocybin-Induced Changes in Self-Processing}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2021.02.036}{doi:10.1016/j.biopsych.2021.02.036}.
\item Hisham Alshaikhli, Redhwan Ahmed Al-Naggar, Gwen Erlam (2021). \textit{Effectiveness of Psilocybin on Depression: A Qualitative Study}. Electronic Journal of General Medicine. [published; OpenAlex]. \href{https://doi.org/10.29333/ejgm/10862}{doi:10.29333/ejgm/10862}.
\item Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM (2021). \textit{Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice.}. Proceedings of the National Academy of Sciences of the United States of America. [published; PubMed]. \href{https://doi.org/10.1073/pnas.2022489118}{doi:10.1073/pnas.2022489118}.
\item Andrew Penn, Janis Phelps, William E. Rosa, Jean Watson (2021). \textit{Psychedelic-Assisted Psychotherapy Practices and Human Caring Science: Toward a Care-Informed Model of Treatment}. Journal of Humanistic Psychology. [published; OpenAlex]. \href{https://doi.org/10.1177/00221678211011013}{doi:10.1177/00221678211011013}.
\item Giovanni Pereira Pio, Aline Moreira Vitorino, Naira Braga Aidar, Alissa Amoras Magalhães, Eduardo Cammerer Mombelli, Gabriela Marques Ferraz, Rodrigo Pereira Pio (2021). \textit{O papel da Psilocibina no tratamento de depressão resistente / The role of Psilocybin in the treatment of resistant depression}. Brazilian Journal of Health Review. [published; OpenAlex]. \href{https://doi.org/10.34119/bjhrv4n2-395}{doi:10.34119/bjhrv4n2-395}.
\item Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021). \textit{Trial of Psilocybin versus Escitalopram for Depression.}. The New England journal of medicine. [published; PubMed]. \href{https://doi.org/10.1056/nejmoa2032994}{doi:10.1056/nejmoa2032994}.
\item Stauffer CS, Anderson BT, Ortigo KM, Woolley J (2021). \textit{Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.0c00169}{doi:10.1021/acsptsci.0c00169}.
\item Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, Franco Corso S, Bjerre Real C, Guss J, Bossis A, Mennenga SE (2021). \textit{Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.1c00020}{doi:10.1021/acsptsci.1c00020}.
\item Gerber K, Flores IG, Ruiz AC, Ali I, Ginsberg NL, Schenberg EE (2021). \textit{Ethical Concerns about Psilocybin Intellectual Property.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.0c00171}{doi:10.1021/acsptsci.0c00171}.
\item Gard DE, Pleet MM, Bradley ER, Penn A, Gallenstein ML, Riley LS, DellaCrosse M, Garfinkle E, Michalak EE, Woolley JD. (2021). \textit{Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2021.04.02.21254838}{doi:10.1101/2021.04.02.21254838}.
\item Dworatzyk K, Jansen T, Schmidt TT. (2021). \textit{Phenomenological assessment of psychedelic induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI)}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/kxmgq}{doi:10.31234/osf.io/kxmgq}.
\item Katharina Dworatzyk, Tallulah Jansen, Timo Torsten Schmidt (2021). \textit{Phenomenological assessment of psychedelic induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI)}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/kxmgq\_v1}{source link}.
\item Nelson Descalço, Ana Beatriz Medeiros, Cátia Fernandes Santos, Guilherme Borges (2021). \textit{Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2021.1114}{doi:10.1192/j.eurpsy.2021.1114}.
\item A. Fraga, Daniel Esteves-Sousa, João Facucho-Oliveira, Margarida Albuquerque, M. Costa, Paulo Santos, Nuno Moura, A. Moutinho (2021). \textit{Effects of psilocybin-assisted therapy on treatment-resistant depression}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2021.1836}{doi:10.1192/j.eurpsy.2021.1836}.
\item Jefsen OH, Elfving B, Wegener G, Müller HK (2021). \textit{Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881120959614}{doi:10.1177/0269881120959614}.
\item Bottemanne H, Claret A, Fossati P (2021). \textit{[Ketamine, psilocybin, and rapid acting antidepressant: new promise for psychiatry?].}. L'Encephale. [published; PubMed]. \href{https://doi.org/10.1016/j.encep.2020.08.006}{doi:10.1016/j.encep.2020.08.006}.
\item Savalia NK, Shao LX, Kwan AC (2021). \textit{A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics.}. Trends in neurosciences. [published; PubMed]. \href{https://doi.org/10.1016/j.tins.2020.11.008}{doi:10.1016/j.tins.2020.11.008}.
\item Garcia-Romeu A, Barrett FS, Carbonaro TM, Johnson MW, Griffiths RR (2021). \textit{Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881121991822}{doi:10.1177/0269881121991822}.
\item Dos Santos RG, Hallak JE, Baker G, Dursun S (2021). \textit{Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881120986422}{doi:10.1177/0269881120986422}.
\item Stanley N. Caroff (2021). \textit{The Return of Psychedelics: Still Time to Prevent Tragedy}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2021.4.8}{doi:10.1176/appi.pn.2021.4.8}.
\item Teixeira PJ, Johnson M, Timmermann C, Watts R, Erritzoe D, Douglass H, Kettner H, Carhart-Harris R. (2021). \textit{Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/8vks6}{doi:10.31234/osf.io/8vks6}.
\item Pedro Teixeira, Matthew Johnson, Christopher Timmermann, Rosalind Watts, David Erritzoe, Hannah Douglass, Hannes Kettner, Robin Carhart-Harris (2021). \textit{Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/8vks6\_v1}{source link}.
\item Kozłowska U, Klimczak A, Wiatr K, Figiel M. (2021). \textit{The DMT and Psilocin Treatment Changes CD11b+ Activated Microglia Immunological Phenotype}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2021.03.07.434103}{doi:10.1101/2021.03.07.434103}.
\item Burton M. Altura, Bella T. Altura (2021). \textit{Stroke and Adverse Effects on The Immune and Cardiovascular Systems: The Danger of the Rise and Use of Psychedelic Drugs for Depression and PTSD}. Journal of Clinical \& Experimental Immunology. [published; Crossref]. \href{https://doi.org/10.33140/jcei.06.02.01}{doi:10.33140/jcei.06.02.01}.
\item Nick Zagorski (2021). \textit{Session on Psychedelics Sure to Be Enlightening}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2021.3.14}{doi:10.1176/appi.pn.2021.3.14}.
\item Nayak S, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR. (2021). \textit{Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/r726d}{doi:10.31234/osf.io/r726d}.
\item Avinash Hosanagar, Joseph Cusimano, Rajiv Radhakrishnan (2021). \textit{Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2}. The Journal of Clinical Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.4088/jcp.20ac13787}{doi:10.4088/jcp.20ac13787}.
\item Peter G. Brindley (2021). \textit{How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence}. Anesthesia \& Analgesia. [published; OpenAlex]. \href{https://doi.org/10.1213/ane.0000000000005349}{doi:10.1213/ane.0000000000005349}.
\item Thomas CW, Blanco-Duque C, Bréant B, Goodwin GM, Sharp T, Bannerman DM, Vyazovskiy VV. (2021). \textit{Psilocin acutely disrupts sleep and affects local but not global sleep homeostasis in laboratory mice}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2021.02.16.431276}{doi:10.1101/2021.02.16.431276}.
\item De Gregorio D, Aguilar-Valles A, Preller KH, Heifets BD, Hibicke M, Mitchell J, Gobbi G (2021). \textit{Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.}. The Journal of neuroscience: the official journal of the Society for Neuroscience. [published; PubMed]. \href{https://doi.org/10.1523/jneurosci.1659-20.2020}{doi:10.1523/jneurosci.1659-20.2020}.
\item Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D (2021). \textit{Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.}. Acta psychiatrica Scandinavica. [published; PubMed]. \href{https://doi.org/10.1111/acps.13249}{doi:10.1111/acps.13249}.
\item Galvão-Coelho NL, Marx W, Gonzalez M, Sinclair J, de Manincor M, Perkins D, Sarris J (2021). \textit{Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-020-05719-1}{doi:10.1007/s00213-020-05719-1}.
\item Joost J. Breeksema, Martijn H B Koolen, Metten Somers, Robert A. Schoevers (2021). \textit{Behandeling met psilocybine}. Data Archiving and Networked Services (DANS). [published; OpenAlex]. \href{https://research.rug.nl/en/publications/5e83b45d-b208-402a-a435-f0380fad6429}{source link}.
\item Breeksema JJ, Koolen MHB, Somers M, Schoevers RA (2021). \textit{[Treatment with psilocybin: applications for patients with psychiatric disorders].}. Nederlands tijdschrift voor geneeskunde. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/33560605/}{source link}.
\item Raval NR, Johansen A, Donovan LL, Ros NF, Ozenne B, Hansen HD, Knudsen GM (2021). \textit{A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT Receptor Density in the Pig Brain.}. International journal of molecular sciences. [published; PubMed]. \href{https://doi.org/10.3390/ijms22020835}{doi:10.3390/ijms22020835}.
\item Joshua Woolley (2021). \textit{Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT02950467}{source link}.
\item Vagner Fagnani Linartevichi, Matheus Gonzales Froza, Rafael de Morais Cury, Francisney Pinto do Nascimento (2021). \textit{POTENCIAL USO DA PSILOCIBINA NO TRATAMENTO DA DEPRESSÃO: UMA REVISÃO / POTENTIAL USE OF PSILOCYBIN IN THE DEPRESSION TREATMENT: A REVIEW}. Brazilian Journal of Development. [published; OpenAlex]. \href{https://doi.org/10.34117/bjdv7n3-783}{doi:10.34117/bjdv7n3-783}.
\item Yogesh Kumar Chahar (2021). \textit{Unmet need in depression: Psilocybin, a breakthrough treatment option}. International Journal of Advanced Research in Medicine. [published; OpenAlex]. \href{https://doi.org/10.22271/27069567.2021.v3.i1f.159}{doi:10.22271/27069567.2021.v3.i1f.159}.
\item Harmony I. Risca (2021). \textit{Preclinical Behavioral Assessment of Chronic, Intermittent Low-Dose Psilocybin in Rodent Models of Depression and Anxiety}. Western Michigan University ScholarWorks. [published; OpenAlex]. \href{https://scholarworks.wmich.edu/cgi/viewcontent.cgi?article=4777\&context=dissertations}{source link}.
\item Varker T, Watson L, Gibson K, Forbes D, O'Donnell ML (2021). \textit{Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2020.1817639}{doi:10.1080/02791072.2020.1817639}.
\item Donovan LL, Johansen JV, Ros NF, Jaberi E, Linnet K, Johansen SS, Ozenne B, Issazadeh-Navikas S, Hansen HD, Knudsen GM (2021). \textit{Effects of a single dose of psilocybin on behaviour, brain 5-HT receptor occupancy and gene expression in the pig.}. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.euroneuro.2020.11.013}{doi:10.1016/j.euroneuro.2020.11.013}.
\item Tullis P (2021). \textit{How ecstasy and psilocybin are shaking up psychiatry.}. Nature. [published; PubMed]. \href{https://doi.org/10.1038/d41586-021-00187-9}{doi:10.1038/d41586-021-00187-9}.
\item Bouso JC, Ona G, Dos Santos RG, Hallak JEC (2021). \textit{Psychedelic Medicines in Major Depression: Progress and Future Challenges.}. Advances in experimental medicine and biology. [published; PubMed]. \href{https://doi.org/10.1007/978-981-33-6044-0\_26}{doi:10.1007/978-981-33-6044-0\_26}.
\item Williams MT, Davis AK, Xin Y, Sepeda ND, Grigas PC, Sinnott S, Haeny AM (2021). \textit{People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences.}. Drugs (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1080/09687637.2020.1854688}{doi:10.1080/09687637.2020.1854688}.
\item Sheppard B (2021). \textit{A Trip Through Employment Law: Protecting Therapeutic Psilocybin Users in the Workplace.}. Journal of law and health. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/35026878/}{source link}.
\item Tai SJ, Nielson EM, Lennard-Jones M, Johanna Ajantaival RL, Winzer R, Richards WA, Reinholdt F, Richards BD, Gasser P, Malievskaia E (2021). \textit{Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.586682}{doi:10.3389/fpsyt.2021.586682}.
\item Castro Santos H, Gama Marques J (2021). \textit{What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review.}. Porto biomedical journal. [published; PubMed]. \href{https://doi.org/10.1097/j.pbj.0000000000000128}{doi:10.1097/j.pbj.0000000000000128}.
\item Higgins GA, Carroll NK, Brown M, MacMillan C, Silenieks LB, Thevarkunnel S, Izhakova J, Magomedova L, DeLannoy I, Sellers EM (2021). \textit{Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2021.640241}{doi:10.3389/fphar.2021.640241}.
\item Diab H, Malcolm B (2021). \textit{Persistent Tinnitus after Inhaled N,N-dimethyltryptamine (DMT).}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2020.1847366}{doi:10.1080/02791072.2020.1847366}.
\item Rucker JJ, Young AH (2021). \textit{Psilocybin: From Serendipity to Credibility?}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.659044}{doi:10.3389/fpsyt.2021.659044}.
\item Barnett BS, Greer GR (2021). \textit{Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.}. Journal of the Academy of Consultation-Liaison Psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.jaclp.2020.12.011}{doi:10.1016/j.jaclp.2020.12.011}.
\item Eleftheriou ME, Thomas E (2021). \textit{Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.707057}{doi:10.3389/fpsyt.2021.707057}.
\item Dahmane Elyes, Hutson Paul R., Gobburu Jogarao V. S. (2021). \textit{Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin}. Clinical Pharmacology in Drug Development. [published; Crossref]. \href{https://doi.org/10.1002/cpdd.796}{doi:10.1002/cpdd.796}.
\item Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE (2021). \textit{Psychedelics and Other Psychoplastogens for Treating Mental Illness.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.727117}{doi:10.3389/fpsyt.2021.727117}.
\item Williams ML, Korevaar D, Harvey R, Fitzgerald PB, Liknaitzky P, O'Carroll S, Puspanathan P, Ross M, Strauss N, Bennett-Levy J (2021). \textit{Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.737738}{doi:10.3389/fpsyt.2021.737738}.
\item Whitfield HJ (2021). \textit{A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.727572}{doi:10.3389/fpsyt.2021.727572}.
\item Vilca-Melendez S, Uthaug MV, Griffin JL (2021). \textit{H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.742856}{doi:10.3389/fpsyt.2021.742856}.
\item Kelly JR, Gillan CM, Prenderville J, Kelly C, Harkin A, Clarke G, O'Keane V (2021). \textit{Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.800072}{doi:10.3389/fpsyt.2021.800072}.
\item Matzopoulos R, Morlock R, Morlock A, Lerer B, Lerer L (2021). \textit{Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.780696}{doi:10.3389/fpsyt.2021.780696}.
\item Markopoulos A, Inserra A, De Gregorio D, Gobbi G (2021). \textit{Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2021.749068}{doi:10.3389/fphar.2021.749068}.
\item Murphy R, Kettner H, Zeifman R, Giribaldi B, Kartner L, Martell J, Read T, Murphy-Beiner A, Baker-Jones M, Nutt D, Erritzoe D, Watts R, Carhart-Harris R (2021). \textit{Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2021.788155}{doi:10.3389/fphar.2021.788155}.
\item Robert A. Mikos (2020). \textit{We Need a Cole Memorandum for Magic Mushrooms}. SSRN Electronic Journal. [published; OpenAlex]. \href{https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=3839551}{source link}.
\item Nkadimeng SM, Steinmann CML, Eloff JN (2020). \textit{Effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushroom extracts on endothelin-1-induced hypertrophy and cell injury in cardiomyocytes.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-020-79328-5}{doi:10.1038/s41598-020-79328-5}.
\item University Hospital, Basel, Switzerland (2020). \textit{Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy Subjects}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03912974}{source link}.
\item Gill H, Gill B, Chen-Li D, El-Halabi S, Rodrigues NB, Cha DS, Lipsitz O, Lee Y, Rosenblat JD, Majeed A, Mansur RB, Nasri F, Ho R, McIntyre RS (2020). \textit{The emerging role of psilocybin and MDMA in the treatment of mental illness.}. Expert review of neurotherapeutics. [published; PubMed]. \href{https://doi.org/10.1080/14737175.2020.1826931}{doi:10.1080/14737175.2020.1826931}.
\item Goldberg SB, Shechet B, Nicholas CR, Ng CW, Deole G, Chen Z, Raison CL (2020). \textit{Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.}. Psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/s003329172000389x}{doi:10.1017/s003329172000389x}.
\item Raval NR, Johansen A, Donovan LL, Ros NF, Ozenne B, Hansen HD, Knudsen GM. (2020). \textit{A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain}. Preprints.org. [preprint; Europe PMC]. \href{https://doi.org/10.20944/preprints202011.0742.v1}{doi:10.20944/preprints202011.0742.v1}.
\item Mason NL, Kuypers KPC, Müller F, Reckweg J, Tse DHY, Toennes SW, Hutten NRPW, Jansen JFA, Stiers P, Feilding A, Ramaekers JG (2020). \textit{Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/s41386-020-0718-8}{doi:10.1038/s41386-020-0718-8}.
\item Luoma JB, Chwyl C, Bathje G, Davis AK, Lancelotta RL. (2020). \textit{A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/nhbjk}{doi:10.31234/osf.io/nhbjk}.
\item NYU Langone Health (2020). \textit{Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT00957359}{source link}.
\item Russ Curtis, Lisen C. Roberts, Elizabeth Graves, Heather Thompson Rainey, D. D. Wynn, Daphne Krantz, Verena Wieloch (2020). \textit{The Role of Psychedelics and Counseling in Mental Health Treatment}. Journal of Mental Health Counseling. [published; OpenAlex]. \href{https://doi.org/10.17744/mehc.42.4.03}{doi:10.17744/mehc.42.4.03}.
\item Nichols DE (2020). \textit{Psilocybin: from ancient magic to modern medicine.}. The Journal of antibiotics. [published; PubMed]. \href{https://doi.org/10.1038/s41429-020-0311-8}{doi:10.1038/s41429-020-0311-8}.
\item Romeo B, Karila L, Martelli C, Benyamina A (2020). \textit{Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881120919957}{doi:10.1177/0269881120919957}.
\item Cozzi NV, Daley PF (2020). \textit{Synthesis and characterization of high-purity N,N-dimethyltryptamine hemifumarate for human clinical trials.}. Drug testing and analysis. [published; PubMed]. \href{https://doi.org/10.1002/dta.2889}{doi:10.1002/dta.2889}.
\item Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden MT, Dilley PJ, Mitchell J, Woolley J (2020). \textit{Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.}. EClinicalMedicine. [published; PubMed]. \href{https://doi.org/10.1016/j.eclinm.2020.100538}{doi:10.1016/j.eclinm.2020.100538}.
\item Nicole Harrington Cirino (2020). \textit{Wait for the Science Before Widespread Use of Psilocybin}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2020.10a32}{doi:10.1176/appi.pn.2020.10a32}.
\item Vitkauskas M, Mathuru AS (2020). \textit{Total Recall: Lateral Habenula and Psychedelics in the Study of Depression and Comorbid Brain Disorders.}. International journal of molecular sciences. [published; PubMed]. \href{https://doi.org/10.3390/ijms21186525}{doi:10.3390/ijms21186525}.
\item Vargas AS, Luís Â, Barroso M, Gallardo E, Pereira L (2020). \textit{Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases-A Systematic Review and Meta-Analysis of Clinical Trials.}. Biomedicines. [published; PubMed]. \href{https://doi.org/10.3390/biomedicines8090331}{doi:10.3390/biomedicines8090331}.
\item Jones TK, Lippmann S (2020). \textit{Psilocybin Can Diminish Depression.}. The primary care companion for CNS disorders. [published; PubMed]. \href{https://doi.org/10.4088/pcc.19br02580}{doi:10.4088/pcc.19br02580}.
\item Breeksema JJ, Niemeijer AR, Krediet E, Vermetten E, Schoevers RA (2020). \textit{Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies.}. CNS drugs. [published; PubMed]. \href{https://doi.org/10.1007/s40263-020-00748-y}{doi:10.1007/s40263-020-00748-y}.
\item Nkadimeng SM, Nabatanzi A, Steinmann CML, Eloff JN (2020). \textit{Phytochemical, Cytotoxicity, Antioxidant and Anti-Inflammatory Effects of Magic Mushroom.}. Plants (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/plants9091127}{doi:10.3390/plants9091127}.
\item James D. Tucker (2020). \textit{Oregon's Pioneering Effort to Enact State Law to Allow Access to Psilocybin}. SSRN Electronic Journal. [published; OpenAlex]. \href{https://papers.ssrn.com/sol3/Delivery.cfm/SSRN\_ID3783484\_code4550530.pdf?abstractid=3783484\&mirid=1}{source link}.
\item Guss J, Krause R, Sloshower J. (2020). \textit{The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/u6v9y}{doi:10.31234/osf.io/u6v9y}.
\item Jeffrey Guss, Robert Krause, Jordan Sloshower (2020). \textit{The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/u6v9y\_v1}{source link}.
\item Robin Carhart-Harris (2020). \textit{4 Psychedelics: therapeutic mechanisms}. Journal of Neurology Neurosurgery \& Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1136/jnnp-2020-bnpa.4}{doi:10.1136/jnnp-2020-bnpa.4}.
\item Fricke J, Kargbo R, Regestein L, Lenz C, Peschel G, Rosenbaum MA, Sherwood A, Hoffmeister D (2020). \textit{Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin.}. Chemistry (Weinheim an der Bergstrasse, Germany). [published; PubMed]. \href{https://doi.org/10.1002/chem.202000134}{doi:10.1002/chem.202000134}.
\item Luoma JB. (2020). \textit{A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/sgujx}{doi:10.31234/osf.io/sgujx}.
\item Aday JS, Mitzkovitz CM, Bloesch EK, Davoli CC, Davis AK (2020). \textit{Long-term effects of psychedelic drugs: A systematic review.}. Neuroscience and biobehavioral reviews. [published; PubMed]. \href{https://doi.org/10.1016/j.neubiorev.2020.03.017}{doi:10.1016/j.neubiorev.2020.03.017}.
\item Nick Zagorski (2020). \textit{Journal Digest: Home Environment; Postpartum Mental Illness; Placebo in Psychedelic Study; Single Gene Mutation; Topiramate}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2020.6a34}{doi:10.1176/appi.pn.2020.6a34}.
\item Katie R. Barnes, Stephanie N. Lewis (2020). \textit{Binding Interactions of Psilocin and Serotonin in the 5-HT2A Receptor}. VTechWorks (Virginia Tech). [published; OpenAlex]. \href{http://hdl.handle.net/10919/99299}{source link}.
\item Lea T, Amada N, Jungaberle H, Schecke H, Scherbaum N, Klein M (2020). \textit{Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-020-05477-0}{doi:10.1007/s00213-020-05477-0}.
\item Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM, the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research (2020). \textit{Psychedelics and Psychedelic-Assisted Psychotherapy.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.2019.19010035}{doi:10.1176/appi.ajp.2019.19010035}.
\item Kringelbach ML, Cruzat J, Cabral J, Knudsen GM, Carhart-Harris R, Whybrow PC, Logothetis NK, Deco G (2020). \textit{Dynamic coupling of whole-brain neuronal and neurotransmitter systems.}. Proceedings of the National Academy of Sciences of the United States of America. [published; PubMed]. \href{https://doi.org/10.1073/pnas.1921475117}{doi:10.1073/pnas.1921475117}.
\item University of Wisconsin, Madison (2020). \textit{Pharmacokinetics of Psilocybin in Normal Adult Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT02163707}{source link}.
\item Chi T, Gold JA (2020). \textit{A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.}. Journal of the neurological sciences. [published; PubMed]. \href{https://doi.org/10.1016/j.jns.2020.116715}{doi:10.1016/j.jns.2020.116715}.
\item Nick Zagorski (2020). \textit{Psychedelics for Psychiatric Disorders: More Research Needed}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2020.4a14}{doi:10.1176/appi.pn.2020.4a14}.
\item Kargbo RB (2020). \textit{Psilocybin Therapeutic Research: The Present and Future Paradigm.}. ACS medicinal chemistry letters. [published; PubMed]. \href{https://doi.org/10.1021/acsmedchemlett.0c00048}{doi:10.1021/acsmedchemlett.0c00048}.
\item Nutt D, Erritzoe D, Carhart-Harris R (2020). \textit{Psychedelic Psychiatry's Brave New World.}. Cell. [published; PubMed]. \href{https://doi.org/10.1016/j.cell.2020.03.020}{doi:10.1016/j.cell.2020.03.020}.
\item Meghan Hibicke, Charles D. Nichols (2020). \textit{One Dose of Psilocybin in Late Adolescence Mitigates Deleterious Effects of Developmental Stress on Cognition and Behavioral Despair in Adult Female Rats}. The FASEB Journal. [published; OpenAlex]. \href{https://doi.org/10.1096/fasebj.2020.34.s1.02912}{doi:10.1096/fasebj.2020.34.s1.02912}.
\item Richard Simoneaux (2020). \textit{Long-Term Analysis of Psilocybin in Cancer Patients With Distress}. Oncology Times. [published; OpenAlex]. \href{https://doi.org/10.1097/01.cot.0000660232.19098.7f}{doi:10.1097/01.cot.0000660232.19098.7f}.
\item Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD (2020). \textit{Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.9b00493}{doi:10.1021/acschemneuro.9b00493}.
\item Benko J, Vranková S (2020). \textit{Natural Psychoplastogens As Antidepressant Agents.}. Molecules (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/molecules25051172}{doi:10.3390/molecules25051172}.
\item Meikle SE, Liknaitzky P, Rossell SL, Ross M, Strauss N, Thomas N, Murray G, Williams M, Castle DJ (2020). \textit{Psilocybin-assisted therapy for depression: How do we advance the field?}. The Australian and New Zealand journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1177/0004867419888575}{doi:10.1177/0004867419888575}.
\item Mathai DS, Meyer MJ, Storch EA, Kosten TR (2020). \textit{The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2019.12.023}{doi:10.1016/j.jad.2019.12.023}.
\item Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, Bossis AP, Grigsby J, Fischer S, Ross S (2020). \textit{Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881119897615}{doi:10.1177/0269881119897615}.
\item Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR (2020). \textit{The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2020.112749}{doi:10.1016/j.psychres.2020.112749}.
\item Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL (2020). \textit{Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881119895520}{doi:10.1177/0269881119895520}.
\item Heidi Bush (2020). \textit{Psychedelic therapy: Fresh promise for mental health}. Mental Health Weekly. [published; OpenAlex]. \href{https://doi.org/10.1002/mhw.32207}{doi:10.1002/mhw.32207}.
\item Dalton Budhram, Preet Dhaliwal (2020). \textit{Psilocybin Therapy for Depression: A Scoping Review Protocol}. Open MIND. [published; OpenAlex]. \href{https://osf.io/4syt6}{source link}.
\item Brooke Reichenbach (2020). \textit{Is Psilocybin an Effective Treatment to Reduce Depression and Anxiety in Cancer Patients with a Diagnosis of an Anxiety Disorder, Mood Disorder, And/Or Stress Disorder?}. Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine). [published; OpenAlex]. \href{https://digitalcommons.pcom.edu/pa\_systematic\_reviews/531}{source link}.
\item Laura Sanders (2020). \textit{Psilocybin may help cancer patients with depression and anxiety for years}. Access Science. [published; OpenAlex]. \href{https://www.accessscience.com/content/psilocybin-may-help-cancer-patients-with-depression-and-anxiety-for-years/SN2002031}{source link}.
\item Germann CB (2020). \textit{The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging.}. Medical hypotheses. [published; PubMed]. \href{https://doi.org/10.1016/j.mehy.2019.109406}{doi:10.1016/j.mehy.2019.109406}.
\item Lea T, Amada N, Jungaberle H, Schecke H, Klein M (2020). \textit{Microdosing psychedelics: Motivations, subjective effects and harm reduction.}. The International journal on drug policy. [published; PubMed]. \href{https://doi.org/10.1016/j.drugpo.2019.11.008}{doi:10.1016/j.drugpo.2019.11.008}.
\item Dos Santos RG, Hallak JEC (2020). \textit{Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms.}. Neuroscience and biobehavioral reviews. [published; PubMed]. \href{https://doi.org/10.1016/j.neubiorev.2019.12.001}{doi:10.1016/j.neubiorev.2019.12.001}.
\item Schimmel N, Breeksema JJ, Veraart JKE, van den Brink W, Schoevers RA (2020). \textit{[Psychedelics for existential distress in terminally ill patients].}. Tijdschrift voor psychiatrie. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/32816294/}{source link}.
\item Voineskos D, Daskalakis ZJ, Blumberger DM (2020). \textit{Management of Treatment-Resistant Depression: Challenges and Strategies.}. Neuropsychiatric disease and treatment. [published; PubMed]. \href{https://doi.org/10.2147/ndt.s198774}{doi:10.2147/ndt.s198774}.
\item Bienemann B, Ruschel NS, Campos ML, Negreiros MA, Mograbi DC (2020). \textit{Self-reported negative outcomes of psilocybin users: A quantitative textual analysis.}. PloS one. [published; PubMed]. \href{https://doi.org/10.1371/journal.pone.0229067}{doi:10.1371/journal.pone.0229067}.
\item Heuschkel K, Kuypers KPC (2020). \textit{Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2020.00224}{doi:10.3389/fpsyt.2020.00224}.
\item Lea T, Amada N, Jungaberle H (2020). \textit{Psychedelic Microdosing: A Subreddit Analysis.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2019.1683260}{doi:10.1080/02791072.2019.1683260}.
\item Kuypers KPC (2020). \textit{The therapeutic potential of microdosing psychedelics in depression.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/2045125320950567}{doi:10.1177/2045125320950567}.
\item Foldi CJ, Liknaitzky P, Williams M, Oldfield BJ (2020). \textit{Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models.}. Frontiers in neuroscience. [published; PubMed]. \href{https://doi.org/10.3389/fnins.2020.00043}{doi:10.3389/fnins.2020.00043}.
\item Marcus Allgulin (2019). \textit{Psilocybin and LSD in the Treatment of Depression and Anxiety}. Diva portal (Dalarna University Library). [published; OpenAlex]. \href{http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-18843}{source link}.
\item Sofia Gyllvik (2019). \textit{The Therapeutic Potential of Psilocybin and 3,4-Methylenedioxymethamphetamine in the Treatment of Depression and Post-Traumatic Stress Disorder}. Diva portal (Dalarna University Library). [published; OpenAlex]. \href{http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-18729}{source link}.
\item Katariina Sarajärvi (2019). \textit{Psilocybin's effects on the brain and implications for depression treatment}. Epubl LTU. [published; OpenAlex]. \href{http://urn.kb.se/resolve?urn=urn:nbn:se:ltu:diva-79481}{source link}.
\item Reham Shaba (2019). \textit{Development of an improved psilocybin synthesis}. Uppsala University Publications (Uppsala University). [published; OpenAlex]. \href{http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-420295}{source link}.
\item Krishna Kumar Varshney (2019). \textit{Structure Based Drug Design towards Exploring Potential Anti-Psychotic and Anti-Depressant Activity of Possible Stiff Base of Psilocybin}. SSRN Electronic Journal. [published; OpenAlex]. \href{https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=3528349}{source link}.
\item Shore R, Ioudovski P, Goldie C, McKeown S, Dumont E, Queen’s University, Kingston On. (2019). \textit{Mapping Psilocybin-Assisted Therapies: A Scoping Review}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2019.12.04.19013896}{doi:10.1101/2019.12.04.19013896}.
\item Laura Mertens, M.B. Wall, L. Roseman, L. Demetriou, D.J. Nutt, R.L. Carhart-Harris (2019). \textit{P.609 Therapeutic mechanisms of psychedelic drugs: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression}. European Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.euroneuro.2019.09.593}{doi:10.1016/j.euroneuro.2019.09.593}.
\item Adams AM, Kaplan NA, Wei Z, Brinton JD, Monnier CS, Enacopol AL, Ramelot TA, Jones JA (2019). \textit{In vivo production of psilocybin in E. coli.}. Metabolic engineering. [published; PubMed]. \href{https://doi.org/10.1016/j.ymben.2019.09.009}{doi:10.1016/j.ymben.2019.09.009}.
\item Andersson M, Kjellgren A (2019). \textit{Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube.}. Harm reduction journal. [published; PubMed]. \href{https://doi.org/10.1186/s12954-019-0333-3}{doi:10.1186/s12954-019-0333-3}.
\item Fricke J, Sherwood A, Kargbo R, Orry A, Blei F, Naschberger A, Rupp B, Hoffmeister D (2019). \textit{Enzymatic Route toward 6-Methylated Baeocystin and Psilocybin.}. Chembiochem: a European journal of chemical biology. [published; PubMed]. \href{https://doi.org/10.1002/cbic.201900358}{doi:10.1002/cbic.201900358}.
\item Jordan Sloshower, Jeffrey Guss, Robert Krause, Ryan Wallace, Monnica T. Williams, Sara Reed, Matthew D. Skinta (2019). \textit{Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame}. Journal of Contextual Behavioral Science. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jcbs.2019.11.002}{doi:10.1016/j.jcbs.2019.11.002}.
\item Russ SL, Carhart-Harris RL, Maruyama G, Elliott MS (2019). \textit{Replication and extension of a model predicting response to psilocybin.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-019-05279-z}{doi:10.1007/s00213-019-05279-z}.
\item Muttoni S, Ardissino M, John C (2019). \textit{Classical psychedelics for the treatment of depression and anxiety: A systematic review.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2019.07.076}{doi:10.1016/j.jad.2019.07.076}.
\item Dos Santos RG, Bouso JC, Hallak JEC (2019). \textit{Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer.}. BMC psychiatry. [published; PubMed]. \href{https://doi.org/10.1186/s12888-019-2288-z}{doi:10.1186/s12888-019-2288-z}.
\item Nick Zagorski (2019). \textit{Johns Hopkins Opens Research Center on Psychedelics}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2019.10a16}{doi:10.1176/appi.pn.2019.10a16}.
\item Kernel Networks Inc. (2019). \textit{Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease}. Case Medical Research. [published; OpenAlex]. \href{https://doi.org/10.31525/ct1-nct04123314}{doi:10.31525/ct1-nct04123314}.
\item Megha Satyanarayana (2019). \textit{Modified E. coli pump out psilocybin}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-09739-scicon9}{doi:10.1021/cen-09739-scicon9}.
\item Kelley C. O’Donnell, Sarah E. Mennenga, Michael P. Bogenschutz (2019). \textit{Psilocybin for depression: Considerations for clinical trial design}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2019.026}{doi:10.1556/2054.2019.026}.
\item Grandjean J, Buehlmann D, Buerge M, Sigrist H, Seifritz E, Vollenweider FX, Pryce CR, Rudin M. (2019). \textit{Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/751255}{doi:10.1101/751255}.
\item Begola MJ, Schillerstrom JE (2019). \textit{Hallucinogens and Their Therapeutic Use: A Literature Review.}. Journal of psychiatric practice. [published; PubMed]. \href{https://doi.org/10.1097/pra.0000000000000409}{doi:10.1097/pra.0000000000000409}.
\item Dustin Marlan (2019). \textit{Beyond Cannabis: Psychedelic Decriminalization and Social Justice}. eYLS (Yale Law School). [published; OpenAlex]. \href{https://lawcommons.lclark.edu/lclr/vol23/iss3/4}{source link}.
\item Jefsen O, Højgaard K, Christiansen SL, Elfving B, Nutt DJ, Wegener G, Müller HK (2019). \textit{Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat.}. Acta neuropsychiatrica. [published; PubMed]. \href{https://doi.org/10.1017/neu.2019.15}{doi:10.1017/neu.2019.15}.
\item Heifets BD, Malenka RC. (2019). \textit{Disruptive Psychopharmacology.}. JAMA Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.1001/jamapsychiatry.2019.1145}{doi:10.1001/jamapsychiatry.2019.1145}.
\item Anderson T, Petranker R, Christopher A, Rosenbaum D, Weissman C, Dinh-Williams LA, Hui K, Hapke E (2019). \textit{Psychedelic microdosing benefits and challenges: an empirical codebook.}. Harm reduction journal. [published; PubMed]. \href{https://doi.org/10.1186/s12954-019-0308-4}{doi:10.1186/s12954-019-0308-4}.
\item Jihun Lyu, Benjamin C. Hambro, Trisha Suppes (2019). \textit{A SYSTEMATIC REVIEW OF PSILOCYBIN IN THE TREATMENT OF DEPRESSION AND ANXIETY}. Journal of Affective Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jad.2018.10.335}{doi:10.1016/j.jad.2018.10.335}.
\item Richard Simoneaux (2019). \textit{The Potential of Psilocybin Administration in Terminal Cancer Patients}. Oncology Times. [published; OpenAlex]. \href{https://doi.org/10.1097/01.cot.0000574916.46844.cf}{doi:10.1097/01.cot.0000574916.46844.cf}.
\item Cao B, Zhu J, Zuckerman H, Rosenblat JD, Brietzke E, Pan Z, Subramanieapillai M, Park C, Lee Y, McIntyre RS (2019). \textit{Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2019.01.002}{doi:10.1016/j.pnpbp.2019.01.002}.
\item Sakloth F, Leggett E, Moerke MJ, Townsend EA, Banks ML, Negus SS (2019). \textit{Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.}. Experimental and clinical psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1037/pha0000253}{doi:10.1037/pha0000253}.
\item Johnson MW, Hendricks PS, Barrett FS, Griffiths RR (2019). \textit{Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.}. Pharmacology \& therapeutics. [published; PubMed]. \href{https://doi.org/10.1016/j.pharmthera.2018.11.010}{doi:10.1016/j.pharmthera.2018.11.010}.
\item Stenbaek DS, Kristiansen S, Burmester D, Madsen MK, Frokjaer VG, Knudsen GM, Fisher PM (2019). \textit{Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study.}. Human brain mapping. [published; PubMed]. \href{https://doi.org/10.1002/hbm.24511}{doi:10.1002/hbm.24511}.
\item B. Anderson, Alicia Danforth, Robert B. Daroff, Christopher S. Stauffer, James Dilley, Jennifer Mitchell, Joshua Woolley (2019). \textit{T137. Psilocybin-Assisted Group Therapy for Demoralization in Long-Term AIDS Survivors}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2019.03.460}{doi:10.1016/j.biopsych.2019.03.460}.
\item McKenna Silva (2019). \textit{Attitudes Toward Medical Psychedelics}. Dominican Scholar (Dominican University of California). [published; OpenAlex]. \href{https://scholar.dominican.edu/scw/SCW2019/conference-presentations-exhibits-and-performances/83}{source link}.
\item Meghan Hibicke, Alexus N. Landry, Zoe K. Talman, Charles D. Nichols (2019). \textit{Psychedelics Improve the Mental Health of Rats}. The FASEB Journal. [published; OpenAlex]. \href{https://doi.org/10.1096/fasebj.2019.33.1\_supplement.666.1}{doi:10.1096/fasebj.2019.33.1\_supplement.666.1}.
\item Kernel Networks Inc. (2019). \textit{A Study of Psilocybin for Major Depressive Disorder (MDD)}. Case Medical Research. [published; OpenAlex]. \href{https://doi.org/10.31525/ct1-nct03866174}{doi:10.31525/ct1-nct03866174}.
\item Nick Zagorski (2019). \textit{Is Psychedelic Medicine on the Horizon?}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2019.1b1}{doi:10.1176/appi.pn.2019.1b1}.
\item Jenna Varley (2019). \textit{Psychedelic-assisted therapy for anxiety and depression in the face of death: A critical review with an anthropological lens}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2019.005}{doi:10.1556/2054.2019.005}.
\item Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams LA, Hui K, Hapke E, Farb NAS (2019). \textit{Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-018-5106-2}{doi:10.1007/s00213-018-5106-2}.
\item Fricke J, Lenz C, Wick J, Blei F, Hoffmeister D (2019). \textit{Production Options for Psilocybin: Making of the Magic.}. Chemistry (Weinheim an der Bergstrasse, Germany). [published; PubMed]. \href{https://doi.org/10.1002/chem.201802758}{doi:10.1002/chem.201802758}.
\item William G. Crane (2019). \textit{Serotonergic Psychoactive Compounds as a Treatment for Addiction, Anxiety, and Depression: Their Efficacy and Legality}. Furman University Scholar Exchange (Furman University). [published; OpenAlex]. \href{https://scholarexchange.furman.edu/furmanengaged/2019/all/522}{source link}.
\item P. Dürler (2019). \textit{Psilocybin induces aberrant prediction error processing for tactile mismatch responses}. European Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.euroneuro.2018.11.477}{doi:10.1016/j.euroneuro.2018.11.477}.
\item Jacob S. Aday, Christopher C. Davoli, Emily K. Bloesch (2019). \textit{2018: A watershed year for psychedelic science}. Drug Science Policy and Law. [published; OpenAlex]. \href{https://doi.org/10.1177/2050324519872284}{doi:10.1177/2050324519872284}.
\item Nutt D (2019). \textit{Psychedelic drugs-a new era in psychiatry?.}. Dialogues in clinical neuroscience. [published; PubMed]. \href{https://doi.org/10.31887/dcns.2019.21.2/dnutt}{doi:10.31887/dcns.2019.21.2/dnutt}.
\item Corne R, Mongeau R (2019). \textit{[Neurotrophic mechanisms of psychedelic therapy].}. Biologie aujourd'hui. [published; PubMed]. \href{https://doi.org/10.1051/jbio/2019015}{doi:10.1051/jbio/2019015}.
\item Mason NL, Mischler E, Uthaug MV, Kuypers KPC (2019). \textit{Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2019.1580804}{doi:10.1080/02791072.2019.1580804}.
\item Fadiman J, Korb S (2019). \textit{Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2019.1593561}{doi:10.1080/02791072.2019.1593561}.
\item Doblin RE, Christiansen M, Jerome L, Burge B (2019). \textit{The Past and Future of Psychedelic Science: An Introduction to This Issue.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2019.1606472}{doi:10.1080/02791072.2019.1606472}.
\item Rocha JM, Osório FL, Crippa JAS, Bouso JC, Rossi GN, Hallak JEC, Dos Santos RG (2019). \textit{Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/2045125319845774}{doi:10.1177/2045125319845774}.
\item Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC (2019). \textit{Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2019.00672}{doi:10.3389/fpsyt.2019.00672}.
\item Isabella Stendahl (2018). \textit{THE POTENTIAL THERAPEUTIC VALUE OF PSILOCYBIN: In Relation to Depression}. Diva portal (Dalarna University Library). [published; OpenAlex]. \href{http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-17749}{source link}.
\item Kvam TM, Stewart LH, Andreassen OA (2018). \textit{Psychedelic drugs in the treatment of anxiety, depression and addiction.}. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. [published; PubMed]. \href{https://doi.org/10.4045/tidsskr.17.1110}{doi:10.4045/tidsskr.17.1110}.
\item Anderson T, Petranker R, Rosenbaum D, Weissman C, Dinh-Williams L, Hui K, Hapke E, Farb NAS. (2018). \textit{Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/gk4jd}{doi:10.31234/osf.io/gk4jd}.
\item Thomas Anderson, Rotem Petranker, Daniel Rosenbaum, Cory Weissman, Le-Anh Dinh-Williams, Katrina Hui, Emma Hapke, Norman Farb (2018). \textit{Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/gk4jd\_v1}{source link}.
\item Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL (2018). \textit{Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.}. Neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.neuropharm.2017.12.041}{doi:10.1016/j.neuropharm.2017.12.041}.
\item Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE (2018). \textit{The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.}. Neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.neuropharm.2018.05.012}{doi:10.1016/j.neuropharm.2018.05.012}.
\item Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, Carhart-Harris RL (2018). \textit{Effects of psilocybin therapy on personality structure.}. Acta psychiatrica Scandinavica. [published; PubMed]. \href{https://doi.org/10.1111/acps.12904}{doi:10.1111/acps.12904}.
\item Nichols DE (2018). \textit{Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.8b00043}{doi:10.1021/acschemneuro.8b00043}.
\item Geiger HA, Wurst MG, Daniels RN (2018). \textit{DARK Classics in Chemical Neuroscience: Psilocybin.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.8b00186}{doi:10.1021/acschemneuro.8b00186}.
\item Wasko MJ, Witt-Enderby PA, Surratt CK (2018). \textit{DARK Classics in Chemical Neuroscience: Ibogaine.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.8b00294}{doi:10.1021/acschemneuro.8b00294}.
\item Robin Carhart-Harris (2018). \textit{Serotonin, psychedelics and psychiatry}. World Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1002/wps.20555}{doi:10.1002/wps.20555}.
\item Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JEC (2018). \textit{Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.}. Expert review of clinical pharmacology. [published; PubMed]. \href{https://doi.org/10.1080/17512433.2018.1511424}{doi:10.1080/17512433.2018.1511424}.
\item Chu Hsien Lim, Brian D. Kangas, Jack Bergman (2018). \textit{The Utility of Psilocybin in Managing Anxiety and Depression in Cancer Patients}. Biochemistry and Molecular Biology Education. [published; OpenAlex]. \href{https://www.jyi.org/2018-august/2018/7/6/the-utility-of-psilocybin-in-managing-anxiety-and-depression-in-cancer-patients}{source link}.
\item Flanagan TW, Nichols CD (2018). \textit{Psychedelics as anti-inflammatory agents.}. International review of psychiatry (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1080/09540261.2018.1481827}{doi:10.1080/09540261.2018.1481827}.
\item Ross S (2018). \textit{Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.}. International review of psychiatry (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1080/09540261.2018.1482261}{doi:10.1080/09540261.2018.1482261}.
\item Awan AR, Winter JM, Turner D, Shaw WM, Suz LM, Bradshaw AJ, Ellis T, Dentinger BT. (2018). \textit{Convergent evolution of psilocybin biosynthesis by psychedelic mushrooms}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/374199}{doi:10.1101/374199}.
\item Johns Hopkins University (2018). \textit{Psychopharmacology of Psilocybin in Cancer Patients}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT00465595}{source link}.
\item Blei F, Baldeweg F, Fricke J, Hoffmeister D (2018). \textit{Biocatalytic Production of Psilocybin and Derivatives in Tryptophan Synthase-Enhanced Reactions.}. Chemistry (Weinheim an der Bergstrasse, Germany). [published; PubMed]. \href{https://doi.org/10.1002/chem.201801047}{doi:10.1002/chem.201801047}.
\item Lyons T, Carhart-Harris RL (2018). \textit{Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881117748902}{doi:10.1177/0269881117748902}.
\item Kuypers KPC (2018). \textit{Out of the box: A psychedelic model to study the creative mind.}. Medical hypotheses. [published; PubMed]. \href{https://doi.org/10.1016/j.mehy.2018.03.010}{doi:10.1016/j.mehy.2018.03.010}.
\item Whelan A, Johnson MI (2018). \textit{Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?}. Pain management. [published; PubMed]. \href{https://doi.org/10.2217/pmt-2017-0068}{doi:10.2217/pmt-2017-0068}.
\item Byock I (2018). \textit{Taking Psychedelics Seriously.}. Journal of palliative medicine. [published; PubMed]. \href{https://doi.org/10.1089/jpm.2017.0684}{doi:10.1089/jpm.2017.0684}.
\item Carrillo F, Sigman M, Fernández Slezak D, Ashton P, Fitzgerald L, Stroud J, Nutt DJ, Carhart-Harris RL (2018). \textit{Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2018.01.006}{doi:10.1016/j.jad.2018.01.006}.
\item Elaheh Mahmoudi, Mehrdad Faizi, Reza Hajiaghaee, Ali Razmi (2018). \textit{Alteration of Depressive-like Behaviors by Psilocybe cubensis Alkaloid Extract in Mice: the Role of Glutamate Pathway}. DOAJ (DOAJ: Directory of Open Access Journals). [published; OpenAlex]. \href{https://doi.org/10.22127/rjp.2018.58486}{doi:10.22127/rjp.2018.58486}.
\item Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T (2018). \textit{Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2017.09.012}{doi:10.1016/j.pnpbp.2017.09.012}.
\item Stroud JB, Freeman TP, Leech R, Hindocha C, Lawn W, Nutt DJ, Curran HV, Carhart-Harris RL (2018). \textit{Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-017-4754-y}{doi:10.1007/s00213-017-4754-y}.
\item Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ (2018). \textit{Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-017-4771-x}{doi:10.1007/s00213-017-4771-x}.
\item Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N, Roseman L, Feilding A, Nutt D, Carhart-Harris R (2018). \textit{The hidden therapist: evidence for a central role of music in psychedelic therapy.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-017-4820-5}{doi:10.1007/s00213-017-4820-5}.
\item Jessica Hamzelou (2018). \textit{Can psychedelic drug help with depression?}. The New Scientist. [published; OpenAlex]. \href{https://doi.org/10.1016/s0262-4079(18)30332-4}{doi:10.1016/s0262-4079(18)30332-4}.
\item Barrett FS, Griffiths RR (2018). \textit{Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.}. Current topics in behavioral neurosciences. [published; PubMed]. \href{https://doi.org/10.1007/7854\_2017\_474}{doi:10.1007/7854\_2017\_474}.
\item Bogenschutz MP, Ross S (2018). \textit{Therapeutic Applications of Classic Hallucinogens.}. Current topics in behavioral neurosciences. [published; PubMed]. \href{https://doi.org/10.1007/7854\_2016\_464}{doi:10.1007/7854\_2016\_464}.
\item Martin DA, Nichols CD (2018). \textit{The Effects of Hallucinogens on Gene Expression.}. Current topics in behavioral neurosciences. [published; PubMed]. \href{https://doi.org/10.1007/7854\_2017\_479}{doi:10.1007/7854\_2017\_479}.
\item Sherwood AM, Prisinzano TE (2018). \textit{Novel psychotherapeutics - a cautiously optimistic focus on Hallucinogens.}. Expert review of clinical pharmacology. [published; PubMed]. \href{https://doi.org/10.1080/17512433.2018.1415755}{doi:10.1080/17512433.2018.1415755}.
\item Canal CE (2018). \textit{Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.}. Handbook of experimental pharmacology. [published; PubMed]. \href{https://doi.org/10.1007/164\_2018\_107}{doi:10.1007/164\_2018\_107}.
\item De Gregorio D, Enns JP, Nuñez NA, Posa L, Gobbi G (2018). \textit{d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.}. Progress in brain research. [published; PubMed]. \href{https://doi.org/10.1016/bs.pbr.2018.07.008}{doi:10.1016/bs.pbr.2018.07.008}.
\item Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, Belser AB, Agin-Liebes G, Bogenschutz MP, Ross S (2018). \textit{Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2018.00256}{doi:10.3389/fphar.2018.00256}.
\item Barnby JM, Mehta MA (2018). \textit{Psilocybin and Mental Health-Don't Lose Control.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2018.00293}{doi:10.3389/fpsyt.2018.00293}.
\item Lyons T, Carhart-Harris RL (2018). \textit{More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression.}. Frontiers in psychology. [published; PubMed]. \href{https://doi.org/10.3389/fpsyg.2018.01721}{doi:10.3389/fpsyg.2018.01721}.
\item Witkin JM, Knutson DE, Rodriguez GJ, Shi S (2018). \textit{Rapid-Acting Antidepressants.}. Current pharmaceutical design. [published; PubMed]. \href{https://doi.org/10.2174/1381612824666180730104707}{doi:10.2174/1381612824666180730104707}.
\item Anisha Lela Larsson (2017). \textit{Mikrodosering av lysergsyradietylamid och psilocybin och dess effekter på psykisk hälsa}. KTH Publication Database DiVA (KTH Royal Institute of Technology). [published; OpenAlex]. \href{http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-358476}{source link}.
\item University of Helsinki (2017). \textit{Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03380442}{source link}.
\item Joanna Stefaniuk (2017). \textit{„Terapia szokowa”, czyli agoniści receptor 5-HT2A w leczeniu depresji i lęku}. CeON Repository (Centre for Evaluation in Education and Science). [published; OpenAlex]. \href{https://depot.ceon.pl/handle/123456789/13483}{source link}.
\item Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, Thomas CD, Hetzel SJ, Henriquez KM, Ribaudo AS, Hutson PR (2017). \textit{Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.}. Clinical pharmacokinetics. [published; PubMed]. \href{https://doi.org/10.1007/s40262-017-0540-6}{doi:10.1007/s40262-017-0540-6}.
\item Barbara Geller (2017). \textit{Can Psilocybin Treat Severe Depression}. Journal watch. [published; OpenAlex]. \href{https://doi.org/10.1056/nejm-jw.na45292}{doi:10.1056/nejm-jw.na45292}.
\item Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV (2017). \textit{Psychedelic Drugs in Biomedicine.}. Trends in pharmacological sciences. [published; PubMed]. \href{https://doi.org/10.1016/j.tips.2017.08.003}{doi:10.1016/j.tips.2017.08.003}.
\item Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ (2017). \textit{Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-017-13282-7}{doi:10.1038/s41598-017-13282-7}.
\item Carhart-Harris RL, Goodwin GM (2017). \textit{The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/npp.2017.84}{doi:10.1038/npp.2017.84}.
\item Ahmed Al-Imam (2017). \textit{Google Trends Analyses and Case Report: A Persistently Dilated Pupil in Psychedelics’ User}. Global Journal of Health Science. [published; OpenAlex]. \href{https://doi.org/10.5539/gjhs.v9n11p168}{doi:10.5539/gjhs.v9n11p168}.
\item STEVE RITTER (2017). \textit{‘Magic mushroom’ enzyme mystery solved}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-09533-notw1}{doi:10.1021/cen-09533-notw1}.
\item Johnson MW, Garcia-Romeu A, Johnson PS, Griffiths RR (2017). \textit{An online survey of tobacco smoking cessation associated with naturalistic psychedelic use.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881116684335}{doi:10.1177/0269881116684335}.
\item Johnson MW, Griffiths RR (2017). \textit{Potential Therapeutic Effects of Psilocybin.}. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics. [published; PubMed]. \href{https://doi.org/10.1007/s13311-017-0542-y}{doi:10.1007/s13311-017-0542-y}.
\item Majić T, Jungaberle H, Schmidt TT, Zeuch A, Hermle L, Gallinat J (2017). \textit{[Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].}. Fortschritte der Neurologie-Psychiatrie. [published; PubMed]. \href{https://doi.org/10.1055/s-0043-103085}{doi:10.1055/s-0043-103085}.
\item Rosalind Watts, Camilla Day, Jacob Krzanowski, David Nutt, Robin Carhart-Harris (2017). \textit{Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression}. Journal of Humanistic Psychology. [published; OpenAlex]. \href{https://doi.org/10.1177/0022167817709585}{doi:10.1177/0022167817709585}.
\item Strauss N (2017). \textit{Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia.}. The Medical journal of Australia. [published; PubMed]. \href{https://doi.org/10.5694/mja17.00081}{doi:10.5694/mja17.00081}.
\item Thomas Cody Swift, Alexander Belser, Gabrielle Agin-Liebes, Neşe Devenot, Sara Terrana, Harris L. Friedman, Jeffrey Guss, Anthony P. Bossis, Stephen Ross (2017). \textit{Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress}. Journal of Humanistic Psychology. [published; OpenAlex]. \href{https://doi.org/10.1177/0022167817715966}{doi:10.1177/0022167817715966}.
\item Stephen Bright, M.L. Williams, David Caldicott (2017). \textit{Should addiction researchers be interested in psychedelic science?}. Drug and Alcohol Review. [published; OpenAlex]. \href{https://doi.org/10.1111/dar.12544}{doi:10.1111/dar.12544}.
\item Thomas W. Flanagan, Melaine N. Sebastian, Charles D. Nichols (2017). \textit{Anti-inflammatory effects of serotonin 5-HT2A receptor activation in ovalbumin-induced allergic asthma models}. The FASEB Journal. [published; OpenAlex]. \href{https://doi.org/10.1096/fasebj.31.1\_supplement.820.4}{doi:10.1096/fasebj.31.1\_supplement.820.4}.
\item Dos Santos RG, Bouso JC, Hallak JEC (2017). \textit{Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/2045125316689030}{doi:10.1177/2045125316689030}.
\item Idell RD, Florova G, Komissarov AA, Shetty S, Girard RB, Idell S (2017). \textit{The fibrinolytic system: A new target for treatment of depression with psychedelics.}. Medical hypotheses. [published; PubMed]. \href{https://doi.org/10.1016/j.mehy.2017.01.013}{doi:10.1016/j.mehy.2017.01.013}.
\item de Veen BT, Schellekens AF, Verheij MM, Homberg JR (2017). \textit{Psilocybin for treating substance use disorders?}. Expert review of neurotherapeutics. [published; PubMed]. \href{https://doi.org/10.1080/14737175.2016.1220834}{doi:10.1080/14737175.2016.1220834}.
\item Nichols DE, Johnson MW, Nichols CD (2017). \textit{Psychedelics as Medicines: An Emerging New Paradigm.}. Clinical pharmacology and therapeutics. [published; PubMed]. \href{https://doi.org/10.1002/cpt.557}{doi:10.1002/cpt.557}.
\item Henry A. Nasrallah (2017). \textit{Maddening Therapies: How Hallucinogens Morphed into Novel Treatments}. Current psychiatry. [published; OpenAlex]. \href{https://www.questia.com/library/journal/1G1-480992660/maddening-therapies-how-hallucinogens-morphed-into}{source link}.
\item Carlyn Delavan (2017). \textit{Narrative therapy-assisted psilocybin use for treatment of depression}. Seattle Pacific University Research Conference. [published; OpenAlex]. \href{https://digitalcommons.spu.edu/spfc\_research\_conference/spfc\_conf\_2017/spfc\_conf\_2017\_events/43/}{source link}.
\item Mahapatra A, Gupta R (2017). \textit{Role of psilocybin in the treatment of depression.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/2045125316676092}{doi:10.1177/2045125316676092}.
\item Al-Imam A (2017). \textit{Could Hallucinogens Induce Permanent Pupillary Changes in (Ab)users? A Case Report from New Zealand.}. Case reports in neurological medicine. [published; PubMed]. \href{https://doi.org/10.1155/2017/2503762}{doi:10.1155/2017/2503762}.
\item Thomas K, Malcolm B, Lastra D (2017). \textit{Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2017.1320734}{doi:10.1080/02791072.2017.1320734}.
\item Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F (2017). \textit{The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2017.00240}{doi:10.3389/fpsyt.2017.00240}.
\item Roseman L, Nutt DJ, Carhart-Harris RL (2017). \textit{Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2017.00974}{doi:10.3389/fphar.2017.00974}.
\item Daniel J, Haberman M (2017). \textit{Clinical potential of psilocybin as a treatment for mental health conditions.}. The mental health clinician. [published; PubMed]. \href{https://doi.org/10.9740/mhc.2017.01.024}{doi:10.9740/mhc.2017.01.024}.
\item Natalie Engström (2016). \textit{Lysergsyradietylamid (LSD) och psilocybin vid depression och ångestsjukdom: En litteraturstudie om effekter och biverkningar av LSD- och psilocybin-assisterad psykoterapi}. KTH Publication Database DiVA (KTH Royal Institute of Technology). [published; OpenAlex]. \href{http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-136681}{source link}.
\item Barrett FS, Bradstreet MP, Leoutsakos JS, Johnson MW, Griffiths RR (2016). \textit{The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881116678781}{doi:10.1177/0269881116678781}.
\item Rucker JJ, Jelen LA, Flynn S, Frowde KD, Young AH (2016). \textit{Psychedelics in the treatment of unipolar mood disorders: a systematic review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881116679368}{doi:10.1177/0269881116679368}.
\item Nutt D (2016). \textit{Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881116675754}{doi:10.1177/0269881116675754}.
\item Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL (2016). \textit{Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881116675512}{doi:10.1177/0269881116675512}.
\item Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016). \textit{Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881116675513}{doi:10.1177/0269881116675513}.
\item McCorvy JD, Olsen RH, Roth BL (2016). \textit{Psilocybin for depression and anxiety associated with life-threatening illnesses.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881116675771}{doi:10.1177/0269881116675771}.
\item Patra S (2016). \textit{Return of the psychedelics: Psilocybin for treatment resistant depression.}. Asian journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.ajp.2016.08.010}{doi:10.1016/j.ajp.2016.08.010}.
\item Kyzar EJ, Kalueff AV (2016). \textit{Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models.}. Zebrafish. [published; PubMed]. \href{https://doi.org/10.1089/zeb.2016.1251}{doi:10.1089/zeb.2016.1251}.
\item Karolina Dydak, Mariola Śliwińska-Mossoń, Halina Milnerowicz (2016). \textit{Psilocybin as an alternative medicine for patients suffering from depression}. Psychiatria i Psychologia Kliniczna. [published; OpenAlex]. \href{https://doi.org/10.15557/pipk.2016.0023}{doi:10.15557/pipk.2016.0023}.
\item Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016). \textit{Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.}. The lancet. Psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/s2215-0366(16)30065-7}{doi:10.1016/s2215-0366(16)30065-7}.
\item Cowen P (2016). \textit{Altered states: psilocybin for treatment-resistant depression.}. The lancet. Psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/s2215-0366(16)30087-6}{doi:10.1016/s2215-0366(16)30087-6}.
\item Howland RH (2016). \textit{Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor.}. Journal of psychosocial nursing and mental health services. [published; PubMed]. \href{https://doi.org/10.3928/02793695-20160616-09}{doi:10.3928/02793695-20160616-09}.
\item Dos Santos RG, Osório FL, Crippa JA, Riba J, Zuardi AW, Hallak JE (2016). \textit{Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/2045125316638008}{doi:10.1177/2045125316638008}.
\item Joseph A. Zamaria (2016). \textit{A Phenomenological Examination of Psilocybin and its Positive and Persisting Aftereffects}. NeuroQuantology. [published; OpenAlex]. \href{https://doi.org/10.14704/nq.2016.14.2.943}{doi:10.14704/nq.2016.14.2.943}.
\item Nichols DE (2016). \textit{Psychedelics.}. Pharmacological reviews. [published; PubMed]. \href{https://doi.org/10.1124/pr.115.011478}{doi:10.1124/pr.115.011478}.
\item Laura Orsolini, Alessandro Valchera, Duccio Papanti, R. Vecchiotti, Domenico De Berardis (2016). \textit{The “Endless Trip”: Psychopathology and psychopharmacology in the Hallucinogen Persisting Perception Disorder (HPPD)}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.eurpsy.2016.01.1060}{doi:10.1016/j.eurpsy.2016.01.1060}.
\item Kraehenmann R, Schmidt A, Friston K, Preller KH, Seifritz E, Vollenweider FX (2016). \textit{The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.}. NeuroImage. Clinical. [published; PubMed]. \href{https://doi.org/10.1016/j.nicl.2015.08.009}{doi:10.1016/j.nicl.2015.08.009}.
\item Tófoli LF, de Araujo DB (2016). \textit{Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics.}. International review of neurobiology. [published; PubMed]. \href{https://doi.org/10.1016/bs.irn.2016.06.005}{doi:10.1016/bs.irn.2016.06.005}.
\item Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX (2015). \textit{Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.}. Biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.biopsych.2014.04.010}{doi:10.1016/j.biopsych.2014.04.010}.
\item Katrin H. Preller, Thomas Pokorny, Rainer Krähenmann, Milan Scheidegger, I. Dziobek, Philipp Stämpfli, F.X. Vollenweider (2015). \textit{P.1.i.005 The 5-HT2A/1A agonist psilocybin reduces social pain and enhances empathy in healthy volunteers}. European Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/s0924-977x(15)30364-3}{doi:10.1016/s0924-977x(15)30364-3}.
\item D.J. Nutt (2015). \textit{5HT2a Receptors - a New Target for Depression?}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/s0924-9338(15)30027-4}{doi:10.1016/s0924-9338(15)30027-4}.
\item Katrin H. Preller, Thomas Pokorny, Rainer Krähenmann, I. Dziobek, Philipp Stämpfli, F.X. Vollenweider (2015). \textit{The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-making}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/s0924-9338(15)30017-1}{doi:10.1016/s0924-9338(15)30017-1}.
\item Johansen PØ, Krebs TS (2015). \textit{Psychedelics not linked to mental health problems or suicidal behavior: a population study.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881114568039}{doi:10.1177/0269881114568039}.
\item Baumeister D, Barnes G, Giaroli G, Tracy D (2014). \textit{Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/2045125314527985}{doi:10.1177/2045125314527985}.
\item Nichols DE (2014). \textit{The Heffter Research Institute: past and hopeful future.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2014.873688}{doi:10.1080/02791072.2014.873688}.
\item Carhart-Harris RL, Brugger S, Nutt DJ, Stone JM (2013). \textit{Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881113494107}{doi:10.1177/0269881113494107}.
\item Young SN (2013). \textit{Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.}. Journal of psychiatry \& neuroscience: JPN. [published; PubMed]. \href{https://doi.org/10.1503/jpn.120128}{doi:10.1503/jpn.120128}.
\item Michael Kometer, André Schmidt, Lutz Jäncke, Franz X. Vollenweider (2013). \textit{Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on α Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations}. Open MIND. [published; OpenAlex]. \href{https://openalex.org/W6929930661}{source link}.
\item Krebs TS, Johansen PØ (2013). \textit{Psychedelics and mental health: a population study.}. PloS one. [published; PubMed]. \href{https://doi.org/10.1371/journal.pone.0063972}{doi:10.1371/journal.pone.0063972}.
\item Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX (2012). \textit{Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.}. Biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.biopsych.2012.04.005}{doi:10.1016/j.biopsych.2012.04.005}.
\item Norra MacReady (2012). \textit{Opening Doors of Perception: Psychedelic Drugs and End-of-Life Care}. JNCI Journal of the National Cancer Institute. [published; OpenAlex]. \href{https://doi.org/10.1093/jnci/djs468}{doi:10.1093/jnci/djs468}.
\item Roiser JP, Rees G (2012). \textit{Neuroimaging: a scanner, colourfully.}. Current biology: CB. [published; PubMed]. \href{https://doi.org/10.1016/j.cub.2012.02.033}{doi:10.1016/j.cub.2012.02.033}.
\item Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR (2011). \textit{Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.}. Archives of general psychiatry. [published; PubMed]. \href{https://doi.org/10.1001/archgenpsychiatry.2010.116}{doi:10.1001/archgenpsychiatry.2010.116}.
\item Adams JD (2009). \textit{Chemical interactions with pyramidal neurons in layer 5 of the cerebral cortex: control of pain and anxiety.}. Current medicinal chemistry. [published; PubMed]. \href{https://doi.org/10.2174/092986709789057626}{doi:10.2174/092986709789057626}.
\item Briony J. Catlow (2007). \textit{Involvement of 5-HT2A Receptor in the Regulation of Hippocampal-Dependent Learning and Neurogenesis}. Digital Commons - University of South Florida (University of South Florida). [published; OpenAlex]. \href{https://digitalcommons.usf.edu/etd/166}{source link}.
\item Euphrosyne Gouzoulis-Mayfrank, Anna Neukirch, Karsten Heekeren (2005). \textit{Psychopathological effects of S-ketamine and dimethyltryptamine (DMT) in humans: a double-blind, cross-over human experimental study of the NMDA antagonist and the 5HT2A agonist model of psychosis}. Pharmacopsychiatry. [published; OpenAlex]. \href{https://doi.org/10.1055/s-2005-918695}{doi:10.1055/s-2005-918695}.
\item Ben Sessa (2005). \textit{Can psychedelics have a role in psychiatry once again?}. The British Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/bjp.186.6.457}{doi:10.1192/bjp.186.6.457}.
\item Leon Gussow (2003). \textit{Designer Hallucinogens}. Emergency Medicine News. [published; OpenAlex]. \href{https://doi.org/10.1097/00132981-200312000-00015}{doi:10.1097/00132981-200312000-00015}.
\item Felix Hasler, Ulrike Grimberg, Martin Benz, F.X. Vollenweider (2003). \textit{P.6.057 Effects of 2A receptor challenge by psilocybin on cognitive performance and neuroendocrine measures in healthy humans: A serotonin model of psychosis}. European Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/s0924-977x(03)92355-8}{doi:10.1016/s0924-977x(03)92355-8}.
\item Mohan D, Mohandas E, Rajat R (1981). \textit{Chloroquine psychosis: a chemical psychosis?}. Journal of the National Medical Association. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/7310924/}{source link}.
\item Trulson ME, Heym J, Jacobs BL (1981). \textit{Dissociations between the effects of hallucinogenic drugs on behavior and raphe unit activity in freely moving cats.}. Brain research. [published; PubMed]. \href{https://doi.org/10.1016/0006-8993(81)90507-2}{doi:10.1016/0006-8993(81)90507-2}.
\item R Fischer, Diana Warshay (1968). \textit{Psilocybin-induced Autonomic, Perceptual, and Behavioral Change}. Pharmacopsychiatry. [published; OpenAlex]. \href{https://doi.org/10.1055/s-0028-1094227}{doi:10.1055/s-0028-1094227}.
\item Sjoberg BM, Hollister LE. (1965). \textit{The effects of psychotomimetic drugs on primary suggestibility.}. Psychopharmacologia. [published; Europe PMC]. \href{https://doi.org/10.1007/bf00407857}{doi:10.1007/bf00407857}.
\item REDA GC, VELLA G, CANCRINI L, D AGOSTINO E (1964). \textit{[CLINICAL AND PSYCHOPATHOLOGICAL STUDY OF PSILOCYBIN].}. Rivista sperimentale di freniatria e medicina legale delle alienazioni mentali. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/14144273/}{source link}.
\item SERCL M, KOVARIK J, JAROS O (1961). \textit{[Clinical experiences with psilocybin (CY39 Sandoz)].}. Psychiatria et neurologia. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/13910754/}{source link}.
\end{enumerate}
\end{document}
